{
    "results": [
        [
            0,
            "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.",
            [
                " {\n  \"DRUGS\": [\"Progressive mobilization\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"mobilization\", \"laboratory findings\"],\n  \"FREQUENCY\": [\"complete normalization\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            1,
            "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.",
            [
                " {\n  \"DRUGS\": [\"trabectedin\"],\n  \"HERB NAME\": [\"alternative herbal medicine\"],\n  \"STUDY\": \"case report\",\n  \"PARAMETER\": [\"heavy toxicity\", \"rhabdomyolysis\"],\n  \"FREQUENCY\": [\"fourth course\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"patient with retroperitoneal liposarcoma\",\n  \"DURATION\": [\"course\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"rhabdomyolysis\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "rhabdomyolysis",
                        "retroperitoneal liposarcoma",
                        "adverse event"
                    ],
                    "Drug": [
                        "trabectedin"
                    ]
                }
            ]
        ],
        [
            2,
            "In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Surgical study\",\n  \"PARAMETER\": [\"abdominal mass\", \"complete margin\", \"R0 resection\"],\n  \"FREQUENCY\": [\"May 2009\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"2009\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"abdominal mass\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            3,
            "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space.",
            [
                " {\n  \"DRUGS\": [\"chemotherapy\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical observation of lesion progression\",\n  \"PARAMETER\": [\"lesion size\", \"retro-peritoneum space\"],\n  \"FREQUENCY\": [\"rapid progression\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"16 \u00d7 10 cm\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"lesion progression\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            4,
            "Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin.",
            [
                " {\n  \"DRUGS\": [\"trabectedin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"co-morbidity\"],\n  \"FREQUENCY\": [\"absence\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"not specified in the text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"co-morbidity\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "trabectedin"
                    ]
                }
            ]
        ],
        [
            5,
            "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8].",
            [
                " {\n  \"DRUGS\": [\"chemotherapeutic drugs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"study of drug interactions in cancer patients\",\n  \"PARAMETER\": [\"chemotherapeutic drugs\", \"drug interactions\", \"narrow therapeutic index\", \"ancillary medications\", \"cancer-related syndromes\", \"treatment-induced toxicity\"],\n  \"FREQUENCY\": [\"increased number and types of chemotherapeutic drugs\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"cancer patients\",\n  \"DURATION\": [\"prolonged life expectancy\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"cancer-related syndromes\", \"treatment-induced toxicity\"],\n  \"TARGET\": [\"enzymes, transporters,...\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "cancer",
                        "cancer-related syndromes",
                        "treatment-induced toxicity"
                    ]
                }
            ]
        ],
        [
            6,
            "Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms.",
            [
                " {\n  \"DRUGS\": [\"chokeberry juice\"],\n  \"HERB NAME\": [\"chokeberry\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"transport mechanisms\", \"death receptor\"],\n  \"FREQUENCY\": [\"unknown\"],\n  \"HERB PART\": [\"whole chokeberry\"],\n  \"COHORT\": \"patients in the study\",\n  \"DURATION\": [\"unknown\"],\n  \"SEX\": [\"unknown\"],\n  \"AGE\": [\"unknown\"],\n  \"AMOUNT\": [\"unknown\"],\n  \"ETHNIC GROUP\": [\"unknown\"],\n  \"PATHOLOGY\": [\"unknown\"],\n  \"TARGET\": [\"unknown\"],\n  \"EXTRACTION PROCESS\": [\"unknown\"]\n}",
                {
                    "Extraction process": [
                        "chokeberry juice"
                    ]
                }
            ]
        ],
        [
            7,
            "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use.",
            [
                " {\n  \"DRUGS\": [\"medicinal cannabis\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"case report\",\n  \"PARAMETER\": [\"health risks\"],\n  \"FREQUENCY\": [\"complexity\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "cannabis"
                    ]
                }
            ]
        ],
        [
            8,
            "It was discovered that the patient took cannabis for chronic back pain, and a pharmacogenomics (PGx) test indicated the presence of variants for the COMT and HTR2A genes.",
            [
                " {\n  \"DRUGS\": [\"cannabis\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacogenomics (PGx) study\",\n  \"PARAMETER\": [\"COMT\", \"HTR2A\"],\n  \"FREQUENCY\": [\"chronic back pain\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"patient\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"COMT\", \"HTR2A\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "cannabis"
                    ],
                    "Pathology": [
                        "chronic back pain"
                    ]
                }
            ]
        ],
        [
            9,
            "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8].",
            [
                " {\n  \"DRUGS\": [\"carbidopa-levodopa\", \"ropinirole\", \"entacapone\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"dopamine concentrations\", \"movement control\"],\n  \"FREQUENCY\": [\"low dopamine concentrations\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"Not specified in the text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Neuronal death\"],\n  \"TARGET\": [\"dopamine\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "PD"
                    ],
                    "Drug": [
                        "carbidopa-levodopa",
                        "ropinirole",
                        "entacapone"
                    ]
                }
            ]
        ],
        [
            10,
            "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events.",
            [
                " {\n  \"DRUGS\": [\"cannabis\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Case study\",\n  \"PARAMETER\": [\"pharmacokinetic\", \"pharmacodynamic\", \"pharmacogenomic\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"adverse drug events\"],\n  \"TARGET\": []\n}",
                {
                    "Herb name": [
                        "cannabis"
                    ],
                    "Pathology": [
                        "adverse drug events"
                    ]
                }
            ]
        ],
        [
            11,
            "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain.",
            [
                " {\n  \"DRUGS\": [\"PD\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Cohort study\",\n  \"PARAMETER\": [\"spinal stenosis\", \"vitamin D deficiency\", \"frequent falls\", \"nicotine dependence\", \"alcohol dependence\", \"mild kidney disease\", \"chronic neck pain\", \"chronic back pain\", \"chronic shoulder pain\"],\n  \"FREQUENCY\": [\"frequent falls\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Patients with PD\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"spinal stenosis\", \"vitamin D deficiency\", \"mild kidney disease\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "PD",
                        "spinal stenosis",
                        "vitamin D deficiency",
                        "frequent falls",
                        "mild kidney disease",
                        "chronic neck, back, and shoulder pain"
                    ]
                }
            ]
        ],
        [
            12,
            "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1).",
            [
                " {\n  \"DRUGS\": [\"carbidopa-levodopa\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical pharmacist recommendation\",\n  \"PARAMETER\": [\"tremors\"],\n  \"FREQUENCY\": [\"early in the morning\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"tremors\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "carbidopa-levodopa"
                    ],
                    "Pathology": [
                        "tremors"
                    ]
                }
            ]
        ],
        [
            13,
            "However, his PCP determined that additional medication for pain control was warranted.",
            [
                " {\n  \"DRUGS\": [\"additional medication\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"pain control\"],\n  \"FREQUENCY\": [\"additional\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"pain\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            14,
            "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21].",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Comparative study of factors affecting study results\",\n  \"PARAMETER\": [\"pain models\", \"healthy subjects\", \"patients\", \"routes of administration\", \"inhalation\", \"oral\"],\n  \"FREQUENCY\": [\"numerous\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [\"adults\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "pain",
                        "healthy"
                    ]
                }
            ]
        ],
        [
            15,
            "When CB1Rs on presynaptic neurons are activated, inhibitory neurotransmitter levels are reduced and dopamine levels increase [5,24,25].",
            [
                " {\n  \"DRUGS\": [\"dopamine\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Research on the effects of CB1 receptor activation on neurotransmitter levels\",\n  \"PARAMETER\": [\"inhibitory neurotransmitter levels\", \"dopamine levels\"],\n  \"FREQUENCY\": [\"not specified\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [\"not specified\"],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"CB1 receptors\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CB1Rs"
                    ],
                    "Parameter": [
                        "dopamine levels"
                    ]
                }
            ]
        ],
        [
            16,
            "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected.",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Genetic study based on patient's PGx results\",\n  \"PARAMETER\": [\"PGx results\", \"genotype\", \"dopamine levels in synapses\"],\n  \"FREQUENCY\": [\"\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Patient\",\n  \"DURATION\": [],\n  \"SEX\": [\"\"],\n  \"AGE\": [],\n  \"AMOUNT\": [\"\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Higher levels of dopamine in synapses\"],\n  \"TARGET\": [\"COMT\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            17,
            "Additionally, a previous study evaluated patients with PD and their subsequent reactions to cannabis use, reporting that one out of five patients experienced hallucinations [12].",
            [
                " {\n  \"DRUGS\": [\"cannabis\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"previous study evaluating patients with Parkinson's Disease (PD) and their reactions to cannabis use\",\n  \"PARAMETER\": [\"hallucinations\"],\n  \"FREQUENCY\": [\"one out of five patients\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"patients with PD\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"hallucinations\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "PD",
                        "hallucinations"
                    ],
                    "Herb name": [
                        "cannabis"
                    ]
                }
            ]
        ],
        [
            18,
            "Given this patient\u2019s genetic results, guidelines, and current pain status, the clinical pharmacist suggested morphine as an alternative, as it does not utilize CYP2D6 for metabolism [34].",
            [
                " {\n  \"DRUGS\": [\"morphine\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical pharmacist's recommendation\",\n  \"PARAMETER\": [\"CYP2D6\"],\n  \"FREQUENCY\": [\"not applicable\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"alternative to drugs utilizing CYP2D6 for metabolism\"],\n  \"TARGET\": [\"CYP2D6\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "pain"
                    ],
                    "Drug": [
                        "morphine"
                    ]
                }
            ]
        ],
        [
            19,
            "The authors want to thank Katie Meyer for her assistance.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            20,
            "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"conventional medicines\", \"CAM\", \"treatment\"],\n  \"FREQUENCY\": [\"two decades\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"two decades\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nNote: The provided text does not contain specific information about drugs, herbs, cohorts, sexes, ages, amounts, ethnic groups, pathologies, targets, or extraction processes. Therefore, the fields related to these entities are left empty. However, the text does mention the integration of conventional medicines with CAM (Complementary and Alternative Medicine) over a period of two decades, which has been categorized as an observational study.",
                {
                    "Duration": [
                        "the past two decades"
                    ]
                }
            ]
        ],
        [
            21,
            "In China, 93.4% of cancer patients reported having used CAM in 2009-2010 [4].",
            [
                " {\n  \"DRUGS\": [\"CAM\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Survey\",\n  \"PARAMETER\": [\"cancer patients\"],\n  \"FREQUENCY\": [\"93.4%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"China, 2009-2010\",\n  \"DURATION\": [\"2009-2010\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"Chinese\"],\n  \"PATHOLOGY\": [\"cancer\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "cancer"
                    ]
                }
            ]
        ],
        [
            22,
            "In South Korean population reported a range from 29% to 83% [5].",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Population-based study\",\n  \"PARAMETER\": [\"South Korean population\", \"percentage range\"],\n  \"FREQUENCY\": [\"29% to 83%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"South Korean population\",\n  \"DURATION\": [],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"South Korean\"],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Ethnic group": [
                        "South Korean"
                    ]
                }
            ]
        ],
        [
            23,
            "An important fact is that most of these affected drugs have very narrow therapeutic indices.",
            [
                " {\n  \"DRUGS\": [\"drug A\", \"drug B\", \"drug C\"],\n  \"HERB NAME\": [\"herb X\", \"herb Y\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"blood pressure\", \"heart rate\", \"liver enzymes\"],\n  \"FREQUENCY\": [\"daily\", \"weekly\", \"monthly\"],\n  \"HERB PART\": [\"root\", \"leaf\", \"flower\"],\n  \"COHORT\": \"Adult patients with hypertension\",\n  \"DURATION\": [\"6 months\", \"1 year\", \"2 years\"],\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [\"30 years\", \"45 years\", \"60 years\"],\n  \"AMOUNT\": [\"100 mg\", \"200 mg\", \"500 mg\"],\n  \"ETHNIC GROUP\": [\"Asian\", \"Caucasian\", \"African\"],\n  \"PATHOLOGY\": [\"liver toxicity\", \"renal impairment\"],\n  \"TARGET\": [\"CYP3A4 enzyme\", \"P-glycoprotein transporter\"],\n  \"EXTRACTION PROCESS\": [\"solvent extraction\", \"water decoction\", \"steam distillation\"]\n}",
                {}
            ]
        ],
        [
            24,
            "To date an increasing number of studies in evaluating HDIs have been reported [11].",
            [
                " {\n  \"DRUGS\": [\"HDIs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Evaluating HDIs\",\n  \"PARAMETER\": [\"physiological or medical parameters\"],\n  \"FREQUENCY\": [\"increasing number of studies\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"enzymes\", \"transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            25,
            "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs.",
            [
                " {\n  \"DRUGS\": [\"pharmacogenomics\", \"HDIs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"pharmacogenomics studies\",\n  \"PARAMETER\": [\"HDIs\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"clinical study participants\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "pharmacogenomics studies",
                        "clinic study"
                    ]
                }
            ]
        ],
        [
            26,
            "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043).",
            [
                " {\n  \"DRUGS\": [\"thiopurine\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Genetic association study\",\n  \"PARAMETER\": [\"thiopurine S-methyltransferase (TPMT) gene\", \"hypoglycemic effect\", \"P = 0.001\", \"FDR P = 0.043\"],\n  \"FREQUENCY\": [\"significant association\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"not specified\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"hypoglycemia\"],\n  \"TARGET\": [\"thiopurine S-methyltransferase (TPMT) gene\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene"
                    ],
                    "Pathology": [
                        "hypoglycemic"
                    ]
                }
            ]
        ],
        [
            27,
            "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs.",
            [
                " {\n  \"DRUGS\": [\"traditional hypoglycemic herbs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"association study\",\n  \"PARAMETER\": [\"clinical effect\"],\n  \"FREQUENCY\": [\"associated\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "rs1142345"
                    ],
                    "Pathology": [
                        "hypoglycemic"
                    ]
                }
            ]
        ],
        [
            28,
            "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"AUC\", \"concentration-time curve\", \"EMs\", \"poor metabolizer\", \"PM\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "AUC: concentration-time curve"
                    ]
                }
            ]
        ],
        [
            29,
            "With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].",
            [
                " {\n  \"DRUGS\": [\"conventional therapeutic drugs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Increase in the utilization of herbal remedies in combination with other medications over the last decade\",\n  \"PARAMETER\": [\"combination of medications\"],\n  \"FREQUENCY\": [\"increased tremendously over the last decade\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"last decade\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            30,
            "Local names for this shrub include Faangum in Cameroon, Sasanemasa/Sesemasa or Esisimansa in Ghana, Lifui in Togo, and Akoko in Nigeria.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Faangum\"],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"sex\", \"age\", \"ethnic group\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [],\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [\"adults\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"Cameroon\", \"Ghana\", \"Togo\", \"Nigeria\"],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Faangum",
                        "Sasanemasa/Sesemasa",
                        "Esisimansa",
                        "Lifui",
                        "Akoko"
                    ]
                }
            ]
        ],
        [
            31,
            "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14].",
            [
                " {\n  \"DRUGS\": [\"cytochrome P450\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"role of cytochrome P450 enzymes in biotransformation\",\n  \"PARAMETER\": [\"biotransformation\", \"xenobiotics\", \"endogenous substances\"],\n  \"FREQUENCY\": [\"about 70%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"70%\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"side effects\"],\n  \"TARGET\": [\"cytochrome P450 enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "cytochrome P450 (CYP450)"
                    ]
                }
            ]
        ],
        [
            32,
            "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities.",
            [
                " {\n  \"DRUGS\": [\"CYP1A2\", \"CYP2C9\", \"CYP2C19\"],\n  \"HERB NAME\": [\"Newbouldia laevis\", \"Cassia abbreviata\"],\n  \"STUDY\": \"Investigation of potential interaction effects\",\n  \"PARAMETER\": [\"CYP1A2\", \"CYP2C9\", \"CYP2C19\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP1A2\", \"CYP2C9\", \"CYP2C19\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Extraction process": [
                        "extracts"
                    ],
                    "Herb name": [
                        "Newbouldia laevis",
                        "Cassia abbreviata"
                    ],
                    "Target": [
                        "CYP1A2",
                        "CYP2C9",
                        "CYP2C19"
                    ]
                }
            ]
        ],
        [
            33,
            "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples.",
            [
                " {\n  \"DRUGS\": [\"non-targeted approach\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"non-targeted approach\",\n  \"PARAMETER\": [\"time course\", \"K A\"],\n  \"FREQUENCY\": [\"time course\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"time course\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": \"\",\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            34,
            "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract.",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [\"\"],\n  \"STUDY\": \"Estimation of bioavailable concentration of herbal extracts\",\n  \"PARAMETER\": [\"bioavailable concentration\", \"intestinal absorption\", \"plasma concentration\", \"bioavailability\", \"weight extracted powdered material\", \"weight of original starting material\"],\n  \"FREQUENCY\": [\"\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"weight extracted powdered material\", \"weight of original starting material\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Extraction process": [
                        "extracts",
                        "soluble extract"
                    ],
                    "Parameter": [
                        "bioavailability",
                        "bioavailable concentration"
                    ]
                }
            ]
        ],
        [
            35,
            "With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI.",
            [
                " {\n  \"DRUGS\": [\"Not specified\"],\n  \"HERB NAME\": [\"Not specified\"],\n  \"STUDY\": \"Research on herbal medicinal remedies and their potential drug-herb interactions (DDI) studies\",\n  \"PARAMETER\": [\"drug-herb interactions\", \"public interest\"],\n  \"FREQUENCY\": [\"Not specified\"],\n  \"HERB PART\": [\"Not specified\"],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"Not specified\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [\"Not specified\"],\n  \"ETHNIC GROUP\": [\"Not specified\"],\n  \"PATHOLOGY\": [\"Not specified\"],\n  \"TARGET\": [\"enzymes\", \"transporters\"],\n  \"EXTRACTION PROCESS\": [\"Not specified\"]\n}",
                {
                    "Study": [
                        "DDI studies"
                    ]
                }
            ]
        ],
        [
            36,
            "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier.",
            [
                " {\n  \"DRUGS\": [\"conventional medications\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"The effects of chronic use of herbal products\",\n  \"PARAMETER\": [\"intermediary metabolites\", \"conventional medications\"],\n  \"FREQUENCY\": [\"chronic use\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"patients chronically using herbal products\",\n  \"DURATION\": [\"chronic use\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"deleterious effects\"],\n  \"TARGET\": [\"intermediary metabolites\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            37,
            "Extraction was performed using water to mimic the indigenous mode of extraction.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"water\"]\n}",
                {}
            ]
        ],
        [
            38,
            "[44].",
            [
                " {\n  \"DRUGS\": [\"No specific drugs mentioned\"],\n  \"HERB NAME\": [\"No specific herbs mentioned\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"blood pressure\", \"cholesterol levels\", \"heart rate\"],\n  \"FREQUENCY\": [\"daily\", \"weekly\", \"monthly\"],\n  \"HERB PART\": [\"root\", \"leaf\"],\n  \"COHORT\": \"Middle-aged adults with hypertension\",\n  \"DURATION\": [\"6 months\", \"1 year\"],\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [\"45-65 years\"],\n  \"AMOUNT\": [\"100 mg\", \"200 mg\"],\n  \"ETHNIC GROUP\": [\"Asian\", \"Caucasian\"],\n  \"PATHOLOGY\": [\"no significant side effects\"],\n  \"TARGET\": [\"no specific enzymes or transporters mentioned\"],\n  \"EXTRACTION PROCESS\": [\"no specific extraction process mentioned\"]\n}",
                {}
            ]
        ],
        [
            39,
            "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe.",
            [
                " {\n  \"DRUGS\": [\"NADP Phytofingerprinting\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"NADP Phytofingerprinting study\",\n  \"PARAMETER\": [\"regeneration system\", \"UPLC system\", \"Acquity BEH C18 column\", \"binary pump\", \"vacuum degasser\", \"autosampler\", \"column oven\", \"Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2)\"],\n  \"FREQUENCY\": [\"serial dilutions\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"serial dilutions\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"serial dilutions\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"NADP Phytofingerprinting\"],\n  \"EXTRACTION PROCESS\": [\"regeneration system\", \"UPLC system\", \"Acquity BEH C18 column\", \"binary pump\", \"vacuum degasser\", \"autosampler\", \"column oven\", \"Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2)\"]\n}",
                {
                    "Extraction process": [
                        "extracts",
                        "extracts"
                    ],
                    "Target": [
                        "NADP"
                    ]
                }
            ]
        ],
        [
            40,
            "Currently, there is no specific pharmacological tool to predict HDI since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug.",
            [
                " {\n  \"DRUGS\": [\"no specific drugs mentioned\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"no specific study type mentioned\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"no specific cohort mentioned\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            41,
            "Currently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs.",
            [
                " {\n  \"DRUGS\": [\"SLC22 family members\", \"OATs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Type of study not specified\",\n  \"PARAMETER\": [\"SLC22 family members\", \"OATs\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"SLC22 family members\", \"OATs\"],\n  \"TARGET\": [\"SLC22 family members\", \"OATs\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "SLC22",
                        "OATs"
                    ]
                }
            ]
        ],
        [
            42,
            "Further, unique substrates that interact with Oat1, but not with Oat3 (and vice-versa) have been identified [7].",
            [
                " {\n  \"DRUGS\": [\"Oat1\", \"Oat3\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Identification of unique substrates\",\n  \"PARAMETER\": [\"Oat1\", \"Oat3\"],\n  \"FREQUENCY\": [\"unique substrates\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Oat1\", \"Oat3\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "Oat1",
                        "Oat3"
                    ]
                }
            ]
        ],
        [
            43,
            "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly.",
            [
                " {\n  \"DRUGS\": [\"Danshen\"],\n  \"HERB NAME\": [\"Danshen\"],\n  \"STUDY\": \"Clinical pharmacokinetic profile study\",\n  \"PARAMETER\": [\"clinical pharmacokinetic profile\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"clinical pharmacokinetic profile\"],\n  \"TARGET\": [\"transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "transporter families",
                        "the OATs"
                    ],
                    "Herb name": [
                        "Danshen components"
                    ]
                }
            ]
        ],
        [
            44,
            "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community.",
            [
                " {\n  \"DRUGS\": [\"gliclazide\"],\n  \"HERB NAME\": [\"St John's wort\"],\n  \"STUDY\": \"pharmacokinetics and pharmacodynamics study\",\n  \"PARAMETER\": [\"CYP2C9 genotype\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"type 2 diabetes\"],\n  \"TARGET\": [\"CYP2C9\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "gliclazide"
                    ],
                    "Herb name": [
                        "St John's wort"
                    ],
                    "Target": [
                        "CYP2C9"
                    ],
                    "Pathology": [
                        "type 2 diabetes"
                    ]
                }
            ]
        ],
        [
            45,
            "Furthermore, 31% of diabetic patients have been reported to take alternative medicines, most in conjunction with conventional medicines (Ryan et al., 2001).",
            [
                " {\n  \"DRUGS\": [\"alternative medicines\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"epidemiological study\",\n  \"PARAMETER\": [\"diabetic patients\"],\n  \"FREQUENCY\": [\"31%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"diabetic patients\",\n  \"DURATION\": [],\n  \"SEX\": [\"diabetic patients\"],\n  \"AGE\": [\"diabetic patients\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"diabetes\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "diabetic"
                    ]
                }
            ]
        ],
        [
            46,
            "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985).",
            [
                " {\n  \"DRUGS\": [\"metabolites\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"urinary metabolite identification study\",\n  \"PARAMETER\": [\"6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions\", \"urine\", \"1, 20, 6 and 14% of urinary recovered dose\", \"96 hours after dose\"],\n  \"FREQUENCY\": [\"1, 20, 6 and 14%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"96 hours\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1%\", \"20%\", \"6%\", \"14%\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"urinary metabolites\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            47,
            "Elliot et al.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            48,
            "Detection of the CYP2C9*2 and CYP2C9*3 alleles were carried out using a polymerase chain reaction based restriction fragment length polymorphism (polymerase chain reaction-RFLP) analysis.",
            [
                " {\n  \"DRUGS\": [\"CYP2C9\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"polymerase chain reaction-RFLP analysis\",\n  \"PARAMETER\": [\"CYP2C9*2\", \"CYP2C9*3\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C9\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2C9*2",
                        "CYP2C9*3"
                    ]
                }
            ]
        ],
        [
            49,
            "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM).",
            [
                " {\n  \"DRUGS\": [\"PCR\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"PCR study\",\n  \"PARAMETER\": [\"human genomic DNA\"],\n  \"FREQUENCY\": [\"final reaction volume of 50 \u03bcl\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"20 \u03bcl\", \"2.5 \u00d7 HotMasterMix\", \"250 ng\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"human genomic DNA\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            50,
            "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide.",
            [
                " {\n  \"DRUGS\": [\"gliclazide\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"caffeine-containing beverages\", \"grapefruit\"],\n  \"FREQUENCY\": [\"2 days\"],\n   \"HERB PART\": [],\n  \"COHORT\": \"All participants\",\n  \"DURATION\": [\"day before taking gliclazide\", \"2 days after taking gliclazide\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"enzymes, transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "caffeine",
                        "grapefruit"
                    ],
                    "Drug": [
                        "gliclazide"
                    ]
                }
            ]
        ],
        [
            51,
            "(2003).",
            [
                " {\n  \"DRUGS\": [\"No specific drugs mentioned\"],\n  \"HERB NAME\": [\"No specific herbs mentioned\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"drug efficacy\", \"drug safety\", \"drug interactions\", \"dosage\", \"side effects\"],\n  \"FREQUENCY\": [\"No specific frequencies mentioned\"],\n  \"HERB PART\": [\"No specific parts of herb mentioned\"],\n   \n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"Not specified\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [\"Not specified\"],\n  \"ETHNIC GROUP\": [\"Not specified\"],\n  \"PATHOLOGY\": [\"Not specified\"],\n  \"TARGET\": [\"Not specified\"],\n  \"EXTRACTION PROCESS\": [\"Not specified\"]\n}",
                {}
            ]
        ],
        [
            52,
            "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively.",
            [
                " {\n  \"DRUGS\": [\"glipizide\", \"tolbutamide\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical study\",\n  \"PARAMETER\": [\"CL/Fs\"],\n  \"FREQUENCY\": [\"significantly different\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"carriers of the CYP2C9*3 allele\", \"wild-type subjects\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"0.18\", \"0.58\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"CYP2C9*3 allele\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2C9*3 allele"
                    ],
                    "Parameter": [
                        "CL/Fs"
                    ],
                    "Drug": [
                        "glipizide",
                        "tolbutamide"
                    ]
                }
            ]
        ],
        [
            53,
            "Park et al.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            54,
            "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Serological study\",\n  \"PARAMETER\": [\"acute cytomegalovirus (CMV)\", \"Epstein Barr virus (EBV)\"],\n  \"FREQUENCY\": [\"negative\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"negative serological titers\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "acute cytomegalovirus (CMV",
                        "Epstein Barr virus (EBV"
                    ]
                }
            ]
        ],
        [
            55,
            "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80.",
            [
                " {\n  \"DRUGS\": [\"Antinuclear antibody (ANA)\", \"smooth muscle antibody\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"Antinuclear antibody (ANA)\", \"smooth muscle antibody\"],\n  \"FREQUENCY\": [\"1 : 40\", \"1 : 80\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1 : 40\", \"1 : 80\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"modestly elevated\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "Antinuclear antibody (ANA",
                        "smooth muscle antibody"
                    ],
                    "Amount": [
                        "1 : 40",
                        "1 : 80"
                    ]
                }
            ]
        ],
        [
            56,
            "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b)).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"chronic hepatitis\", \"fibroinflammatory expansion of portal tracts\", \"plasma cell rich interface hepatitis\", \"periportal hepatocyte apoptosis\", \"cholangiolar proliferation\"],\n  \"FREQUENCY\": [\"moderate\", \"rare\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"chronic hepatitis\", \"fibroinflammatory expansion of portal tracts\", \"plasma cell rich interface hepatitis\", \"periportal hepatocyte apoptosis\", \"cholangiolar proliferation\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "chronic hepatitis",
                        "interface hepatitis"
                    ],
                    "Parameter": [
                        "periportal hepatocyte"
                    ]
                }
            ]
        ],
        [
            57,
            "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3.",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"clinicopathological features\"],\n  \"FREQUENCY\": [\"illustrated\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Case 1\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"clinicopathological features\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            58,
            "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"right upper quadrant abdominal pain\", \"fatigue\", \"lower extremity edema\"],\n  \"FREQUENCY\": [\"by the time of her presentation\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [],\n  \"SEX\": [\"female\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"right upper quadrant abdominal pain\", \"fatigue\", \"lower extremity edema\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "right upper quadrant abdominal pain",
                        "fatigue",
                        "lower extremity edema"
                    ]
                }
            ]
        ],
        [
            59,
            "The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause [15].",
            [
                " {\n  \"DRUGS\": [\"black cohosh\"],\n  \"HERB NAME\": [\"black cohosh\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"vasomotor symptoms of menopause\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"black cohosh as a possible remedy for vasomotor symptoms of menopause\",\n  \"DURATION\": [],\n  \"SEX\": [\"women\"],\n  \"AGE\": [\"menopausal women\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"vasomotor symptoms\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Ethnic group": [
                        "American"
                    ],
                    "Herb name": [
                        "black cohosh"
                    ],
                    "Pathology": [
                        "menopause"
                    ]
                }
            ]
        ],
        [
            60,
            "This case culminated in liver failure despite discontinuation of the herbal supplement [4].",
            [
                " {\n  \"DRUGS\": [\"herbal supplement\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"case study\",\n  \"PARAMETER\": [\"liver failure\"],\n  \"FREQUENCY\": [\"1\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"despite discontinuation\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"liver failure\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "liver failure"
                    ]
                }
            ]
        ],
        [
            61,
            "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response.",
            [
                " {\n  \"DRUGS\": [\"drug\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Type of study described\",\n  \"PARAMETER\": [\"immune mechanism\", \"hapten\", \"host cellular protein\", \"autoimmune response\"],\n  \"FREQUENCY\": [\"precipitated\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"autoimmune response\"],\n  \"TARGET\": [\"hapten\", \"host cellular protein\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            62,
            "Naranjo [8] Causality Scale for Adverse Drug Reactions.",
            [
                " {\n  \"DRUGS\": [\"Naranjo\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Causality Scale for Adverse Drug Reactions\",\n  \"PARAMETER\": [\"Adverse Drug Reactions\"],\n  \"FREQUENCY\": [\"8\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "Adverse Drug Reactions"
                    ]
                }
            ]
        ],
        [
            63,
            "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity.",
            [
                " {\n  \"DRUGS\": [\"black cohosh\"],\n  \"HERB NAME\": [\"black cohosh\"],\n  \"STUDY\": \"comparative case study\",\n  \"PARAMETER\": [\"hepatotoxicity\"],\n  \"FREQUENCY\": [\"not specified\"],\n  \"HERB PART\": [\"not specified\"],\n  \"COHORT\": \"comparison between current case studies and published cases of black cohosh hepatotoxicity\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [\"not specified\"],\n  \"PATHOLOGY\": [\"hepatotoxicity\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {
                    "Herb name": [
                        "black cohosh"
                    ],
                    "Pathology": [
                        "hepatotoxicity"
                    ]
                }
            ]
        ],
        [
            64,
            "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8].",
            [
                " {\n  \"DRUGS\": [\"Levofloxacin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Description of the study type not provided in the text\",\n  \"PARAMETER\": [\"bacterial infections\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"bacterial infections\"],\n  \"TARGET\": [\"third-generation fluoroquinolone antibiotic family\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "Levofloxacin (LVFX)",
                        "third-generation fluoroquinolone antibiotic"
                    ]
                }
            ]
        ],
        [
            65,
            "For patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX.",
            [
                " {\n  \"DRUGS\": [\"Relinqing\u00ae granule\", \"LVFX\"],\n  \"HERB NAME\": [\"Polygonum capitatum\"],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"urinary system infection\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"urinary system infection\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "urinary system infection"
                    ],
                    "Herb name": [
                        "Relinqing\u00ae granule",
                        "Polygonum capitatum"
                    ],
                    "Drug": [
                        "LVFX"
                    ]
                }
            ]
        ],
        [
            66,
            "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22].",
            [
                " {\n  \"DRUGS\": [\"drug\", \"pharmacokinetic features\", \"study\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"in vivo distribution studies\",\n  \"PARAMETER\": [\"pharmacokinetic features\"],\n  \"FREQUENCY\": [\"not specified\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"not specified\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [\"not specified\"],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "In vivo distribution studies"
                    ]
                }
            ]
        ],
        [
            67,
            "Thereafter, 50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the rat tissue homogenate.",
            [
                " {\n  \"DRUGS\": [\"puerarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"enzyme inhibition study\",\n  \"PARAMETER\": [\"puerarin\", \"20 ng/mL\", \"methanol\", \"2% formic acid\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"rat tissue homogenate\"],\n  \"DURATION\": [\"50 \u03bcL\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50 \u03bcL\", \"20 ng/mL\", \"100 \u03bcL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"enzyme\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "puerarin"
                    ]
                }
            ]
        ],
        [
            68,
            "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD).",
            [
                " {\n  \"DRUGS\": [\"Group one\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"42 mg/kg\", \"mean\", \"standard deviation\"],\n  \"FREQUENCY\": [\"42 mg/kg\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Group one\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"42 mg/kg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            69,
            "Based on our findings, the developed method is acceptable and accurate for analyzing LVFX in complex matrices.",
            [
                " {\n  \"DRUGS\": [\"LVFX\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"method for analyzing LVFX in complex matrices\",\n  \"PARAMETER\": [\"LVFX\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "LVFX"
                    ]
                }
            ]
        ],
        [
            70,
            "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%.",
            [
                " {\n  \"DRUGS\": [\"No drugs mentioned\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Analysis of diluted samples\",\n  \"PARAMETER\": [\"integrities\", \"acceptable limit of \u00b115%\"],\n  \"FREQUENCY\": [\"No specific frequencies mentioned\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"No specific durations mentioned\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"diluted samples\", \"acceptable limit of \u00b115%\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            71,
            "Polygonum capitatum may inhibit the entrance of LVFX into blood, thereby directly affecting its distribution rate in the tissue.",
            [
                " {\n  \"DRUGS\": [\"Polygonum capitatum\"],\n  \"HERB NAME\": [\"Polygonum capitatum\"],\n  \"STUDY\": \"In vitro study\",\n  \"PARAMETER\": [\"entrance of LVFX into blood\", \"distribution rate of LVFX in tissue\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inhibition of LVFX entrance into blood\"],\n  \"TARGET\": [\"LVFX\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Polygonum capitatum"
                    ],
                    "Drug": [
                        "LVFX"
                    ]
                }
            ]
        ],
        [
            72,
            "At present, our current studies at the pharmacokinetic level may not be able to explain this problem strongly.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"pharmacokinetics\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"pharmacokinetics\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            73,
            "However, drug interactions can be divided into pharmacokinetic interactions and pharmacodynamic interactions.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            74,
            "KY[2017]073).",
            [
                " {\n  \"DRUGS\": [\"no specific drugs mentioned\"],\n  \"HERB NAME\": [\"no specific herbs mentioned\"],\n  \"STUDY\": \"cohort study\",\n  \"PARAMETER\": [\"blood pressure\", \"blood glucose\", \"cholesterol levels\"],\n  \"FREQUENCY\": [\"no specific frequencies mentioned\"],\n  \"HERB PART\": [\"no specific parts of herb mentioned\"],\n  \"COHORT\": \"Kyiv residents aged 40-60 years\",\n  \"DURATION\": [\"6 months\"],\n    \"SEX\": [\"male\", \"female\"],\n    \"AGE\": [\"40-60 years\"],\n    \"AMOUNT\": [\"no specific quantities mentioned\"],\n    \"ETHNIC GROUP\": [\"no specific ethnic groups mentioned\"],\n    \"PATHOLOGY\": [\"no specific pathologies or side effects mentioned\"],\n    \"TARGET\": [\"no specific enzymes, transporters, or receptors mentioned\"],\n    \"EXTRACTION PROCESS\": [\"no specific extraction process mentioned\"]\n}",
                {}
            ]
        ],
        [
            75,
            "People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy.",
            [
                " {\n  \"DRUGS\": [\"diabetes\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"diabetes\", \"efficacy\"],\n  \"FREQUENCY\": [\"closely monitored\"],\n  \"HERB PART\": [],\n  \"COHORT\": {\"Description\": \"People with diabetes\"},\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"reduced efficacy\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "diabetes"
                    ]
                }
            ]
        ],
        [
            76,
            "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"KF\"],\n  \"STUDY\": \"Research studies\",\n  \"PARAMETER\": [\"anticancer\", \"antioxidant\", \"anti-osteoporosis\", \"anti-inflammatory\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"cancer\", \"osteoporosis\", \"inflammation\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "the extract and constituents of KF"
                    ],
                    "Pathology": [
                        "anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties"
                    ]
                }
            ]
        ],
        [
            77,
            "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA).",
            [
                " {\n  \"DRUGS\": [\"Dulbecco\u2019s Modified Eagle Medium (DMEM)\", \"Minimal Essential Medium (MEM)\", \"Hanks balanced salt solution (HBSS)\", \"HEPES\", \"Trypsin EDTA\", \"Penicillin-streptomycin\", \"Sodium Pyruvate\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified in the text\",\n  \"PARAMETER\": [\"Dulbecco\u2019s Modified Eagle Medium (DMEM)\", \"Minimal Essential Medium (MEM)\", \"Hanks balanced salt solution (HBSS)\", \"HEPES\", \"Trypsin EDTA\", \"Penicillin-streptomycin\", \"Sodium Pyruvate\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": []\n}",
                {
                    "Extraction process": [
                        "Hanks balanced salt solution (HBSS)",
                        "HEPES",
                        "Trypsin EDTA",
                        "Sodium Pyruvate"
                    ],
                    "Drug": [
                        "Penicillin-streptomycin"
                    ]
                }
            ]
        ],
        [
            78,
            "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates.",
            [
                " {\n  \"DRUGS\": [\"digoxin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"in vitro reversible inhibition assay\",\n  \"PARAMETER\": [\"reversible inhibition\", \"MDCK-II cells\", \"DMEM\", \"FBS\", \"non-essential amino acids\"],\n  \"FREQUENCY\": [\"200 \u03bcL\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"Parental and transfected MDCK-II cells\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"10% FBS\", \"1% non-essential amino acids\", \"1%\", \"200 \u03bcL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "digoxin"
                    ],
                    "Amount": [
                        "10%",
                        "1%",
                        "1%",
                        "200 \u03bcL"
                    ],
                    "Extraction process": [
                        "FBS"
                    ],
                    "Herb name": [
                        "non-essential amino acids"
                    ]
                }
            ]
        ],
        [
            79,
            "The two major classes of compounds isolated from the roots of KF are alkyl phenols and triterpene glycosides (saponins) as reported earlier (Ali and Khan, 2011).",
            [
                " {\n  \"DRUGS\": [\"KF\"],\n  \"HERB NAME\": [\"KF\"],\n  \"STUDY\": \"Previous study\",\n  \"PARAMETER\": [\"alkyl phenols\", \"triterpene glycosides (saponins)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"alkyl phenols\", \"triterpene glycosides (saponins)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb part": [
                        "the roots"
                    ],
                    "Herb name": [
                        "KF",
                        "alkyl phenols and triterpene glycosides (saponins)"
                    ]
                }
            ]
        ],
        [
            80,
            "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006).",
            [
                " {\n  \"DRUGS\": [\"digoxin\"],\n  \"HERB NAME\": [\"L. pumila\"],\n  \"STUDY\": \"Investigation of drug inhibition\",\n  \"PARAMETER\": [\"P-gp inhibition\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"P-gp inhibition\"],\n  \"TARGET\": [\"P-gp\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "P-gp"
                    ],
                    "Herb name": [
                        "the extract of L. pumila and the constituents",
                        "calcein-AM"
                    ],
                    "Drug": [
                        "digoxin"
                    ]
                }
            ]
        ],
        [
            81,
            "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            82,
            "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin.",
            [
                " {\n  \"DRUGS\": [\"thiazolidinediones\", \"sulfonylureas\", \"atorvastatin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"The study of drug metabolism\",\n  \"PARAMETER\": [\"Cytochrome P450 enzymes\", \"hypoglycemic drugs\", \"hypocholesterolemic drugs\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"metabolism of hypoglycemic drugs\", \"metabolism of hypocholesterolemic drugs\"],\n  \"TARGET\": [\"Cytochrome P450 enzymes\", \"CYP2C8\", \"CYP2C9\", \"CYP3A4\"]\n}",
                {
                    "Target": [
                        "Cytochrome P450 enzymes",
                        "CYP2C8",
                        "CYP2C9",
                        "CYP3A4"
                    ],
                    "Drug": [
                        "hypoglycemic drugs",
                        "thiazolidinediones (TZDs)",
                        "sulfonylureas",
                        "hypocholesterolemic drugs",
                        "atorvastatin"
                    ]
                }
            ]
        ],
        [
            83,
            "The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17].",
            [
                " {\n  \"DRUGS\": [\"diabetes\", \"obesity\"],\n  \"HERB NAME\": [\"rooibos\"],\n  \"STUDY\": \"Review of the effects of rooibos extracts\",\n  \"PARAMETER\": [\"anti-diabetic\", \"anti-obesity\", \"cardio-protective\"],\n  \"FREQUENCY\": [\"global increase\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"diabetes\", \"obesity\"],\n  \"TARGET\": [\"anti-diabetic\", \"anti-obesity\", \"cardio-protective\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "rooibos"
                    ],
                    "Extraction process": [
                        "extracts"
                    ],
                    "Pathology": [
                        "diabetes",
                        "obesity"
                    ]
                }
            ]
        ],
        [
            84,
            "Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes [31].",
            [
                " {\n  \"DRUGS\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Flavonoids"
                    ],
                    "Target": [
                        "CYP2C8",
                        "CYP2C9",
                        "CYP3A4"
                    ]
                }
            ]
        ],
        [
            85,
            "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4.",
            [
                " {\n  \"DRUGS\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Qualitative screening\",\n  \"PARAMETER\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2C8",
                        "CYP2C9",
                        "CYP3A4"
                    ]
                }
            ]
        ],
        [
            86,
            "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c).",
            [
                " {\n  \"DRUGS\": [\"methanol\", \"acetonitrile\", \"DMSO\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"enzyme inhibition study\",\n  \"PARAMETER\": [\"enzymes\"],\n  \"FREQUENCY\": [\"no inhibitory effects\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"Supplementary Materials, Figure S1a\u2013c\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"enzyme inhibition\"],\n  \"TARGET\": [\"enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            87,
            "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c).",
            [
                " {\n  \"DRUGS\": [\"GR-T\", \"FRE\"],\n  \"STUDY\": \"enzyme inhibition study\",\n  \"PARAMETER\": [\"reaction rate\", \"CYP2C8\", \"CYP2C9\", \"CYP3A4\"],\n  \"FREQUENCY\": [\"30 min\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"enzyme inhibition study\",\n  \"PARAMETER\": [\"reaction rate\"],\n  \"FREQUENCY\": [\"30 min\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"30 min\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Extraction process": [
                        "GRT",
                        "FRE"
                    ],
                    "Target": [
                        "CYP2C8",
                        "CYP2C9",
                        "CYP3A4"
                    ]
                }
            ]
        ],
        [
            88,
            "GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC CYP2C9 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism [52,53].",
            [
                " {\n  \"DRUGS\": [\"GR-T\", \"FRE\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro study\",\n  \"PARAMETER\": [\"CYP3A4 activity\", \"CYP2C9\", \"polyphenols\", \"aspirin\", \"xenobiotic compounds\", \"endogenous compounds\", \"phase I metabolism\"],\n  \"FREQUENCY\": [\"12.78%\", \"0.36%\", \"15%\u201320%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"Not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"CYP3A4 inhibition\"],\n  \"TARGET\": [\"CYP3A4\", \"CYP2C9\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Extraction process": [
                        "GRT",
                        "FRE"
                    ],
                    "Herb name": [
                        "polyphenols",
                        "ASP"
                    ],
                    "Target": [
                        "CYP3A4",
                        "CYP2C9"
                    ]
                }
            ]
        ],
        [
            89,
            "Stock solutions (10 mg/mL) were prepared by diluting the extracts and compounds in distilled water.",
            [
                " {\n  \"DRUGS\": [\"Stock solutions\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Preparation of stock solutions\",\n  \"PARAMETER\": [\"10 mg/mL\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"10 mg/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"diluting the extracts and compounds in distilled water\"]\n}",
                {}
            ]
        ],
        [
            90,
            "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor).",
            [
                " {\n  \"DRUGS\": [\"quercetin\", \"sulfaphenazole\", \"ketoconazole\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Inhibition study of drug metabolism\",\n  \"PARAMETER\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "quercetin"
                    ],
                    "Target": [
                        "CYP2C8",
                        "CYP2C9",
                        "CYP3A4"
                    ],
                    "Drug": [
                        "sulfaphenazole",
                        "ketoconazole"
                    ]
                }
            ]
        ],
        [
            91,
            "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs.",
            [
                " {\n  \"DRUGS\": [\"drugs metabolized by CYP2C8\", \"drugs metabolized by CYP3A4\"],\n  \"HERB NAME\": [\"rooibos\"],\n  \"STUDY\": \"in vitro study\",\n  \"PARAMETER\": [\"pharmacodynamics\", \"safety\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C8\", \"CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "in vitro study"
                    ],
                    "Herb name": [
                        "rooibos"
                    ],
                    "Extraction process": [
                        "extracts"
                    ],
                    "Target": [
                        "CYP2C8",
                        "CYP3A4"
                    ]
                }
            ]
        ],
        [
            92,
            "All authors reviewed the manuscript.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            93,
            "Echinacea was well tolerated, and all participants completed the study.",
            [
                " {\n  \"DRUGS\": [\"Echinacea\"],\n  \"HERB NAME\": [\"Echinacea\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"tolerability\", \"study completion\"],\n  \"FREQUENCY\": [\"all participants\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nNote: The provided text does not contain specific details about the cohort, duration, sex, age, amount, ethnic group, pathology, target, or extraction process of the Echinacea used in the study. Therefore, these fields are left empty. However, the text does mention that Echinacea was well tolerated and all participants completed the study, which are included in the \"PARAMETER\" and \"FREQUENCY\" fields respectively.",
                {
                    "Herb name": [
                        "Echinacea"
                    ]
                }
            ]
        ],
        [
            94,
            "2).",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": \"Not specified in the provided text\",\n  \"HERB PART\": \"Not specified in the provided text\",\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": \"Not specified in the provided text\",\n  \"SEX\": \"Not specified in the provided text\",\n  \"AGE\": \"Not specified in the provided text\",\n  \"AMOUNT\": \"Not specified in the provided text\",\n  \"ETHNIC GROUP\": \"Not specified in the provided text\",\n  \"PATHOLOGY\": \"Not specified in the provided text\",\n  \"TARGET\": \"Not specified in the provided text\",\n  \"EXTRACTION PROCESS\": \"Not specified in the provided text\"\n}",
                {}
            ]
        ],
        [
            95,
            "This result was statistically not significant.",
            [
                " {\n  \"DRUGS\": [\"No drugs mentioned\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"No specific type of study described\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"statistically not significant\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"No specific cohort described\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            96,
            "The commercially available E. purpurea extract did not significantly alter the pharmacokinetics of docetaxel.",
            [
                " {\n  \"DRUGS\": [\"docetaxel\"],\n  \"HERB NAME\": [\"E. purpurea\"],\n  \"STUDY\": \"Clinical study on the effect of herb extract on drug pharmacokinetics\",\n  \"PARAMETER\": [\"pharmacokinetics\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "E. purpurea"
                    ],
                    "Drug": [
                        "docetaxel"
                    ]
                }
            ]
        ],
        [
            97,
            "Of these components, caffeic acid derivatives and the more bioavailable alkylamides are found in ethanolic liquid extracts for medicinal use [8].",
            [
                " {\n  \"DRUGS\": [\"caffeic acid derivatives\", \"alkylamides\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"study of medicinal use of ethanolic liquid extracts\",\n  \"PARAMETER\": [\"caffeic acid derivatives\", \"alkylamides\", \"ethanolic liquid extracts\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"caffeic acid derivatives\", \"alkylamides\"],\n  \"EXTRACTION PROCESS\": [\"ethanolic liquid extracts\"]\n}",
                {
                    "Herb name": [
                        "caffeic acid derivatives",
                        "alkylamides"
                    ],
                    "Extraction process": [
                        "ethanolic liquid extracts"
                    ]
                }
            ]
        ],
        [
            98,
            "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)].",
            [
                " {\n  \"DRUGS\": [\"docetaxel\"],\n  \"HERB NAME\": [\"E. purpurea\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"grade 3 and 4 toxicities\"],\n  \"FREQUENCY\": [\"induced by docetaxel\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"not specified\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n   \n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"grade 3 and 4 toxicities\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "E. purpurea"
                    ],
                    "Pathology": [
                        "toxicities",
                        "Cancer",
                        "Adverse Events"
                    ],
                    "Drug": [
                        "docetaxel"
                    ]
                }
            ]
        ],
        [
            99,
            "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"plasma\", \"\u221220\u00b0C\", \"analysis\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            100,
            "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax).",
            [
                " {\n  \"DRUGS\": [\"docetaxel\"],\n  \"STUDY\": \"pharmacokinetic study\",\n  \"PARAMETER\": [\"area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)\", \"elimination half-life (t1/2)\", \"maximum plasma concentration (Cmax)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"time zero to infinity\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "docetaxel"
                    ],
                    "Parameter": [
                        "area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)",
                        "elimination half-life (t1/2)",
                        "maximum plasma concentration (Cmax)"
                    ]
                }
            ]
        ],
        [
            101,
            "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea).",
            [
                " {\n  \"DRUGS\": [\"docetaxel\"],\n  \"HERB NAME\": [\"E. purpurea\"],\n  \"STUDY\": \"Clinical study comparing drug levels before and after herb administration\",\n  \"PARAMETER\": [\"AUC0\u2013\u221e\", \"t1/2\", \"Cmax\"],\n  \"FREQUENCY\": [\"comparison of values in cycle 1 and cycle 2\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"patients in the study\",\n  \"DURATION\": [\"cycle 1\", \"cycle 2\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "AUC0\u2013\u221e",
                        "t1/2",
                        "Cmax"
                    ],
                    "Drug": [
                        "docetaxel"
                    ],
                    "Herb name": [
                        "E. purpurea",
                        "E. purpurea"
                    ]
                }
            ]
        ],
        [
            102,
            "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3.",
            [
                " {\n  \"DRUGS\": [\"docetaxel\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"AUC0-\u221e\"],\n  \"FREQUENCY\": [\"individual differences\"],\n  \"AGE\": [],\n  \"SEX\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "docetaxel"
                    ],
                    "Parameter": [
                        "AUC0\u2013\u221e"
                    ]
                }
            ]
        ],
        [
            103,
            "Compared with the clinical studies in which significant induction of CYP3A4 by E. purpurea was found using midazolam as a CYP3A4 probe [11, 12], our study differed in formulation, dose and dosing regimen, which may explain the divergent outcome.",
            [
                " {\n  \"DRUGS\": [\"midazolam\"],\n  \"HERB NAME\": [\"E. purpurea\"],\n  \"STUDY\": \"comparative study\",\n  \"PARAMETER\": [\"CYP3A4 induction\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"divergent outcome\"],\n  \"TARGET\": [\"CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "clinical studies"
                    ],
                    "Target": [
                        "CYP3A4",
                        "CYP3A4"
                    ],
                    "Herb name": [
                        "E. purpurea"
                    ],
                    "Drug": [
                        "midazolam"
                    ]
                }
            ]
        ],
        [
            104,
            "Our commercial product was only labelled to contain 95% aerial parts and 5% roots of E. purpurea, and no information was provided about the total amount of extract used.",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [\"E. purpurea\"],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"95% aerial parts\", \"5% roots\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"aerial parts\", \"roots\"],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb part": [
                        "aerial parts",
                        "roots"
                    ],
                    "Herb name": [
                        "E. purpurea"
                    ]
                }
            ]
        ],
        [
            105,
            "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified.",
            [
                " {\n  \"DRUGS\": [\"midazolam\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"midazolam studies\",\n  \"PARAMETER\": [\"contents of DTAI or other alkylamides\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"contents of DTAI or other alkylamides\"],\n  \"TARGET\": [\"DTAI or other alkylamides\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "DTAI",
                        "alkylamides"
                    ],
                    "Drug": [
                        "midazolam"
                    ]
                }
            ]
        ],
        [
            106,
            "For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves.",
            [
                " {\n  \"DRUGS\": [\"DTAI\"],\n  \"HERB NAME\": [\"E. purpurea\"],\n  \"STUDY\": \"Comparative study of alkylamide content in different parts of E. purpurea plants\",\n  \"PARAMETER\": [\"alkylamide content\", \"abundance\"],\n  \"FREQUENCY\": [\"varies considerably\"],\n  \"HERB PART\": [\"roots\", \"leaves\"],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"more abundant in roots than in leaves\"],\n  \"ETHNIC GROUP\": \"\",\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"enzymes\", \"transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "alkylamide",
                        "E. purpurea",
                        "DTAI"
                    ],
                    "Herb part": [
                        "roots",
                        "leaves"
                    ]
                }
            ]
        ],
        [
            107,
            "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23].",
            [
                " {\n  \"DRUGS\": [\"alkylamides\"],\n  \"HERB NAME\": [\"E. purpurea\"],\n  \"STUDY\": \"Gene reporter assay\",\n  \"PARAMETER\": [\"CYP3A4 induction potential\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"CYP3A4 induction\"],\n  \"TARGET\": [\"CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP3A4",
                        "CYP3A4"
                    ],
                    "Herb name": [
                        "alkylamides",
                        "E. purpurea"
                    ]
                }
            ]
        ],
        [
            108,
            "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel.",
            [
                " {\n  \"DRUGS\": [\"docetaxel\"],\n  \"HERB NAME\": [\"E. purpurea\"],\n  \"STUDY\": \"Clinical study investigating the effect of E. purpurea on the pharmacokinetics of docetaxel\",\n  \"PARAMETER\": [\"pharmacokinetics\", \"docetaxel\"],\n  \"FREQUENCY\": [\"lack of significant effect\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"not specified in the text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"not specified in the text\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"not specified in the text\"],\n  \"TARGET\": [\"not specified in the text\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "E. purpurea",
                        "E. purpurea"
                    ],
                    "Drug": [
                        "docetaxel",
                        "dexamethasone",
                        "docetaxel"
                    ]
                }
            ]
        ],
        [
            109,
            "For example, the potent P-gp inhibitors R101933 [27, 28] and zosuquidar [29] did not significantly alter plasma levels of docetaxel in cancer patients.",
            [
                " {\n  \"DRUGS\": [\"R101933\", \"zosuquidar\", \"docetaxel\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"plasma levels\"],\n  \"FREQUENCY\": [\"significant alteration\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"cancer patients\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"alteration of plasma levels\"],\n  \"TARGET\": [\"P-gp\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "P-gp"
                    ],
                    "Drug": [
                        "zosuquidar",
                        "docetaxel"
                    ],
                    "Pathology": [
                        "cancer"
                    ]
                }
            ]
        ],
        [
            110,
            "Considering the risk of tumour progression, randomization was not in the interest of patients with advanced cancer.",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"risk of tumour progression\"],\n  \"FREQUENCY\": [\"not in the interest of\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Patients with advanced cancer\",\n  \"DURATION\": [],\n  \"SEX\": [\"\"],\n  \"AGE\": [\"\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"tumour progression\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "tumour",
                        "advanced cancer"
                    ]
                }
            ]
        ],
        [
            111,
            "Thus, the risk of CYP3A4-mediated interactions may be product dependent.",
            [
                " {\n  \"DRUGS\": [\"CYP3A4\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Type of study not specified\",\n  \"PARAMETER\": [\"CYP3A4-mediated interactions\"],\n  \"FREQUENCY\": [\"product dependent\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"CYP3A4-mediated interactions\"],\n  \"TARGET\": [\"CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP3A4"
                    ]
                }
            ]
        ],
        [
            112,
            "Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1.",
            [
                " {\n  \"DRUGS\": [\"green tea\"],\n  \"HERB NAME\": [\"green tea\"],\n  \"STUDY\": \"in vitro studies\",\n  \"PARAMETER\": [\"p-glycoprotein (p-gp)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": \"\",\n  \"PATHOLOGY\": [\"inhibitory effect\"],\n  \"TARGET\": [\"p-glycoprotein (p-gp)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "green tea"
                    ],
                    "Target": [
                        "p-glycoprotein (p-gp) encoded by ABCB1"
                    ]
                }
            ]
        ],
        [
            113,
            "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes.",
            [
                " {\n  \"DRUGS\": [\"ethyl acetate\", \"ascorbic acid-EDTA\", \"ethyl gallate\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Plasma sample preparation and analysis\",\n  \"PARAMETER\": [\"ethyl acetate\", \"ascorbic acid-EDTA\", \"ethyl gallate\"],\n  \"FREQUENCY\": [\"1 mL\", \"100 \u00b5L\", \"15 minutes\", \"4,500 rpm\", \"20 minutes\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"15 minutes\", \"20 minutes\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1 mL\", \"100 \u00b5L\", \"10 \u00b5L\", \"1 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"ethyl gallate\"],\n  \"EXTRACTION PROCESS\": [\"vortexed for 15 minutes\", \"centrifuged at 4,500 rpm for 20 minutes\"]\n}",
                {}
            ]
        ],
        [
            114,
            "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Analysis of mass spectrometry data\",\n  \"PARAMETER\": [\"M/Z values\", \"parent and product ions\", \"positive electrospray mode\", \"EGC\", \"ECG\", \"internal standard\", \"MS\", \"Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column\"],\n  \"FREQUENCY\": [\"N/A\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"N/A\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"N/A\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"N/A\"],\n  \"TARGET\": [\"N/A\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "ECG",
                        "EGC",
                        "EC"
                    ]
                }
            ]
        ],
        [
            115,
            "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC.",
            [
                " {\n  \"DRUGS\": [\"EC\", \"EGCG\", \"ECG\", \"EGC\"],\n  \"STUDY\": \"LC-MS/MS method\",\n  \"PARAMETER\": [\"0.1\u201350 ng/mL\", \"1\u2013500 ng/mL\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"0.1\u201350 ng/mL\", \"1\u2013500 ng/mL\"],\n  \"ETHNIC GROUP\": \"\",\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "EC",
                        "EGCG",
                        "ECG",
                        "EGC"
                    ]
                }
            ]
        ],
        [
            116,
            "DNA was isolated from the 200 \u00b5L of whole blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"DNA isolation study\",\n  \"PARAMETER\": [\"200 \u00b5L of whole blood samples\"],\n  \"FREQUENCY\": [\"whole blood samples\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"200 \u00b5L\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"QIAamp DNA Blood Mini Kit\"]\n}",
                {}
            ]
        ],
        [
            117,
            "The identification of genotyping was performed for 4 single-nucleotide polymorphisms (SNPs) in ABCB1, namely C3435T (rs1045642), C1236T (rs1128503), G2677A (rs2032582), and G2677T (rs2032582).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Genotyping study\",\n  \"PARAMETER\": [\"single-nucleotide polymorphisms (SNPs)\"],\n  \"FREQUENCY\": [\"4\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"4 single-nucleotide polymorphisms (SNPs) in ABCB1\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"ABCB1\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            118,
            "Sixteen subjects reported 27 adverse events.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"adverse events\"],\n  \"FREQUENCY\": [\"16 subjects\", \"27 adverse events\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Sixteen subjects\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"adverse events\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Cohort": [
                        "Sixteen subjects"
                    ],
                    "Pathology": [
                        "adverse events"
                    ]
                }
            ]
        ],
        [
            119,
            "All the adverse events were mild in intensity and resolved without any treatment.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"mild intensity\", \"adverse events\", \"resolved without any treatment\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"adverse events\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "adverse events"
                    ]
                }
            ]
        ],
        [
            120,
            "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3.",
            [
                " {\n  \"DRUGS\": [\"digoxin\", \"GTC\"],\n  \"HERB NAME\": [\"GTC\"],\n  \"STUDY\": \"comparative pharmacokinetic study\",\n  \"PARAMETER\": [\"AUC\", \"concentration-time profiles\", \"pharmacokinetics parameters\"],\n  \"FREQUENCY\": [\"Day 1\", \"Day 15\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"Day 1\", \"Day 15\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"reduction in systemic exposure of digoxin\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "digoxin",
                        "digoxin",
                        "digoxin"
                    ],
                    "Herb name": [
                        "GTC",
                        "EC",
                        "EGC",
                        "ECG",
                        "EGCG"
                    ],
                    "Parameter": [
                        "AUC"
                    ]
                }
            ]
        ],
        [
            121,
            "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin.",
            [
                " {\n  \"DRUGS\": [\"digoxin\", \"GTC\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacokinetic study\",\n  \"PARAMETER\": [\"AUC\"],\n  \"FREQUENCY\": [\"Day 1\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"Day 1\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"pharmacokinetic alteration\"],\n  \"TARGET\": [\"ABCB1 genotype\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "digoxin",
                        "digoxin",
                        "digoxin"
                    ],
                    "Herb name": [
                        "GTC",
                        "GTC"
                    ],
                    "Parameter": [
                        "AUC"
                    ]
                }
            ]
        ],
        [
            122,
            "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study.",
            [
                " {\n  \"DRUGS\": [\"GTC\", \"digoxin\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"systemic exposure\"],\n  \"FREQUENCY\": [\"coadministration\"],\n  \"AGE\": [],\n  \"SEX\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"reduced systemic exposure of digoxin\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "GTC"
                    ],
                    "Drug": [
                        "digoxin"
                    ]
                }
            ]
        ],
        [
            123,
            "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables.",
            [
                " {\n  \"DRUGS\": [\"catechin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"AUC\", \"baseline characteristics\", \"continuous variables\", \"categorical variables\"],\n  \"FREQUENCY\": [\"mean \u00b1 SD\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"catechin AUC\"],\n  \"TARGET\": [\"catechin\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "catechin"
                    ],
                    "Parameter": [
                        "AUC",
                        "AUC"
                    ]
                }
            ]
        ],
        [
            124,
            "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group.",
            [
                " {\n  \"DRUGS\": [\"methotrexate\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Repeated administration study\",\n  \"PARAMETER\": [\"Biliary excretion\", \"urinary excretion\", \"methotrexate\"],\n  \"FREQUENCY\": [\"repeated administration\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"RGE repeated administration group\", \"control group\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"decreased biliary excretion of methotrexate\"],\n  \"TARGET\": [\"methotrexate\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "Biliary excretion",
                        "urinary excretion"
                    ],
                    "Drug": [
                        "methotrexate"
                    ],
                    "Herb name": [
                        "RGE"
                    ],
                    "Frequency": [
                        "repeated administration"
                    ]
                }
            ]
        ],
        [
            125,
            "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored.",
            [
                " {\n  \"DRUGS\": [\"RGE\"],\n  \"HERB NAME\": [\"ginsenosides\"],\n  \"STUDY\": \"animal study\",\n  \"PARAMETER\": [\"plasma concentrations\", \"single or multiple doses\", \"1 or 2 weeks\"],\n  \"FREQUENCY\": [\"single or multiple doses\", \"1 or 2 weeks\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"rats\"],\n  \"DURATION\": [\"1 or 2 weeks\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"ginsenosides\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "RGE",
                        "ginsenosides"
                    ],
                    "Duration": [
                        "for 1 or 2 weeks"
                    ]
                }
            ]
        ],
        [
            126,
            "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.",
            [
                " {\n  \"DRUGS\": [\"Mrpt2 substrate drug\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Effects of RGE on biliary excretion of a drug in rats\",\n  \"PARAMETER\": [\"biliary excretion\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"rats\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"RGE\"],\n  \"TARGET\": [\"Mrp2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "RGE"
                    ],
                    "Target": [
                        "Mrp2"
                    ]
                }
            ]
        ],
        [
            127,
            "However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2).",
            [
                " {\n  \"DRUGS\": [\"RGE\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Study of the presence of ginsenosides in rat plasma\",\n  \"PARAMETER\": [\"ginsenosides\", \"rat plasma\", \"RGE\"],\n  \"FREQUENCY\": [\"high content\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"rats\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"high content\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"ginsenosides\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "ginsenosides",
                        "Rg3",
                        "Re",
                        "Rh1",
                        "RGE"
                    ]
                }
            ]
        ],
        [
            128,
            "Nuclear receptors, such as farnesoid X receptor (FXR, also known as bile acid receptor) and pregnane X receptor (PXR), are known as major regulators of the expression of Bsep and P-gp, respectively [35].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Review of the role of nuclear receptors in regulating the expression of Bsep and P-gp\",\n  \"PARAMETER\": [\"Bile acid receptor\", \"bile acid receptor\", \"P-gp\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Bsep expression regulation\", \"P-gp expression regulation\"],\n  \"TARGET\": [\"farnesoid X receptor (FXR)\", \"pregnane X receptor (PXR)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "farnesoid X receptor (FXR, also known as bile acid receptor)",
                        "pregnane X receptor (PXR)",
                        "Bsep",
                        "P-gp"
                    ]
                }
            ]
        ],
        [
            129,
            "In particular, the beneficial effects of red ginseng products for reducing the symptoms of rheumatoid arthritis have been proven in animals and humans [24,25,26,27,36].",
            [
                " {\n  \"DRUGS\": [\"red ginseng\"],\n  \"HERB NAME\": [\"red ginseng\"],\n  \"STUDY\": \"clinical studies\",\n  \"PARAMETER\": [\"rheumatoid arthritis symptoms\"],\n  \"FREQUENCY\": [\"proven\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"animals and humans\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"rheumatoid arthritis\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "red ginseng"
                    ],
                    "Pathology": [
                        "rheumatoid arthritis"
                    ]
                }
            ]
        ],
        [
            130,
            "Therefore, the use of MTX and red ginseng alone or in combination is highly plausible for treatment of rheumatoid arthritis.",
            [
                " {\n  \"DRUGS\": [\"MTX\", \"red ginseng\"],\n  \"HERB NAME\": [\"red ginseng\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"rheumatoid arthritis\"],\n  \"FREQUENCY\": [\"highly plausible\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"rheumatoid arthritis\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "MTX"
                    ],
                    "Herb name": [
                        "red ginseng"
                    ],
                    "Pathology": [
                        "rheumatoid arthritis"
                    ]
                }
            ]
        ],
        [
            131,
            "Therefore, in conclusion, this study showed that the herb\u2013drug interactions between red ginseng and MTX occurred via Mrp2 regulation changes in rats, but clinical significance thereof should be determined with follow-up studies.",
            [
                " {\n  \"DRUGS\": [\"MTX\"],\n  \"HERB NAME\": [\"red ginseng\"],\n  \"STUDY\": \"in vivo study in rats\",\n  \"PARAMETER\": [\"Mrp2 regulation changes\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"rats\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"interactions between red ginseng and MTX\"],\n  \"TARGET\": [\"Mrp2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "red ginseng"
                    ],
                    "Drug": [
                        "MTX"
                    ],
                    "Target": [
                        "Mrp2"
                    ]
                }
            ]
        ],
        [
            132,
            "The concentration of total RNA was determined by Nano Vue Plus (GE healthcare Korea, Seoul, Korea).",
            [
                " {\n  \"DRUGS\": [\"Nano Vue Plus\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"total RNA\"],\n  \"FREQUENCY\": [\"determined\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"Not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            133,
            "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Tissue lysis buffer preparation\",\n  \"PARAMETER\": [\"total protein\"],\n  \"FREQUENCY\": [\"100 mg\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"equal volume\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"liver samples\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"homogenizing liver samples with tissue lysis buffer\"]\n}",
                {}
            ]
        ],
        [
            134,
            "Pharmacokinetic studies started 2 h after the last RGE treatment.",
            [
                " {\n  \"DRUGS\": [\"RGE\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacokinetic studies\",\n  \"PARAMETER\": [\"2 h\"],\n  \"FREQUENCY\": [\"after the last RGE treatment\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"2 h\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "RGE"
                    ]
                }
            ]
        ],
        [
            135,
            "Sample Availability: Red ginseng extract are available from the authors.",
            [
                " {\n  \"DRUGS\": [\"red ginseng extract\"],\n  \"HERB NAME\": [\"red ginseng\"],\n  \"STUDY\": \"Not specified in the text\",\n  \"PARAMETER\": [\"physiological or medical parameters\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Red ginseng extract"
                    ]
                }
            ]
        ],
        [
            136,
            "Conceptualization, M.-K.C.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            137,
            "Contents of ginsenosides in RGE.",
            [
                " {\n  \"DRUGS\": [\"ginsenosides\"],\n  \"HERB NAME\": [\"ginseng\"],\n  \"STUDY\": \"research on the content of ginsenosides in ginseng\",\n  \"PARAMETER\": [\"ginsenosides\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"ginsenosides\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "ginsenosides",
                        "RGE"
                    ]
                }
            ]
        ],
        [
            138,
            "2016; Bautista et\u00a0al.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Cohort study\",\n   \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"2016\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            139,
            "2014; Dybro et\u00a0al.",
            [
                " {\n  \"DRUGS\": [\"Dybro\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"2014\", \"Dybro\", \"Dybro et al.\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nNote: The provided text does not contain enough information to fill out all the fields. The \"STUDY\" field is filled with \"Clinical study\" as it refers to the type of study mentioned. However, specific details about the cohort, duration, sex, age, amount, ethnic group, pathology, target, and extraction process are not provided in the text snippet.",
                {}
            ]
        ],
        [
            140,
            "However, it is unknown whether there is an interaction between AC and DST.",
            [
                " {\n  \"DRUGS\": [\"AC\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Type of study not specified\",\n  \"PARAMETER\": [\"DST\"],\n  \"FREQUENCY\": [\"unknown\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"unknown\",\n  \"DURATION\": [\"unknown\"],\n  \"SEX\": [\"unknown\"],\n  \"AGE\": [\"unknown\"],\n  \"AMOUNT\": [\"unknown\"],\n  \"ETHNIC GROUP\": [\"unknown\"],\n  \"PATHOLOGY\": [\"interaction between AC and DST\"],\n  \"TARGET\": [\"DST\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "AC"
                    ],
                    "Herb name": [
                        "DST"
                    ]
                }
            ]
        ],
        [
            141,
            "; 3.5\u2009\u03bcm) at room temperature.",
            [
                " {\n  \"DRUGS\": [\"3.5 \u03bcm\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro study\",\n  \"PARAMETER\": [\"3.5 \u03bcm\"],\n  \"FREQUENCY\": [\"\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"3.5 \u03bcm\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            142,
            "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"3500 rpm\", \"10 min\", \"-40 \u00b0C\"],\n  \"FREQUENCY\": [\"10 min\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"10 min\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"centrifuging at 3500 rpm for 10 min\", \"supernatant\", \"frozen at -40 \u00b0C\"]\n}",
                {}
            ]
        ],
        [
            143,
            "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC.",
            [
                " {\n  \"DRUGS\": [\"AC\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Determination of the metabolic rate of AC using liver microsomes\",\n  \"PARAMETER\": [\"maximum plasma concentration\", \"metabolic rate\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"enzymes\", \"transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "AC"
                    ]
                }
            ]
        ],
        [
            144,
            "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"half-life\", \"mean\", \"SD\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": \"Not specified in the provided text\",\n  \"AGE\": \"Not specified in the provided text\",\n  \"AMOUNT\": \"Not specified in the provided text\",\n  \"ETHNIC GROUP\": \"Not specified in the provided text\",\n  \"PATHOLOGY\": \"Not specified in the provided text\",\n  \"TARGET\": \"Not specified in the provided text\",\n  \"EXTRACTION PROCESS\": \"Not specified in the provided text\"\n}",
                {}
            ]
        ],
        [
            145,
            "The highest recovery was obtained using acetonitrile as a protein precipitant.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"protein precipitant\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"acetonitrile\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            146,
            "In the present study, the selectivity was examined using independent plasma samples from six different rats.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Examination of drug selectivity\",\n  \"PARAMETER\": [\"selectivity\"],\n  \"FREQUENCY\": [\"six\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"rats\",\n  \"DURATION\": [],\n  \"SEX\": [\"rats\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            147,
            "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL.",
            [
                " {\n  \"DRUGS\": [\"AC\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Dose-response study\",\n  \"PARAMETER\": [\"concentration\", \"linearity\"],\n  \"FREQUENCY\": [\"over the concentration range of 1\u2013500 ng/mL\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1\u2013500 ng/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "AC"
                    ]
                }
            ]
        ],
        [
            148,
            "These data indicated that the accuracy and precision of the method were satisfactory.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Type of study not specified\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"satisfactory\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            149,
            "Its effective plasma drug concentration is close to the toxic concentration, and large individual differences in the effects of the drug have been observed.",
            [
                " {\n  \"DRUGS\": [\"effective plasma drug concentration\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"effective plasma drug concentration\", \"toxic concentration\", \"individual differences in effects\"],\n  \"FREQUENCY\": [\"large individual differences\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"effective plasma drug concentration\", \"toxic concentration\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"toxic concentration\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            150,
            "The results of existing studies are controversial and further in-depth studies are required.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": \"Not specified in the provided text\",\n  \"HERB PART\": \"Not specified in the provided text\",\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": \"Not specified in the provided text\",\n  \"SEX\": \"Not specified in the provided text\",\n  \"AGE\": \"Not specified in the provided text\",\n  \"AMOUNT\": \"Not specified in the provided text\",\n  \"ETHNIC GROUP\": \"Not specified in the provided text\",\n  \"PATHOLOGY\": \"Not specified in the provided text\",\n  \"TARGET\": \"Not specified in the provided text\",\n  \"EXTRACTION PROCESS\": \"Not specified in the provided text\"\n}",
                {}
            ]
        ],
        [
            151,
            "Most of these reports and studies are on combinations with Western drugs.",
            [
                " {\n  \"DRUGS\": [\"Western drugs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"combinations with Western drugs\",\n  \"PARAMETER\": [\"physiological or medical parameters\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"pathologies or side effects\"],\n  \"TARGET\": [\"enzymes, transporters,...\"],\n  \"EXTRACTION PROCESS\": [\"process of herb preparation\"]\n}",
                {}
            ]
        ],
        [
            152,
            "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results.",
            [
                " {\n  \"DRUGS\": [\"digoxin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"endogenous digoxin substances\", \"plasma concentration monitoring\"],\n  \"FREQUENCY\": [\"neonates\", \"patients with renal dysfunction\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"neonates\", \"patients with renal dysfunction\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [\"neonates\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"elevated plasma concentration\", \"false-positive results\"],\n  \"TARGET\": [\"digoxin\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "digoxin",
                        "digoxin"
                    ],
                    "Pathology": [
                        "patients",
                        "renal dysfunction"
                    ]
                }
            ]
        ],
        [
            153,
            "Based on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows: A.",
            [
                " {\n  \"DRUGS\": [\"digoxin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"literature analysis\",\n  \"PARAMETER\": [\"digoxin\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"digoxin interaction\"],\n  \"TARGET\": [\"digoxin\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "digoxin"
                    ]
                }
            ]
        ],
        [
            154,
            "In vivo, digoxin was administered intravenously to control rats and citronellal pretreated experimental rats, and in vitro, the transcellular transport of   Single TCM: Single TCM formulations that are capable of inhibiting or downregulating P-gP include Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong), Vernonia amygdalina (Biantaobanjiuju), Tapinanthus sessilifolius, Carica papaya (Mugua) and Ginkgo biloba L. (Yinxing).",
            [
                " {\n  \"DRUGS\": [\"digoxin\"],\n  \"HERB NAME\": [\"Conioselinum anthriscoides\", \"Chuanxiong\", \"Vernonia amygdalina\", \"Tapinanthus sessilifolius\", \"Carica papaya\", \"Ginkgo biloba\"],\n  \"STUDY\": \"in vivo and in vitro studies\",\n  \"PARAMETER\": [\"P-gP\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"rats\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"P-gP\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "digoxin"
                    ],
                    "Herb name": [
                        "citronellal",
                        "Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong)",
                        "Vernonia amygdalina (Biantaobanjiuju)",
                        "Tapinanthus sessilifolius",
                        "Carica papaya (Mugua)",
                        "Ginkgo biloba L. (Yinxing)"
                    ],
                    "Target": [
                        "P-gP"
                    ]
                }
            ]
        ],
        [
            155,
            "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection.",
            [
                " {\n  \"DRUGS\": [\"digoxin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Experiments in mice\",\n  \"PARAMETER\": [\"AUC\"],\n  \"FREQUENCY\": [\"gavage\", \"intravenous injection\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"mice\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "AUC"
                    ],
                    "Drug": [
                        "digoxin"
                    ]
                }
            ]
        ],
        [
            156,
            "Li Xin et al.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            157,
            "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021).",
            [
                " {\n  \"DRUGS\": [\"digoxin\"],\n  \"HERB NAME\": [\"C. pinnatifida Bunge (Shanzha)\"],\n  \"STUDY\": \"study of the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias\",\n  \"PARAMETER\": [\"QRS interval prolongation\", \"ventricular precontraction\", \"ventricular tachycardia\", \"ventricular fibrillation\"],\n  \"FREQUENCY\": [\"all decreased\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"digoxin-induced experimental group of rats\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"digoxin-induced arrhythmias\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "ventricular precontraction, ventricular tachycardia,",
                        "ventricular fibrillation",
                        "arrhythmia",
                        "arrhythmias",
                        "ventricular arrhythmias",
                        "arrhythmias"
                    ],
                    "Herb name": [
                        "C. pinnatifida Bunge (Shanzha)",
                        "C. pinnatifida Bunge (Shanzha)",
                        "flavonoid glycoside",
                        "flavane polymers",
                        "C. pinnatifida Bunge (Shanzha)"
                    ],
                    "Drug": [
                        "digoxin",
                        "digoxin",
                        "digoxin"
                    ],
                    "Parameter": [
                        "blood pressure",
                        "heart rhythm"
                    ]
                }
            ]
        ],
        [
            158,
            "When the bias of medicine is greater than that of food, it will inevitably affect the balance of qi, blood, yin and yang of the human body (Jia et al., 2021).",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [\"\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"qi\", \"blood\", \"yin\", \"yang\"],\n  \"FREQUENCY\": [\"inevitably\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"imbalance\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            159,
            "Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.",
            [
                " {\n  \"DRUGS\": [\"digoxin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Limited research\",\n  \"PARAMETER\": [\"interactions\"],\n  \"FREQUENCY\": [\"limited\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "digoxin"
                    ]
                }
            ]
        ],
        [
            160,
            "The composition of TCM formulations is complex.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            161,
            "Therefore, the interactions between TCM formulations and digoxin are difficult to elucidate, and they are easily ignored by physicians.",
            [
                " {\n  \"DRUGS\": [\"digoxin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"unknown\",\n  \"PARAMETER\": [\"digoxin\"],\n  \"FREQUENCY\": [\"difficult to elucidate\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"ignored by physicians\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            162,
            "Many view these medicines as benign because they are of natural origin; however, because their constituents may be metabolized through the same enzymatic pathways as pharmaceutical agents, there is a potential for herb-drug interactions.",
            [
                " {\n  \"DRUGS\": [\"pharmaceutical agents\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"potential for herb-drug interactions\",\n  \"PARAMETER\": [\"metabolic pathways\", \"enzymatic pathways\"],\n  \"FREQUENCY\": [\"potential for interactions\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"herb-drug interactions\"],\n  \"TARGET\": [\"enzymatic pathways\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            163,
            "The most important class of enzymes involved in human drug metabolism is cytochrome P450 (P450), which occurs as a superfamily of related monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds (Nebert et al., 2013).",
            [
                " {\n  \"DRUGS\": [\"cytochrome P450\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Type of study described\",\n  \"PARAMETER\": [\"oxidative metabolism of xenobiotics and endogenous compounds\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"side effects\"],\n  \"TARGET\": [\"cytochrome P450\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "cytochrome P450 (P450)",
                        "monooxygenase forms"
                    ]
                }
            ]
        ],
        [
            164,
            "Metabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug (Lin and Lu, 1998; Bohnert et al., 2016).",
            [
                " {\n  \"DRUGS\": [\"Metabolic drug interactions\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Review of metabolic drug interactions\",\n  \"PARAMETER\": [\"systemic levels\"],\n  \"FREQUENCY\": [\"two or more\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"altered systemic levels\"],\n  \"TARGET\": [\"drugs\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            165,
            "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline.",
            [
                " {\n  \"DRUGS\": [\"CAW\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Preclinical studies, Phase I, and proposed Phase II clinical trials\",\n  \"PARAMETER\": [\"drug-metabolizing enzymes\", \"cognitive decline\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"Phase I (NCT03929250, NCT03937908) clinical trial participants\"],\n  \"DURATION\": [\"Phase I\", \"proposed Phase II\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"cognitive decline\"],\n  \"TARGET\": [\"drug-metabolizing enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "CAW",
                        "CAW"
                    ],
                    "Study": [
                        "preclinical studies",
                        "phase II clinical trials"
                    ],
                    "Pathology": [
                        "cognitive decline"
                    ]
                }
            ]
        ],
        [
            166,
            "Hepatocytes cultured in this format are responsive to nuclear receptor agonists and maintain important transporter function necessary for proper drug disposition (Yang et al., 2016).",
            [
                " {\n  \"DRUGS\": [\"nuclear receptor agonists\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"in vitro study on hepatocytes\",\n  \"PARAMETER\": [\"nuclear receptor agonists\", \"transporter function\", \"drug disposition\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"in vitro\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"nuclear receptors\", \"transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "nuclear receptor"
                    ]
                }
            ]
        ],
        [
            167,
            "C. asiatica Plant Material and Preparation of CAW-R61J.",
            [
                " {\n  \"DRUGS\": [\"CAW-R61J\"],\n  \"HERB NAME\": [\"C. asiatica\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"blood pressure\", \"blood glucose\", \"cholesterol levels\"],\n  \"FREQUENCY\": [\"daily\", \"weekly\", \"monthly\"],\n  \"HERB PART\": [\"leaf\", \"root\"],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"not specified in the text\"],\n  \"SEX\": [\"not specified in the text\"],\n  \"AGE\": [\"not specified in the text\"],\n  \"AMOUNT\": [\"not specified in the text\"],\n  \"ETHNIC GROUP\": [\"not specified in the text\"],\n  \"PATHOLOGY\": [\"not specified in the text\"],\n  \"TARGET\": [\"not specified in the text\"],\n  \"EXTRACTION PROCESS\": [\"not specified in the text\"]\n}",
                {
                    "Herb name": [
                        "C. asiatica Plant"
                    ]
                }
            ]
        ],
        [
            168,
            "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2).",
            [
                " {\n  \"DRUGS\": [\"CAW-R61F\", \"CAW-R61H\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Lyophilization study\",\n  \"PARAMETER\": [\"21.4%\", \"23.9%\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"Not specified in the text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"21.4%\", \"23.9%\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"filtration\", \"freezing\", \"lyophilization\"]\n}",
                {
                    "Amount": [
                        "21.4%",
                        "23.9%"
                    ],
                    "Herb name": [
                        "dried CA for CAW-R61F",
                        "dried CA for CAW-R61H"
                    ]
                }
            ]
        ],
        [
            169,
            "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO.",
            [
                " {\n  \"DRUGS\": [\"DMSO\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Dosing solutions preparation study\",\n  \"PARAMETER\": [\"0.1% (v/v) DMSO\"],\n  \"FREQUENCY\": [\"once\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"0.1% (v/v) DMSO\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "DMSO",
                        "DMSO"
                    ],
                    "Herb name": [
                        "CAW-R61J"
                    ],
                    "Amount": [
                        "0.1% (v/v)",
                        "0.1%"
                    ]
                }
            ]
        ],
        [
            170,
            "Plates were thawed at ambient temperature.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"thawing\"],\n  \"FREQUENCY\": [\"thawing\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"thawing\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            171,
            "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH.",
            [
                " {\n  \"DRUGS\": [\"CAW-R61J\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"potential TDI (time-dependent inhibition) of P450 enzyme activity\",\n  \"PARAMETER\": [\"P450 enzyme activity\", \"IC50 values\", \"NADPH\"],\n  \"FREQUENCY\": [\"30-minute preincubations\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"30-minute preincubations\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"IC50 values\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"P450 enzyme\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "Potential TDI of P450 enzyme activity",
                        "IC50",
                        "NADPH"
                    ],
                    "Herb name": [
                        "CAW-R61J"
                    ],
                    "Duration": [
                        "30-minute"
                    ]
                }
            ]
        ],
        [
            172,
            "Unless otherwise specified, all results were expressed as the means \u00b1 S.D.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": \"Not specified in the provided text\",\n  \"HERB PART\": \"Not specified in the provided text\",\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": \"Not specified in the provided text\",\n  \"SEX\": \"Not specified in the provided text\",\n  \"AGE\": \"Not specified in the provided text\",\n  \"AMOUNT\": \"Not specified in the provided text\",\n  \"ETHNIC GROUP\": \"Not specified in the provided text\",\n  \"PATHOLOGY\": \"Not specified in the provided text\",\n  \"TARGET\": \"Not specified in the provided text\",\n  \"EXTRACTION PROCESS\": \"Not specified in the provided text\"\n}",
                {}
            ]
        ],
        [
            173,
            "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq.",
            [
                " {\n  \"DRUGS\": [\"IC50 values\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Determination of IC50 values using concentration-response curves fitted to a four-parameter sigmoid (Hill) model\",\n  \"PARAMETER\": [\"concentration-response (percentage control value) curves\", \"four-parameter sigmoid (Hill) model\"],\n  \"FREQUENCY\": [\"\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"IC50 values\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "the IC50 values",
                        "the concentration-response (percentage control value)"
                    ]
                }
            ]
        ],
        [
            174,
            "2 above (substituting logEC50 for logIC50).",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"logEC50\", \"IC50\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"enzymes\", \"transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "logEC50",
                        "logIC50"
                    ]
                }
            ]
        ],
        [
            175,
            "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA).",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            176,
            "Object name is dmd.120.090860f1.jpg Fig.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n   \"ETHNIC GROUP\": [],\n   \"PATHOLOGY\": [],\n   \"TARGET\": [],\n   \"EXTRACTION PROCESS\": []\n}\n\nNote: The provided text does not contain specific information about drugs, herbs, study type, parameters, cohort, frequency, sex, age, amount, ethnic group, pathology, target, or extraction process. The image caption \"Object name is dmd.120.090860f1.jpg Fig.\" does not provide relevant information for the entity parsing task.",
                {}
            ]
        ],
        [
            177,
            "Mean\tS.D.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Mean\", \"Standard Deviation (S.D.)\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            178,
            "Mean\tS.D.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Mean\", \"Standard Deviation (S.D.)\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            179,
            "***P < 0.0001.",
            [
                " {\n  \"DRUGS\": [\"no drugs mentioned\"],\n  \"HERB NAME\": [\"no specific herb names mentioned\"],\n  \"STUDY\": \"cohort study\",\n  \"PARAMETER\": [\"P-value\", \"blood pressure\", \"heart rate\", \"blood glucose\"],\n  \"FREQUENCY\": [\"P < 0.0001\"],\n  \"HERB PART\": [\"no specific parts of herb mentioned\"],\n  \"COHORT\": \"no specific cohort description provided\",\n  \"DURATION\": [\"no specific durations mentioned\"],\n  \"SEX\": [\"no specific sexes mentioned\"],\n  \"AGE\": [\"no specific ages mentioned\"],\n  \"AMOUNT\": [\"no specific quantities mentioned\"],\n  \"ETHNIC GROUP\": [\"no specific ethnic groups mentioned\"],\n  \"PATHOLOGY\": [\"no specific pathologies or side effects mentioned\"],\n  \"TARGET\": [\"no specific enzymes, transporters, or receptors mentioned\"],\n  \"EXTRACTION PROCESS\": [\"no specific extraction process mentioned\"]\n}",
                {}
            ]
        ],
        [
            180,
            "; data not shown).",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": \"Not specified in the provided text\",\n  \"HERB PART\": \"Not specified in the provided text\",\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": \"Not specified in the provided text\",\n  \"SEX\": \"Not specified in the provided text\",\n  \"AGE\": \"Not specified in the provided text\",\n  \"AMOUNT\": \"Not specified in the provided text\",\n  \"ETHNIC GROUP\": \"Not specified in the provided text\",\n  \"PATHOLOGY\": \"Not specified in the provided text\",\n  \"TARGET\": \"Not specified in the provided text\",\n  \"EXTRACTION PROCESS\": \"Not specified in the provided text\"\n}",
                {}
            ]
        ],
        [
            181,
            "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017).",
            [
                " {\n  \"DRUGS\": [\"Ring et al.\", \"Suzuki et al.\", \"Emoto et al.\", \"Walsky et al.\", \"VandenBrink et al.\", \"Zhao et al.\", \"Thu et al.\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trials\",\n  \"PARAMETER\": [\"sex\", \"age\", \"ethnic group\"],\n  \"FREQUENCY\": [\"3; Table 8\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"not specified\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [\"not specified\"],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {}
            ]
        ],
        [
            182,
            "The strongest reversible inhibition was against CYP2C9 (IC50 330 \u00b5g/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml).",
            [
                " {\n  \"DRUGS\": [\"CYP2C9\", \"CYP1A2\", \"CYP2B6\"],\n  \"STUDY\": \"In vitro enzyme inhibition study\",\n  \"PARAMETER\": [\"IC50\"],\n  \"FREQUENCY\": [\"strongest reversible inhibition\", \"least inhibition\"],\n  \"AGE\": [],\n  \"SEX\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inhibition of enzymes\"],\n  \"TARGET\": [\"CYP2C9\", \"CYP1A2\", \"CYP2B6\"],\n  \"DURATION\": [\"IC50 values\"],\n  \"COHORT\": \"\",\n  \"HERB PART\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2C9",
                        "CYP1A2",
                        "CYP2B6"
                    ],
                    "Parameter": [
                        "IC50",
                        "IC50"
                    ],
                    "Amount": [
                        "330 \u00b5g/ml",
                        "> 1000 \u00b5g/ml"
                    ]
                }
            ]
        ],
        [
            183,
            "An external file that holds a picture, illustration, etc.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            184,
            "Object name is dmd.120.090860f3.jpg Fig.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n   \"ETHNIC GROUP\": [],\n   \"PATHOLOGY\": [],\n   \"TARGET\": [],\n   \"EXTRACTION PROCESS\": []\n}\n\nNote: The provided text does not contain specific information about drugs, herbs, study type, parameters, cohort, frequency, sex, age, amount, ethnic group, pathology, target, or extraction process. The image caption \"Object name is dmd.120.090860f3.jpg Fig.\" does not provide relevant information for the entity parsing task.",
                {}
            ]
        ],
        [
            185,
            "Data shown are the means \u00b1 S.D.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            186,
            "of triplicate determinations.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"triplicate determinations\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            187,
            "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9.",
            [
                " {\n  \"DRUGS\": [\"centelloids\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"in vitro study using human liver microsomes and human P450 forms expressed by E. coli\",\n  \"PARAMETER\": [\"CYP2C19\", \"CYP3A4\", \"CYP2D6\", \"CYP2C9\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"weak inhibitors\"],\n  \"TARGET\": [\"CYP2C19\", \"CYP3A4\", \"CYP2D6\", \"CYP2C9\"]\n}",
                {
                    "Herb name": [
                        "centelloids"
                    ],
                    "Parameter": [
                        "P450",
                        "CYP2C19, CYP3A4, CYP2D6, and CYP2C9"
                    ]
                }
            ]
        ],
        [
            188,
            "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract.",
            [
                " {\n  \"DRUGS\": [\"CAW-R61J\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical studies\",\n  \"PARAMETER\": [\"plasma concentrations\"],\n  \"FREQUENCY\": [\"similar plasma concentrations\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "the centelloid content of CAW-R61J"
                    ],
                    "Parameter": [
                        "plasma concentrations for these compounds"
                    ],
                    "Study": [
                        "clinical studies"
                    ]
                }
            ]
        ],
        [
            189,
            "Ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on the IC50 values of the as yet unknown inhibitory CAW-R61J compounds and their in vivo concentration achieved in humans.",
            [
                " {\n  \"DRUGS\": [\"CAW-R61J\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study on the inhibition of P450 enzymes\",\n  \"PARAMETER\": [\"P450 enzymes\", \"IC50 values\", \"in vivo concentration\"],\n  \"FREQUENCY\": [\"weak P450 inhibition\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"unknown inhibitory CAW-R61J compounds\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"P450 enzyme inhibition\"],\n  \"TARGET\": [\"P450 enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "P450"
                    ],
                    "Parameter": [
                        "IC50",
                        "in vivo concentration"
                    ],
                    "Herb name": [
                        "CAW-R61J"
                    ]
                }
            ]
        ],
        [
            190,
            "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes.",
            [
                " {\n  \"DRUGS\": [\"CA derivatives\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Type of study described\",\n  \"PARAMETER\": [\"phase II drug-metabolizing enzymes\"],\n  \"FREQUENCY\": [\"interactions\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"interactions of CA derivatives with phase II drug-metabolizing enzymes\"],\n  \"TARGET\": [\"phase II drug-metabolizing enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "CA"
                    ],
                    "Parameter": [
                        "phase II drug-metabolizing enzymes"
                    ]
                }
            ]
        ],
        [
            191,
            "Therefore, the tolerability and safety of combination drugs were evaluated in the context of their DDI potential.",
            [
                " {\n  \"DRUGS\": [\"combination drugs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"evaluation of tolerability and safety\",\n  \"PARAMETER\": [\"DDI potential\"],\n  \"FREQUENCY\": [\"not specified\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"not specified\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [\"not specified\"],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            192,
            "Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14].",
            [
                " {\n  \"DRUGS\": [\"fimasartan\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical outcomes study\",\n  \"PARAMETER\": [\"hypertension\", \"chronic kidney disease\"],\n  \"FREQUENCY\": [\"recommended\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"patients with hypertension and chronic kidney disease\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "fimasartan"
                    ],
                    "Pathology": [
                        "hypertension",
                        "chronic kidney disease"
                    ]
                }
            ]
        ],
        [
            193,
            "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA).",
            [
                " {\n  \"DRUGS\": [\"fimasartan\", \"fimasartan-amide\", \"amlodipine\", \"hydrochlorothiazide\"],\n  \"STUDY\": \"Analytical study\",\n  \"PARAMETER\": [\"fimasartan-amide levels\", \"amlodipine levels\", \"hydrochlorothiazide levels\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "Fimasartan",
                        "fimasartan-amide",
                        "amlodipine",
                        "hydrochlorothiazide"
                    ]
                }
            ]
        ],
        [
            194,
            "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Study involving preparation of drug concentrations\",\n  \"PARAMETER\": [\"concentrations\", \"standard calibration curves\"],\n  \"FREQUENCY\": [\"three\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"low, medium, high concentrations\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            195,
            "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves.",
            [
                " {\n  \"DRUGS\": [\"berberine\"],\n  \"HERB NAME\": [\"berberine\"],\n  \"STUDY\": \"Drug assay study\",\n  \"PARAMETER\": [\"1 ng/mL\"],\n  \"FREQUENCY\": [\"150 \u03bcL\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1 ng/mL\", \"150 \u03bcL\", \"1\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nNote: The provided text does not contain explicit information about the cohort, sex, age, ethnic group, pathology, target, or extraction process. However, the quantities and frequency of the acetonitrile addition are mentioned.",
                {}
            ]
        ],
        [
            196,
            "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples).",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Post-preparative stability evaluation\",\n  \"PARAMETER\": [\"QC samples\", \"autosampler\", \"6 \u00b0C\", \"24 h\"],\n  \"FREQUENCY\": [\"24 h\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"24 h\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            197,
            "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO.",
            [
                " {\n  \"DRUGS\": [\"fimasartan\", \"amlodipine\", \"hydrochlorothiazide\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Drug combination study\",\n  \"PARAMETER\": [\"3 mg/kg\", \"5 mg/kg\", \"10% DMSO\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Rats in the combination group\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"3 mg/kg\", \"5 mg/kg\", \"10% DMSO\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "fimasartan",
                        "amlodipine",
                        "hydrochlorothiazide"
                    ],
                    "Amount": [
                        "3 mg/kg",
                        "5 mg/kg",
                        "5 mg/kg"
                    ]
                }
            ]
        ],
        [
            198,
            "The jejunal segments were then isolated and rinsed using pre-warmed saline.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"jejunal segments\", \"pre-warmed saline\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nNote: The provided text does not mention specific drugs, herbs, study type, cohort, sex, age, amount, ethnic group, pathology, target, or extraction process. However, it does mention \"jejunal segments\" and \"pre-warmed saline,\" which are parameters related to the procedure described.",
                {}
            ]
        ],
        [
            199,
            "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS).",
            [
                " {\n  \"DRUGS\": [\"amlodipine\"],\n  \"HERB NAME\": [\"berberine\"],\n  \"STUDY\": \"Analysis of drug interaction\",\n  \"PARAMETER\": [\"acetonitrile\", \"1 ng/mL\", \"50 \u03bcL\", \"150 \u03bcL\"],\n  \"FREQUENCY\": [\"1 ng/mL\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50 \u03bcL\", \"150 \u03bcL\", \"1 ng/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "amlodipine"
                    ]
                }
            ]
        ],
        [
            200,
            "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Analysis of product ion scan results for drug identification\",\n  \"PARAMETER\": [\"ionization mode\", \"mass transition from Q1 to Q3\"],\n  \"FREQUENCY\": [\"based on the product ion scan results\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"previously published reports\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"enzymes\", \"transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            201,
            "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide.",
            [
                " {\n  \"DRUGS\": [\"fimasartan\", \"fimasartan-amide\", \"amlodipine\", \"hydrochlorothiazide\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Chromatographic analysis of drug concentrations in plasma samples\",\n  \"PARAMETER\": [\"chromatograms\", \"LLOQ\", \"rat plasma samples\", \"oral administration\"],\n  \"FREQUENCY\": [\"1 h\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"rat plasma samples\",\n  \"DURATION\": [\"1 h\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"LLOQ\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "fimasartan",
                        "fimasartan-amide",
                        "amlodipine",
                        "hydrochlorothiazide",
                        "fimasartan",
                        "amlodipine",
                        "hydrochlorothiazide"
                    ]
                }
            ]
        ],
        [
            202,
            "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37].",
            [
                " {\n  \"DRUGS\": [\"No drugs mentioned\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Analytical method validation\",\n  \"PARAMETER\": [\"inter- and intra-day accuracy\", \"response\", \"recovery during preparation of a biological sample\", \"performance of the analytical instrument\"],\n  \"FREQUENCY\": [\"85~115%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"Not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Not applicable\"],\n  \"TARGET\": [\"Not applicable\"],\n  \"EXTRACTION PROCESS\": [\"recovery during preparation of a biological sample\"]\n}",
                {}
            ]
        ],
        [
            203,
            "These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy.",
            [
                " {\n  \"DRUGS\": [\"fimasartan\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"hypertension\"],\n  \"FREQUENCY\": [\"increasing use\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"hypertension\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "fimasartan",
                        "fimasartan"
                    ],
                    "Pathology": [
                        "hypertension"
                    ]
                }
            ]
        ],
        [
            204,
            "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1).",
            [
                " {\n  \"DRUGS\": [\"fimasartan\", \"amlodipine\", \"hydrochlorothiazide\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Previous published reports\",\n  \"PARAMETER\": [\"mass fragmentation patterns\"],\n  \"FREQUENCY\": [\"different mass fragmentation patterns\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "fimasartan",
                        "amlodipine",
                        "hydrochlorothiazide"
                    ]
                }
            ]
        ],
        [
            205,
            "and M.P.",
            [
                " {\n  \"DRUGS\": [\"Methylphenidate\", \"Amphetamine\", \"Methamphetamine\", \"Bupropion\", \"Varenicline\"],\n  \"HERB NAME\": [\"Ginseng\", \"Turmeric\", \"Ginkgo biloba\"],\n  \"STUDY\": \"Clinical trials\",\n  \"PARAMETER\": [\"Plasma concentration\", \"Drug efficacy\", \"Side effects\", \"Drug metabolism\", \"Drug-drug interactions\"],\n  \"FREQUENCY\": [\"daily\", \"weekly\", \"monthly\", \"yearly\"],\n  \"HERB PART\": [\"root\", \"rhizome\", \"fresh\", \"dried\", \"extracted\"],\n  \"COHORT\": \"Adults aged 18-65 with mild to moderate depressive symptoms\",\n  \"DURATION\": [\"6 months\", \"12 months\", \"24 months\"],\n  \"SEX\": [\"male\", \"female\", \"male\", \"female\", \"male\", \"female\"],\n  \"AGE\": [\"18\", \"25\", \"40\", \"55\", \"65\"],\n  \"AMOUNT\": [\"5 mg\", \"10 mg\", \"150 mg\", \"200 mg\", \"100 mg\", \"300 mg\", \"1 g\", \"2 g\", \"500 mg\"],\n  \"ETHNIC GROUP\": [\"Caucasian\", \"African American\", \"Asian\", \"Hispanic\"],\n  \"PATHOLOGY\": [\"Tardive dyskinesia\", \"Dry mouth\", \"Insomnia\", \"Increased heart rate\", \"Drug-induced liver injury\"],\n  \"TARGET\": [\"Catechol-O-methyltransferase (COMT)\", \"P-glycoprotein\", \"Nicotinic acetylcholine receptors\", \"Dopamine transporters\"]\n}",
                {}
            ]
        ],
        [
            206,
            "Data represented as mean and CV from five or six independent experiments.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Type of study described\",\n  \"PARAMETER\": [\"mean\", \"CV\"],\n  \n  \"FREQUENCY\": [\"mean and CV from five or six independent experiments\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            207,
            "However, there are several challenges associated with the chronic nature of HAART administration.",
            [
                " {\n  \"DRUGS\": [\"HAART\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Study of chronic HAART administration\",\n  \"PARAMETER\": [\"chronic nature\", \"HAART administration\"],\n  \"FREQUENCY\": [\"chronic\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"chronic\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"HAART-related side effects\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "HAART"
                    ]
                }
            ]
        ],
        [
            208,
            "However, attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].",
            [
                " {\n  \"DRUGS\": [\"ART\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Shift in focus from reduction in mortality to improvement of quality of life for people taking ART\",\n  \"PARAMETER\": [\"quality of life\"],\n  \"FREQUENCY\": [\"improvement of quality of life\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"people taking ART\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "ART"
                    ]
                }
            ]
        ],
        [
            209,
            "EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10].",
            [
                " {\n  \"DRUGS\": [\"EFV\", \"NVP\"],\n  \"STUDY\": \"Clinical study\",\n   \"PARAMETER\": [\"liver damage\", \"nausea\", \"vomiting\", \"fever\", \"diarrhoea\", \"dyslipidemia\", \"headache\"],\n  \"FREQUENCY\": [\"a number of\"],\n  \"AGE\": [],\n  \"SEX\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"liver damage\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "EFV",
                        "NVP"
                    ],
                    "Pathology": [
                        "side effects",
                        "liver damage",
                        "nausea",
                        "vomiting",
                        "fever",
                        "diarrhoea",
                        "dyslipidemia",
                        "headache"
                    ]
                }
            ]
        ],
        [
            210,
            "There is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"medicinal plants\"],\n  \"STUDY\": \"evidence supporting the potential of medicinal plants\",\n  \"PARAMETER\": [\"diseases\"],\n  \"FREQUENCY\": [\"substantial\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"developing countries\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"developing countries\"],\n  \"PATHOLOGY\": [\"diseases\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nNote: The provided text does not contain specific names of drugs, herbs, or details about the extraction process, cohort characteristics, or other specific entities. Therefore, the fields related to these entities are left empty. However, the text does mention \"medicinal plants\" and \"diseases,\" which have been included in the respective categories.",
                {}
            ]
        ],
        [
            211,
            "Although effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [\"\"],\n  \"STUDY\": \"Type of study not specified\",\n  \"PARAMETER\": [\"effectiveness in the treatment of some diseases\"],\n  \"FREQUENCY\": [\"\"],\n  \"HERB PART\": [\"\"],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"unknown mechanisms of action\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            212,
            "Genetic polymorphism in CYP2B6 have been implicated in variations in the activity of the enzyme in metabolizing xenobiotics [26].",
            [
                " {\n  \"DRUGS\": [\"xenobiotics\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Genetic polymorphism study\",\n  \"PARAMETER\": [\"CYP2B6\", \"activity\", \"metabolizing xenobiotics\"],\n  \"FREQUENCY\": [\"variations\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"\"],\n  \"TARGET\": [\"CYP2B6\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2B6"
                    ]
                }
            ]
        ],
        [
            213,
            "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract.",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [\"\"],\n  \"STUDY\": \"Estimated bioavailability study\",\n  \"PARAMETER\": [\"bioavailable concentration\", \"intestinal absorption\", \"plasma concentrations\", \"bioavailability\", \"soluble extract\"],\n  \"FREQUENCY\": [\"\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"% yield\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Extraction process": [
                        "extracts",
                        "soluble extract"
                    ],
                    "Parameter": [
                        "bioavailability",
                        "bioavailable concentration"
                    ]
                }
            ]
        ],
        [
            214,
            "Note: values are expressed as mg\u00b7kg Structures of the phenolic compounds identified and quantified from crude herbal extracts (1) Caffeic acid; (2) Catechin; (3) Chlorogenic acid; (4) Epicatechin; (5) p-Coumaric acid.",
            [
                " {\n  \"DRUGS\": [\"Caffeic acid\", \"Catechin\", \"Chlorogenic acid\", \"Epicatechin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Analysis of phenolic compounds in crude herbal extracts\",\n  \"PARAMETER\": [\"Caffeic acid\", \"Catechin\", \"Chlorogenic acid\", \"Epicatechin\", \"p-Coumaric acid\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "phenolic compounds",
                        "Caffeic acid",
                        "Catechin",
                        "Chlorogenic acid",
                        "Epicatechin",
                        "p-Coumaric acid"
                    ],
                    "Extraction process": [
                        "crude herbal extracts"
                    ]
                }
            ]
        ],
        [
            215,
            "The advantage of phytochemical profiling is that similar drug interacting constituents could be identified in other related herbs that are used for therapeutic purposes and that necessary mechanistic studies are performed on them.",
            [
                " {\n  \"DRUGS\": [\"phytochemicals\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"phytochemical profiling\",\n  \"PARAMETER\": [\"drug interacting constituents\", \"therapeutic purposes\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"enzymes\", \"transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            216,
            "The study showed that Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6.",
            [
                " {\n  \"DRUGS\": [\"Launaea taraxacifolia\", \"Boerhavia diffusa\", \"Myrothamnus flabellifolius\"],\n  \"HERB NAME\": [\"Launaea taraxacifolia\", \"Boerhavia diffusa\", \"Myrothamnus flabellifolius\"],\n  \"STUDY\": \"In vitro study\",\n  \"PARAMETER\": [\"CYP2B6\"],\n  \"FREQUENCY\": [\"concentration-dependent inhibition\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inhibition of CYP2B6\"],\n  \"TARGET\": [\"CYP2B6\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Launaea taraxacifolia",
                        "Hyptis suaveolens",
                        "Boerhavia diffusa",
                        "Myrothamnus flabellifolius"
                    ],
                    "Extraction process": [
                        "extracts"
                    ],
                    "Target": [
                        "CYP2B6"
                    ]
                }
            ]
        ],
        [
            217,
            "Ethical approval was obtained from the University of Cape Town Human Research Ethics committee with number HREC REF: 826/2014.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Ethical approval for a study\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            218,
            "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated.",
            [
                " {\n  \"DRUGS\": [\"No drugs mentioned\"],\n  \"HERB NAME\": [\"No specific herb name mentioned\"],\n  \"STUDY\": \"Extraction and preparation study\",\n  \"PARAMETER\": [\"72 h\", \"room temperature\", \"supernatant\", \"solid residue\", \"purified water\"],\n  \"FREQUENCY\": [\"every 24 h\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"72 h\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"same volume of purified water\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"72 h at room temperature\", \"supernatant decanted every 24 h\", \"solid residue reconstituted in the same volume of purified water\"]\n}",
                {
                    "Duration": [
                        "for 72 h"
                    ],
                    "Frequency": [
                        "every 24 h"
                    ]
                }
            ]
        ],
        [
            219,
            "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented.",
            [
                " {\n  \"DRUGS\": [\"No drugs mentioned\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Commentary by experts\",\n  \"PARAMETER\": [\"sex\", \"age\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"No specific cohort mentioned\",\n  \"DURATION\": [],\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [\"no specific ages mentioned\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            220,
            "All authors reviewed the final manuscript.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            221,
            "GGT with five major ingredients also possesses chance of drug interactions when co-administering with other drugs.",
            [
                " {\n  \"DRUGS\": [\"GGT\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"drug interactions\"],\n  \"FREQUENCY\": [\"chance\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"drug interactions\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nNote: The provided text does not mention specific drugs, herbs, cohorts, durations, sexes, ages, amounts, ethnic groups, pathologies, or extraction processes. Therefore, these fields are left empty. However, \"GGT\" is mentioned as a drug, and \"drug interactions\" are referred to as a parameter.",
                {
                    "Herb name": [
                        "GGT"
                    ]
                }
            ]
        ],
        [
            222,
            "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"7 \u00b1 1-day washout period\"],\n  \"FREQUENCY\": [\"three treatments\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"7 \u00b1 1-day washout period\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            223,
            "Therefore, we applied this dose of GGT in our study.",
            [
                " {\n  \"DRUGS\": [\"GGT\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"GGT\"],\n  \"FREQUENCY\": [\"this dose\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"this dose\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"GGT\"],\n  \"EXTRACTION PROCESS\": []\n}\n\nNote: The provided text does not mention specific drugs, herbs, cohort details, sexes, ages, ethnic groups, pathologies, or extraction processes related to the study. Therefore, those fields are left empty. However, \"GGT\" is mentioned as a parameter, which could be a drug or a target, depending on the context. Since it's not explicitly stated as a drug, it's listed under \"PARAMETER\" and \"TARGET\".",
                {
                    "Herb name": [
                        "GGT"
                    ]
                }
            ]
        ],
        [
            224,
            "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23].",
            [
                " {\n  \"DRUGS\": [\"AAP\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"common cold\", \"dose\", \"1000 mg\", \"maximum dose\", \"8 tablets\"],\n  \"FREQUENCY\": [\"1000 mg to the maximum dose of 1000 mg \u00d7 4 times\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"Not specified in the text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1000 mg\", \"8 tablets\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"common cold\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "AAP"
                    ],
                    "Amount": [
                        "1000 mg",
                        "1000 mg"
                    ],
                    "Frequency": [
                        "4 times (8 tablets) per day"
                    ],
                    "Pathology": [
                        "common cold"
                    ]
                }
            ]
        ],
        [
            225,
            "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week.",
            [
                " {\n  \"DRUGS\": [\"AAP\", \"GGT\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Simulation study\",\n  \"PARAMETER\": [\"AAP dosage\", \"GGT dosage\", \"daily frequency\", \"weekly duration\"],\n  \"FREQUENCY\": [\"once daily\", \"four times daily\", \"weekly\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"a week\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1000 mg\", \"7680 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "AAP",
                        "AAP"
                    ],
                    "Amount": [
                        "1000 mg",
                        "7680 mg",
                        "1000 mg",
                        "7680 mg"
                    ],
                    "Frequency": [
                        "once daily",
                        "once daily",
                        "4 times daily",
                        "once daily"
                    ],
                    "Herb name": [
                        "GGT",
                        "GGT"
                    ],
                    "Duration": [
                        "week"
                    ]
                }
            ]
        ],
        [
            226,
            "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.",
            [
                " {\n  \"DRUGS\": [\"Aripiprazole\", \"Glutathione (GGT)\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"Aripiprazole dosage\", \"Glutathione (GGT) level\", \"Daily frequency of administration\"],\n  \"FREQUENCENCY\": [\"1000 mg\", \"4 times a day\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"Not specified in the text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1000 mg\", \"7680 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"GGT (Glutathione) level\"],\n  \"TARGET\": [\"Aripiprazole\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "AAP"
                    ],
                    "Frequency": [
                        "once a day",
                        "4 times a day",
                        "daily"
                    ],
                    "Amount": [
                        "1000 mg",
                        "7680 mg"
                    ],
                    "Herb name": [
                        "GGT"
                    ]
                }
            ]
        ],
        [
            227,
            "and Y.C.P.",
            [
                " {\n  \"DRUGS\": [\"Y.C.P.\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"pharmacokinetics\", \"pharmacodynamics\", \"adverse effects\"],\n  \"FREQUENCY\": [\"daily\", \"weekly\", \"monthly\"],\n  \"HERB PART\": [\"root\", \"leaf\"],\n  \"COHORT\": \"Adult patients with chronic respiratory conditions\",\n  \"DURATION\": [\"6 months\", \"1 year\"],\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [\"25-45\", \"46-65\"],\n  \"AMOUNT\": [\"500 mg\", \"1000 mg\"],\n  \"ETHNIC GROUP\": [\"Asian\", \"Caucasian\"],\n  \"PATHOLOGY\": [\"respiratory distress\", \"inflammation\"],\n  \"TARGET\": [\"cytochrome P450 enzymes\", \"lung tissue receptors\"],\n  \"EXTRACTION PROCESS\": [\"solvent extraction\", \"water decoction\"]\n}",
                {}
            ]
        ],
        [
            228,
            "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.",
            [
                " {\n  \"DRUGS\": [\"Q.T.T.\", \"H.-m.B.\", \"L.T.N.\", \"J.-w.C.\", \"H.-y.Y.\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"cohort study\",\n  \"PARAMETER\": [\"sex\", \"age\", \"ethnic group\", \"pathology\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified in the text\",\n  \"DURATION\": [],\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [\"not specified in the text\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"not specified in the text\"],\n  \"PATHOLOGY\": [\"not specified in the text\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            229,
            "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP.",
            [
                " {\n  \"DRUGS\": [\"AAP\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Non-compartmental analysis (NCA) of pharmacokinetic (PK) parameters\",\n  \"PARAMETER\": [\"pharmacokinetic (PK) parameters\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "AAP"
                    ]
                }
            ]
        ],
        [
            230,
            "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity in elderly subjects.",
            [
                " {\n  \"DRUGS\": [\"St. John\u2019s wort\", \"garlic oil\", \"Panax ginseng\", \"Ginkgo biloba\"],\n  \"HERB NAME\": [\"St. John\u2019s wort\", \"garlic\", \"Panax ginseng\", \"Ginkgo\"],\n  \"STUDY\": \"long-term supplementation study\",\n  \"PARAMETER\": [\"CYP1A2\", \"CYP2D6\", \"CYP2E1\", \"CYP3A4\"],\n  \"FREQUENCY\": [\"long-term\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"elderly subjects\",\n  \"DURATION\": [\"long-term\"],\n  \"SEX\": [],\n  \"AGE\": [\"elderly\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP1A2\", \"CYP2D6\", \"CYP2E1\", \"CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "St. John\u2019s wort",
                        "garlic oil",
                        "Panax ginseng",
                        "Ginkgo biloba"
                    ],
                    "Target": [
                        "CYP1A2",
                        "CYP2D6",
                        "CYP2E1",
                        "CYP3A4"
                    ]
                }
            ]
        ],
        [
            231,
            "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age.",
            [
                " {\n  \"DRUGS\": [\"prescription medications\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"surveys\",\n  \"PARAMETER\": [\"patients taking prescription medications\", \"greater than 65 years of age\"],\n  \"FREQUENCY\": [\"prevalent\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"patients taking prescription medications greater than 65 years of age\"],\n   \n  \"AGE\": [\"greater than 65 years of age\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "surveys"
                    ],
                    "Age": [
                        "greater than 65 years of age"
                    ]
                }
            ]
        ],
        [
            232,
            "Moreover, age-related changes have been observed in the pharmacokinetics of several CYP substrates,[28\u201330] as well as certain CYP enzymes,[29,30] thus the question remains as to whether such effects may extend to botanical supplements and their effect on drug metabolism in the elderly.",
            [
                " {\n  \"DRUGS\": [\"CYP substrates\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study on pharmacokinetics of drugs and botanical supplements\",\n  \"PARAMETER\": [\"pharmacokinetics\", \"drug metabolism\"],\n  \"FREQUENCY\": [\"age-related changes\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"elderly\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"elderly\"],\n  \"AGE\": [\"elderly\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"age-related changes in CYP substrates and enzymes\"],\n  \"TARGET\": [\"CYP substrates\", \"certain CYP enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP"
                    ]
                }
            ]
        ],
        [
            233,
            "Adherence to these restrictions was further emphasized five days before each probe drug administration.",
            [
                " {\n  \"DRUGS\": [\"probe drug\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"longitudinal cohort study\",\n  \"PARAMETER\": [\"adherence\", \"drug administration\"],\n  \"FREQUENCY\": [\"five days\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified in the provided text\",\n  \"DURATION\": [\"not specified in the provided text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            234,
            "Peaks were assigned by a comparison of retention times and ultraviolet absorption spectra.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Comparison of retention times and ultraviolet absorption spectra\",\n  \"PARAMETER\": [\"retention times\", \"ultraviolet absorption spectra\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            235,
            "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation.",
            [
                " {\n  \"DRUGS\": [\"Not specified\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"subjects\", \"serious adverse events\"],\n  \"FREQUENCY\": [\"All subjects\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"All subjects\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"No serious adverse events\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            236,
            "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Phenotypic ratio study\",\n  \"PARAMETER\": [\"CYP phenotypic ratio\", \"95% confidence intervals\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"Not specified in the provided text\"],\n  \"DURATION\": [\"Pre-supplementation\", \"Postsupplementation\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            237,
            "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance.",
            [
                " {\n  \"DRUGS\": [\"midazolam\"],\n  \"HERB NAME\": [\"St. John\u2019s wort\"],\n  \"STUDY\": \"single-time point phenotypic ratio approach\",\n  \"PARAMETER\": [\"midazolam clearance\"],\n  \"FREQUENCY\": [\"other investigators\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"single-time point\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "St. John\u2019s wort"
                    ],
                    "Parameter": [
                        "area-under-the-curve",
                        "clearance"
                    ],
                    "Drug": [
                        "midazolam"
                    ]
                }
            ]
        ],
        [
            238,
            "This finding also corroborates the results of an earlier study in young individuals.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Type of study described\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"earlier study\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"young individuals\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"young\"],\n  \"AGE\": [\"young\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            239,
            "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort.",
            [
                " {\n  \"DRUGS\": [\"St. John's wort\"],\n  \"HERB NAME\": [\"St. John's wort\"],\n  \"STUDY\": \"Potential interaction study\",\n  \"PARAMETER\": [\"interactions between drugs and herbs\"],\n  \"FREQUENCY\": [\"potential\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"interactions\"],\n  \"TARGET\": [\"unknown\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "St. John\u2019s wort"
                    ]
                }
            ]
        ],
        [
            240,
            "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements.",
            [
                " {\n  \"DRUGS\": [\"allyl sulfide\"],\n  \"HERB NAME\": [\"garlic\"],\n  \"STUDY\": \"comparison of inhibition of CYP2E1\",\n  \"PARAMETER\": [\"allyl sulfide content\", \"CYP2E1 responsivity\"],\n  \"FREQUENCY\": [\"age groups\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"two age groups\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [\"two age groups\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"age-related diminution in CYP2E1 responsivity\"],\n  \"TARGET\": [\"CYP2E1\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2E1"
                    ],
                    "Herb name": [
                        "allyl sulfide",
                        "garlic"
                    ]
                }
            ]
        ],
        [
            241,
            "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy.",
            [
                " {\n  \"DRUGS\": [\"anticoagulant therapy\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"anticoagulant therapy\", \"elderly patients\"],\n  \"FREQUENCY\": [\"particularly relevant\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"elderly patients\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"elderly patients\"],\n  \"AGE\": [\"elderly patients\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"interaction\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "anticoagulant therapy"
                    ]
                }
            ]
        ],
        [
            242,
            "This interaction appears attributable to the inhibition of platelet activating factor by various ginkgolides.",
            [
                " {\n  \"DRUGS\": [\"ginkgolides\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"inhibition study\",\n  \"PARAMETER\": [\"platelet activating factor\"],\n  \"FREQUENCY\": [\"various\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inhibition of platelet activating factor\"],\n  \"TARGET\": [\"platelet activating factor\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "platelet activating factor"
                    ],
                    "Herb name": [
                        "ginkgolides"
                    ]
                }
            ]
        ],
        [
            243,
            "[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms.",
            [
                " {\n  \"DRUGS\": [\"Ginkgo biloba\"],\n  \"HERB NAME\": [\"Ginkgo biloba\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"CYP isoforms\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP isoforms\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "G. biloba"
                    ],
                    "Target": [
                        "CYP"
                    ]
                }
            ]
        ],
        [
            244,
            "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study.",
            [
                " {\n  \"DRUGS\": [\"G. biloba\", \"Panax ginseng\"],\n  \"HERB NAME\": [\"Ginkgo biloba\", \"Panax ginseng\"],\n  \"STUDY\": \"Investigation of drug effects on specific CYP isoforms\",\n  \"PARAMETER\": [\"CYP isoforms\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP isoforms\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "G. biloba",
                        "Panax ginseng"
                    ],
                    "Target": [
                        "CYP"
                    ]
                }
            ]
        ],
        [
            245,
            "[62] CYP2C9 is the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [\"ginseng\"],\n  \"STUDY\": \"reports\",\n  \"PARAMETER\": [\"CYP2C9\", \"S-warfarin\"],\n  \"FREQUENCY\": [\"strongly\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"ginseng-mediated induction\"],\n  \"TARGET\": [\"CYP2C9\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2C9"
                    ],
                    "Drug": [
                        "warfarin",
                        "warfarin"
                    ],
                    "Study": [
                        "reports"
                    ],
                    "Herb name": [
                        "ginseng"
                    ]
                }
            ]
        ],
        [
            246,
            "Therefore, botanical supplements, when taken concomitantly with conventional medications, can give rise to serious herb-drug interactions.",
            [
                " {\n  \"DRUGS\": [\"conventional medications\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"serious herb-drug interactions\"],\n  \"FREQUENCY\": [\"not specified\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"serious herb-drug interactions\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            247,
            "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method.",
            [
                " {\n  \"DRUGS\": [\"quinine\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Analysis of plasma levels\",\n  \"PARAMETER\": [\"plasma quinine\", \"3-hydroxyquinine\"],\n  \"FREQUENCY\": [\"blood samples collected\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "quinine",
                        "3-hydroxyquinine"
                    ]
                }
            ]
        ],
        [
            248,
            "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola.",
            [
                " {\n  \"DRUGS\": [\"kolaviron\"],\n  \"HERB NAME\": [\"G. kola\"],\n  \"STUDY\": \"phytochemical analysis\",\n  \"PARAMETER\": [\"benxophenones\", \"xanthones\", \"alkaloids\", \"phenols\", \"tannins\", \"saponins\", \"metallic ions (aluminum, magnesium, calcium, copper)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"major chemical components\"],\n  \"ETHNIC GROUP\": \"\",\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"enzymes\", \"transporters\", \"biflavonoid complex\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "G. kola",
                        "benxophenones",
                        "xanthones",
                        "alkaloids",
                        "phenols",
                        "tannins",
                        "saponins",
                        "kolaviron",
                        "biflavonoid complex",
                        "G. kola"
                    ],
                    "Herb part": [
                        "seeds"
                    ]
                }
            ]
        ],
        [
            249,
            "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study.",
            [
                " {\n  \"DRUGS\": [\"G. kola seeds\"],\n  \"HERB NAME\": [\"G. kola\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"pregnancy\", \"breastfeeding\", \"histories of hypersensitivity to quinine or similar agents\", \"adverse side effects\"],\n  \"FREQUENCY\": [\"used as exclusion criteria\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [],\n  \"SEX\": [\"females\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"adverse side effects\"],\n  \"TARGET\": [\"quinine or similar agents\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "Pregnancy",
                        "breastfeeding",
                        "hypersensitivity",
                        "adverse side effects"
                    ],
                    "Drug": [
                        "quinine"
                    ],
                    "Herb name": [
                        "G. kola"
                    ],
                    "Herb part": [
                        "seeds"
                    ]
                }
            ]
        ],
        [
            250,
            "Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"healthy\", \"medical history\", \"clinical examination\", \"laboratory tests\", \"written informed consent\"],\n  \"FREQUENCY\": [\"certified healthy\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Participants certified healthy by a physician\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "healthy"
                    ]
                }
            ]
        ],
        [
            251,
            "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England).",
            [
                " {\n  \"DRUGS\": [\"quinine sulphate\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"overnight fast\", \"oral dose\", \"600 mg\"],\n  \"FREQUENCY\": [\"single oral dose\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"each subject in the respective groups\"],\n  \"DURATION\": [\"overnight fast\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"600 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Amount": [
                        "600 mg"
                    ],
                    "Drug": [
                        "quinine sulphate"
                    ]
                }
            ]
        ],
        [
            252,
            "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola.",
            [
                " {\n  \"DRUGS\": [\"quinine sulphate\"],\n  \"HERB NAME\": [\"G. kola\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"Venous blood samples\", \"time zero\", \"1, 2, 3,4, 6, 8, 12, 24, 36, 48 h\", \"quinine\", \"G. kola\", \"heparinised tubes\"],\n  \"FREQUENCY\": [\"5ml\", \"just before\", \"1, 2, 3,4, 6, 8, 12, 24, 36, 48 h\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Participants who received quinine alone or concurrently with the scheduled dose of G. kola\",\n  \"DURATION\": [\"1, 2, 3,4, 6, 8, 12, 24, 36, 48 h\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"5ml\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"quinine\"],\n  \"TARGET\": [\"quinine\", \"G. kola\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "quinine sulphate",
                        "quinine"
                    ],
                    "Herb name": [
                        "G. kola"
                    ]
                }
            ]
        ],
        [
            253,
            "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively.",
            [
                " {\n  \"DRUGS\": [\"quinine\", \"3-hydroxyquinine\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"0.37\u00b5g/ml\", \"0.5\u00b5g/ml\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"0.37\u00b5g/ml\", \"0.5\u00b5g/ml\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nNote: Since the provided text does not contain specific information about herbs, cohorts, sexes, ages, ethnic groups, pathologies, targets, or extraction processes, these fields are left empty.",
                {
                    "Drug": [
                        "quinine",
                        "3-hydroxyquinine"
                    ]
                }
            ]
        ],
        [
            254,
            "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %.",
            [
                " {\n  \"DRUGS\": [\"quinine\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"study of the effect of quinine on pharmacokinetics\",\n  \"PARAMETER\": [\"AUC0\u2013\u221e\"],\n  \"FREQUENCY\": [\"slightly reduced by about 9 %\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"reduced AUC0\u2013\u221e\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "AUC0\u2013\u221e"
                    ],
                    "Drug": [
                        "quinine"
                    ]
                }
            ]
        ],
        [
            255,
            "Precisely, only 3 participants complained of very light dizziness.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"dizziness\"],\n  \"FREQUENCY\": [\"3 participants\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"dizziness\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nNote: Since the provided text does not mention any drugs, herbs, specific study details, cohort characteristics, durations, sexes, ages, amounts, ethnic groups, pathologies, or extraction processes, these fields are left empty. However, \"dizziness\" is mentioned as a parameter, and \"3 participants\" is the frequency of the event.",
                {
                    "Pathology": [
                        "light dizziness"
                    ]
                }
            ]
        ],
        [
            256,
            "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination.",
            [
                " {\n  \"DRUGS\": [\"quinine\"],\n  \"HERB NAME\": [\"G. kola\"],\n  \"STUDY\": \"interaction study\",\n  \"PARAMETER\": [\"Cmax\", \"tmax\"],\n  \"FREQUENCY\": [\"significant reduction\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"current study\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"delayed and decreased absorption\"],\n  \"TARGET\": [\"quinine\", \"trace metals\", \"flavonoids\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "quinine",
                        "quinine",
                        "quinine"
                    ],
                    "Herb name": [
                        "G. kola",
                        "flavonoids",
                        "G. kola"
                    ],
                    "Parameter": [
                        "Cmax",
                        "tmax"
                    ]
                }
            ]
        ],
        [
            257,
            "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola.",
            [
                " {\n  \"DRUGS\": [\"quinine\"],\n  \"HERB NAME\": [\"G. kola\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"T1/2\", \"CL/F\"],\n  \"FREQUENCY\": [\"not specified\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"study groups\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [\"not specified\"],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "T1/2",
                        "CL/F"
                    ],
                    "Drug": [
                        "quinine"
                    ],
                    "Herb name": [
                        "G. kola"
                    ]
                }
            ]
        ],
        [
            258,
            "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            259,
            "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo.",
            [
                " {\n  \"DRUGS\": [\"S. frutescens\"],\n  \"HERB NAME\": [\"S. frutescens\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"1,200 mg\"],\n  \"FREQUENCY\": [\"77 additional participants\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"77 additional participants randomized to either S. frutescens or placebo\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1,200 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Amount": [
                        "1,200 mg"
                    ],
                    "Herb name": [
                        "S. frutescens"
                    ]
                }
            ]
        ],
        [
            260,
            "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11].",
            [
                " {\n  \"DRUGS\": [\"TCAM\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"ART initiation\", \"TCAM use\"],\n  \"FREQUENCY\": [\"More than 50% of adults\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Adults in KwaZulu-Natal attending public sector facilities for ART initiation\",\n  \"DURATION\": [],\n  \"SEX\": [\"Adults\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"KwaZulu-Natal\"],\n  \"PATHOLOGY\": [\"\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "ART"
                    ],
                    "Pathology": [
                        "HIV positive"
                    ]
                }
            ]
        ],
        [
            261,
            "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group.",
            [
                " {\n  \"DRUGS\": [\"MOS-HIV\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"failure differences\", \"placebo\", \"1200 mg\"],\n  \"FREQUENCY\": [\"differences\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"MOS-HIV trial participants\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1200 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"failure differences\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Amount": [
                        "1200 mg",
                        "1200mg"
                    ]
                }
            ]
        ],
        [
            262,
            "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Serial electrocardiograms study\",\n  \"PARAMETER\": [\"PR interval\", \"QRS duration\", \"corrected QT interval (QTc)\"],\n  \"FREQUENCY\": [\"similar in both arms\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"not specified in the text\"],\n  \"DURATION\": [\"not specified in the text\"],\n  \"SEX\": [\"not specified in the text\"],\n  \"AGE\": [\"not specified in the text\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "the PR interval",
                        "QRS duration",
                        "corrected QT interval (QTc)"
                    ],
                    "Study": [
                        "both arms"
                    ]
                }
            ]
        ],
        [
            263,
            "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"HDL\", \"LDL\"],\n  \"FREQUENCY\": [\"P-value for interaction effect of groups over time\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "HDL (high density lipoprotein)",
                        "LDL (low density lipoprotein)"
                    ]
                }
            ]
        ],
        [
            264,
            "(PDF) Click here for additional data file.",
            [
                " {\n  \"DRUGS\": [\"Drug X\", \"Drug Y\", \"Drug Z\"],\n  \"HERB NAME\": [\"Herb A\", \"Herb B\", \"Herb C\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"blood pressure\", \"heart rate\", \"blood glucose levels\"],\n  \"FREQUENCY\": [\"annual\", \"biannual\", \"quarterly\"],\n  \"HERB PART\": [\"root\", \"leaf\", \"flower\"],\n  \"COHORT\": \"Adults aged 30-60 years\",\n  \"DURATION\": [\"6 months\", \"1 year\", \"2 years\"],\n  \"SEX\": [\"Male\", \"Female\"],\n  \"AGE\": [\"30\", \"40\", \"50\", \"60\"],\n  \"AMOUNT\": [\"100 mg\", \"200 mg\", \"500 mg\"],\n  \"ETHNIC GROUP\": [\"Caucasian\", \"African American\", \"Asian\"],\n  \"PATHOLOGY\": [\"hypertension\", \"diabetes\", \"liver toxicity\"],\n  \"TARGET\": [\"Cytochrome P450 enzymes\", \"P-glycoprotein transporters\"],\n  \"EXTRACTION PROCESS\": [\"solvent extraction\", \"water leaching\", \"drying and grinding\"]\n}",
                {}
            ]
        ],
        [
            265,
            "Thabethe, D.A.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            266,
            "Data were reported as prevalence (percent) of the occurrence.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"prevalence (percent)\", \"sex\", \"age\", \"ethnic group\"],\n  \"FREQUENCY\": [\"prevalence (percent)\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            267,
            "Chronic kidney disease (CKD) is a global public health problem with an increasing incidence and a lot of economic burden for treatment.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"Chronic kidney disease (CKD)\", \"economic burden\"],\n  \"FREQUENCY\": [\"increasing incidence\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Chronic kidney disease\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "Chronic kidney disease (CKD)"
                    ]
                }
            ]
        ],
        [
            268,
            "However, a large number of these therapies have been shown that they are not safe and can be harmful due to their interactions with other drugs which are used contemporaneously.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"interactions with other drugs\", \"safety\", \"harmful effects\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"interactions with other drugs\", \"harmful effects\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            269,
            "After obtaining institutional ethics committee approval (project number and ethics code: 294155) from the university research affairs, patients' demographic information (sex, age, educational status, occupational status, and marital status) were collected from patients' hospital records or by direct interviewing of patients and filled in a specially designed form for this study.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"patients' demographic information\", \"hospital records\", \"direct interviewing\"],\n  \"FREQUENCY\": [\"patients' demographic information collected\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Patients involved in the study\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            270,
            "Regarding CAM nonusers, the majority were in the age group of 20\u201360 years with the male/female ratio of 73/27 percent.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Comparative analysis of complementary and alternative medicine (CAM) users and nonusers\",\n  \"PARAMETER\": [\"age group\", \"male/female ratio\"],\n  \"FREQUENCY\": [\"majority\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"CAM users and nonusers\",\n  \"DURATION\": [\"20\u201360 years\"],\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [\"20\u201360 years\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Age": [
                        "20\u201360 years"
                    ],
                    "Sex": [
                        "male",
                        "female"
                    ]
                }
            ]
        ],
        [
            271,
            "The others (13.23%) consisted of congenital kidney disease, polycystic kidney disease, drug-induced renal failure, and acute kidney injury.",
            [
                " {\n  \"DRUGS\": [\"drug-induced renal failure\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Cohort study\",\n  \"PARAMETER\": [\"congenital kidney disease\", \"polycystic kidney disease\", \"acute kidney injury\"],\n  \"FREQUENCY\": [\"13.23%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"Not specified in the text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"congenital kidney disease\", \"polycystic kidney disease\", \"acute kidney injury\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "congenital kidney disease",
                        "polycystic kidney disease",
                        "drug-induced renal failure",
                        "acute kidney injury"
                    ]
                }
            ]
        ],
        [
            272,
            "The majority of the patients identified as herbal users were in the age range of 50\u201370 years, and herbal usage prevalence was high among this age range.",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [\"\"],\n  \"STUDY\": \"Prevalence study\",\n  \"PARAMETER\": [\"age range\", \"herbal usage prevalence\"],\n  \"FREQUENCY\": [\"high\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"majority of patients identified as herbal users\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [\"\"],\n  \"AGE\": [\"50\u201370 years\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Age": [
                        "50\u201370 years"
                    ]
                }
            ]
        ],
        [
            273,
            "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups.",
            [
                " {\n  \"DRUGS\": [\"no drugs mentioned\"],\n  \"HERB NAME\": [\"no herbs mentioned\"],\n  \"STUDY\": \"clinical study\",\n  \"PARAMETER\": [\"middle-aged (50\u201364) patients\"],\n  \"FREQUENCY\": [\"more prevalent\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"middle-aged (50\u201364) patients\",\n  \"DURATION\": [],\n  \"SEX\": [\"middle-aged\"],\n  \"AGE\": [\"50\u201364\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Age": [
                        "50\u201364"
                    ]
                }
            ]
        ],
        [
            274,
            "[2526] Iranian borage (E. amoenum) as unformulated and anticough syrups as formulated herbal products were the most used ones in our study population, while common cold and respiratory problems were determined to be the main indications for this trend.",
            [
                " {\n  \"DRUGS\": [\"anticough syrups\"],\n  \"HERB NAME\": [\"Iranian borage (E. amoenum)\"],\n  \"STUDY\": \"observational study\",\n  \"PARAMETER\": [\"common cold\", \"respiratory problems\"],\n  \"FREQUENCY\": [\"most used ones\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"study population\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"Iranian\"],\n  \"PATHOLOGY\": [\"common cold\", \"respiratory problems\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Iranian borage (E. amoenum)"
                    ]
                }
            ]
        ],
        [
            275,
            "[27] In the study performed by Roozbeh et al.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            276,
            "The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM).",
            [
                " {\n  \"DRUGS\": [\"temozolomide\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Radiotherapy and temozolomide treatment\",\n  \"PARAMETER\": [\"Karnofsky performance status scale\", \"neurological deficiencies\"],\n  \"FREQUENCY\": [\"90%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Patient referred to the department\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"neurological deficiencies\"],\n  \"TARGET\": [\"\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "neurological deficiencies"
                    ],
                    "Drug": [
                        "temozolomide"
                    ]
                }
            ]
        ],
        [
            277,
            "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy.",
            [
                " {\n  \"DRUGS\": [\"fluorethylenthyrosin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"positron emission tomography study\",\n  \"PARAMETER\": [\"residual tumor\"],\n  \"FREQUENCY\": [\"2 months\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"after the end of radiotherapy\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"positive residual tumor\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "tumor"
                    ]
                }
            ]
        ],
        [
            278,
            "Therefore, we think that a comprehensive management of our patients should also include education about the risk of interactions with herbal formulas.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"risk of interactions\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"risk of interactions\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            279,
            "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"whole blood\", \"normal saline\", \"37 \u00b0C\", \"6 min\"],\n  \"FREQUENCY\": [\"at least 6 min\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"at least 6 min\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"0.5 mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            280,
            "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical study\",\n  \"PARAMETER\": [\"International normalized ratio\"],\n  \"FREQUENCY\": [\"at each blood sampling time\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"before and after warfarin dosing\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"International normalized ratio\"],\n  \"TARGET\": [\"warfarin\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "International normalized ratio",
                        "International normalized ratio"
                    ],
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            281,
            "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time.",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical study\",\n  \"PARAMETER\": [\"factor activity\", \"clotting time\"],\n  \"FREQUENCY\": [\"different dilutions\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"unknown\",\n  \"DURATION\": [\"unknown\"],\n  \"SEX\": [\"unknown\"],\n  \"AGE\": [\"unknown\"],\n  \"AMOUNT\": [\"unknown\"],\n  \"ETHNIC GROUP\": [\"unknown\"],\n  \"PATHOLOGY\": [\"unknown\"],\n  \"TARGET\": [\"factor activity\", \"clotting time\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "clotting time"
                    ]
                }
            ]
        ],
        [
            282,
            "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"half-life\", \"apparent clearance (CL/F)\", \"apparent volume of distribution (V/F)\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "half-life",
                        "CL/F",
                        "AUC0\u2212\u221e",
                        "CL/kel"
                    ]
                }
            ]
        ],
        [
            283,
            "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration.",
            [
                " {\n  \"DRUGS\": [\"S-warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"two-compartment pharmacokinetic model and indirect pharmacodynamic model\",\n  \"PARAMETER\": [\"S-warfarin concentration\", \"prothrombin complex activity\", \"INR data\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"not specified in the text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"not specified in the text\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"prothrombin complex activity\"],\n  \"TARGET\": [\"not specified in the text\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "S-warfarin",
                        "S-warfarin"
                    ],
                    "Parameter": [
                        "prothrombin complex activity (PCA",
                        "INR"
                    ]
                }
            ]
        ],
        [
            284,
            "However, this did not reach statistical significance (data not shown).",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            285,
            "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax.",
            [
                " {\n  \"DRUGS\": [\"warfarin\", \"cranberry\", \"garlic\"],\n  \"HERB NAME\": [\"cranberry\", \"garlic\"],\n  \"STUDY\": \"Pharmacokinetic parameters of S-warfarin and R-warfarin\",\n  \"PARAMETER\": [\"tmax (h)\", \"Cmax (\u03bcg\u2009mL\u22121)\", \"t1/2 (h)\", \"AUC (\u03bcg\u2009mL\u22121\u2009h)\", \"CL/F (mL\u2009h\u22121)\", \"Fraction unbound (fu)\"],\n  \"FREQUENCENCE\": {\n    \"tmax (h)\": [\"1.4\", \"1.9\", \"1.3\", \"1.4\", \"1.8\", \"1.9\"],\n    \"Cmax (\u03bcg\u2009mL\u22121)\": [\"1.8\", \"1.7\", \"1.9\", \"NA\", \"1.8\", \"1.9\"],\n    \"t1/2 (h)\": [\"38.6\", \"34.9\", \"41.2\", \"213\", \"204\", \"202\"],\n    \"AUC (\u03bcg\u2009mL\u22121\u2009h)\": [\"60.3\", \"63.0\", \"65.5\", \"213\", \"204\", \"202\"],\n    \"CL/F (mL\u2009h\u22121)\": [\"213\", \"204\", \"202\", \"0.89\", \"1.05\", \"1.12\"],\n    \"Fraction unbound (fu)\": [\"0.010\", \"0.010\", \"0.011\", \"0.90\", \"1.02\", \"0.95\"]\n  },\n  \"COHORT\": \"Patients taking S-warfarin and R-warfarin\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Warfarin only\", \"",
                {
                    "Drug": [
                        "S-warfarin",
                        "R-warfarin",
                        "Warfarin",
                        "Warfarin",
                        "Warfarin",
                        "Warfarin",
                        "warfarin",
                        "Warfarin",
                        "warfarin",
                        "S-warfarin",
                        "R-warfarin"
                    ],
                    "Herb name": [
                        "cranberry",
                        "garlic",
                        "cranberry",
                        "garlic"
                    ],
                    "Parameter": [
                        "tmax",
                        "Cmax",
                        "AUC",
                        "CL/F",
                        "tmax",
                        "Cmax",
                        "t1/2",
                        "AUC",
                        "CL/F",
                        "AUC, area under the plasma concentration\u2013time curve",
                        "CL, clearance",
                        "CL/F, apparent clearance",
                        "Cmax, maximum concentration",
                        "F, bioavailability",
                        "tmax, time to Cmax"
                    ]
                }
            ]
        ],
        [
            286,
            "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"population pharmacokinetic-pharmacodynamic modelling\",\n  \"PARAMETER\": [\"population PKPD parameter estimates\"],\n  \"FREQUENCY\": [\"\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"not specified\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [\"not specified\"],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            287,
            "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [\"cranberry juice\"],\n  \"STUDY\": \"clinical study\",\n  \"PARAMETER\": [\"AUC of S-warfarin\"],\n  \"FREQUENCY\": [\"5 days\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"not specified\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"no clinically significant change\"],\n  \"TARGET\": [\"S-warfarin\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "cranberry"
                    ],
                    "Extraction process": [
                        "juice"
                    ],
                    "Duration": [
                        "for 5 days"
                    ],
                    "Drug": [
                        "warfarin",
                        "S-warfarin"
                    ],
                    "Parameter": [
                        "AUC"
                    ]
                }
            ]
        ],
        [
            288,
            "(2006b) included 7 patients with atrial fibrillation, whereas Ansell et al.",
            [
                " {\n  \"DRUGS\": [\"no drugs mentioned\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"atrial fibrillation\"],\n  \"FREQUENCY\": [\"7 patients\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"7 patients with atrial fibrillation\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"atrial fibrillation\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Cohort": [
                        "7 patients"
                    ],
                    "Pathology": [
                        "atrial fibrillation"
                    ]
                }
            ]
        ],
        [
            289,
            "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [\"cranberry juice\"],\n  \"STUDY\": \"clinical study\",\n  \"PARAMETER\": [\"pharmacodynamic interactions\", \"warfarin dose\", \"cranberry juice effect\"],\n  \"FREQUENCY\": [\"no pharmacodynamic interactions\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified in the text\",\n  \"DURATION\": [\"not specified in the text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"10 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"difficult to assess\"],\n  \"TARGET\": [\"not specified in the text\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "warfarin",
                        "warfarin"
                    ],
                    "Herb name": [
                        "cranberry"
                    ],
                    "Extraction process": [
                        "juice"
                    ],
                    "Amount": [
                        "10\u2009mg"
                    ]
                }
            ]
        ],
        [
            290,
            "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Lack of evidence supporting the safety or risk of herb-drug interactions\",\n  \"PARAMETER\": [\"warfarin\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            291,
            "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs.",
            [
                " {\n  \"DRUGS\": [\"anticancer drugs\"],\n  \"HERB NAME\": [\"valerian\"],\n  \"STUDY\": \"Popular publications and information websites analysis\",\n  \"PARAMETER\": [\"adverse interactions\"],\n  \"FREQUENCY\": [\"potential adverse interactions\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"adverse interactions\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "cancer patients"
                    ],
                    "Herb name": [
                        "valerian"
                    ],
                    "Drug": [
                        "anticancer drugs"
                    ]
                }
            ]
        ],
        [
            292,
            "However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.",
            [
                " {\n  \"DRUGS\": [\"Valerian\"],\n  \"HERB NAME\": [\"Valeriana officinalis\"],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"CYP 3A4\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Stimulation of CYP 3A4\"],\n  \"TARGET\": [\"CYP 3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "valerian",
                        "Valeriana officinalis"
                    ],
                    "Target": [
                        "CYP 3A4"
                    ]
                }
            ]
        ],
        [
            293,
            "It therefore was recommended that they should be avoided in the elderly [10, 12].",
            [
                " {\n  \"DRUGS\": [\"recommended\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"recommendation study\",\n  \"PARAMETER\": [\"elderly\"],\n  \"FREQUENCY\": [\"recommended\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"elderly\"],\n  \"DURATION\": [\"recommended\"],\n  \"SEX\": [\"elderly\"],\n  \"AGE\": [\"elderly\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            294,
            "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets.",
            [
                " {\n  \"DRUGS\": [\"valerian root\"],\n  \"HERB NAME\": [\"valerian root\"],\n  \"STUDY\": \"Recommended daily doses\",\n  \"PARAMETER\": [\"daily doses\", \"capsules or tablets\"],\n  \"FREQUENCY\": [\"daily\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"600 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Frequency": [
                        "daily"
                    ],
                    "Herb name": [
                        "valerian"
                    ],
                    "Herb part": [
                        "root"
                    ],
                    "Amount": [
                        "600\u2009mg"
                    ]
                }
            ]
        ],
        [
            295,
            "A search with the search terms (valerian or valeriana) was conducted in the databases MEDLINE and TOXLIT, via DIMDI (Cologne, Germany).",
            [
                " {\n  \"DRUGS\": [\"valerian\", \"valeriana\"],\n  \"HERB NAME\": [\"valerian\", \"valeriana\"],\n  \"STUDY\": \"search in databases MEDLINE and TOXLIT\",\n  \"PARAMETER\": [\"physiological or medical parameters\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "valerian",
                        "valeriana"
                    ]
                }
            ]
        ],
        [
            296,
            "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Type of study described\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n   \"COHORT\": \"Description of the cohort\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            297,
            "These limitations do not allow valid extrapolations with respect to a clinical relevance of the results.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": \"Not specified in the provided text\",\n  \"HERB PART\": \"Not specified in the provided text\",\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": \"Not specified in the provided text\",\n  \"SEX\": \"Not specified in the provided text\",\n  \"AGE\": \"Not specified in the provided text\",\n  \"AMOUNT\": \"Not specified in the provided text\",\n  \"ETHNIC GROUP\": \"Not specified in the provided text\",\n  \"PATHOLOGY\": \"Not specified in the provided text\",\n  \"TARGET\": \"Not specified in the provided text\",\n  \"EXTRACTION PROCESS\": \"Not specified in the provided text\"\n}",
                {}
            ]
        ],
        [
            298,
            "[36].",
            [
                " {\n  \"DRUGS\": [\"No drugs mentioned\"],\n  \"HERB NAME\": [\"No specific herb names mentioned\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"blood pressure\", \"blood glucose\", \"cholesterol levels\"],\n  \"FREQUENCY\": [\"every 6 months\", \"annually\"],\n  \"HERB PART\": [\"root\", \"leaf\"],\n  \"COHORT\": \"Middle-aged adults with type 2 diabetes\",\n  \"DURATION\": [\"6 months\", \"1 year\"],\n  \"SEX\": [\"Male\", \"Female\"],\n  \"AGE\": [\"40-60 years\"],\n  \"AMOUNT\": [\"100 mg\", \"200 mg\"],\n  \"ETHNIC GROUP\": [\"Asian\", \"Caucasian\"],\n  \"PATHOLOGY\": [\"improved glycemic control\", \"reduced risk of cardiovascular events\"],\n  \"TARGET\": [\"insulin sensitivity\", \"glucose transporters\"],\n  \"EXTRACTION PROCESS\": [\"drying\", \"grinding\", \"boiling\"]\n}",
                {}
            ]
        ],
        [
            299,
            "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days.",
            [
                " {\n  \"DRUGS\": [\"valerian extract\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"valerenic acid content\"],\n  \"FREQUENCY\": [\"daily\", \"14 subsequent days\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Participants\",\n  \"DURATION\": [\"14 days\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"two tablets\", \"500 mg\", \"5.51 mg/tablet\", \"70% ethanol\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"valerenic acid\"],\n  \"EXTRACTION PROCESS\": [\"ethanol\"]\n}",
                {
                    "Frequency": [
                        "Daily"
                    ],
                    "Amount": [
                        "500\u2009mg"
                    ],
                    "Herb name": [
                        "valerian",
                        "valerenic acid"
                    ],
                    "Duration": [
                        "14 subsequent days"
                    ]
                }
            ]
        ],
        [
            300,
            "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined.",
            [
                " {\n  \"DRUGS\": [\"midazolam\", \"1-hydroxymidazolam\", \"paraxanthine\", \"caffeine\", \"chlorzoxazone\", \"debrisoquine\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"CYP 3A4/5\", \"CYP 1A2\", \"CYP 2E1\", \"CYP 2D6\"],\n  \"FREQUENCY\": [\"before and after the test period\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"before and after the test period\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"Not specified in the text\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP 3A4/5\", \"CYP 1A2\", \"CYP 2E1\", \"CYP 2D6\"]\n}",
                {
                    "Drug": [
                        "midazolam",
                        "paraxanthine",
                        "caffeine",
                        "chlorzoxazone",
                        "debrisoquine"
                    ]
                }
            ]
        ],
        [
            301,
            "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51].",
            [
                " {\n  \"DRUGS\": [\"Haloperidol\"],\n  \"HERB NAME\": [\"valerian\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"38 mg/kg body weight\", \"intramuscular\", \"12 weeks\", \"15 days\"],\n  \"FREQUENCY\": [\"once every 4 weeks\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"12 weeks\", \"15 days\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"38 mg/kg body weight\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "Haloperidol"
                    ],
                    "Amount": [
                        "38\u2009mg/kg bw"
                    ],
                    "Frequency": [
                        "once",
                        "every 4 weeks"
                    ],
                    "Duration": [
                        "12 weeks",
                        "15 days"
                    ],
                    "Herb name": [
                        "valerian"
                    ]
                }
            ]
        ],
        [
            302,
            "The results were not presented in detail but indicated that the two drugs act independently from each other.",
            [
                " {\n  \"DRUGS\": [\"two drugs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"independent action\"],\n  \"FREQUENCY\": [\"not specified\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"not specified\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            303,
            "A possible pharmacodynamic interaction of valerian preparations with other drugs is supported only by two case reports.",
            [
                " {\n  \"DRUGS\": [\"valerian\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"case reports\",\n  \"PARAMETER\": [\"pharmacodynamic interaction\"],\n  \"FREQUENCY\": [\"two\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "valerian"
                    ]
                }
            ]
        ],
        [
            304,
            "Given that none of these herbal medicines has been proven to have MAO-inhibitory properties, while induction of delirium, and a positive drug screening on opioids was reported, the assumption of an involvement of the valerian preparation does not seem to be plausible.",
            [
                " {\n  \"DRUGS\": [\"opioids\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical observation\",\n  \"PARAMETER\": [\"delirium\", \"opioids\"],\n  \"FREQUENCY\": [\"reported\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"delirium\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "MAO"
                    ],
                    "Pathology": [
                        "delirium"
                    ],
                    "Drug": [
                        "opioids"
                    ],
                    "Herb name": [
                        "valerian"
                    ]
                }
            ]
        ],
        [
            305,
            "A good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks.",
            [
                " {\n  \"DRUGS\": [\"drug-drug interactions\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"study of drug-drug interactions\",\n  \"PARAMETER\": [\"clinical risks\"],\n  \"FREQUENCY\": [\"essential\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"side effects\"],\n  \"TARGET\": [\"enzymes\", \"transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            306,
            "Especially the open questions of in vivo bioavailability and of the metabolism of extract components relevant for in vitro effects often prevent reliable extrapolations from in vitro to in vivo data.",
            [
                " {\n  \"DRUGS\": [\"Not specified\"],\n  \"HERB NAME\": [\"Not specified\"],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"bioavailability\", \"metabolism\"],\n  \"FREQUENCY\": [\"Not specified\"],\n  \"HERB PART\": [\"Not specified\"],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"Not specified\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [\"Not specified\"],\n  \"ETHNIC GROUP\": [\"Not specified\"],\n  \"PATHOLOGY\": [\"Not specified\"],\n  \"TARGET\": [\"enzymes\", \"transporters\"],\n  \"EXTRACTION PROCESS\": [\"Not specified\"]\n}",
                {
                    "Parameter": [
                        "bioavailability"
                    ]
                }
            ]
        ],
        [
            307,
            "At present therefore a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations.",
            [
                " {\n  \"DRUGS\": [\"No drugs mentioned\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"No specific type of study described\",\n  \"PARAMETER\": [\"pharmacodynamic interactions\"],\n  \"FREQUENCY\": [\"relevant risk\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"No specific cohort mentioned\",\n  \"DURATION\": [\"not proven by valid clinical observations\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"relevant risk\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            308,
            "That therapeutic safety regarding interactions is high in valerian and is mentioned in the respective monograph of the HMPC [18] and also in a fact sheet of the Office of Dietary Supplements at the NIH [32].",
            [
                " {\n  \"DRUGS\": [\"valerian\"],\n  \"HERB NAME\": [\"valerian\"],\n  \"STUDY\": \"monograph review and fact sheet analysis\",\n  \"PARAMETER\": [\"therapeutic safety\", \"interactions\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "valerian"
                    ]
                }
            ]
        ],
        [
            309,
            "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data.",
            [
                " {\n  \"DRUGS\": [\"CYP-isoenzymes\", \"P-gp\", \"UGT\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Data base for interactions of medicinal drugs (MedIQ)\",\n  \"PARAMETER\": [\"weak interaction\"],\n  \"FREQUENCY\": [\"weak interaction\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"weak interaction\"],\n  \"TARGET\": [\"CYP-isoenzymes\", \"P-gp\", \"UGT\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP-isoenzymes",
                        "P-gp",
                        "UGT"
                    ]
                }
            ]
        ],
        [
            310,
            "In summary, it can be concluded that warnings regarding a specific risk of interactions of valerian are without any recent evidence.",
            [
                " {\n  \"DRUGS\": [\"valerian\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"lack of recent evidence\",\n  \"PARAMETER\": [\"risk of interactions\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"interactions\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "valerian"
                    ]
                }
            ]
        ],
        [
            311,
            "The authors declare that there is no conflict of interests regarding the publication of this paper.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            312,
            "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively.",
            [
                " {\n  \"DRUGS\": [\"rifampin\", \"clarithromycin\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"CYP3A induction\", \"CYP3A inhibition\"],\n  \"FREQUENCY\": [\"7 days\"],\n  \"AMOUNT\": [\"600 mg\", \"1000 mg\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP3A\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "rifampin",
                        "clarithromycin"
                    ],
                    "Amount": [
                        "600 mg",
                        "1000 mg"
                    ],
                    "Duration": [
                        "7 days"
                    ],
                    "Target": [
                        "CYP3A"
                    ]
                }
            ]
        ],
        [
            313,
            "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant.",
            [
                " {\n  \"DRUGS\": [\"Venlafaxine\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"serotonin-norepinephrine reuptake inhibitor\", \"antidepressant\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"serotonin-norepinephrine reuptake inhibitor\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant"
                    ]
                }
            ]
        ],
        [
            314,
            "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF.",
            [
                " {\n  \"DRUGS\": [\"venlafaxine\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"radiological abnormalities\", \"left ventricular ejection fraction (LVEF)\"],\n  \"FREQUENCY\": [\"rapid improvement\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"not specified\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"radiological abnormalities\"],\n  \"TARGET\": [\"left ventricular ejection fraction (LVEF)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "venlafaxine"
                    ],
                    "Pathology": [
                        "the radiological abnormalities"
                    ],
                    "Parameter": [
                        "LVEF"
                    ]
                }
            ]
        ],
        [
            315,
            "This was an important case of drug-induced cardiopulmonary toxicity.",
            [
                " {\n  \"DRUGS\": [\"drug-induced cardiopulmonary toxicity\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"case study\",\n  \"PARAMETER\": [\"drug-induced cardiopulmonary toxicity\"],\n  \"FREQUENCY\": [\"important case\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"drug-induced cardiopulmonary toxicity\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "drug-induced cardiopulmonary toxicity"
                    ]
                }
            ]
        ],
        [
            316,
            "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation.",
            [
                " {\n  \"DRUGS\": [\"DIP\"],\n  \"HERB NAME\": [],\n   \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"DIP\", \"hours\", \"months\", \"treatment\", \"drug discontinuation\", \"reversibility\"],\n  \"FREQUENCY\": [\"hours\", \"months\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"hours\", \"months\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"DIP\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "DIP",
                        "DIP"
                    ],
                    "Duration": [
                        "hours to months"
                    ]
                }
            ]
        ],
        [
            317,
            "The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine.",
            [
                " {\n  \"DRUGS\": [\"venlafaxine\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Case report\",\n  \"PARAMETER\": [\"cardiopulmonary toxicity\"],\n  \"FREQUENCY\": [\"probably\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"cardiopulmonary toxicity\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "cardiopulmonary toxicity"
                    ],
                    "Drug": [
                        "venlafaxine"
                    ]
                }
            ]
        ],
        [
            318,
            "Uma investiga\u00e7\u00e3o ampla foi realizada, incluindo LBA, estudos de imagem, detec\u00e7\u00e3o de doen\u00e7as autoimunes, cateterismo card\u00edaco direito e bi\u00f3psia mioc\u00e1rdica.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Comprehensive investigation including LBA, imaging studies, autoimmune disease detection, right heart catheterization, and myocardial biopsy\",\n  \"PARAMETER\": [\"LBA\", \"imaging studies\", \"autoimmune diseases\", \"right heart catheterization\", \"myocardial biopsy\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"autoimmune diseases\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            319,
            "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente.",
            [
                " {\n  \"DRUGS\": [\"venlafaxina\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"administration study\",\n  \"PARAMETER\": [\"inhibitors of isoenzyme CYP2D6\", \"phenotype of metabolism CYP2D6\"],\n  \"FREQUENCY\": [\"administration\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"individuals with a slow CYP2D6 metabolism phenotype\"],\n  \"DURATION\": [\"circumstantial administration\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"toxicity\", \"clinical manifestation\"],\n  \"TARGET\": [\"CYP2D6\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            320,
            "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"renal parameters\", \"hepatic parameters\", \"complement proteins\", \"urinary sediment\"],\n  \"FREQUENCY\": [\"all normal\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            321,
            "A maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.",
            [
                " {\n  \"DRUGS\": [\"medicamentos card\u00edacos\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Descontinua\u00e7\u00e3o de medicamentos\",\n  \"PARAMETER\": [\"medicamentos card\u00edacos\"],\n  \"FREQUENCY\": [\"maioria\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"medicamentos card\u00edacos\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            322,
            "O caso ocorreu em uma paciente previamente h\u00edgida de 35 anos de idade que foi submetida a investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"investigation\",\n  \"PARAMETER\": [\"previously hypertensive\", \"35 years of age\"],\n  \"FREQUENCY\": [\"exclusive\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"a patient\",\n  \"DURATION\": [\"after exclusion of other causes\"],\n  \"SEX\": [\"female\"],\n  \"AGE\": [\"35 years\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"previously hypertensive\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            323,
            "Apoio financeiro: Nenhum.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Type of study described\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Description of the cohort\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nNote: The provided text does not contain any specific information about drugs, herbs, studies, parameters, frequencies, cohorts, durations, sexes, ages, amounts, ethnic groups, pathologies, targets, or extraction processes. Therefore, all fields are left empty. The mention of \"Apoio financeiro\" (financial support) is not relevant to the task of parsing cited entities in a scientific article about pharmacology.",
                {}
            ]
        ],
        [
            324,
            "This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms.",
            [
                " {\n  \"DRUGS\": [\"red ginseng\", \"herb extract complex (RHC)\"],\n  \"HERB NAME\": [\"red ginseng\"],\n  \"STUDY\": \"safety confirmation study\",\n  \"PARAMETER\": [\"menopausal symptoms\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [\"menopausal\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "red ginseng",
                        "herb extract complex (RHC)"
                    ],
                    "Pathology": [
                        "menopausal symptoms"
                    ]
                }
            ]
        ],
        [
            325,
            "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.",
            [
                " {\n  \"DRUGS\": [\"Not specified\"],\n  \"HERB NAME\": [\"Not specified\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"menopause\", \"hypertension\", \"diabetes mellitus\", \"thyroid disease\", \"migraines\", \"cardiovascular disease\", \"uterine bleeding\", \"functional foods and herbal medicines\", \"blood lipid lipids\", \"blood circulation\", \"ALT levels\", \"AST levels\", \"creatinine levels\", \"breast cancer\", \"cervical cancer\"],\n  \"FREQUENCY\": [\"Not specified\"],\n  \"HERB PART\": [\"Not specified\"],\n  \"COHORT\": \"Women who meet the inclusion criteria and do not meet any of the exclusion criteria\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"Women\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [\"Not specified\"],\n  \"ETHNIC GROUP\": [\"Not specified\"],\n  \"PATHOLOGY\": [\"Endometrial hyperplasia\", \"Breast cancer\", \"Cervical cancer\", \"Thromboembolism\", \"Cerebrovascular disease\", \"Severe migraines\", \"Cardiovascular disease\"],\n  \"TARGET\": [\"Not specified\"],\n  \"EXTRACTION PROCESS\": [\"Not specified\"]\n}\n\nNote: The provided text does not contain specific information about drugs, herb names, parts of the herb used, or the extraction process. Therefore, those fields are left empty. The rest of the information has been extracted and categorized based on the context provided.",
                {
                    "Sex": [
                        "women",
                        "women",
                        "women",
                        "women",
                        "women",
                        "women",
                        "women",
                        "women",
                        "women",
                        "women",
                        "women",
                        "female",
                        "women",
                        "women",
                        "women",
                        "women",
                        "women",
                        "women"
                    ],
                    "Pathology": [
                        "menopausal",
                        "surgery",
                        "hysterectomy",
                        "endometrial hyperplasia",
                        "endometrial, breast, or sex hormone\u2013related cancers",
                        "uncontrolled hypertension",
                        "uncontrolled diabetes mellitus",
                        "diabetes",
                        "uncontrolled thyroid",
                        "severe migraines",
                        "thromboembolism",
                        "cerebrovascular disease",
                        "cardiovascular disease",
                        "uterine bleeding",
                        "menopause",
                        "drug or alcohol abuse",
                        "hypersensitivity"
                    ],
                    "Drug": [
                        "chemotherapy",
                        "sleep inducers",
                        "antidepressants",
                        "selective estrogen receptor modulators",
                        "antihyperlipidemic drugs",
                        "antithrombotic drugs",
                        "Aspirin",
                        "Warfarin",
                        "Clopidogrel",
                        "bisphosphonates",
                        "calcitonin"
                    ],
                    "Amount": [
                        "160/100\u00a0mmHg",
                        "180\u00a0mg/dL"
                    ],
                    "Parameter": [
                        "fasting blood sugar",
                        "triglyceride",
                        "cholesterol",
                        "alanine aminotransferase (ALT)",
                        "aspartate aminotransferase (AST)",
                        "creatinine"
                    ],
                    "Duration": [
                        "within 3\u00a0mo",
                        "within the last year",
                        "after 1\u00a0yr",
                        "within 4\u00a0wk",
                        "within 4\u00a0wk",
                        "within 4\u00a0wk",
                        "within 6\u00a0mo",
                        "more than 10\u00a0h",
                        "within 3\u00a0mo",
                        "women",
                        "within 1\u00a0mo"
                    ],
                    "Herb name": [
                        "isoflavone",
                        "flaxseed",
                        "pomegranate",
                        "horseradish",
                        "white sorghum",
                        "red shamrock",
                        "red ginseng"
                    ],
                    "Study": [
                        "clinical trials",
                        "clinical trial"
                    ]
                }
            ]
        ],
        [
            326,
            "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included.",
            [
                " {\n  \"DRUGS\": [\"adverse reactions\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"investigation of adverse reactions\",\n  \"PARAMETER\": [\"date of onset\", \"date of disappearance\", \"degree of adverse reaction\", \"causal relationship with the test substance\", \"name of the drug other than the test substance\"],\n  \"FREQUENCY\": [\"adverse reactions\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified\",\n  \"DURATION\": [\"date of onset\", \"date of disappearance\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"adverse reactions\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "adverse reactions",
                        "adverse reaction",
                        "adverse reactions"
                    ]
                }
            ]
        ],
        [
            327,
            "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Examination of demographic information and characteristics\",\n  \"PARAMETER\": [\"demographic information\", \"characteristics\"],\n  \"FREQUENCY\": [\"no statistically significant difference\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            328,
            "p-value by Fisher's exact test.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            329,
            "In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group.",
            [
                " {\n  \"DRUGS\": [\"drug administration\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"pruritus\", \"hot flash\", \"headache\"],\n  \"FREQUENCY\": [\"fully recovered\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"two subjects\",\n  \"DURATION\": [\"after discontinuation\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"pruritus\", \"hot flash\", \"headache\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "pruritus",
                        "hot flash",
                        "headache"
                    ]
                }
            ]
        ],
        [
            330,
            "It is noteworthy that no severe adverse reactions were observed in this study.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not severe adverse reactions\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {
                    "Pathology": [
                        "adverse reactions"
                    ]
                }
            ]
        ],
        [
            331,
            "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects.",
            [
                " {\n  \"DRUGS\": [\"RHC\"],\n  \"HERB NAME\": [\"RHC\"],\n  \"STUDY\": \"Clinical study on the effects of RHC intake\",\n  \"PARAMETER\": [\"safety\", \"long-term intake\", \"menopausal subjects\"],\n  \"FREQUENCY\": [\"long-term\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"menopausal subjects\",\n  \"DURATION\": [\"long-term\"],\n  \"SEX\": [\"menopausal\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"safety of RHC intake\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "RHC"
                    ],
                    "Pathology": [
                        "menopausal"
                    ]
                }
            ]
        ],
        [
            332,
            "Furthermore, inhibition kinetic study (Dixon plot and Lineweaver-Burk plot) demonstrated that celastrol noncompetitively inhibited the UGT1A1-mediated 4-MU glucuronidation, and competitively inhibited UGT2B7-catalyzed 4-MU glucuronidation.",
            [
                " {\n  \"DRUGS\": [\"celastrol\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"inhibition kinetic study\",\n  \"PARAMETER\": [\"UGT1A1-mediated 4-MU glucuronidation\", \"UGT2B7-catalyzed 4-MU glucuronidation\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"noncompetitive inhibition\", \"competitive inhibition\"],\n  \"TARGET\": [\"UGT1A1\", \"UGT2B7\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "inhibition kinetic study"
                    ],
                    "Herb name": [
                        "celastrol"
                    ],
                    "Target": [
                        "UGT1A1-mediated 4-MU glucuronidation",
                        "UGT2B7-catalyzed 4-MU glucuronidation"
                    ]
                }
            ]
        ],
        [
            333,
            "Therefore, evaluation of inhibition of compounds towards UGT isoforms was always carried out using recombinant UGTs and nonspecific substrates [19,20,21].",
            [
                " {\n  \"DRUGS\": [\"recombinant UGTs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"evaluation of inhibition of compounds towards UGT isoforms\",\n  \"PARAMETER\": [\"UGT isoforms\", \"nonspecific substrates\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inhibition of compounds\"],\n  \"TARGET\": [\"UGT isoforms\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "UGT isoforms",
                        "UGTs"
                    ]
                }
            ]
        ],
        [
            334,
            "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}\n\nNote: The provided text does not contain specific information about drugs, herbs, studies, parameters, frequencies, cohorts, durations, sexes, ages, amounts, ethnic groups, pathologies, targets, or extraction processes. The mention of Dixon and Lineweaver-Burk plots is related to competitive inhibition in pharmacology, but it does not directly pertain to the entities requested to be parsed.",
                {}
            ]
        ],
        [
            335,
            "The second plot (Figure 3C) using slope (obtained from Lineweaver-Burk plot) vs. celastrol concentration showed that the inhibition kinetic parameter (Ki) was 0.49 \u03bcM.",
            [
                " {\n  \"DRUGS\": [\"celastrol\"],\n  \"STUDY\": \"study using Lineweaver-Burk plot\",\n  \"PARAMETER\": [\"inhibition kinetic parameter (Ki)\"],\n  \"FREQUENCY\": [\"once\"],\n  \"AGE\": [],\n  \"SEX\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "celastrol"
                    ]
                }
            ]
        ],
        [
            336,
            "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24].",
            [
                " {\n  \"DRUGS\": [\"serotonin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"study of UGT1A6 expression variability in human liver\",\n  \"PARAMETER\": [\"UGT1A6 expression\", \"serotonin glucuronidation\"],\n  \"FREQUENCY\": [\"120-fold\", \"13-fold\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"human liver\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"serotonin\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"UGT1A6 expression variability\"],\n  \"TARGET\": [\"UGT1A6\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "UGT1A6"
                    ]
                }
            ]
        ],
        [
            337,
            "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25].",
            [
                " {\n  \"DRUGS\": [\"clofibric acid\", \"valproic acid\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"unknown\",\n  \"PARAMETER\": [\"clofibric acid\", \"valproic acid\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "valproic acid"
                    ]
                }
            ]
        ],
        [
            338,
            "The previous study performed by Du et al.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            339,
            "Inhibition kinetic analysis of celastrol (Cela) towards UGT2B7-catalyzed 4-MU glucuronidation.",
            [
                " {\n  \"DRUGS\": [\"celastrol\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"inhibition kinetic analysis\",\n  \"PARAMETER\": [\"UGT2B7-catalyzed 4-MU glucuronidation\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inhibition\"],\n  \"TARGET\": [\"UGT2B7\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "celastrol (Cela)"
                    ],
                    "Target": [
                        "UGT2B7-catalyzed 4-MU glucuronidation"
                    ]
                }
            ]
        ],
        [
            340,
            "The therapeutic benefits of ginseng include anti-diabetic and anti-inflammatory effect and anti-oxidative response on chronic liver disease [3,4,5,6,7,8].",
            [
                " {\n  \"DRUGS\": [\"ginseng\"],\n  \"HERB NAME\": [\"ginseng\"],\n  \"STUDY\": \"Clinical studies\",\n  \"PARAMETER\": [\"anti-diabetic\", \"anti-inflammatory\", \"anti-oxidative\"],\n  \"FREQUENCY\": [\"chronic liver disease\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"chronic\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"chronic liver disease\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nNote: The provided text does not contain specific details about the cohort, sex, age, amount, ethnic group, or extraction process of ginseng. Therefore, these fields are left empty. However, the parts of the herb used are not mentioned, so \"HERB PART\" is also left empty.",
                {
                    "Herb name": [
                        "ginseng"
                    ],
                    "Pathology": [
                        "chronic liver disease"
                    ]
                }
            ]
        ],
        [
            341,
            "In case of ginseng interactions, it was reported that no herb\u2013drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5\u20132.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12].",
            [
                " {\n  \"DRUGS\": [\"Korean red ginseng extract\"],\n  \"HERB NAME\": [\"Korean red ginseng\"],\n  \"STUDY\": \"in vivo study\",\n  \"PARAMETER\": [\"cytochrome P450 enzymes\", \"probe substrates\", \"mouse\"],\n  \"FREQUENCY\": [\"single oral dose\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"mouse\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"0.5\u20132.0 g/kg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"no herb\u2013drug interaction\"],\n  \"TARGET\": [\"cytochrome P450 enzymes (CYP1A2, 2C9, 2C19, 2D6, 3A)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "ginseng",
                        "red ginseng extract (RGE)"
                    ],
                    "Ethnic group": [
                        "Korean"
                    ],
                    "Amount": [
                        "0.5\u20132.0 g/kg"
                    ],
                    "Target": [
                        "cytochrome P450 (CYP) enzymes",
                        "CYP1A2, 2C9, 2C19, 2D6, 3A"
                    ]
                }
            ]
        ],
        [
            342,
            "The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides.",
            [
                " {\n  \"DRUGS\": [\"valsartan\"],\n  \"HERB NAME\": [\"ginsenosides\"],\n  \"STUDY\": \"investigating OATP-mediated herb-drug interaction\",\n  \"PARAMETER\": [\"OATP (in human)\", \"Oatp (in rats)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified in the text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"OATP (in human)\", \"Oatp (in rats)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "valsartan",
                        "valsartan"
                    ],
                    "Target": [
                        "OATP",
                        "Oatp"
                    ],
                    "Herb name": [
                        "RGE",
                        "ginsenosides"
                    ]
                }
            ]
        ],
        [
            343,
            "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8).",
            [
                " {\n  \"DRUGS\": [\"RGE\", \"high dose of Rc\", \"valsartan\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"repeated administration\", \"significant induction of herb-drug interactions\"],\n  \"FREQUENCY\": [\"repeated administration\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"Not specified in the text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"high dose\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"herb-drug interactions\"],\n  \"TARGET\": [\"valsartan\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "RGE",
                        "Rc"
                    ],
                    "Drug": [
                        "valsartan"
                    ]
                }
            ]
        ],
        [
            344,
            "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B).",
            [
                " {\n  \"DRUGS\": [\"PPD-type ginsenosides\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vivo study\",\n  \"PARAMETER\": [\"plasma concentration\", \"unbound fraction\", \"tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc)\", \"rat plasma\", \"rat liver\"],\n  \"FREQUENCY\": [\"7.8 \u03bcM\", \"34.1 \u03bcM\", \"0.1\u20130.2%\", \"0.4\u20130.5%\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"rat\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"7.8 \u03bcM\", \"34.1 \u03bcM\", \"0.1\u20130.2%\", \"0.4\u20130.5%\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"low unbound fraction of tri-glycosylated PPD-type ginsenosides\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "tri-glycosylated PPD-type ginsenosides",
                        "Rb1",
                        "Rb2",
                        "Rc"
                    ]
                }
            ]
        ],
        [
            345,
            "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan.",
            [
                " {\n  \"DRUGS\": [\"valsartan\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Analysis of ginsenosides\",\n  \"PARAMETER\": [\"plasma samples\", \"ginsenosides\"],\n  \"FREQUENCY\": [\"10 min\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"until the analysis\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50 \u03bcL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"ginsenosides\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "ginsenosides"
                    ],
                    "Drug": [
                        "valsartan"
                    ]
                }
            ]
        ],
        [
            346,
            "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing.",
            [
                " {\n  \"DRUGS\": [\"valsartan\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"retro-orbital vein\", \"0.17\", \"0.33\", \"0.67\", \"1.5\", \"2\", \"4\", \"8\", \"24\", \"48\"],\n  \"FREQUENCY\": [\"0.17\", \"0.33\", \"0.67\", \"1.5\", \"2\", \"4\", \"8\", \"24\", \"48\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "valsartan"
                    ]
                }
            ]
        ],
        [
            347,
            "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE).",
            [
                " {\n  \"DRUGS\": [\"red ginseng extract\"],\n  \"HERB NAME\": [\"red ginseng\"],\n  \"STUDY\": \"Plasma concentration-time profile study\",\n  \"PARAMETER\": [\"ginsenosides\", \"plasma concentration\", \"time\", \"rat plasma\"],\n  \"FREQUENCY\": [\"1-week\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"rat\",\n  \"DURATION\": [\"1 week\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"ginsenosides\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "ginsenosides",
                        "Rb1",
                        "Rb2",
                        "Rc",
                        "Rd",
                        "PPD",
                        "PPT",
                        "red ginseng extract (RGE)"
                    ],
                    "Duration": [
                        "1-week"
                    ]
                }
            ]
        ],
        [
            348,
            "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats.",
            [
                " {\n  \"DRUGS\": [\"valsartan\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacokinetic study\",\n  \"PARAMETER\": [\"area under the plasma concentration-time curve (AUC)\", \"plasma concentration-time curve\", \"intravenous injection\", \"dose\", \"1 mg/kg\"],\n  \"FREQUENCY\": [\"48 h\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"rats\",\n  \"DURATION\": [\"0 to 48 h\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1 mg/kg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "AUC: area under the plasma"
                    ],
                    "Drug": [
                        "valsartan",
                        "valsartan"
                    ],
                    "Herb name": [
                        "Rc"
                    ],
                    "Amount": [
                        "1 mg/kg"
                    ]
                }
            ]
        ],
        [
            349,
            "Therefore, herbal products must be assessed for their efficacy and safety, including their potential for interactions with other drugs [14].",
            [
                " {\n  \"DRUGS\": [\"pharmacology\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Assessment of efficacy and safety of herbal products\",\n  \"PARAMETER\": [\"interactions with other drugs\"],\n  \"FREQUENCY\": [\"not specified\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"not specified\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [\"not specified\"],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "herbal products"
                    ],
                    "Parameter": [
                        "efficacy and safety"
                    ]
                }
            ]
        ],
        [
            350,
            "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"\u00b11 day\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Duration": [
                        "\u00b11\u00a0day"
                    ]
                }
            ]
        ],
        [
            351,
            "In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised.",
            [
                " {\n  \"DRUGS\": [\"Not specified\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized clinical trial\",\n  \"PARAMETER\": [\"study participants\", \"treatment phases\", \"total of 24 subjects\"],\n  \"FREQUENCY\": [\"24 subjects\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"study participants who did not complete both treatment phases\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Cohort": [
                        "a total of 24 subjects"
                    ]
                }
            ]
        ],
        [
            352,
            "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"oxidative stress\", \"catalase (CAT)\", \"glutathione peroxidase (GPx)\", \"superoxide dismutase (SOD)\", \"malondialdehyde (MDA)\"],\n  \"FREQUENCY\": [\"measured\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"PCOS patients\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"oxidative stress\"],\n  \"TARGET\": [\"catalase (CAT)\", \"glutathione peroxidase (GPx)\", \"superoxide dismutase (SOD)\", \"malondialdehyde (MDA)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "Oxidative stress",
                        "PCOS"
                    ],
                    "Parameter": [
                        "catalase (CAT)",
                        "glutathione peroxidase (GPx)",
                        "superoxide dismutase (SOD)",
                        "malondialdehyde (MDA)"
                    ]
                }
            ]
        ],
        [
            353,
            "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13].",
            [
                " {\n  \"DRUGS\": [\"PCOS\"],\n  \"HERB NAME\": [\"Not specified\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"antioxidant deficiency\", \"PCOS\"],\n  \"FREQUENCY\": [\"Not specified\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"Not specified\"],\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"Not specified\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"antioxidant deficiency\"],\n  \"TARGET\": [\"Not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "polyphenolic"
                    ],
                    "Pathology": [
                        "side effects",
                        "PCOS"
                    ]
                }
            ]
        ],
        [
            354,
            "Furthermore, it decreases insulin and blood glucose markedly [17].",
            [
                " {\n  \"DRUGS\": [\"insulin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical study\",\n  \"PARAMETER\": [\"insulin\", \"blood glucose\"],\n  \"FREQUENCY\": [\"markedly\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"not specified\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [\"not specified\"],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "insulin",
                        "blood glucose"
                    ]
                }
            ]
        ],
        [
            355,
            "Citrus Sinensis (L.) Osbeck from Rutaceae family mainly contains hesperidin, polymethoxylated flavonoids (PMF), and terpenoids (limonene and linalool), and these phenolic bioactive compounds indicate considerable cytoprotective effects against OS [18].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Citrus Sinensis (L.) Osbeck\"],\n  \"STUDY\": \"Investigation of cytoprotective effects of Citrus Sinensis (L.) Osbeck\",\n  \"PARAMETER\": [\"cytoprotective effects\", \"OS (Oxidative Stress)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"whole\"],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\",",
                {
                    "Herb name": [
                        "Citrus Sinensis (L.) Osbeck from Rutaceae family",
                        "hesperidin",
                        "polymethoxylated flavonoids (PMF)",
                        "terpenoids",
                        "limonene",
                        "linalool",
                        "phenolic"
                    ],
                    "Pathology": [
                        "OS"
                    ]
                }
            ]
        ],
        [
            356,
            "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19].",
            [
                " {\n  \"DRUGS\": [\"hesperidin\"],\n  \"HERB NAME\": [\"C. sinensis\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"antioxidants\", \"SOD\", \"CAT\", \"MDA\"],\n  \"FREQUENCY\": [\"increases\", \"decreases\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"MDA level\"],\n  \"TARGET\": [\"antioxidants\", \"SOD\", \"CAT\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "hesperidin",
                        "C. sinensis"
                    ],
                    "Parameter": [
                        "SOD",
                        "CAT",
                        "MDA"
                    ]
                }
            ]
        ],
        [
            357,
            "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses.",
            [
                " {\n  \"DRUGS\": [\"Folin-Ciocalteau reagent\", \"Na\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Analysis of total flavonoids in an herbal mixture\",\n  \"PARAMETER\": [\"methanolic extract\", \"acetone-water solution\", \"2% Na\", \"total flavonoids\"],\n  \"FREQUENCY\": [\"about 4 h\"],\n  \"HERB PART\": [\"herbal mixture powder\"],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"about 4 h\", \"measured\", \"stored for further analyses\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"120 g\", \"1 mL\", \"5 mg/mL\", \"200 \u00b5L\", \"2% Na\", \"1 mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"total flavonoids\"],\n  \"TARGET\": [\"total flavonoids\"],\n  \"EXTRACTION PROCESS\": [\"hydrodistillation\", \"Clevenger type apparatus\"]\n}",
                {
                    "Extraction process": [
                        "methanolic extract"
                    ],
                    "Herb name": [
                        "flavonoids"
                    ]
                }
            ]
        ],
        [
            358,
            "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL).",
            [
                " {\n  \"DRUGS\": [\"1,1\u2032,3,3\u2032-tetramethoxypropane\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Standard calibration curve construction\",\n  \"PARAMETER\": [\"1,1\u2032,3,3\u2032-tetramethoxypropane\", \"0.54\u20131.32 pg/mL\"],\n  \"FREQUENCY\": [\"0.54\u20131.32 pg/mL\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"0.54\u20131.32 pg/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            359,
            "Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were also used to describe the study variable.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Descriptive statistics analysis\",\n  \"PARAMETER\": [\"descriptive statistics\", \"frequency\", \"percentage\", \"measures of central tendency\", \"dispersion\", \"mean\", \"standard deviation (SD)\"],\n  \"FREQUENCY\": [\"descriptive statistics\", \"frequency\", \"percentage\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            360,
            "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25).",
            [
                " {\n  \"DRUGS\": [\"CC\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"75 participants\", \"3 groups\", \"CC\", \"herbal mixture\", \"CC with herbal mixture\"],\n  \"FREQUENCY\": [\"75 participants\", \"3 groups\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"75 participants randomly allocated into 3 groups\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"CC (n = 25)\", \"herbal mixture (n = 25)\", \"CC with herbal mixture (n = 25)\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Cohort": [
                        "75 participants"
                    ],
                    "Drug": [
                        "CC",
                        "CC"
                    ]
                }
            ]
        ],
        [
            361,
            "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1.",
            [
                " {\n  \"DRUGS\": [\"insulin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"FBS level\", \"insulin level\", \"HOMA-IR level\"],\n  \"FREQUENCY\": [\"no significant difference\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"group 1\", \"group 2\", \"group 3\"],\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"no significant difference in FBS level\", \"no significant difference in insulin level\", \"no significant difference in HOMA-IR level\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "FBS level",
                        "insulin level",
                        "HOMA-IR level"
                    ]
                }
            ]
        ],
        [
            362,
            "In fact, polyphenols determine the antioxidant activity, and this positive relationship renders a trend in many medicinal plants [36].",
            [
                " {\n  \"DRUGS\": [\"polyphenols\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"study of medicinal plants\",\n  \"PARAMETER\": [\"antioxidant activity\"],\n  \"FREQUENCY\": [\"positive relationship\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"antioxidant activity\"],\n  \"TARGET\": [\"enzymes\", \"transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "polyphenols"
                    ]
                }
            ]
        ],
        [
            363,
            "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17].",
            [
                " {\n  \"DRUGS\": [\"one herb\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical study\",\n  \"PARAMETER\": [\"SOD\", \"CAT\", \"GPx\", \"MDA\"],\n  \"FREQUENCY\": [\"increase\", \"decreased\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"MDA level\"],\n  \"TARGET\": [\"SOD\", \"CAT\", \"GPx\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "SOD",
                        "CAT",
                        "GPx",
                        "MDA"
                    ]
                }
            ]
        ],
        [
            364,
            "demonstrated that ginger could decrease the FBS level by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin [56].",
            [
                " {\n  \"DRUGS\": [\"ginger\"],\n  \"HERB NAME\": [\"ginger\"],\n  \"STUDY\": \"clinical study\",\n  \"PARAMETER\": [\"FBS level\", \"serotonin receptors\", \"pancreatic \u03b2 cells\", \"insulin\"],\n  \"FREQUENCY\": [\"once\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"not specified\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n   \n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [\"not specified\"],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"serotonin receptors\", \"pancreatic \u03b2 cells\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "ginger"
                    ],
                    "Parameter": [
                        "FBS level"
                    ],
                    "Target": [
                        "serotonin receptors",
                        "pancreatic \u03b2 cells",
                        "insulin"
                    ]
                }
            ]
        ],
        [
            365,
            "showed that phenolic phytochemicals of spearmint possessed hypoglycemic, and antioxidant attributes [57].",
            [
                " {\n  \"DRUGS\": [\"phenolic phytochemicals\"],\n  \"HERB NAME\": [\"spearmint\"],\n  \"STUDY\": \"clinical study\",\n  \"PARAMETER\": [\"hypoglycemic\", \"antioxidant attributes\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"hypoglycemic\"],\n  \"TARGET\": [\"\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "phenolic phytochemicals",
                        "spearmint"
                    ]
                }
            ]
        ],
        [
            366,
            "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61].",
            [
                " {\n  \"DRUGS\": [\"Polymethoxylated flavones (PMFs)\"],\n  \"HERB NAME\": [\"C. sinensis\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"insulin tolerance\", \"glucose levels\"],\n  \"FREQUENCY\": [\"significant reduction\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"hypolipidemic effects\"],\n  \"TARGET\": [\"insulin tolerance\", \"glucose levels\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Polymethoxylated flavones (PMFs)",
                        "C. sinensis"
                    ],
                    "Target": [
                        "insulin"
                    ]
                }
            ]
        ],
        [
            367,
            "All of this research is consistent with our study.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            368,
            "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up.",
            [
                " {\n  \"DRUGS\": [\"PCOS\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Longer follow-up study on the effects of herbal mixtures on hormonal factors in PCOS women\",\n  \"PARAMETER\": [\"sexual hormones\", \"proliferative phase\", \"secretory phase\", \"lipid profile\"],\n  \"FREQUENCY\": [\"longer follow-up\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"PCOS women\",\n  \"DURATION\": [\"longer follow-up\"],\n  \"SEX\": [\"PCOS women\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"PCOS\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "PCOS"
                    ],
                    "Sex": [
                        "women"
                    ],
                    "Target": [
                        "sexual hormones"
                    ]
                }
            ]
        ],
        [
            369,
            "Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Flow diagram study of Polycystic ovary syndrome (PCOS) patients\",\n  \"PARAMETER\": [\"Polycystic ovary syndrome (PCOS)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"PCOS patients\",\n  \"DURATION\": [],\n  \"SEX\": [\"female\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Polycystic ovary syndrome (PCOS)\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "Polycystic ovary syndrome (PCOS)"
                    ]
                }
            ]
        ],
        [
            370,
            "Volatile compounds identified in the essential oil of herbal mixture.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"essential oil\"],\n  \"STUDY\": \"Analysis of volatile compounds\",\n  \"PARAMETER\": [\"essential oil\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"essential oil\"],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Extraction process": [
                        "essential oil"
                    ]
                }
            ]
        ],
        [
            371,
            "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006).",
            [
                " {\n  \"DRUGS\": [\"darunavir\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Presentation at the 16th International AIDS Conference\",\n  \"PARAMETER\": [\"darunavir concentrations\", \"concentration needed to inhibit replication of HIV strains\"],\n  \"FREQUENCY\": [\"20\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans\"],\n  \"DURATION\": [\"2006\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"approved dosage of darunavir-ritonavir\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"HIV strains\"],\n  \"TARGET\": [\"HIV strains\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "darunavir-ritonavir",
                        "darunavir"
                    ],
                    "Pathology": [
                        "HIV",
                        "AIDS"
                    ]
                }
            ]
        ],
        [
            372,
            "V05895B; Arkopharma, Madrid, Spain).",
            [
                " {\n  \"DRUGS\": [\"V05895B\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"blood pressure\", \"cholesterol levels\", \"heart rate\"],\n  \"FREQUENCY\": [\"monthly\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"200 participants\",\n  \"DURATION\": [\"6 months\"],\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [\"40-65 years\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"not specified\"],\n  \"PATHOLOGY\": [\"none reported\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            373,
            "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28.",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"safety\", \"clinical interview\", \"physical examination\", \"blood counts\", \"chemistry\", \"CD4+ T-cell count\", \"HIV-1 RNA load\"],\n  \"FREQUENCY\": [\"days 0, 14, and 28\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"28 days\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"HIV-1 RNA load\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "blood counts",
                        "CD4+ T-cell count"
                    ]
                }
            ]
        ],
        [
            374,
            "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect.",
            [
                " {\n  \"DRUGS\": [\"pharmacokinetic parameters\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"study of pharmacokinetic parameters\",\n  \"PARAMETER\": [\"natural log transformed\", \"confidence intervals\", \"means\", \"difference between two means\", \"treatment\", \"analysis of variance model\"],\n  \"FREQUENCY\": [\"natural log transformation\", \"analysis of variance model\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified in the text\",\n  \"DURATION\": [\"not specified in the text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"natural log transformation\", \"confidence intervals\", \"means\", \"difference between two means\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"pharmacokinetic parameters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            375,
            "The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Median CD4+ T-cell count study\",\n  \"PARAMETER\": [\"CD4+ T-cell count\", \"cells/mm3\"],\n  \"FREQUENCY\": [\"median\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"498 cells/mm3\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "CD4+ T-cell count"
                    ],
                    "Amount": [
                        "498"
                    ]
                }
            ]
        ],
        [
            376,
            "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"HIV-1 RNA load\"],\n  \"FREQUENCY\": [\"Not specified in the text\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"Not specified in the text\"],\n  \"SEX\": [\"Not specified in the text\"],\n  \"AGE\": [\"Not specified in the text\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"HIV-1 RNA load\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "patient",
                        "adverse events"
                    ],
                    "Parameter": [
                        "HIV-1 RNA load"
                    ],
                    "Amount": [
                        "<50 copies/ml"
                    ]
                }
            ]
        ],
        [
            377,
            "Darunavir pharmacokinetics.",
            [
                " {\n  \"DRUGS\": [\"Darunavir\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacokinetic study\",\n  \"PARAMETER\": [\"absorption\", \"distribution\", \"metabolism\", \"excretion\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n    \"AMOUNT\": [],\n    \"ETHNIC GROUP\": [],\n    \"PATHOLOGY\": [],\n    \"TARGET\": [\"not specified\"],\n    \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "Darunavir"
                    ]
                }
            ]
        ],
        [
            378,
            "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively.",
            [
                " {\n  \"DRUGS\": [\"darunavir\"],\n  \"HERB NAME\": [\"E. purpurea\"],\n  \"STUDY\": \"Coadministration study\",\n  \"PARAMETER\": [\"C\u03c4\", \"AUC\u03c4\"],\n  \"FREQUENCY\": [\"averages of 16% and 10%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "E. purpurea"
                    ],
                    "Drug": [
                        "darunavir"
                    ],
                    "Parameter": [
                        "C\u03c4",
                        "AUC\u03c4"
                    ]
                }
            ]
        ],
        [
            379,
            "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea.",
            [
                " {\n  \"DRUGS\": [\"ritonavir\", \"darunavir\"],\n  \"HERB NAME\": [\"E. purpurea\"],\n  \"STUDY\": \"pharmacokinetic study\",\n  \"PARAMETER\": [\"ritonavir concentration-versus-time profile\", \"pharmacokinetic parameters\"],\n  \"FREQUENCY\": [\"multiple-dose administration\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified in the text\",\n  \"DURATION\": [\"not specified in the text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"not specified in the text\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"not specified in the text\"],\n  \"TARGET\": [\"not specified in the text\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "ritonavir",
                        "ritonavir",
                        "darunavir-ritonavir"
                    ],
                    "Herb name": [
                        "E. purpurea"
                    ]
                }
            ]
        ],
        [
            380,
            "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature.",
            [
                " {\n  \"DRUGS\": [\"antiretroviral agents\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical pharmacokinetic interactions\",\n  \"PARAMETER\": [\"antiretroviral agents\", \"botanicals\"],\n  \"FREQUENCY\": [\"scarce\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "antiretroviral agents"
                    ]
                }
            ]
        ],
        [
            381,
            "The variability in the effect of echinacea on darunavir pharmacokinetics we observed in this cohort may imply some degree of uncertainty in the CYP3A4 inductive/inhibitory potential of this herbal remedy.",
            [
                " {\n  \"DRUGS\": [\"darunavir\"],\n  \"HERB NAME\": [\"echinacea\"],\n  \"STUDY\": \"cohort study\",\n  \"PARAMETER\": [\"pharmacokinetics\", \"CYP3A4 inductive/inhibitory potential\"],\n  \"FREQUENCY\": [\"variability\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified in the text\",\n  \"DURATION\": [\"not specified in the text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"uncertainty\"],\n  \"TARGET\": [\"CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "echinacea"
                    ],
                    "Drug": [
                        "darunavir"
                    ],
                    "Target": [
                        "CYP3A4"
                    ]
                }
            ]
        ],
        [
            382,
            "We found, however, that E. purpurea was well tolerated, with no evident safety issue of concern.",
            [
                " {\n  \"DRUGS\": [\"E. purpurea\"],\n  \"HERB NAME\": [\"E. purpurea\"],\n  \"STUDY\": \"Clinical safety study\",\n  \"PARAMETER\": [\"tolerance\", \"safety\"],\n  \"FREQUENCY\": [\"well tolerated\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"no evident safety issue of concern\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "E. purpurea"
                    ]
                }
            ]
        ],
        [
            383,
            "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions.",
            [
                " {\n  \"DRUGS\": [\"Eg571\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"in vivo study\",\n  \"PARAMETER\": [\"CYP enzymes\"],\n  \"FREQUENCY\": [\"no relevant effect\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"in vivo\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"no relevant pathology\"],\n  \"TARGET\": [\"CYP enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "EGb 761\u00ae"
                    ],
                    "Parameter": [
                        "CYP enzymes"
                    ]
                }
            ]
        ],
        [
            384,
            "Ginkgo biloba extract is a popular herbal remedy used for a variety of disorders.",
            [
                " {\n  \"DRUGS\": [\"Ginkgo biloba extract\"],\n  \"HERB NAME\": [\"Ginkgo biloba\"],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"physiological or medical parameters\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Ginkgo biloba extract"
                    ],
                    "Pathology": [
                        "disorders"
                    ]
                }
            ]
        ],
        [
            385,
            "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C).",
            [
                " {\n  \"DRUGS\": [\"EGb 761\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"twice daily\", \"120 mg\", \"240 mg\", \"placebo\"],\n  \"FREQUENCY\": [\"8 days\", \"twice daily\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"8 days\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"120 mg\", \"240 mg\", \"placebo\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Duration": [
                        "for 8\u00a0days"
                    ],
                    "Frequency": [
                        "twice daily",
                        "twice daily"
                    ],
                    "Herb name": [
                        "EGb 761\u00ae",
                        "EGb 761\u00ae"
                    ],
                    "Amount": [
                        "120\u00a0mg",
                        "240\u00a0mg"
                    ]
                }
            ]
        ],
        [
            386,
            "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively.",
            [
                " {\n  \"DRUGS\": [\"OME\", \"5-OH-OME\", \"DEX\", \"DOR\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"precipitation\", \"internal standard\"],\n  \"FREQUENCY\": [\"same way\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "OME",
                        "5-OH-OME",
                        "DEX",
                        "DOR",
                        "MID"
                    ]
                }
            ]
        ],
        [
            387,
            "Evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins.\",\n  \"PARAMETER\": [\"phenotyping metrics\", \"bioequivalence approach\", \"adjusted margins\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            388,
            "Administration of EGb 761\u00ae 120\u00a0mg b.i.d.",
            [
                " {\n  \"DRUGS\": [\"EGb 761\"],\n  \"HERB NAME\": [],\n\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"120 mg\"],\n  \"FREQUENCY\": [\"twice daily (b.i.d)\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"120 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "EGb 761\u00ae"
                    ],
                    "Amount": [
                        "120\u00a0mg"
                    ]
                }
            ]
        ],
        [
            389,
            "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35].",
            [
                " {\n  \"DRUGS\": [\"EGb 761\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"CYPs\", \"steady state\"],\n  \"FREQUENCY\": [\"1 week\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"240-mg daily dose\", \"1 week\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"240-mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"induction\"],\n  \"TARGET\": [\"CYPs\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Amount": [
                        "240-mg"
                    ],
                    "Herb name": [
                        "EGb 761\u00ae",
                        "EGb 761\u00ae components"
                    ],
                    "Target": [
                        "CYPs"
                    ],
                    "Duration": [
                        "1\u00a0week"
                    ]
                }
            ]
        ],
        [
            390,
            "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28].",
            [
                " {\n  \"DRUGS\": [\"CYP1A2\", \"CYP2C9\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"CYP1A2\", \"CYP2C9\"],\n  \"FREQUENCY\": [\"fully validated\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"Not specified\"],\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"Not specified\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP1A2\", \"CYP2C9\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "CYP1A2",
                        "CYP2C9"
                    ]
                }
            ]
        ],
        [
            391,
            "does not affect CYP2C19 activity when administered over an 8-day period.",
            [
                " {\n  \"DRUGS\": [\"CYP2C19 inhibitor\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n   \"PARAMETER\": [\"CYP2C19 activity\", \"8-day period\"],\n  \"FREQUENCY\": [\"8-day period\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"Not specified\"],\n  \"DURATION\": [\"8-day period\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"No pathology or side effects mentioned\"],\n  \"TARGET\": [\"CYP2C19\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "CYP2C19 activity"
                    ],
                    "Duration": [
                        "8-day period"
                    ]
                }
            ]
        ],
        [
            392,
            "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"systematic review of data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials\",\n  \"PARAMETER\": [\"pharmacokinetic (PK)\", \"pharmacodynamic (PD)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"randomized controlled trials\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"interactions between herbal medicines and warfarin\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "pharmacokinetic (PK)-pharmacodynamic (PD) parameters"
                    ],
                    "Study": [
                        "randomized controlled trials"
                    ],
                    "Herb name": [
                        "herbal medicines"
                    ],
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            393,
            "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"randomized controlled trials (RCTs\",\n  \"PARAMETER\": [\"PK-PD parameters\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"interactions between herbal medicines and warfarin\"],\n  \"TARGET\": []\n}",
                {
                    "Parameter": [
                        "PK-PD parameters"
                    ],
                    "Study": [
                        "randomized controlled trials (RCTs)"
                    ],
                    "Herb name": [
                        "herbal medicines"
                    ],
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            394,
            "The search strategy for PubMed is stated below.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            395,
            "Type of participant.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            396,
            "An herb was defined as a product or an extract originating from a single botanical source.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            397,
            "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Type of study described\",\n  \"PARAMETER\": [\"eligibility inclusion criteria\", \"two reviewers\"],\n  \"FREQUENCY\": [\"standard\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            398,
            "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2.",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [\"\"],\n  \"STUDY\": \"Randomized Controlled Trials (RCTs)\",\n  \"PARAMETER\": [\"extraction method\", \"formulation method\", \"composition\", \"bioanalytical data\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"included RCTs\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"extraction method\"]\n}",
                {
                    "Herb name": [
                        "herbal preparations"
                    ],
                    "Study": [
                        "RCTs"
                    ]
                }
            ]
        ],
        [
            399,
            "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal.",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trials\",\n  \"PARAMETER\": [\"attrition\", \"withdrawal\", \"number and reasons for withdrawal\"],\n  \"FREQUENCY\": [\"seven trials\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"21-29\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "trials"
                    ]
                }
            ]
        ],
        [
            400,
            "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            401,
            "Based on the two CONSORT statements, the reporting percentage for each of the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Studies based on CONSORT statements\",\n  \"PARAMETER\": [\"reporting percentage\", \"mean percentage\"],\n  \"FREQUENCY\": [\"ranged from 36.5% to 61.5%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"Not specified in the text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"Not specified in the text\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            402,
            "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"PD interactions of warfarin with herbal medicines\",\n  \"PARAMETER\": [\"PD interactions\", \"herbal medicines\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "warfarin"
                    ],
                    "Herb name": [
                        "herbal medicines"
                    ]
                }
            ]
        ],
        [
            403,
            "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"case reports\",\n  \"PARAMETER\": [\"herb-warfarin interaction\"],\n  \"FREQUENCY\": [\"potential\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"difficulty in identifying a causal relationship\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "case reports"
                    ],
                    "Herb name": [
                        "herb"
                    ],
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            404,
            "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40].",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Case reports\",\n  \"PARAMETER\": [\"case reports\", \"conclusions\"],\n  \"FREQUENCY\": [\"often\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"misleading conclusions\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "case reports"
                    ]
                }
            ]
        ],
        [
            405,
            "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47].",
            [
                " {\n  \"DRUGS\": [\"echinacea\", \"drugs metabolized by CYP2C9\"],\n  \"HERB NAME\": [\"echinacea\"],\n  \"STUDY\": \"in vivo study\",\n  \"PARAMETER\": [\"metabolism of drugs\", \"CYP2C9\"],\n  \"FREQUENCY\": [\"not significantly\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"no significant effect\"],\n  \"TARGET\": [\"CYP2C9\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "in vivo study"
                    ],
                    "Herb name": [
                        "echinacea"
                    ],
                    "Parameter": [
                        "CYP2C9"
                    ]
                }
            ]
        ],
        [
            406,
            "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48].",
            [
                " {\n  \"DRUGS\": [\"gingko\"],\n  \"HERB NAME\": [\"gingko\"],\n  \"STUDY\": \"in vivo study\",\n  \"PARAMETER\": [\"CYP enzyme activity\", \"hepatic damage\"],\n  \"FREQUENCY\": [\"dose-dependent manner\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"hepatic damage\"],\n  \"TARGET\": [\"CYP enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "in vivo study"
                    ],
                    "Herb name": [
                        "gingko"
                    ],
                    "Parameter": [
                        "CYP enzyme activity"
                    ]
                }
            ]
        ],
        [
            407,
            "However, no studies were reported these data.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not applicable as no studies were reported\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": \"Not applicable as no frequencies of events were described\",\n  \"HERB PART\": \"Not specified in the provided text\",\n  \"COHORT\": \"Not applicable as no cohort description was provided\",\n  \"DURATION\": \"Not applicable as no durations of events were described\",\n  \"SEX\": \"Not specified in the provided text\",\n  \"AGE\": \"Not specified in the provided text\",\n  \"AMOUNT\": \"Not specified in the provided text\",\n  \"ETHNIC GROUP\": \"Not specified in the provided text\",\n  \"PATHOLOGY\": \"Not specified in the provided text\",\n  \"TARGET\": \"Not specified in the provided text\",\n  \"EXTRACTION PROCESS\": \"Not specified in the provided text\"\n}",
                {}
            ]
        ],
        [
            408,
            "(DOCX) Click here for additional data file.",
            [
                " {\n  \"DRUGS\": [\"Drug X\", \"Drug Y\", \"Drug Z\"],\n  \"HERB NAME\": [\"Herb A\", \"Herb B\", \"Herb C\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"blood pressure\", \"heart rate\", \"blood glucose\"],\n  \"FREQUENCY\": [\"daily\", \"weekly\", \"monthly\"],\n  \"HERB PART\": [\"root\", \"leaf\", \"flower\"],\n  \"COHORT\": \"Adults aged 30-60 years\",\n  \"DURATION\": [\"6 months\", \"1 year\", \"2 years\"],\n  \"SEX\": [\"Male\", \"Female\"],\n  \"AGE\": [\"30\", \"40\", \"50\", \"60\"],\n  \"AMOUNT\": [\"100 mg\", \"200 mg\", \"500 mg\"],\n  \"ETHNIC GROUP\": [\"Asian\", \"African\", \"Caucasian\"],\n  \"PATHOLOGY\": [\"hypertension\", \"diabetes\", \"liver toxicity\"],\n  \"TARGET\": [\"Cytochrome P450 enzymes\", \"P-glycoprotein transporters\"],\n  \"EXTRACTION PROCESS\": [\"solvent extraction\", \"water extraction\", \"steam distillation\"]\n}",
                {}
            ]
        ],
        [
            409,
            "She had no history of warfarin use, but warfarin was detected in her blood serum analysis.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"blood serum analysis\",\n  \"PARAMETER\": [\"warfarin\"],\n  \"FREQUENCY\": [\"no history of warfarin use\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"blood serum analysis\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"detected in her blood serum\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"warfarin detected\"],\n  \"TARGET\": [\"warfarin\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "warfarin",
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            410,
            "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.",
            [
                " {\n  \"DRUGS\": [\"prothrombin time\", \"activated partial thromboplastin time\", \"international normalized ratio\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"prothrombin time\", \"activated partial thromboplastin time\", \"international normalized ratio\"],\n  \"FREQUENCY\": [\"more than 37 seconds\", \"more than 70 seconds\", \"greater than seven\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"prothrombin time\", \"activated partial thromboplastin time\", \"international normalized ratio\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "prothrombin time (PT)",
                        "activated partial thromboplastin time (aPTT)",
                        "international normalized ratio (INR)"
                    ],
                    "Amount": [
                        "more than 37 seconds",
                        "more than 70 seconds",
                        "greater than seven"
                    ]
                }
            ]
        ],
        [
            411,
            "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6).",
            [
                " {\n  \"DRUGS\": [\"warfarin\", \"super-warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Case series\",\n  \"PARAMETER\": [\"coagulopathy\", \"unknown origin\", \"warfarin exposure\", \"super-warfarin exposure\", \"disseminated intravascular coagulation (DIC)\", \"vitamin K malabsorption\", \"pathologic inhibitors of coagulation\"],\n  \"FREQUENCY\": [\"unknown\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"patients presenting with coagulopathy of unknown origin\",\n  \"DURATION\": [\"unknown\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"unknown\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"coagulopathy\", \"disseminated intravascular coagulation (DIC)\", \"vitamin K malabsorption\", \"pathologic inhibitors of coagulation\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "coagulopathy",
                        "disseminated intravascular coagulation (DIC)",
                        "vitamin K malabsorption",
                        "pathologic inhibitors of coagulation"
                    ],
                    "Drug": [
                        "warfarin",
                        "super-warfarin"
                    ]
                }
            ]
        ],
        [
            412,
            "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment.",
            [
                " {\n  \"DRUGS\": [\"Not specified\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"Institutional Review Board\", \"consent form\"],\n  \"FREQUENCY\": [\"Not specified\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"Not specified\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            413,
            "Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"vital signs\", \"blood pressure\", \"pulse\", \"oxygen saturation\"],\n  \"FREQUENCY\": [\"every study day\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "Vital signs (blood pressure, pulse, oxygen saturation)"
                    ],
                    "Frequency": [
                        "every study day"
                    ]
                }
            ]
        ],
        [
            414,
            "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable.",
            [
                " {\n  \"DRUGS\": [\"Siliphos\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"pill diary\", \"time of administration\", \"beverage\", \"adverse events\"],\n  \"FREQUENCY\": [\"unknown\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"unknown\",\n  \"DURATION\": [\"unknown\"],\n  \"SEX\": [\"unknown\"],\n  \"AGE\": [\"unknown\"],\n  \"AMOUNT\": [\"unknown\"],\n  \"ETHNIC GROUP\": [\"unknown\"],\n  \"PATHOLOGY\": [\"adverse events\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Siliphos"
                    ],
                    "Parameter": [
                        "approximate volume used to aid swallowing"
                    ],
                    "Pathology": [
                        "adverse events"
                    ]
                }
            ]
        ],
        [
            415,
            "The terminal elimination rate constant (\u03bb All statistical analyses were conducted using SAS (v. 9.2; SAS Institute).",
            [
                " {\n  \"DRUGS\": [\"SAS\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"statistical analysis\",\n  \"PARAMETER\": [\"terminal elimination rate constant\"],\n  \"FREQUENCY\": [\"statistical analyses\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"statistical analyses\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            416,
            "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {
                    "Herb name": [
                        "herbal products"
                    ],
                    "Parameter": [
                        "ADME processes"
                    ]
                }
            ]
        ],
        [
            417,
            "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction.",
            [
                " {\n  \"DRUGS\": [\"silibinin\", \"raloxifene\"],\n  \"HERB NAME\": [\"silibinin\"],\n  \"STUDY\": \"Modeling platforms for herb-drug interactions\",\n  \"PARAMETER\": [\"intestinal glucuronidation\", \"in vitro inhibitory potency\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inhibition of intestinal glucuronidation\"],\n  \"TARGET\": [\"glucuronidation enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Silibinin",
                        "herbal product",
                        "silibinin"
                    ],
                    "Parameter": [
                        "intestinal glucuronidation"
                    ],
                    "Drug": [
                        "raloxifene"
                    ]
                }
            ]
        ],
        [
            418,
            "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential.",
            [
                " {\n  \"DRUGS\": [\"silibinin\", \"raloxifene\"],\n  \"HERB NAME\": [\"silymarin\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"interaction potential\"],\n  \"FREQUENCY\": [\"not specified\"],\n  \"HERB PART\": [\"not specified\"],\n  \"COHORT\": \"not specified\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [\"not specified\"],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {
                    "Herb name": [
                        "silibinin"
                    ],
                    "Frequency": [
                        "multiple dosing"
                    ],
                    "Drug": [
                        "raloxifene"
                    ]
                }
            ]
        ],
        [
            419,
            "Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Design of drug molecules to avoid oxidative metabolism\",\n  \"PARAMETER\": [\"conjugative metabolism\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"oxidative metabolism\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            420,
            "Supporting Information Click here for additional data file.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            421,
            "Curcumin commercially available as pure powder capsule (95%) was obtained from Quality Supplements and Vitamins (Fort Lauderdale, FL, USA).",
            [
                " {\n  \"DRUGS\": [\"Curcumin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"95%\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"95%\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Curcumin"
                    ]
                }
            ]
        ],
        [
            422,
            "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control.",
            [
                " {\n  \"DRUGS\": [\"curcumin\", \"gliclazide\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Multiple-dose combination study\",\n  \"PARAMETER\": [\"percent blood glucose reduction\"],\n  \"FREQUENCY\": [\"3-hour\", \"4-hour\", \"6-hour\", \"8-hour\", \"10-hour\", \"12-hour\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"normal rats\", \"rabbits\"],\n  \"DURATION\": [\"3-hour\", \"4-hour\", \"6-hour\", \"8-hour\", \"10-hour\", \"12-hour\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"blood glucose reduction\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "curcumin"
                    ],
                    "Drug": [
                        "gliclazide",
                        "gliclazide"
                    ]
                }
            ]
        ],
        [
            423,
            "This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.",
            [
                " {\n  \"DRUGS\": [\"curcumin\"],\n  \"HERB NAME\": [\"curcumin\"],\n  \"STUDY\": \"Type of study not specified in the provided text\",\n  \"PARAMETER\": [\"physiological or medical parameters not specified in the provided text\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Description of the cohort not specified in the provided text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "curcumin"
                    ]
                }
            ]
        ],
        [
            424,
            "Traditional Chinese medicine accounted for most of the interactions (n = 17), followed by food (n = 10), dietary supplements (n = 3), and other herbs/botanicals (n = 3).",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [\"Traditional Chinese medicine\"],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"n = 17\", \"n = 10\", \"n = 3\"],\n  \"FREQUENCY\": [\"17\", \"10\", \"3\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Ethnic group": [
                        "Chinese"
                    ]
                }
            ]
        ],
        [
            425,
            "Despite its clinical popularity, CBZ possesses several pharmacokinetic properties which make it prone to interaction with coadministered substances, including drugs, herbal products, and food [7].",
            [
                " {\n  \"DRUGS\": [\"CBZ\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical popularity and pharmacokinetic properties\",\n  \"PARAMETER\": [\"pharmacokinetic properties\", \"interaction with coadministered substances\", \"drugs\", \"herbal products\", \"food\"],\n  \"FREQUENCY\": [\"several\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "CBZ"
                    ]
                }
            ]
        ],
        [
            426,
            "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions.",
            [
                " {\n  \"DRUGS\": [\"CBZ\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"systematic review\",\n  \"PARAMETER\": [\"CBZ\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "CBZ"
                    ]
                }
            ]
        ],
        [
            427,
            "2012), Cochrane Database of Systematic Reviews (2005\u2013Dec.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Cochrane Database of Systematic Reviews\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"2012\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            428,
            "2012).",
            [
                " {\n  \"DRUGS\": [\"No specific drugs mentioned\"],\n  \"HERB NAME\": [\"No specific herbs mentioned\"],\n  \"STUDY\": \"Cohort study\",\n  \"PARAMETER\": [\"drug efficacy\", \"drug safety\", \"drug side effects\"],\n  \"FREQUENCY\": [\"No specific frequencies mentioned\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"No specific cohort description provided\",\n  \"DURATION\": [\"No specific durations mentioned\"],\n  \"SEX\": [\"No specific sexes mentioned\"],\n  \"AGE\": [\"No specific ages mentioned\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            429,
            "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365].",
            [
                " {\n  \"DRUGS\": [\"CBZ\"],\n  \"HERB NAME\": [\"honey\"],\n  \"STUDY\": \"in vivo study in rabbits and human pharmacokinetic study\",\n  \"PARAMETER\": [\"oral bioavailability\", \"pharmacokinetic parameters\"],\n  \"FREQUENCY\": [\"no effect\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"rabbits\", \"humans\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"no effect on pharmacokinetic parameters of CBZ in humans\"],\n  \"TARGET\": [\"oral bioavailability\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "oral bioavailability"
                    ],
                    "Drug": [
                        "CBZ",
                        "CBZ"
                    ]
                }
            ]
        ],
        [
            430,
            "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70].",
            [
                " {\n  \"DRUGS\": [\"CBZ\", \"nicotinamide\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical studies and animal studies\",\n  \"PARAMETER\": [\"plasma level\", \"clearance\"],\n  \"FREQUENCY\": [\"two children\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"rats\", \"two children with epilepsy\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"epilepsy\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "CBZ",
                        "folinic acid",
                        "CBZ",
                        "nicotinamide",
                        "CBZ"
                    ],
                    "Parameter": [
                        "clearance"
                    ],
                    "Cohort": [
                        "two children"
                    ],
                    "Pathology": [
                        "epilepsy"
                    ]
                }
            ]
        ],
        [
            431,
            "Patients on antiepileptic therapy are usually on a long-term basis.",
            [
                " {\n  \"DRUGS\": [\"antiepileptic therapy\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"long-term basis\"],\n  \"FREQUENCY\": [\"usually\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"long-term\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "Patients"
                    ],
                    "Drug": [
                        "antiepileptic therapy"
                    ]
                }
            ]
        ],
        [
            432,
            "In order to achieve a comprehensive literature search, a total of eleven databases were searched.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            433,
            "These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases.",
            [
                " {\n  \"DRUGS\": [\"drug name1\", \"drug name2\", \"drug name3\"],\n  \"HERB NAME\": [\"herb name1\", \"herb name2\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"blood pressure\", \"heart rate\", \"blood glucose\"],\n  \"FREQUENCY\": [\"daily\", \"weekly\", \"monthly\"],\n  \"HERB PART\": [\"root\", \"leaf\", \"flower\"],\n  \"COHORT\": \"Adult patients with type 2 diabetes\",\n  \"DURATION\": [\"6 months\", \"1 year\", \"2 years\"],\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [\"30 years\", \"45 years\", \"60 years\"],\n  \"AMOUNT\": [\"100 mg\", \"200 mg\", \"500 mg\"],\n  \"ETHNIC GROUP\": [\"Chinese\", \"European\", \"African\"],\n  \"PATHOLOGY\": [\"hypertension\", \"hyperlipidemia\", \"diabetic neuropathy\"],\n  \"TARGET\": [\"insulin receptor\", \"PPAR\u03b3\", \"CYP2C\"],\n  \"EXTRACTION PROCESS\": [\"solvent extraction\", \"water extraction\", \"steam distillation\"]\n}",
                {
                    "Ethnic group": [
                        "Chinese"
                    ]
                }
            ]
        ],
        [
            434,
            "Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption.",
            [
                " {\n  \"DRUGS\": [\"Ispaghula husk\", \"septilin\", \"soybean\", \"Xiao-cha-hu-tang\", \"CBZ\"],\n  \"HERB NAME\": [\"Xiao-cha-hu-tang\"],\n  \"STUDY\": \"Drug interaction study\",\n  \"PARAMETER\": [\"plasma level\", \"gastric absorption\"],\n  \"FREQUENCY\": [\"reduced\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"gastric absorption\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Ispaghula husk",
                        "septilin",
                        "soybean",
                        "Xiao-cha-hu-tang"
                    ],
                    "Drug": [
                        "CBZ"
                    ]
                }
            ]
        ],
        [
            435,
            "Caution should also be paid for beverage containing alcohol.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            436,
            "In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder.",
            [
                " {\n  \"DRUGS\": [\"Xiao-yao-san\", \"CBZ\"],\n  \"STUDY\": \"randomized double-blinded control trial\",\n  \"PARAMETER\": [\"dizziness\", \"blurred vision\", \"skin rash\", \"nausea\"],\n  \"FREQUENCY\": [\"increased incidence\"],\n  \"AGE\": [\"patients\"],\n  \"SEX\": [\"patients\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"CBZ-related side effects\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "a randomized double-blinded control trial"
                    ],
                    "Herb name": [
                        "Xiao-yao-san"
                    ],
                    "Drug": [
                        "CBZ"
                    ],
                    "Pathology": [
                        "dizziness",
                        "blurred vision",
                        "skin rash",
                        "nausea",
                        "major depression",
                        "bipolar disorder"
                    ]
                }
            ]
        ],
        [
            437,
            "Composition of individual herbs in the included herbal formulae.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            438,
            "Fifty percent of the informants used herbal medicines alongside their prescription drugs.",
            [
                " {\n  \"DRUGS\": [\"prescription drugs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"prescription drugs\", \"herbal medicines\"],\n  \"FREQUENCY\": [\"fifty percent\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Informants\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"fifty percent\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            439,
            "In identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of patients' use of herbal medicines.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Type of study described\",\n  \"PARAMETER\": [\"proactive monitoring\", \"patients' use of herbal medicines\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthcare professionals\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"interactions\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            440,
            "A significant relationship between variables was identified if p < 0.05.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            441,
            "A summary of the background characteristics of the interviewed patients is given in Table 1.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Type of study described\",\n  \"PARAMETER\": [\"physiological or medical parameters found in text\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Description of the cohort\",\n  \"DURATION\": [\"List of durations of events found in text\"],\n  \"SEX\": [\"List of sexes found in text\"],\n  \"AGE\": [\"List of ages found in text\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"List of ethnic groups found in text\"],\n  \"PATHOLOGY\": [\"List of pathologies or side effects found in text\"],\n  \"TARGET\": [\"List of enzymes, transporters,... found in text\"],\n  \"EXTRACTION PROCESS\": [\"List of process of herb preparation found in text\"]\n}",
                {}
            ]
        ],
        [
            442,
            "This is possibly because the highest number of patients with type-2 diabetes fell within that age group.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Type of study not specified, but it seems to be a clinical study or trial\",\n  \"PARAMETER\": [\"type-2 diabetes\", \"age group\"],\n  \"FREQUENCY\": [\"highest number of patients\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"patients with type-2 diabetes\",\n  \"DURATION\": [\"not specified in the provided text\"],\n  \"SEX\": [],\n  \"AGE\": [\"age group\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"type-2 diabetes\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "type-2 diabetes"
                    ]
                }
            ]
        ],
        [
            443,
            "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents.",
            [
                " {\n  \"DRUGS\": [\"Hypoglycemic agents\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Tabular summary of the pharmacological management of patients based on their prescribed hypoglycemic agents\",\n  \"PARAMETER\": [\"prescribed hypoglycemic agents\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"patients\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [\"not specified\"],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "hypoglycaemic agents"
                    ]
                }
            ]
        ],
        [
            444,
            "For all of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management have been published.",
            [
                " {\n  \"DRUGS\": [\"pharmacological evidence\"],\n  \"HERB NAME\": [\"12 identified plants\"],\n  \"STUDY\": \"studies published\",\n  \"PARAMETER\": [\"diabetes management\"],\n  \"FREQUENCY\": [\"not specified\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"diabetes\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "diabetes"
                    ]
                }
            ]
        ],
        [
            445,
            "An analysis of the drugs commonly prescribed to patients with diabetes show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions.",
            [
                " {\n  \"DRUGS\": [\"drugs commonly prescribed to patients with diabetes\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"analysis of the drugs commonly prescribed to patients with diabetes\",\n  \"PARAMETER\": [\"pharmacokinetic parameters\", \"drug interactions\"],\n  \"FREQUENCY\": [\"most of these\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"patients with diabetes\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"diabetes\"],\n  \"TARGET\": [\"substrates or modulators of known pharmacokinetic parameters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "diabetes"
                    ]
                }
            ]
        ],
        [
            446,
            "Healthcare practitioners who are aware of their patients' use of herbal medicines and its identity can more easily monitor them for any possible interactions using available information, such as that presented in Tables 3, 4.",
            [
                " {\n  \"DRUGS\": [\"not specified in the provided text\"],\n  \"HERB NAME\": [\"not specified in the provided text\"],\n  \"STUDY\": \"not specified in the provided text\",\n  \"PARAMETER\": [\"physiological or medical parameters\", \"possible interactions\"],\n  \"FREQUENCY\": [\"not specified in the provided text\"],\n  \"HERB PART\": [\"not specified in the provided text\"],\n  \"COHORT\": \"patients using herbal medicines\",\n  \"DURATION\": [\"not specified in the provided text\"],\n  \"SEX\": [\"not specified in the provided text\"],\n  \"AGE\": [\"not specified in the provided text\"],\n  \"AMOUNT\": [\"not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"not specified in the provided text\"],\n  \"PATHOLOGY\": [\"not specified in the provided text\"],\n  \"TARGET\": [\"not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            447,
            "Herb\u2013drug interactions strongly challenge the clinical combined application of herbs and drugs.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            448,
            "Herbs have been used for primary health care for thousands of years before the advent of modern medicines.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {
                    "Herb name": [
                        "Herbs"
                    ],
                    "Duration": [
                        "for thousands of years"
                    ]
                }
            ]
        ],
        [
            449,
            "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Study of hepatocellular carcinoma cells expressing liver-specific enzymes\",\n  \"PARAMETER\": [\"liver-specific enzymes\", \"hepatocellular carcinoma\"],\n  \"FREQUENCY\": [\"large panel\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"HepaRG cell line derived from hepatocellular carcinoma\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"hepatocellular carcinoma\"],\n  \"TARGET\": [\"liver-specific enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "carcinoma"
                    ],
                    "Parameter": [
                        "liver-specific enzymes"
                    ]
                }
            ]
        ],
        [
            450,
            "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12].",
            [
                " {\n  \"DRUGS\": [\"aspirin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"elimination half-life\"],\n  \"FREQUENCY\": [\"approximately 15 min\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nNote: The provided text does not mention any specific drugs other than aspirin, herbs, or their parts, nor does it specify a cohort, duration, sex, age, amount, ethnic group, pathology, target, or extraction process.",
                {
                    "Drug": [
                        "aspirin"
                    ],
                    "Parameter": [
                        "an elimination half-life"
                    ],
                    "Duration": [
                        "15 min"
                    ]
                }
            ]
        ],
        [
            451,
            "A total of 22 compounds were identified or tentatively identified (Figure 1).",
            [
                " {\n  \"DRUGS\": [\"22 compounds\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"compounds\"],\n  \"FREQUENCY\": [\"22 compounds\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            452,
            "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL).",
            [
                " {\n  \"DRUGS\": [\"BNPP\", \"PNS\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"68 \u00b5g/mL\", \"150 \u00b5g/mL\"],\n  \"FREQUENCY\": [\"no significant difference\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"68 \u00b5g/mL\", \"150 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "BNPP"
                    ],
                    "Amount": [
                        "68 \u00b5g/mL",
                        "150 \u00b5g/mL"
                    ],
                    "Herb name": [
                        "PNS"
                    ]
                }
            ]
        ],
        [
            453,
            "Liver drug enzymes are the common sites of drug interaction in human.",
            [
                " {\n  \"DRUGS\": [\"drug enzymes\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"study of drug interactions\",\n  \"PARAMETER\": [\"liver drug enzymes\"],\n  \"FREQUENCY\": [\"common\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"drug interactions\"],\n  \"TARGET\": [\"drug enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "Liver drug enzymes"
                    ]
                }
            ]
        ],
        [
            454,
            "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).",
            [
                " {\n  \"DRUGS\": [\"notoginsenoside R\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Ultra-Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS/MS) analysis\",\n  \"PARAMETER\": [\"notoginsenoside R\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"notoginsenoside R\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "PNS",
                        "notoginsenoside R"
                    ]
                }
            ]
        ],
        [
            455,
            "The influence test for PON was conducted by the method of Furlong et al.",
            [
                " {\n  \"DRUGS\": [\"PON\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"influence test\",\n  \"PARAMETER\": [\"PON\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "PON"
                    ]
                }
            ]
        ],
        [
            456,
            "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China).",
            [
                " {\n  \"DRUGS\": [\"Trizol\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Cellular RNA extraction study\",\n  \"PARAMETER\": [\"2 \u00d7 10 Total RNA\"],\n  \"FREQUENCY\": [\"\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"2 \u00d7 10\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"Trizol\"]\n}",
                {
                    "Amount": [
                        "2 \u00d7 10"
                    ],
                    "Parameter": [
                        "Total RNA"
                    ]
                }
            ]
        ],
        [
            457,
            "The present work provides an insight into the mechanism exploration governing HDI between aspirin and PNS.",
            [
                " {\n  \"DRUGS\": [\"aspirin\", \"PNS\"],\n  \"STUDY\": \"Mechanism exploration\",\n  \"PARAMETER\": [\"HDI (Hemodynamic Interaction) between aspirin and PNS\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "aspirin"
                    ],
                    "Herb name": [
                        "PNS"
                    ]
                }
            ]
        ],
        [
            458,
            "conceived and designed the whole experiments.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            459,
            "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively).",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"p-value\", \"age\", \"sex\", \"duration\", \"dose\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            460,
            "However, there is hardly any data on the pharmacological safety of these two herbal medicines.",
            [
                " {\n  \"DRUGS\": [\"Pharmacological safety\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Limited pharmacological safety data\",\n  \"PARAMETER\": [\"pharmacological safety\"],\n  \"FREQUENCY\": [\"limited\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"pharmacological safety\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            461,
            "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates.",
            [
                " {\n  \"DRUGS\": [\"cytochrome P450 enzymes\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Quantification of drug interactions\",\n  \"PARAMETER\": [\"cytochrome P450 enzymes\", \"drug transporters\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inhibition of cytochrome P450 enzymes\", \"inhibition of drug transporters\"],\n  \"TARGET\": [\"cytochrome P450 enzymes\", \"drug transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "cytochrome P450 enzymes (CYPs)"
                    ]
                }
            ]
        ],
        [
            462,
            "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown).",
            [
                " {\n  \"DRUGS\": [\"Samento\", \"Banderol\"],\n  \"HERB NAME\": [\"Samento\"],\n  \"STUDY\": \"Cellular study\",\n  \"PARAMETER\": [\"intracellular calcein fluorescence\", \"L-MDR1 cells\", \"human P-glycoprotein (P-gp)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"lack of P-gp inhibition\"],\n  \"TARGET\": [\"human P-glycoprotein (P-gp)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Samento",
                        "Banderol"
                    ],
                    "Target": [
                        "P-glycoprotein (P-gp)",
                        "P-gp"
                    ]
                }
            ]
        ],
        [
            463,
            "The highest inhibition was demonstrated for CYP3A4 by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%) and for CYP2C19 by Banderol (about 20% at a concentration of 1%).",
            [
                " {\n  \"DRUGS\": [\"Samento\", \"Banderol\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro enzyme inhibition study\",\n  \"PARAMETER\": [\"CYP3A4\", \"CYP2C19\"],\n  \"FREQUENCY\": [\"around 40%\", \"around 20%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"at a concentration of 1%\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"around 40%\", \"around 20%\", \"1%\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP3A4\", \"CYP2C19\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP3A4",
                        "CYP2C19"
                    ],
                    "Herb name": [
                        "Samento",
                        "Banderol",
                        "Banderol"
                    ]
                }
            ]
        ],
        [
            464,
            "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B).",
            [
                " {\n  \"DRUGS\": [\"omeprazole\"],\n  \"HERB NAME\": [\"Samento\"],\n  \"STUDY\": \"Effects of Samento on aryl hydrocarbon receptor (AhR) activation\",\n  \"PARAMETER\": [\"aryl hydrocarbon receptor (AhR) activation\"],\n  \"FREQUENCY\": [\"minor effect\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"AhR activation\"],\n  \"TARGET\": [\"aryl hydrocarbon receptor (AhR)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "aryl hydrocarbon receptor (AhR)",
                        "CYP1A",
                        "AhR"
                    ],
                    "Herb name": [
                        "Samento"
                    ],
                    "Drug": [
                        "omeprazole"
                    ]
                }
            ]
        ],
        [
            465,
            "This study, therefore, scrutinized in vitro whether Samento and Banderol can inhibit the activity or induce the expression of important drug metabolizing enzymes and drug transporters.",
            [
                " {\n  \"DRUGS\": [\"Samento\", \"Banderol\"],\n  \"HERB NAME\": [\"Samento\"],\n  \"STUDY\": \"in vitro study\",\n  \"PARAMETER\": [\"drug metabolizing enzymes\", \"drug transporters\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"drug metabolizing enzymes\", \"drug transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "in vitro"
                    ],
                    "Herb name": [
                        "Samento",
                        "Banderol"
                    ]
                }
            ]
        ],
        [
            466,
            "PXR activating drugs (e.g., rifampicin) or herbal preparations (e.g., St. John\u2019s Wort) consequently induce drug metabolizing enzymes, and drug transporters can deteriorate drug efficacy by reducing the bioavailability or increasing the clearance of concomitantly used drugs, being substrates of such enzymes and/or transporters [16,17].",
            [
                " {\n  \"DRUGS\": [\"rifampicin\", \"St. John\u2019s Wort\"],\n  \"HERB NAME\": [\"St. John\u2019s Wort\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"drug metabolizing enzymes\", \"drug transporters\", \"bioavailability\", \"clearance\"],\n  \"FREQUENCY\": [\"consequent induction\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"reduced bioavailability\", \"increased clearance\"],\n  \"TARGET\": [\"drug metabolizing enzymes\", \"drug transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "PXR"
                    ],
                    "Drug": [
                        "rifampicin"
                    ],
                    "Herb name": [
                        "John\u2019s Wort"
                    ],
                    "Parameter": [
                        "bioavailability"
                    ]
                }
            ]
        ],
        [
            467,
            "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24].",
            [
                " {\n  \"DRUGS\": [\"BCRP\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Flow cytometry study using pheophorbide A as a specific BCRP substrate\",\n  \"PARAMETER\": [\"BCRP\"],\n  \"FREQUENCY\": [\"not specified\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"MDCKII-BCRP cells\", \"MDCKII cell line\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"BCRP inhibition\"],\n  \"TARGET\": [\"BCRP\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "BCRP",
                        "BCRP"
                    ]
                }
            ]
        ],
        [
            468,
            "Results for the positive controls rifampicin and cyclosporine A were published previously [25].",
            [
                " {\n  \"DRUGS\": [\"rifampicin\", \"cyclosporine A\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"drug concentrations\", \"pharmacokinetics\"],\n  \"FREQUENCY\": [\"previously published\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"not specified in the text\"],\n  \"DURATION\": [\"not specified in the text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"not specified in the text\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "rifampicin",
                        "cyclosporine A"
                    ]
                }
            ]
        ],
        [
            469,
            "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay.",
            [
                " {\n  \"DRUGS\": [\"Samento\", \"Banderol\"],\n  \"HERB NAME\": [\"Samento\"],\n  \"STUDY\": \"Induction assay\",\n  \"PARAMETER\": [\"dilution\"],\n  \"FREQUENCY\": [\"up to a dilution of 1%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1%\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Samento",
                        "Banderol"
                    ]
                }
            ]
        ],
        [
            470,
            "RNA was isolated using the GeneElute Mammalian Total RNA Miniprep Kit and cDNA was synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit according to the manufacturers\u2019 instructions.",
            [
                " {\n  \"DRUGS\": [\"GeneElute Mammalian Total RNA Miniprep Kit\", \"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"RNA isolation and cDNA synthesis study\",\n  \"PARAMETER\": [\"RNA\", \"cDNA\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"according to the manufacturers\u2019 instructions\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"GeneElute Mammalian Total RNA Miniprep Kit\", \"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\"]\n}",
                {}
            ]
        ],
        [
            471,
            "Data were evaluated as described previously [28].",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Type of study described\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": \"Not specified in the provided text\",\n  \"HERB PART\": \"Not specified in the provided text\",\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": \"Not specified in the provided text\",\n  \"SEX\": \"Not specified in the provided text\",\n  \"AGE\": \"Not specified in the provided text\",\n  \"AMOUNT\": \"Not specified in the provided text\",\n  \"ETHNIC GROUP\": \"Not specified in the provided text\",\n  \"PATHOLOGY\": \"Not specified in the provided text\",\n  \"TARGET\": \"Not specified in the provided text\",\n  \"EXTRACTION PROCESS\": \"Not specified in the provided text\"\n}",
                {}
            ]
        ],
        [
            472,
            "IC In conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.",
            [
                " {\n  \"DRUGS\": [\"Samento\", \"Banderol\"],\n  \"HERB NAME\": [\"Samento\"],\n  \"STUDY\": \"in vitro study\",\n  \"PARAMETER\": [\"in vitro profile\", \"herb\u2013drug interactions\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Samento",
                        "Banderol"
                    ],
                    "Study": [
                        "in vitro"
                    ]
                }
            ]
        ],
        [
            473,
            "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript.",
            [
                " {\n  \"DRUGS\": [\"P388\", \"P388/dx\", \"MDCKII-BCRP\", \"HEK-OATP1B1\", \"HEK-OATP1B3\", \"AZ-AhR\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro studies\",\n  \"PARAMETER\": [\"P388\", \"P388/dx\", \"MDCKII-BCRP\", \"HEK-OATP1B1\", \"HEK-OATP1B3\", \"AZ-AhR\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"OATP1B1\", \"OATP1B3\"]\n}",
                {
                    "Pathology": [
                        "Cancer"
                    ]
                }
            ]
        ],
        [
            474,
            "* p < 0.05, ** p < 0.01.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            475,
            "Results of the reporter gene assays.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Reporter gene assays\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            476,
            "(a) Concentration-dependent effect of Samento and the positive control rifampicin (insert) on pregnane x receptor (PXR) activity.",
            [
                " {\n  \"DRUGS\": [\"Samento\", \"rifampicin\"],\n  \"HERB NAME\": [\"Samento\"],\n  \"STUDY\": \"Concentration-dependent study\",\n  \"PARAMETER\": [\"pregnane x receptor (PXR) activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"pregnane x receptor (PXR)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Samento"
                    ],
                    "Drug": [
                        "rifampicin"
                    ],
                    "Target": [
                        "pregnane x receptor (PXR)"
                    ]
                }
            ]
        ],
        [
            477,
            "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure.",
            [
                " {\n  \"DRUGS\": [\"Samento\", \"rifampicin\"],\n  \"HERB NAME\": [\"Samento\"],\n  \"STUDY\": \"Protein expression study\",\n  \"PARAMETER\": [\"P-glycoprotein (P-gp) protein expression\"],\n  \"FREQUENCY\": [\"four days\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"0.033-1%\", \"20 \u00b5M\", \"four days\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"0.033-1%\", \"20 \u00b5M\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"P-glycoprotein (P-gp) protein expression\"],\n  \"TARGET\": [\"P-glycoprotein (P-gp)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Samento"
                    ],
                    "Drug": [
                        "rifampicin"
                    ],
                    "Target": [
                        "P-glycoprotein (P-gp)"
                    ],
                    "Duration": [
                        "after four days"
                    ]
                }
            ]
        ],
        [
            478,
            "Effect of Samento on CYP2J2 mRNA decay in LS180 cells.",
            [
                " {\n  \"DRUGS\": [\"Samento\"],\n  \"HERB NAME\": [\"Samento\"],\n  \"STUDY\": \"In vitro study on LS180 cells\",\n  \"PARAMETER\": [\"CYP2J2 mRNA decay\"],\n  \"FREQUENCY\": [\"Not specified\"],\n  \"HERB PART\": [\"Not specified\"],\n  \"COHORT\": \"Not applicable\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"Not specified\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [\"Not specified\"],\n  \"ETHNIC GROUP\": [\"Not specified\"],\n  \"PATHOLOGY\": [\"Not specified\"],\n  \"TARGET\": [\"CYP2J2 mRNA\"],\n  \"EXTRACTION PROCESS\": [\"Not specified\"]\n}",
                {
                    "Herb name": [
                        "Samento"
                    ],
                    "Target": [
                        "CYP2J2 mRNA"
                    ]
                }
            ]
        ],
        [
            479,
            "Expression of CYP2J2 mRNA was quantified by RT-PCR and results normalized to \u03b22mg and to t = 0.",
            [
                " {\n  \"DRUGS\": [\"CYP2J2\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Quantification of CYP2J2 mRNA by RT-PCR\",\n  \"PARAMETER\": [\"CYP2J2 mRNA\", \"RT-PCR\", \"\u03b22-microglobulin\"],\n  \"FREQUENCY\": [\"t = 0\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"t = 0\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"\u03b22-microglobulin\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2J2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2J2 mRNA",
                        "\u03b22mg"
                    ]
                }
            ]
        ],
        [
            480,
            "Drug interactions may occur between woohwangcheongsimwon suspension and bupropion.",
            [
                " {\n  \"DRUGS\": [\"woohwangcheongsimwon suspension\", \"bupropion\"],\n  \"STUDY\": \"Drug interaction study\",\n  \"PARAMETER\": [\"drug interactions\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "woohwangcheongsimwon suspension"
                    ],
                    "Drug": [
                        "bupropion"
                    ]
                }
            ]
        ],
        [
            481,
            "Its original formulation was in a tablet form.",
            [
                " {\n  \"DRUGS\": [\"drug name not specified\"],\n  \"HERB NAME\": [\"not specified\"],\n  \"STUDY\": \"not specified\",\n  \"PARAMETER\": [\"not specified\"],\n  \"FREQUENCY\": [\"not specified\"],\n  \"HERB PART\": [\"not specified\"],\n  \"COHORT\": \"not specified\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [\"not specified\"],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}\n\n\nSince the provided text does not contain specific information about drugs, herbs, study type, parameters, cohort, frequency, parts of herb, duration, sex, age, amount, ethnic group, pathology, target, or extraction process, the output reflects the absence of such details. If there were details in the text, they would be listed in the respective categories.",
                {}
            ]
        ],
        [
            482,
            "It has been officially listed in the Korean Pharmaceutical Codex for a long time and an aqueous suspension has recently been developed for convenient administration [1].",
            [
                " {\n  \"DRUGS\": [\"Korean Pharmaceutical Codex\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Development of an aqueous suspension\",\n  \"PARAMETER\": [\"Korean Pharmaceutical Codex\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"recently\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Ethnic group": [
                        "Korean"
                    ],
                    "Extraction process": [
                        "aqueous suspension"
                    ]
                }
            ]
        ],
        [
            483,
            "Table 1  The major ingredients of woohwangchengonsimwon suspension (Kwang-Dong Pharmaceutical Company, Seoul, Korea) Ingredients\tQuantity in 30 ml (mg) Bovis Calculus\t14 Dioscoreae Rhizoma\t282 Glycyrrhizae Radix et Rhizoma\t202 Ginseng Radix\t97 Typhae Pollen\t100 Massa Medicata Fermentata\t100 Glycine Semen Germinatum\t70 Cinnamomi cortex\t70 Paeoniae Radix\t60 Liriopis Tuber\t60 Scutellariae Radix\t60 Angelicae Gigantis Radix\t60 Saposhnikoviae Radix\t60 Atractylodis Rhizoma Alba\t60 Bupleuri Radix\t50 Platycodonis Radix\t50 Armeniacae Semen\t50 Poria Sclerotium\t50 Cnidii Rhizoma\t50 Civet\t15 Antelopis Cornu\t35 Borneolum*\t41 Ampelopsis Radis\t30 Zingiberis Rhizoma\t30 Open in a separate window *Borneolum included 38.58 mg of borneol and isoborneol.",
            [
                " {\n  \"DRUGS\": [\"Bovis Calculus\", \"Dioscoreae Rhizoma\", \"Glycyrrhizae Radix et Rhizoma\", \"Ginseng Radix\", \"Massa Medicata Fermentata\", \"Cinnamomi cortex\", \"Paeoniae Radix\", \"Liriopis Tuber\", \"Scutellariae Radix\", \"Angelicae Gigantis Radix\", \"Saposhnikoviae Radix\", \"Atractylodis Rhizoma Alba\", \"Bupleuri Radix\", \"Platycodonis Radix\", \"Armeniacae Semen\", \"Poria Sclerotium\", \"Cnidii Rhizoma\", \"Borneolum\"],\n  \"HERB NAME\": [\"Dioscoreae Rhizoma\", \"Ginseng Radix\", \"Paeoniae Radix\", \"Liriopis Tuber\", \"Scutellariae Radix\", \"Angelicae Gigantis Radix\", \"Saposhnikoviae Radix\", \"Atractylodis Rhizoma Alba\", \"Bupleuri Radix\", \"Platycodonis Radix\", \"Armeniacae Semen\", \"Poria Sclerotium\", \"Cnidii Rhizoma\"],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"Bovis Calculus\", \"Dioscoreae Rhizoma\", \"Glycyrrhizae Radix et Rhizoma\", \"Ginseng Radix\", \"Massa Medicata Fermentata\", \"Cinnamomi cortex\", \"Paeoniae Radix\", \"Liriopis Tuber\", \"Scutellariae Radix\", \"Angelicae Gigantis Radix\", \"Saposhnikoviae Radix\", \"Atractylodis Rhizoma Alba\", \"Bupleuri Radix\", \"Platycodonis Radix\", \"Armeniacae Semen\", \"Poria Sclerotium\", \"Cnidii Rhizoma\", \"Borneolum\"],\n  \"FREQUENCY\": [\"30 ml\"],\n  \"HERB PART\": [\"Radix\", \"Radix et Rhizoma",
                {
                    "Herb name": [
                        "woohwangchengonsimwon suspension",
                        "Dioscoreae",
                        "Glycyrrhizae",
                        "Ginseng",
                        "Typhae",
                        "Massa Medicata Fermentata",
                        "Cinnamomi",
                        "Paeoniae",
                        "Liriopis",
                        "Scutellariae",
                        "Angelicae Gigantis",
                        "Saposhnikoviae",
                        "Atractylodis",
                        "Bupleuri",
                        "Platycodonis",
                        "Armeniacae",
                        "Poria Sclerotium",
                        "Cnidii",
                        "Civet",
                        "Borneolum",
                        "Ampelopsis",
                        "Zingiberis",
                        "Borneolum",
                        "borneol",
                        "isoborneol"
                    ],
                    "Herb part": [
                        "Rhizoma",
                        "Radix",
                        "Rhizoma",
                        "Radix",
                        "Pollen",
                        "cortex",
                        "Radix",
                        "Tuber",
                        "Radix",
                        "Radix",
                        "Radix",
                        "Rhizoma",
                        "Radix",
                        "Radix",
                        "Rhizoma",
                        "Radis",
                        "Rhizoma"
                    ]
                }
            ]
        ],
        [
            484,
            "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period.",
            [
                " {\n  \"DRUGS\": [\"prescription and over the counter medications\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"prescription and over the counter medications\", \"2 weeks\"],\n  \"FREQUENCY\": [\"2 weeks\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Subjects\",\n  \"DURATION\": [\"2 weeks\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"2 weeks\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            485,
            "CYP2B6 genotyping  CYP2B6 genotyping was performed by pyrosequencing of polymerase chain reaction (PCR) products as described previously [13].",
            [
                " {\n  \"DRUGS\": [\"CYP2B6\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Genotyping study\",\n  \"PARAMETER\": [\"CYP2B6\"],\n  \"FREQUENCY\": [\"pyrosequencing of PCR products\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"as described previously\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2B6\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2B6",
                        "CYP2B6"
                    ]
                }
            ]
        ],
        [
            486,
            "Safety monitoring was performed throughout the study.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Safety monitoring study\",\n  \"PARAMETER\": [\"Safety monitoring\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"Not specified in the provided text\"],\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            487,
            "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified in the text provided\",\n  \"PARAMETER\": [\"positive ion mode\", \"5500 V\", \"500\u00b0C\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            488,
            "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA).",
            [
                " {\n  \"DRUGS\": [\"Analyst software\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Analytical study\",\n  \"PARAMETER\": [\"physiological or medical parameters\"],\n  \"FREQUENCY\": [\"frequencies of events\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"not specified in the text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            489,
            "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion.",
            [
                " {\n  \"DRUGS\": [\"bupropion\", \"4-hydroxybupropion\"],\n  \"STUDY\": \"study of pharmacokinetics\",\n  \"PARAMETER\": [\"AUC(0,\u221e)\", \"Cmax\"],\n  \"FREQUENCY\": [\"geometric means\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "AUC(0,\u221e)",
                        "Cmax"
                    ],
                    "Drug": [
                        "bupropion",
                        "4-hydroxybupropion"
                    ]
                }
            ]
        ],
        [
            490,
            "Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Type of study described\",\n  \"PARAMETER\": [\"geometric mean ratios (GMRs)\", \"90% confidence intervals (CIs)\", \"log transformation\"],\n  \"FREQUENCY\": [\"after log transformation of within-subject data\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"Not specified in the text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            491,
            "No clinically significant alterations in blood pressure, heart rate or body temperature were observed.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"blood pressure\", \"heart rate\", \"body temperature\"],\n  \"FREQUENCY\": [\"No clinically significant alterations observed\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "blood pressure",
                        "heart rate",
                        "body temperature"
                    ]
                }
            ]
        ],
        [
            492,
            "Go to: Discussion  In this study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion.",
            [
                " {\n  \"DRUGS\": [\"bupropion\"],\n  \"HERB NAME\": [\"woohwangcheongsimwon\"],\n  \"STUDY\": \"CYP2B6 inhibitory effects study\",\n  \"PARAMETER\": [\"pharmacokinetics\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2B6\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2B6"
                    ],
                    "Herb name": [
                        "woohwangcheongsimwon suspension"
                    ],
                    "Drug": [
                        "bupropion"
                    ]
                }
            ]
        ],
        [
            493,
            "The herbal reaction toward different types of statins is varied so that grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types.",
            [
                " {\n  \"DRUGS\": [\"statins\"],\n  \"HERB NAME\": [\"grapefruit\", \"pomegranate\"],\n  \"STUDY\": \"interaction study\",\n  \"PARAMETER\": [\"statin types\"],\n  \"FREQUENCY\": [\"varied\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"interaction\"],\n  \"TARGET\": [\"statins\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "statins",
                        "statins",
                        "statin"
                    ],
                    "Herb name": [
                        "grapefruit",
                        "pomegranate"
                    ]
                }
            ]
        ],
        [
            494,
            "The overexpression or somatic mutations of tyrosine kinases are dysregulated in various malignancies [3].",
            [
                " {\n  \"DRUGS\": [\"tyrosine kinases\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Type of study described\",\n  \"PARAMETER\": [\"dysregulated\", \"malignancies\"],\n  \"FREQUENCY\": [\"various\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"dysregulated\", \"malignancies\"],\n  \"TARGET\": [\"tyrosine kinases\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "tyrosine kinases"
                    ]
                }
            ]
        ],
        [
            495,
            "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05).",
            [
                " {\n  \"DRUGS\": [\"DAS\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro and in vivo study\",\n  \"PARAMETER\": [\"Pgp/MDR1 protein\", \"inhibition\", \"65.38%\", \"69.90%\", \"p < 0.05\"],\n  \"FREQUENCY\": [\"significant inhibition\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"APG-pretreated rats\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Pgp/MDR1 protein inhibition\"],\n  \"TARGET\": [\"Pgp/MDR1 protein\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "APG"
                    ],
                    "Target": [
                        "Pgp",
                        "MDR1"
                    ],
                    "Drug": [
                        "DAS"
                    ]
                }
            ]
        ],
        [
            496,
            "The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated and shown in Figure 5A,B.",
            [
                " {\n  \"DRUGS\": [\"APG\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Investigation of inhibitory potential\",\n  \"PARAMETER\": [\"BCRP/ABCG2 protein expression\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inhibitory potential\"],\n  \"TARGET\": [\"BCRP/ABCG2 protein expression\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "APG"
                    ],
                    "Target": [
                        "BCRP",
                        "ABCG2"
                    ]
                }
            ]
        ],
        [
            497,
            "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05).",
            [
                " {\n  \"DRUGS\": [\"APG\", \"DAS\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro and in vivo study\",\n  \"PARAMETER\": [\"BCPR/ABCG2 protein\", \"inhibition\", \"p < 0.05\"],\n  \"FREQUENCY\": [\"significant inhibition\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"APG-pretreated rats\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"66.77%\", \"41.06%\", \"p < 0.05\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"BCPR/ABCG2 protein inhibition\"],\n  \"TARGET\": [\"BCPR/ABCG2 protein\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "APG"
                    ],
                    "Target": [
                        "BCPR",
                        "ABCG2"
                    ],
                    "Drug": [
                        "DAS"
                    ]
                }
            ]
        ],
        [
            498,
            "Inhibition and/or induction of drug-metabolizing enzymes (DME) and or drug transporters mediated by herbs is the most typical mechanism of herb-drug interactions, which in turn alters the pharmacokinetic disposition of the drug [24,25].",
            [
                " {\n  \"DRUGS\": [\"drug-metabolizing enzymes (DME)\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Review of herb-drug interactions\",\n  \"PARAMETER\": [\"drug-metabolizing enzymes (DME)\", \"drug transporters\"],\n  \"FREQUENCY\": [\"typical\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"alteration of pharmacokinetic disposition\"],\n  \"TARGET\": [\"drug-metabolizing enzymes\", \"drug transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            499,
            "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact.",
            [
                " {\n  \"DRUGS\": [\"APG\", \"DAS\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacokinetic interaction study\",\n  \"PARAMETER\": [\"pharmacokinetic interaction\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "APG"
                    ],
                    "Drug": [
                        "DAS"
                    ]
                }
            ]
        ],
        [
            500,
            "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O.",
            [
                " {\n  \"DRUGS\": [\"DAS\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"radical alteration in pharmacokinetic parameters\",\n  \"PARAMETER\": [\"pharmacokinetic parameters\"],\n  \"FREQUENCY\": [\"radical alteration\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"per dose\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"DAS 25 mg/kg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "DAS"
                    ],
                    "Amount": [
                        "25 mg/kg"
                    ]
                }
            ]
        ],
        [
            501,
            "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Experimental study on animals\",\n  \"PARAMETER\": [\"polypropylene cages\", \"12-h light/dark cycle\", \"25 \u00b0C\", \"humane conditions\", \"free access to food and water\", \"adapted to living conditions\", \"fasting for 12 h\"],\n  \"FREQUENCY\": [\"6 animals per cage\", \"12-h light/dark cycle\", \"1 week adaptation\", \"12-h fasting\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Animals categorized into four groups (n = 6) with a 12-hour fasting period before the experiment\",\n  \"DURATION\": [\"12-hour fasting\", \"1 week adaptation\", \"12-hour light/dark cycle\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"6 animals per cage\", \"12-hour fasting\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Cohort": [
                        "four groups (n = 6)"
                    ]
                }
            ]
        ],
        [
            502,
            "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day.",
            [
                " {\n  \"DRUGS\": [\"DAS\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"normal saline\", \"7 days\", \"25 mg/kg\"],\n  \"FREQUENCY\": [\"7 days\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Group I and Group II\",\n  \"DURATION\": [\"7 days\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"25 mg/kg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Duration": [
                        "for 7 days"
                    ],
                    "Drug": [
                        "DAS"
                    ],
                    "Amount": [
                        "25 mg/kg)"
                    ]
                }
            ]
        ],
        [
            503,
            "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days.",
            [
                " {\n  \"DRUGS\": [\"APG 40\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Drug administration study\",\n  \"PARAMETER\": [\"2 h\", \"7 days\"],\n  \"FREQUENCY\": [\"2 h after administration\", \"7 days of administration\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Group IV\",\n  \"DURATION\": [\"7 days\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"40 mg/kg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "APG",
                        "APG"
                    ],
                    "Amount": [
                        "40 mg/kg",
                        "40 mg/kg"
                    ],
                    "Duration": [
                        "for 7 days"
                    ]
                }
            ]
        ],
        [
            504,
            "Electrospray ionization was used to ionize samples in a positive direction.",
            [
                " {\n  \"DRUGS\": [\"Electrospray ionization\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Drug analysis using electrospray ionization\",\n  \"PARAMETER\": [\"electrospray ionization\", \"positive direction\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            505,
            "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings.",
            [
                " {\n  \"DRUGS\": [\"APG\u2013DAS\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"in vivo studies\",\n  \"PARAMETER\": [\"interaction\"],\n  \"FREQUENCY\": [\"thorough\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"not specified\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "in vivo studies"
                    ],
                    "Herb name": [
                        "APG"
                    ],
                    "Drug": [
                        "DAS"
                    ]
                }
            ]
        ],
        [
            506,
            "and M.A.A.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            507,
            "; supervision, K.M.A.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            508,
            "All authors have read and agreed to the published version of the manuscript.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            509,
            "The research was approved by the Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58).",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            510,
            "All results are presented as the average \u00b1 SD.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            511,
            "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment.",
            [
                " {\n  \"DRUGS\": [\"DAS\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Drug interaction study with pretreatment\",\n  \"PARAMETER\": [\"Hepatic protein expression\", \"Intestinal protein expression\", \"BCRP/ABCG2 protein expression\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"Rats\"],\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Not specified\"],\n  \"TARGET\": [\"BCRP/ABCG2 protein\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "BCRP",
                        "ABCG2"
                    ],
                    "Drug": [
                        "DAS"
                    ],
                    "Herb name": [
                        "APG"
                    ]
                }
            ]
        ],
        [
            512,
            "Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions.",
            [
                " {\n  \"DRUGS\": [\"cytochrome P-450\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity\",\n  \"PARAMETER\": [\"cytochrome P-450 activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"herb-drug interactions\"],\n  \"TARGET\": [\"cytochrome P-450\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            513,
            "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population.",
            [
                " {\n  \"DRUGS\": [\"CYP\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical relevance study\",\n  \"PARAMETER\": [\"CYP activity\"],\n  \"FREQUENCY\": [\"greater clinical relevance\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"Not specified\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"Not specified\"],\n  \"PATHOLOGY\": [\"CYP activity changes\"],\n  \"TARGET\": [\"CYP\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            514,
            "Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly.",
            [
                " {\n  \"DRUGS\": [\"prescription medications\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"concomitant ingestion of botanical supplements with prescription medications\",\n  \"PARAMETER\": [\"elderly\"],\n  \"FREQUENCY\": [\"strongly discouraged\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"elderly\"],\n  \"DURATION\": [],\n  \"SEX\": [\"elderly\"],\n  \"AGE\": [\"elderly\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            515,
            "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women.",
            [
                " {\n  \"DRUGS\": [\"SC extract\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"quadriceps muscle strength\", \"lactate\"],\n  \"FREQUENCY\": [\"adult women\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Adult women\",\n  \"DURATION\": [],\n  \"SEX\": [\"adult women\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "SC extract"
                    ],
                    "Parameter": [
                        "quadriceps muscle strength (QMS)",
                        "lactate"
                    ],
                    "Sex": [
                        "women"
                    ]
                }
            ]
        ],
        [
            516,
            "In ANOVA results, QMS (p = 0.001) and lactate level (p = 0.038) showed significant interactions.",
            [
                " {\n  \"DRUGS\": [\"None\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"ANOVA results\",\n  \"PARAMETER\": [\"QMS\", \"lactate level\"],\n  \"FREQUENCY\": [\"significant interactions\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"significant interactions\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "lactate level"
                    ]
                }
            ]
        ],
        [
            517,
            "Our first hypothesis is that the supplementation of SC extract in humans can increase muscle strength.",
            [
                " {\n  \"DRUGS\": [\"SC extract\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Hypothesis study\",\n  \"PARAMETER\": [\"muscle strength\"],\n  \"FREQUENCY\": [\"increase\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "SC extract"
                    ],
                    "Parameter": [
                        "muscle strength"
                    ]
                }
            ]
        ],
        [
            518,
            "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study involving isokinetic knee extension exercises\",\n  \"PARAMETER\": [\"5 isokinetic knee extensions\", \"angular velocity of 60 degrees/second\", \"2 min recovery time\"],\n  \"FREQUENCY\": [\"5 sets of measurements\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Subjects in the main test session\",\n  \"DURATION\": [\"2 min recovery time between sets\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"5 isokinetic knee extensions\", \"60 degrees/second\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            519,
            "The subject\u2019s knee joint center, measured using the femoral epicondyles as a joint center reference, was aligned with the axis of the isokinetic dynamometer.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study using isokinetic dynamometer\",\n  \"PARAMETER\": [\"knee joint center\", \"femoral epicondyles\", \"axis of the isokinetic dynamometer\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            520,
            "Plasma samples were obtained by centrifugation and stored at \u221280 \u00b0C.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"plasma samples\", \"centrifugation\", \"storage at \u221280 \u00b0C\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"plasma samples\", \"\u221280 \u00b0C\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            521,
            "The mean SC extract supplementation and placebo compliance were 97.3% (90.2\u2212100%) in the SC group and 95.8% (86.7\u2013100%) in the placebo group.",
            [
                " {\n  \"DRUGS\": [\"SC extract\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"SC extract supplementation\", \"placebo compliance\"],\n  \"FREQUENCY\": [\"97.3%\", \"90.2%\", \"100%\", \"95.8%\", \"86.7%\", \"100%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "SC extract",
                        "SC"
                    ]
                }
            ]
        ],
        [
            522,
            "There were no significant differences between the groups for height, weight, or BMI at baseline (Table 1).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"height\", \"weight\", \"BMI\"],\n  \"FREQUENCY\": [\"no significant differences\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"not specified\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "BMI"
                    ]
                }
            ]
        ],
        [
            523,
            "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2.",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"Resting lactate level\"],\n  \"FREQUENCY\": [\"12 weeks\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"Not specified\"],\n  \"DURATION\": [\"12 weeks\"],\n  \"SEX\": [\"Not specified\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [\"Not specified\"],\n  \"ETHNIC GROUP\": [\"Not specified\"],\n  \"PATHOLOGY\": [\"Resting lactate level\"],\n  \"TARGET\": [\"Not specified\"],\n  \"EXTRACTION PROCESS\": [\"Not specified\"]\n}",
                {
                    "Parameter": [
                        "lactate level"
                    ],
                    "Duration": [
                        "12 weeks"
                    ]
                }
            ]
        ],
        [
            524,
            "have shown the association between high lactate production and reduced oxidative metabolism [47].",
            [
                " {\n  \"DRUGS\": [\"lactate\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"association between high lactate production and reduced oxidative metabolism\",\n  \"PARAMETER\": [\"high lactate production\", \"reduced oxidative metabolism\"],\n  \"FREQUENCY\": [\"high lactate production\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"reduced oxidative metabolism\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "lactate"
                    ]
                }
            ]
        ],
        [
            525,
            "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago.",
            [
                " {\n  \"DRUGS\": [\"St. John's wort\"],\n  \"HERB NAME\": [\"St. John's wort\"],\n  \"STUDY\": \"clinical study\",\n  \"PARAMETER\": [\"anti-depressant effects\", \"bioavailability\", \"efficacy\"],\n  \"FREQUENCY\": [\"about 20 years ago\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"interactions with other drugs\"],\n  \"TARGET\": [\"drugs\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "reports"
                    ],
                    "Herb name": [
                        "St. John's wort (SJW)"
                    ],
                    "Parameter": [
                        "bioavailability"
                    ]
                }
            ]
        ],
        [
            526,
            "These interactions were caused by pregnane\u2010X\u2010receptor (PXR) activation.",
            [
                " {\n  \"DRUGS\": [\"pregnane-X-receptor\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"The study described involves the activation of pregnane-X-receptor (PXR) and its interactions.\",\n  \"PARAMETER\": [\"pregnane-X-receptor activation\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"interactions\"],\n  \"TARGET\": [\"pregnane-X-receptor\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "pregnane\u2010X\u2010receptor (PXR)"
                    ]
                }
            ]
        ],
        [
            527,
            "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006).",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Clinical studies\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            528,
            "SJW extracts as well as isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated in vitro and in vivo for their interactions with a variety of potentially relevant targets for depression.",
            [
                " {\n  \"DRUGS\": [\"SJW extracts\", \"isolated constituents\", \"hyperforin\", \"hypericin\", \"flavonoids\"],\n  \"HERB NAME\": [\"SJW\"],\n  \"STUDY\": \"in vitro and in vivo studies\",\n  \"PARAMETER\": [\"interactions\", \"relevant targets for depression\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"depression\"],\n  \"TARGET\": [\"enzymes\", \"transporters\", \"relevant targets for depression\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "SJW extracts",
                        "hyperforin",
                        "hypericin",
                        "flavonoids"
                    ],
                    "Study": [
                        "in vitro",
                        "in vivo"
                    ],
                    "Pathology": [
                        "depression"
                    ]
                }
            ]
        ],
        [
            529,
            "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test.",
            [
                " {\n  \"DRUGS\": [\"SJW extracts\"],\n  \"HERB NAME\": [\"SJW\"],\n  \"STUDY\": \"Tail suspension test\",\n  \"PARAMETER\": [\"time of immobility\"],\n  \"FREQUENCY\": [\"significantly reduced\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"rodents\"],\n  \"DURATION\": [\"after antidepressant treatment\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "antidepressant treatment,"
                    ],
                    "Herb name": [
                        "SJW extracts"
                    ]
                }
            ]
        ],
        [
            530,
            "In the network of genes involved in drug metabolism, the PXR functions as a xenobiotic receptor or \u201cxenosensor,\u201d which, after ligand binding, translocates to the nucleus, where it binds to specific PXR response elements (PXRRE) in the promotor of various genes, modulating their transcription.",
            [
                " {\n  \"DRUGS\": [\"drug metabolism\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Network of genes involved in drug metabolism\",\n  \"PARAMETER\": [\"ligand binding\", \"nucleus\", \"transcription\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"PXR\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "PXR",
                        "PXR response elements (PXRRE)"
                    ]
                }
            ]
        ],
        [
            531,
            "For OATP2B1, we have recently shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018), thus influencing the intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019).",
            [
                " {\n  \"DRUGS\": [\"hyperforin\"],\n  \"HERB NAME\": [\"SJW\"],\n  \"STUDY\": \"clinical study\",\n  \"PARAMETER\": [\"OATP2B1\", \"PXR\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inhibition of OATP2B1\", \"influence on PXR transactivation\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "OATP2B1",
                        "PXR"
                    ],
                    "Herb name": [
                        "hyperforin",
                        "SJW",
                        "hyperforin"
                    ]
                }
            ]
        ],
        [
            532,
            "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019).",
            [
                " {\n  \"DRUGS\": [\"seven test drugs\"],\n  \"HERB NAME\": [\"low\u2010hyperforin SJW extract\"],\n  \"STUDY\": \"pharmacokinetic interaction study\",\n  \"PARAMETER\": [\"clinically relevant interactions\"],\n  \"FREQUENCY\": [\"no interactions found\"],\n  \"HERB PART\": [\"hyperforin\"],\n  \"COHORT\": \"not specified in the text\",\n  \"DURATION\": [\"not specified in the text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"low\u2010hyperforin\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"not specified in the text\"],\n  \"TARGET\": [\"enzymes, transporters\"],\n  \"EXTRACTION PROCESS\": [\"not specified in the text\"]\n}",
                {
                    "Herb name": [
                        "low\u2010hyperforin SJW extract"
                    ]
                }
            ]
        ],
        [
            533,
            "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies.",
            [
                " {\n  \"DRUGS\": [\"pharmacoepidemiology methods\", \"bioinformatics\", \"data mining\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"high quality clinical data\",\n  \"PARAMETER\": [\"clinical meaningful herb-drug interactions\", \"cancer therapies\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"high quality clinical data\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"cancer therapies\"],\n  \"TARGET\": [\"enzymes\", \"transporters\", \"bioinformatics\", \"data mining\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "cancer"
                    ]
                }
            ]
        ],
        [
            534,
            "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions.",
            [
                " {\n  \"DRUGS\": [\"Lingzhi\", \"Yunzhi\"],\n  \"HERB NAME\": [\"Lingzhi\", \"Yunzhi\"],\n  \"STUDY\": \"systematic reviews and meta-analysis\",\n  \"PARAMETER\": [\"clinical outcomes\"],\n  \"FREQUENCY\": [\"mostly\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"no specific durations mentioned\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"potential beneficial or harmful interactions\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Lingzhi",
                        "Yunzhi"
                    ],
                    "Pathology": [
                        "cancer"
                    ]
                }
            ]
        ],
        [
            535,
            "If the control group also received medicinal mushrooms, there should be significant dosage differences of the mushrooms in the treatment group.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            536,
            "Figure\u00a01 summarizes the process of database searching and literature selection.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Database searching and literature selection\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            537,
            "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100].",
            [
                " {\n  \"DRUGS\": [\"5-FU\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"preclinical studies\",\n  \"PARAMETER\": [\"T cell apoptosis\", \"caspase 3 activity\", \"CD4, CD4/CD8 T cells count\", \"NK cells\", \"platelets\", \"WBC\", \"intestinal damage\", \"phagocytic activity\", \"antibody production\", \"delayed hypersensitivity\", \"tumor inhibition\", \"apoptotic rate\", \"cell cycle arrest\"],\n  \"FREQUENCY\": [\"Increase in efficacy and survival\", \"better symptomatic relief\", \"increase in T cells count\", \"increase appetite\", \"Less reduction in WBC\", \"platelets\", \"Greater recovery rate from intestinal damage\", \"Increase in survival\", \"cytotoxicity and inhibit metastasis\", \"Reduce immunosuppression\", \"induce cell cycle arrest\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"Not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"T cell apoptosis\", \"caspase 3 activity\", \"WBC reduction\", \"intestinal damage\", \"immunosuppression\"],\n  \"TARGET\": [\"Bax expression\", \"CD4, CD4/CD8 T cells\", \"NK cells\", \"platelets\", \"WBC\", \"intestinal damage\", \"phagocytic activity\", \"antibody production\", \"delayed hypersensitivity\", \"tumor inhibition\", \"apoptotic rate\", \"cell cycle arrest\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "T cell apoptosis",
                        "caspase 3 activity",
                        "Bax expression",
                        "cells count",
                        "CD4",
                        "CD4",
                        "CD8",
                        "WBC",
                        "CD3+",
                        "CD4+ T cells",
                        "NK cells",
                        "platelets",
                        "WBC",
                        "platelets",
                        "bone marrow cells",
                        "phagocytic activity",
                        "antibody production",
                        "caspase 3"
                    ],
                    "Study": [
                        "preclinical studies"
                    ],
                    "Pathology": [
                        "intestinal damage",
                        "metastasis"
                    ],
                    "Drug": [
                        "5-FU",
                        "5-FU"
                    ]
                }
            ]
        ],
        [
            538,
            "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49].",
            [
                " {\n  \"DRUGS\": [\"5-FU\", \"carboplatin\", \"cisplatin\", \"cyclophosphamide\", \"doxorubicin\", \"etoposide\", \"UFT\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical studies on drug combinations\",\n  \"PARAMETER\": [\"tumor recurrence\", \"metastasis\"],\n  \"FREQUENCY\": [\"reduced\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"tumor recurrence\", \"metastasis\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Yunzhi"
                    ],
                    "Drug": [
                        "5-FU",
                        "carboplatin",
                        "cisplatin",
                        "cyclophosphamide",
                        "doxorubicin",
                        "etoposide",
                        "UFT"
                    ],
                    "Pathology": [
                        "tumor",
                        "metastasis"
                    ]
                }
            ]
        ],
        [
            539,
            "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124].",
            [
                " {\n  \"DRUGS\": [\"antitumor effect\", \"inhibition\", \"angiogenesis\", \"reactive oxygen species\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"tumor cell angiogenesis\", \"reactive oxygen species production\"],\n  \"FREQUENCY\": [\"inhibition\", \"increase\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"tumor cell angiogenesis\", \"reactive oxygen species\"],\n  \"TARGET\": [\"angiogenesis\", \"reactive oxygen species\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            540,
            "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97].",
            [
                " {\n  \"DRUGS\": [\"paclitaxel\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"recent study\",\n  \"PARAMETER\": [\"tumor metabolism\", \"Warburg-related proteins\", \"gut dysbiosis\"],\n  \"FREQUENCY\": [\"recent\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"gut dysbiosis\"],\n  \"TARGET\": [\"Warburg-related proteins\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "gut dysbiosis"
                    ],
                    "Drug": [
                        "paclitaxel"
                    ]
                }
            ]
        ],
        [
            541,
            "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131].",
            [
                " {\n  \"DRUGS\": [\"anticancer drugs\"],\n  \"HERB NAME\": [\"Yunzhi\"],\n  \"STUDY\": \"Mechanism of action study of Yunzhi on anticancer drugs\",\n  \"PARAMETER\": [\"cytotoxic and tumor-infiltrating lymphocytes\", \"suppressor T cells\", \"superoxide dismutase (SOD)\", \"lipid peroxide levels\"],\n  \"FREQUENCY\": [\"direct increase\", \"decrease\", \"increase\", \"decrease\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"cytotoxicity\", \"tumor\"],\n  \"TARGET\": [\"cytotoxic and tumor-infiltrating lymphocytes\", \"suppressor T cells\", \"superoxide dismutase (SOD)\", \"lipid peroxide levels\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Yunzhi"
                    ],
                    "Drug": [
                        "anticancer drugs"
                    ],
                    "Parameter": [
                        "suppressor T cells",
                        "superoxide dismutase (SOD)",
                        "lipid peroxide levels"
                    ],
                    "Pathology": [
                        "cancer"
                    ]
                }
            ]
        ],
        [
            542,
            "a.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": \"Not specified in the provided text\",\n  \"HERB PART\": \"Not specified in the provided text\",\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": \"Not specified in the provided text\",\n  \"SEX\": \"Not specified in the provided text\",\n  \"AGE\": \"Not specified in the provided text\",\n  \"AMOUNT\": \"Not specified in the provided text\",\n  \"ETHNIC GROUP\": \"Not specified in the provided text\",\n  \"PATHOLOGY\": \"Not specified in the provided text\",\n  \"TARGET\": \"Not specified in the provided text\",\n  \"EXTRACTION PROCESS\": \"Not specified in the provided text\"\n}",
                {}
            ]
        ],
        [
            543,
            "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171].",
            [
                " {\n  \"DRUGS\": [\"T-bet\", \"GATA-3\", \"Bax\", \"caspase 3\", \"Foxp3\", \"PD-1\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Mechanisms involved in modulating T helper cell balance, T cell apoptosis, and immune response regulation\",\n  \"PARAMETER\": [\"T helper cell balance\", \"T cell apoptosis\", \"immune responses\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"T cell apoptosis\"],\n  \"TARGET\": [\"T-bet\", \"GATA-3\", \"Bax\", \"caspase 3\", \"Foxp3\", \"PD-1\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "T-box protein expressed in T cells (T-bet)",
                        "GATA-3",
                        "caspase 3",
                        "T cell",
                        "Forkhead box protein 3 (Foxp3)",
                        "programmed death 1 (PD-1)"
                    ]
                }
            ]
        ],
        [
            544,
            "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings.",
            [
                " {\n  \"DRUGS\": [\"medicinal mushrooms\", \"chemotherapeutic drugs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"outcomes\",\n  \"PARAMETER\": [\"adverse effects\"],\n  \"FREQUENCY\": [\"great potential\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"adverse effects\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "adverse effects"
                    ]
                }
            ]
        ],
        [
            545,
            "Table S4.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Type of study described\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Description of the cohort\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\n*Note: Since the provided text does not contain specific information about drugs, herbs, study details, parameters, frequencies, cohort descriptions, durations, sexes, ages, amounts, ethnic groups, pathologies, targets, or extraction processes, the fields are left empty.*",
                {}
            ]
        ],
        [
            546,
            "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All.",
            [
                " {\n  \"DRUGS\": [\"Drug X\", \"Drug Y\"],\n  \"HERB NAME\": [\"Herb A\", \"Herb B\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"blood pressure\", \"heart rate\", \"blood glucose\"],\n  \"FREQUENCY\": [\"annual\", \"monthly\"],\n  \"HERB PART\": [\"root\", \"leaf\"],\n  \"COHORT\": \"Adults aged 30-60 with type 2 diabetes\",\n  \"DURATION\": [\"6 months\", \"1 year\"],\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [\"30\", \"45\", \"60\"],\n  \"AMOUNT\": [\"100 mg\", \"200 mg\"],\n  \"ETHNIC GROUP\": [\"Asian\", \"Caucasian\"],\n  \"PATHOLOGY\": [\"hypertension\", \"diabetes\"],\n  \"TARGET\": [\"insulin receptor\", \"glucose transporter\"],\n  \"EXTRACTION PROCESS\": [\"solvent extraction\", \"water decoction\"]\n}",
                {}
            ]
        ],
        [
            547,
            "Not applicable.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": \"Not specified in the provided text\",\n  \"HERB PART\": \"Not specified in the provided text\",\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": \"Not specified in the provided text\",\n  \"SEX\": \"Not specified in the provided text\",\n  \"AGE\": \"Not specified in the provided text\",\n  \"AMOUNT\": \"Not specified in the provided text\",\n  \"ETHNIC GROUP\": \"Not specified in the provided text\",\n  \"PATHOLOGY\": \"Not specified in the provided text\",\n  \"TARGET\": \"Not specified in the provided text\",\n  \"EXTRACTION PROCESS\": \"Not specified in the provided text\"\n}",
                {}
            ]
        ],
        [
            548,
            "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy.",
            [
                " {\n  \"DRUGS\": [\"complementary and alternative (CAM) treatment options\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study of women diagnosed with breast cancer seeking CAM treatments\",\n  \"PARAMETER\": [\"breast cancer\", \"conventional cancer therapy\", \"side effects\"],\n  \"FREQUENCY\": [\"frequently\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Women diagnosed with breast cancer\",\n  \"DURATION\": [],\n  \"SEX\": [\"women\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"breast cancer\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "breast cancer",
                        "side effects",
                        "cancer"
                    ]
                }
            ]
        ],
        [
            549,
            "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.",
            [
                " {\n  \"DRUGS\": [\"hormonal therapy\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"estrogen receptor (ER) positive\"],\n  \"FREQUENCY\": [\"70-80%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"early stage\", \"metastatic\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"estrogen receptor (ER) positive\"],\n  \"TARGET\": [\"estrogen receptor\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "breast tumors",
                        "ER-positive breast cancer"
                    ],
                    "Target": [
                        "estrogen receptor (ER)"
                    ],
                    "Drug": [
                        "hormonal therapy"
                    ]
                }
            ]
        ],
        [
            550,
            "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313].",
            [
                " {\n  \"DRUGS\": [\"Viscum album extracts\"],\n  \"HERB NAME\": [\"Viscum album\"],\n  \"STUDY\": \"Clinical studies\",\n  \"PARAMETER\": [\"breast cancer\", \"other types of cancer\"],\n  \"FREQUENCY\": [\"not specified\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"breast cancer patients\", \"other types of cancer patients\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"cancer\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "Clinical studies"
                    ],
                    "Herb name": [
                        "Viscum album extracts (VAE)"
                    ],
                    "Pathology": [
                        "breast cancer",
                        "cancer"
                    ]
                }
            ]
        ],
        [
            551,
            "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec.",
            [
                " {\n  \"DRUGS\": [\"Iscador\"],\n  \"HERB NAME\": [\"Mistletoe\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"5\u2009mg\", \"total mistletoe lectin concentration 306\u2009ng/mL\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"host tree Malus domestica\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"5\u2009mg\", \"306\u2009ng/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"total mistletoe lectin\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Amount": [
                        "5\u2009mg"
                    ],
                    "Herb name": [
                        "VAEM",
                        "Malus domestica",
                        "mistletoe lectin",
                        "Iscador Qu"
                    ]
                }
            ]
        ],
        [
            552,
            "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA).",
            [
                " {\n  \"DRUGS\": [\"(4-hydroxy-N-desmethyltamoxifen hydrochloride\", \"\u03b2-estradiol\", \"dextrorphan-d\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pooled human liver microsomes (HLMs) study\",\n  \"PARAMETER\": [\"\u03b2-estradiol\", \"dextrorphan-d\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"50 donors, mixed gender\",\n  \"DURATION\": [],\n  \"SEX\": [\"mixed gender\"],\n  \"AGE\": [],\n  \"AMOUNT\": [\"HLMs\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)",
                        "dextrorphan-d"
                    ],
                    "Target": [
                        "\u03b2-estradiol (E2)"
                    ]
                }
            ]
        ],
        [
            553,
            "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig.",
            [
                " {\n  \"DRUGS\": [\"endoxifen\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"proliferation\"],\n  \"FREQUENCY\": [\"concentration-dependent inhibition\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"VAEM untreated values\"],\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inhibition of proliferation\"],\n  \"TARGET\": [\"proliferation\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "VAEM",
                        "VAEM"
                    ],
                    "Drug": [
                        "endoxifen"
                    ]
                }
            ]
        ],
        [
            554,
            "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33].",
            [
                " {\n  \"DRUGS\": [\"no drugs mentioned\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Genotype-phenotype correlation study\",\n  \"PARAMETER\": [\"poor, intermediate, extensive, or ultra-rapid metabolizers\"],\n  \"FREQUENCY\": [\"no specific frequencies mentioned\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"patients classified based on genotype combinations\",\n  \"DURATION\": [\"no specific durations mentioned\"],\n  \"SEX\": [\"no specific sexes mentioned\"],\n  \"AGE\": [\"no specific ages mentioned\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"no pathologies or side effects mentioned\"],\n  \"TARGET\": [\"enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            555,
            "The metabolic activity of CYP2D6 was suggested to be associated with the long-term outcomes in breast cancer, although the studies are inconsistent [35].",
            [
                " {\n  \"DRUGS\": [\"CYP2D6\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical studies\",\n  \"PARAMETER\": [\"metabolic activity\", \"long-term outcomes\"],\n  \"FREQUENCY\": [\"inconsistent\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"not specified\"],\n  \"DURATION\": [\"long-term\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"CYP2D6\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2D6"
                    ],
                    "Pathology": [
                        "breast cancer"
                    ]
                }
            ]
        ],
        [
            556,
            "The significant inter-individual variability of CYP2D6 activity due to genetic polymorphisms was mitigated by the use of pooled microsomes from 50 donors [41].",
            [
                " {\n  \"DRUGS\": [\"CYP2D6\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Use of pooled microsomes from donors\",\n  \"PARAMETER\": [\"CYP2D6 activity\", \"genetic polymorphisms\"],\n  \"FREQUENCY\": [\"50 donors\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"50 donors\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"pooled microsomes\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inter-individual variability\"],\n  \"TARGET\": [\"CYP2D6\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2D6"
                    ]
                }
            ]
        ],
        [
            557,
            "(PDF 36 kb) Figure S2.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            558,
            "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM).",
            [
                " {\n  \"DRUGS\": [\"Dextromethorphan\", \"Quinidine\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"in vitro inhibition study\",\n  \"PARAMETER\": [\"CYP2D6\", \"inhibition profiles\", \"Quinidine\"],\n  \"FREQUENCY\": [\"0.1-1-2-5-10-100 \u03bcM\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"in vitro\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"0.1-1-2-5-10-100 \u03bcM\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"CYP2D6 inhibition\"],\n  \"TARGET\": [\"CYP2D6\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "Dextromethorphan",
                        "Quinidine"
                    ],
                    "Study": [
                        "in vitro"
                    ],
                    "Target": [
                        "CYP2D6"
                    ]
                }
            ]
        ],
        [
            559,
            "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            560,
            "To our knowledge, there is no available information regarding pharmacokinetic interactions between captopril and H. sabdariffa.",
            [
                " {\n  \"DRUGS\": [\"captopril\"],\n  \"HERB NAME\": [\"H. sabdariffa\"],\n  \"STUDY\": \"unknown\",\n  \"PARAMETER\": [\"pharmacokinetic interactions\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "captopril"
                    ],
                    "Herb name": [
                        "H. sabdariffa"
                    ]
                }
            ]
        ],
        [
            561,
            "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min.",
            [
                " {\n  \"DRUGS\": [\"captopril\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"derivatization study\",\n  \"PARAMETER\": [\"plasma\", \"2-4-dibromoacetophenone\", \"ammonia\"],\n  \"FREQUENCY\": [\"30 seconds\", \"30 min\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"30 minutes\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"180 \u00b5L\", \"20 \u00b5L\", \"520 ppm\", \"5%\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"2-4-dibromoacetophenone\", \"ammonia\"],\n  \"EXTRACTION PROCESS\": [\"mixing\", \"vortexing\", \"incubating\"]\n}",
                {
                    "Drug": [
                        "captopril"
                    ]
                }
            ]
        ],
        [
            562,
            "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)",
            [
                " {\n  \"DRUGS\": [\"captopril\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"morning dosage\", \"body weight (BW)\"],\n  \"FREQUENCY\": [\"daily\", \"two weeks\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"two weeks\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"4.5 mg/200 g BW\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nNote: The text provided does not mention specific herbs, ethnic groups, sexes, ages, or extraction processes, hence those fields are left empty.",
                {
                    "Frequency": [
                        "daily"
                    ],
                    "Duration": [
                        "for two weeks"
                    ],
                    "Drug": [
                        "captopril"
                    ],
                    "Amount": [
                        "4.5\u2009mg/200\u2009g BW"
                    ]
                }
            ]
        ],
        [
            563,
            "The animals were anaesthetized before blood collection process.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"blood collection\"],\n  \"FREQUENCY\": [\"anaesthetized\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"anaesthetized\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            564,
            "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)",
            [
                " {\n  \"DRUGS\": [\"1.0 mL saline solution\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"loss of body fluid\", \"saline solution\"],\n  \"FREQUENCY\": [\"1.0 mL\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1.0 mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            565,
            "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3).",
            [
                " {\n  \"DRUGS\": [\"captopril\"],\n  \"STUDY\": \"Analysis of captopril\",\n  \"PARAMETER\": [\"within-run accuracy\", \"precision\"],\n  \"FREQUENCY\": [\"1.56%\", \"14.38%\"],\n  \"DURATION\": [\"within-run\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nNote: The provided text does not mention specific drugs, herbs, cohorts, durations, sexes, ages, ethnic groups, pathologies, targets, or extraction processes. Therefore, these fields are left empty.",
                {
                    "Drug": [
                        "captopril"
                    ]
                }
            ]
        ],
        [
            566,
            "In selectivity testing, six rats plasma was used.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"selectivity testing\",\n  \"PARAMETER\": [\"rats plasma\"],\n  \"FREQUENCY\": [\"six\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"six rats\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"plasma\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            567,
            "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups.",
            [
                " {\n  \"DRUGS\": [\"2-4-dibromoacetophenone\", \"captopril\"],\n  \"STUDY\": \"Experiment\",\n  \"PARAMETER\": [\"plasma sulfhydryl groups\"],\n  \"FREQUENCY\": [\"2-4-dibromoacetophenone\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Experiment\",\n  \"PARAMETER\": [\"plasma sulfhydryl groups\"],\n  \"FREQUENCY\": [\"2-4-dibromoacetophenone\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"2-4-dibromoacetophenone\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"binding of captopril to plasma sulfhydryl groups\"],\n  \"TARGET\": [\"sulfhydryl group\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "captopril"
                    ]
                }
            ]
        ],
        [
            568,
            "Ammonia was used during derivatization since the reaction is optimal at basic pH.",
            [
                " {\n  \"DRUGS\": [\"Ammonia\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Derivatization study\",\n  \"PARAMETER\": [\"basic pH\"],\n  \"FREQUENCY\": [\"optimal\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"Ammonia\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nNote: The provided text does not mention specific drugs, herbs, cohorts, sexes, ages, pathologies, or extraction processes related to the study. Therefore, those fields are left empty.",
                {}
            ]
        ],
        [
            569,
            "The reaction was then stopped by adding formic acid [17].",
            [
                " {\n  \"DRUGS\": [\"formic acid\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"formic acid\"],\n  \"FREQUENCY\": [\"stopped\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"formic acid\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            570,
            "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter.",
            [
                " {\n  \"DRUGS\": [\"H. sabdariffa extract\"],\n  \"HERB NAME\": [\"H. sabdariffa\"],\n  \"STUDY\": \"coadministration study\",\n  \"PARAMETER\": [\"GSH level\", \"expression of the PEPT1 transporter\"],\n  \"FREQUENCY\": [\"two weeks\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"two weeks\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"affect GSH level\", \"affect expression of PEPT1 transporter\"],\n  \"TARGET\": [\"PEPT1 transporter\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Duration": [
                        "Two weeks"
                    ],
                    "Herb name": [
                        "H. sabdariffa"
                    ],
                    "Target": [
                        "GSH",
                        "PEPT1 transporter"
                    ]
                }
            ]
        ],
        [
            571,
            "2016; Eng et\u00a0al.",
            [
                " {\n  \"DRUGS\": [\"Engenol B\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"blood pressure\", \"blood glucose levels\", \"cholesterol levels\"],\n  \"FREQUENCY\": [\"every 6 months\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Adults with type 2 diabetes\",\n  \"DURATION\": [\"6 months\"],\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [\"adults\"],\n  \"AMOUNT\": [\"100 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"improved blood glucose levels\", \"reduced cholesterol levels\"],\n  \"TARGET\": [\"diabetes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            572,
            "2016).",
            [
                " {\n  \"DRUGS\": [\"No specific drugs mentioned\"],\n  \"HERB NAME\": [\"No specific herbs mentioned\"],\n  \"STUDY\": \"Cohort study\",\n  \"PARAMETER\": [\"drug efficacy\", \"drug safety\", \"drug side effects\"],\n  \"FREQUENCY\": [\"No specific frequencies mentioned\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"No specific cohort description provided\",\n  \"DURATION\": [\"No specific durations mentioned\"],\n  \"SEX\": [\"No specific sexes mentioned\"],\n  \"AGE\": [\"No specific ages mentioned\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            573,
            "Water and food (laboratory rodent chow, Shanghai, China) were allowed ad libitum.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Laboratory study\",\n  \"PARAMETER\": [\"water\", \"food\", \"laboratory rodent chow\"],\n  \"FREQUENCY\": [\"ad libitum\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Laboratory rodents\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"laboratory rodent chow\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            574,
            "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA).",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"liquid chromatography system\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            575,
            "Statistical analysis of results obtained from clinical study was performed using Student\u2019s paired t-test.",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical study\",\n  \"PARAMETER\": [\"physiological or medical parameters\"],\n  \"FREQUENCY\": [\"Statistical analysis\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "clinical study"
                    ]
                }
            ]
        ],
        [
            576,
            "The results suggest that the herb-drug interaction between GLT and AC might occur when they were co-administered.",
            [
                " {\n  \"DRUGS\": [\"GLT\", \"AC\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"herb-drug interaction\"],\n  \"FREQUENCY\": [\"occur\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"interaction\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "GLT"
                    ],
                    "Drug": [
                        "AC"
                    ]
                }
            ]
        ],
        [
            577,
            "HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            578,
            "(n\u00a0=\u00a06).",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {
                    "Amount": [
                        "6"
                    ]
                }
            ]
        ],
        [
            579,
            "wrote the manuscript.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            580,
            "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S.",
            [
                " {\n  \"DRUGS\": [\"No drugs mentioned\"],\n  \"HERB NAME\": [\"No specific herb names mentioned\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"sex\", \"age\", \"duration of treatment\", \"dose\", \"frequency of administration\", \"side effects\"],\n  \"FREQUENCY\": [\"daily\", \"weekly\", \"monthly\", \"yearly\"],\n  \"HERB PART\": [\"root\", \"leaf\", \"flower\"],\n  \"COHORT\": \"A group of individuals with specific characteristics (e.g., age, sex, health status) participating in a study\",\n  \"DURATION\": [\"short-term\", \"long-term\"],\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [\"adults\", \"elderly\"],\n  \"AMOUNT\": [\"dose\", \"quantity of herb used\"],\n  \"ETHNIC GROUP\": [\"No specific ethnic groups mentioned\"],\n  \"PATHOLOGY\": [\"No specific pathologies or side effects mentioned\"],\n  \"TARGET\": [\"No specific enzymes, transporters, or receptors mentioned\"],\n  \"EXTRACTION PROCESS\": [\"No specific extraction process mentioned\"]\n}",
                {}
            ]
        ],
        [
            581,
            "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.",
            [
                " {\n  \"DRUGS\": [\"No drugs mentioned in the text\"],\n  \"HERB NAME\": [\"No specific herb names mentioned in the text\"],\n  \"STUDY\": \"Cohort study\",\n  \"PARAMETER\": [\"No specific physiological or medical parameters mentioned in the text\"],\n  \"FREQUENCY\": [\"No specific frequencies of events mentioned in the text\"],\n  \"HERB PART\": [\"No specific parts of herb used mentioned in the text\"],\n  \"COHORT\": \"The cohort consisted of S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.\",\n  \"DURATION\": [\"No specific durations of events mentioned in the text\"],\n  \"SEX\": [\"S.M., Y.O., R.T., J.K., H.W., M.F., K.S.\"],\n  \"AGE\": [\"No specific ages mentioned in the text\"],\n  \"AMOUNT\": [\"No specific quantities mentioned in the text\"],\n  \"ETHNIC GROUP\": [\"No specific ethnic groups mentioned in the text\"],\n  \"PATHOLOGY\": [\"No specific pathologies or side effects mentioned in the text\"],\n  \"TARGET\": [\"No specific enzymes, transporters, or other targets mentioned in the text\"],\n  \"EXTRACTION PROCESS\": [\"No specific process of herb preparation mentioned in the text\"]\n}",
                {}
            ]
        ],
        [
            582,
            "Eugenia jambolana (EJ) is an Indian traditional herb widely used for the treatment of diabetes mellitus.",
            [
                " {\n  \"DRUGS\": [\"Eugenia jambolana (EJ)\"],\n  \"HERB NAME\": [\"Eugenia jambolana\"],\n  \"STUDY\": \"Use of traditional herb for the treatment of diabetes mellitus\",\n  \"PARAMETER\": [\"diabetes mellitus\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"Indian\"],\n  \"PATHOLOGY\": [\"diabetes mellitus\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Eugenia jambolana (EJ)"
                    ],
                    "Ethnic group": [
                        "Indian"
                    ],
                    "Pathology": [
                        "diabetes mellitus"
                    ]
                }
            ]
        ],
        [
            583,
            "Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study.",
            [
                " {\n  \"DRUGS\": [\"SITA\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"pharmacodynamic study\",\n  \"PARAMETER\": [\"blood glucose level\"],\n  \"FREQUENCY\": [\"significant reduction\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"low levels of SITA\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "SITA"
                    ],
                    "Parameter": [
                        "blood glucose level"
                    ],
                    "Study": [
                        "pharmacodynamic study"
                    ]
                }
            ]
        ],
        [
            584,
            "(EJ) are considered to be functional foods owing to their anti-diabetic Several research groups studying the protective and therapeutic effect of EJE and have identified presence of various classes of bioactive constituents like anthocyanins, flavonoids Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4).",
            [
                " {\n  \"DRUGS\": [\"Gliptins\"],\n  \"HERB NAME\": [\"EJ\"],\n  \"STUDY\": \"Research on the protective and therapeutic effect of EJ\",\n  \"PARAMETER\": [\"anti-diabetic\", \"bioactive constituents\", \"anthocyanins\", \"flavonoids\", \"competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"anti-diabetic\"],\n  \"TARGET\": [\"dipeptidyl peptidase-4 (DDP-4)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "EJ",
                        "EJE",
                        "anthocyanins",
                        "flavonoids"
                    ],
                    "Drug": [
                        "Gliptins",
                        "oral anti-diabetic agents"
                    ],
                    "Target": [
                        "enzyme dipeptidyl peptidase-4 (DDP-4)"
                    ]
                }
            ]
        ],
        [
            585,
            "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.",
            [
                " {\n  \"DRUGS\": [\"diabetic\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Safety and efficacy study\",\n  \"PARAMETER\": [\"diabetic patient\"],\n  \"FREQUENCY\": [\"during the course of his treatment\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"course of his treatment\"],\n  \"SEX\": [\"\"],\n  \"AGE\": [\"\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"diabetes\"],\n  \"TARGET\": [\"diabetic patient\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "diabetic"
                    ]
                }
            ]
        ],
        [
            586,
            "Dried seed of Eugenia jambolana were powdered and used for preparation of aqueous extract by using the double maceration technique.",
            [
                " {\n  \"DRUGS\": [\"Eugenia jambolana\"],\n  \"HERB NAME\": [\"Eugenia jambolana\"],\n  \"STUDY\": \"Preparation of aqueous extract\",\n  \"PARAMETER\": [\"double maceration technique\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Dried seed\"],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"Dried seed\"],\n  \"ETHNIC GROUP\": \"\",\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"double maceration technique\"]\n}",
                {
                    "Herb part": [
                        "seed"
                    ],
                    "Herb name": [
                        "Eugenia jambolana"
                    ],
                    "Extraction process": [
                        "aqueous extract",
                        "double maceration technique"
                    ]
                }
            ]
        ],
        [
            587,
            "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing.",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [\"\"],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"filtered\", \"refrigerator\", \"processing\"],\n  \"FREQUENCY\": [\"seven days\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"seven days\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            588,
            "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate.",
            [
                " {\n  \"DRUGS\": [\"List of drugs found in text\"],\n  \"HERB NAME\": [\"List of herbs found in text\"],\n  \"STUDY\": \"Type of study described\",\n  \"PARAMETER\": [\"List of physiological or medical parameters found in text\"],\n  \"FREQUENCY\": \"frequences of events described in text\",\n  \"HERB PART\": [\"List of parts of herb used found in text\"],\n  \"COHORT\": \"Description of the cohort\",\n  \"DURATION\": [\"List of durations of events found in text\"],\n  \"SEX\": [\"List of sexes found in text\"],\n  \"AGE\": [\"List of ages found in text\"],\n  \"AMOUNT\": [\"List of quantities found in text\"],\n  \"ETHNIC GROUP\": [\"List of ethnic groups found in text\"],\n  \"PATHOLOGY\": [\"List of pathologies or side effects found in text\"],\n  \"TARGET\": [\"List of enzymes, transporters,... found in text\"],\n  \"EXTRACTION PROCESS\": [\"List of process of herb preparation found in text\"]\n}\n\nNote: The actual content for each field should be filled in with the relevant information extracted from the scientific article. Since the provided text does not contain specific details, placeholders are used.",
                {}
            ]
        ],
        [
            589,
            "Glucose level was determined using GOD-POD Erba diagnostic kits.",
            [
                " {\n  \"DRUGS\": [\"GOD-POD\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"diagnostic study\",\n  \"PARAMETER\": [\"glucose level\"],\n  \"FREQUENCY\": [\"\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "Glucose level"
                    ]
                }
            ]
        ],
        [
            590,
            "3a and b).",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            591,
            "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin).",
            [
                " {\n  \"DRUGS\": [\"SITA\", \"PRM\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Chromatographic study\",\n  \"PARAMETER\": [\"0.642min\", \"0.482min\"],\n  \"FREQUENCY\": [\"Peak\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"Chromatographic study\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "SITA",
                        "PRM",
                        "SITA",
                        "PRM"
                    ]
                }
            ]
        ],
        [
            592,
            "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response.",
            [
                " {\n  \"DRUGS\": [\"diabetes\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Type of study not specified\",\n  \"PARAMETER\": [\"oxidative stress\", \"inflammatory response\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"liver damage\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "diabetes",
                        "liver damage",
                        "oxidative stress",
                        "aberrant inflammatory response"
                    ]
                }
            ]
        ],
        [
            593,
            "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"mean \u00b1 SEM\"],\n  \"FREQUENCY\": [\"six rats\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            594,
            "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.",
            [
                " {\n  \"DRUGS\": [\"No drugs mentioned\"],\n  \"HERB NAME\": [\"No specific herb names mentioned\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"physiological or medical parameters\"],\n  \"FREQUENCY\": [\"significantly different from normal group\", \"p\u00a0<\u00a00.001\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"Not specified\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"different from normal group\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "diabetic"
                    ]
                }
            ]
        ],
        [
            595,
            "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig.",
            [
                " {\n  \"DRUGS\": [\"EJE\", \"EJE + SITA\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"BUN (Blood Urea Nitrogen)\"],\n  \"FREQUENCY\": [\"p < 0.001\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"Not specified\"],\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"elevated levels of BUN\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "EJE",
                        "EJE\u202f"
                    ],
                    "Drug": [
                        "\u202fSITA"
                    ],
                    "Parameter": [
                        "BUN"
                    ]
                }
            ]
        ],
        [
            596,
            "9, Table\u00a02).",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Cohort study\",\n  \"PARAMETER\": [\"drug efficacy\", \"drug safety\", \"drug-herb interactions\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            597,
            "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.",
            [
                " {\n  \"DRUGS\": [\"No drugs mentioned\"],\n  \"HERB NAME\": [\"No specific herb names mentioned\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"physiological or medical parameters\"],\n  \"FREQUENCY\": [\"significantly different from normal group\", \"p\u00a0<\u00a00.001\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"Not specified\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"different from normal group\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "diabetic"
                    ]
                }
            ]
        ],
        [
            598,
            "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.",
            [
                " {\n  \"DRUGS\": [\"indomethacin\"],\n  \"HERB NAME\": [\"A.\u00a0officinarum\"],\n  \"STUDY\": \"clinical study\",\n  \"PARAMETER\": [\"pharmacokinetic parameters\"],\n  \"FREQUENCY\": [\"significant alterations\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "A.\u00a0officinarum"
                    ],
                    "Drug": [
                        "indomethacin"
                    ]
                }
            ]
        ],
        [
            599,
            "A.\u00a0Officinarum could accelerate the excretions of indomethacin and its three metabolites in the bile and feces of rats in the excretion study.",
            [
                " {\n  \"DRUGS\": [\"indomethacin\"],\n  \"HERB NAME\": [\"Officinarum\"],\n  \"STUDY\": \"excretion study\",\n  \"PARAMETER\": [\"excretions of indomethacin and its three metabolites\", \"bile\", \"feces\"],\n  \"FREQUENCY\": [\"accelerate\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"rats\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "A.\u00a0Officinarum"
                    ],
                    "Drug": [
                        "indomethacin"
                    ]
                }
            ]
        ],
        [
            600,
            "Tissue homogenates were treated by the same method as plasma sample preparation except dilution process.",
            [
                " {\n  \"DRUGS\": [\"plasma sample preparation\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Tissue homogenates treatment\",\n  \"PARAMETER\": [\"tissue homogenates\", \"plasma sample preparation\"],\n  \"FREQUENCY\": [\"same method\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            601,
            "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group.",
            [
                " {\n  \"DRUGS\": [\"No drugs mentioned\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Experimental study with animal model\",\n  \"PARAMETER\": [\"six rats\"],\n  \"FREQUENCY\": [\"two groups\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Model group and M-AOE group, each with six rats\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            602,
            "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing.",
            [
                " {\n  \"DRUGS\": [\"bile\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Dosing study\",\n  \"PARAMETER\": [\"0\u20131 h\", \"1\u20132 h\", \"2\u20133 h\", \"3\u20134 h\", \"4\u20135 h\", \"5\u20136 h\", \"6\u20137 h\"],\n  \"FREQUENCY\": [\"dosing\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"0\u20131 h\", \"1\u20132 h\", \"2\u20133 h\", \"3\u20134 h\", \"4\u20135 h\", \"5\u20136 h\", \"6\u20137 h\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            603,
            "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"urine\", \"feces\"],\n  \"FREQUENCY\": [\"0\u20136 h\", \"6\u201318 h\", \"18\u201328 h\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"0\u20136 h\", \"6\u201318 h\", \"18\u201328 h\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            604,
            "The method was fully validated in compliance with the U.S. Food and Drug Administration (USFDA) guidelines for bioanalytical method validation, including selectivity, matrix effect, linearity, recovery, accuracy and precision, dilution integrity, and stability evaluations.",
            [
                " {\n  \"DRUGS\": [\"Not specified\"],\n  \"HERB NAME\": [\"Not specified\"],\n  \"STUDY\": \"bioanalytical method validation\",\n  \"PARAMETER\": [\"selectivity\", \"matrix effect\", \"linearity\", \"recovery\", \"accuracy\", \"precision\", \"dilution integrity\", \"stability\"],\n  \"FREQUENCY\": [\"Not specified\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            605,
            "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert.",
            [
                " {\n  \"DRUGS\": [\"indomethacin\"],\n  \"HERB NAME\": [\"A. officinarum\"],\n  \"STUDY\": \"study of the protective effect of A. officinarum on indomethacin-induced gastric injury\",\n  \"PARAMETER\": [\"pharmacokinetics\", \"indomethacin\", \"indomethacin metabolites\", \"gastric injury\"],\n  \"FREQUENCY\": [\"not specified\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"gastric injury\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "A.\u00a0officinarum"
                    ],
                    "Drug": [
                        "indomethacin"
                    ],
                    "Pathology": [
                        "gastric injury"
                    ]
                }
            ]
        ],
        [
            606,
            "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig.",
            [
                " {\n  \"DRUGS\": [\"indomethacin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical study\",\n  \"PARAMETER\": [\"plasma concentration-time curves\"],\n  \"FREQUENCY\": [\"similar trends\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"S-AOE group\", \"M-AOE group\", \"model group\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n   \n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            607,
            "1).",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": \"Not specified in the provided text\",\n  \"HERB PART\": \"Not specified in the provided text\",\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": \"Not specified in the provided text\",\n  \"SEX\": \"Not specified in the provided text\",\n  \"AGE\": \"Not specified in the provided text\",\n  \"AMOUNT\": \"Not specified in the provided text\",\n  \"ETHNIC GROUP\": \"Not specified in the provided text\",\n  \"PATHOLOGY\": \"Not specified in the provided text\",\n  \"TARGET\": \"Not specified in the provided text\",\n  \"EXTRACTION PROCESS\": \"Not specified in the provided text\"\n}",
                {}
            ]
        ],
        [
            608,
            "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study monitoring INR levels in patients on warfarin therapy\",\n  \"PARAMETER\": [\"INR\", \"warfarin dosage\", \"monthly INR monitoring\"],\n  \"FREQUENCY\": [\"monthly\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Patients on maintenance daily dose of warfarin\",\n  \"DURATION\": [\"ongoing\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1.875 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"therapeutic INR (1.7\u20132.5)\"],\n  \"TARGET\": [\"warfarin\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "INR",
                        "monitoring"
                    ],
                    "Amount": [
                        "1.7\u20132.5",
                        "1.875 mg"
                    ],
                    "Frequency": [
                        "daily"
                    ],
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            609,
            "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy.",
            [
                " {\n  \"DRUGS\": [\"wine\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical study\",\n  \"PARAMETER\": [\"thrombin times (TTs)\", \"anticoagulant therapy\"],\n  \"FREQUENCY\": [\"moderate intake of alcohol occasionally\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"not specified\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"375 ml\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"outside the therapeutic range\"],\n  \"TARGET\": [\"thrombin times\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Amount": [
                        "375 ml"
                    ],
                    "Extraction process": [
                        "wine"
                    ],
                    "Parameter": [
                        "thrombin times (TTs)"
                    ],
                    "Drug": [
                        "anticoagulant therapy"
                    ]
                }
            ]
        ],
        [
            610,
            "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.).",
            [
                " {\n  \"DRUGS\": [\"Pharmacological agents\"],\n  \"HERB NAME\": [\"Dang Gui\", \"Danshen\", \"Ginkgo biloba\"],\n  \"STUDY\": \"Clinical trials, observational studies, pharmacokinetic studies\",\n  \"PARAMETER\": [\"Drug efficacy\", \"Drug safety\", \"Drug metabolism\", \"Drug-herb interactions\"],\n  \"FREQUENCY\": [\"Not specified\"],\n  \"HERB PART\": [\"Not specified\"],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"Not specified\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [\"Not specified\"],\n  \"ETHNIC GROUP\": [\"Not specified\"],\n  \"PATHOLOGY\": [\"Not specified\"],\n  \"TARGET\": [\"Not specified\"],\n  \"EXTRACTION PROCESS\": [\"Not specified\"]\n}",
                {
                    "Herb name": [
                        "Danshen",
                        "Ginkgo biloba",
                        "Dong quai"
                    ]
                }
            ]
        ],
        [
            611,
            "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [\"Gouqizi\"],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"warfarin consumption\"],\n  \"FREQUENCY\": [\"daily diet\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"Chinese\"],\n  \"PATHOLOGY\": [\"difficulty in implementing prohibition of consumption\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Gouqizi"
                    ],
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            612,
            "Due to public concern regarding the risk of bleeding during treatment with warfarin, as well as the uneasy relationship between allopathic doctors and their patients, no more than 10% of patients with atrial fibrillation take warfarin in China [5].",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"bleeding risk\", \"atrial fibrillation\", \"warfarin usage\"],\n  \"FREQUENCY\": [\"less than 10% of patients\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"patients with atrial fibrillation in China\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"less than 10%\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"bleeding risk\"],\n  \"TARGET\": [\"warfarin\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "bleeding",
                        "atrial fibrillation"
                    ],
                    "Drug": [
                        "warfarin",
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            613,
            "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [\"warfarin effects\", \"prosthetic heart valves\"],\n  \"FREQUENCY\": [\"three patients\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"patients with prosthetic heart valves taking warfarin\",\n  \"DURATION\": [\"3 days\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"6 g\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"no enhanced effects of warfarin\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Frequency": [
                        "daily"
                    ],
                    "Herb name": [
                        "Gouqizi"
                    ],
                    "Amount": [
                        "6 g"
                    ],
                    "Ethnic group": [
                        "Chinese"
                    ],
                    "Duration": [
                        "for 3 days"
                    ],
                    "Drug": [
                        "warfarin",
                        "warfarin"
                    ],
                    "Pathology": [
                        "prosthetic heart"
                    ]
                }
            ]
        ],
        [
            614,
            "Go to: Conflict of interests  There is no conflict of interests.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            615,
            "The interaction study of warfarin and Lycium barbarum L.  Methods  This project about the interaction study of warfarin and Lycium barbarum L. is approved by Fujian Medical University Union Hospital ethics committee (NO: 2015KY002).",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [\"Lycium barbarum\"],\n  \"STUDY\": \"interaction study\",\n  \"PARAMETER\": [\"warfarin\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "warfarin",
                        "warfarin"
                    ],
                    "Herb name": [
                        "Lycium barbarum L.",
                        "Lycium barbarum L."
                    ]
                }
            ]
        ],
        [
            616,
            "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner.",
            [
                " {\n  \"DRUGS\": [\"HS extract\"],\n  \"HERB NAME\": [\"HS\"],\n  \"STUDY\": \"Animal studies\",\n  \"PARAMETER\": [\"blood pressure\"],\n  \"FREQUENCY\": [\"consistently\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"blood pressure reduction\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nNote: The provided text does not mention specific details about the cohort, sex, age, amount, ethnic group, pathology, target, or extraction process. Therefore, these fields are left empty.",
                {
                    "Study": [
                        "Animal studies"
                    ],
                    "Herb name": [
                        "HS extract"
                    ],
                    "Parameter": [
                        "blood pressure"
                    ]
                }
            ]
        ],
        [
            617,
            "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"HS\"],\n  \"STUDY\": \"Investigation of the active constituents in HS\",\n  \"PARAMETER\": [\"antihypertensive\", \"antioxidant\", \"hypocholesterolemic effects\"],\n  \"FREQUENCY\": [\"high relative quantities\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"delphinidin-3-sambubioside\", \"cyanidin-3-sambubioside\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"antihypertensive\", \"antioxidant\", \"hypocholesterolemic effects\"],\n  \"TARGET\": [\"enzymes, transporters,...\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside",
                        "HS"
                    ],
                    "Pathology": [
                        "antihypertensive, antioxidant, and hypocholesterolemic"
                    ],
                    "Extraction process": [
                        "aqueous extracts"
                    ]
                }
            ]
        ],
        [
            618,
            "The HS varieties with deeper red calyxes exhibited greater antioxidant activity as compared to lighter red or white varieties [44, 45].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"HS varieties\"],\n  \"STUDY\": \"Comparative study of antioxidant activity in different varieties of a herb\",\n  \"PARAMETER\": [\"antioxidant activity\", \"red calyxes\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"red calyxes\"],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"greater antioxidant activity\"],\n  \"TARGET\": [\"enzymes, transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "HS"
                    ],
                    "Herb part": [
                        "calyxes"
                    ],
                    "Pathology": [
                        "antioxidant activity"
                    ]
                }
            ]
        ],
        [
            619,
            "7.2.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            620,
            "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides.",
            [
                " {\n  \"DRUGS\": [\"cholesterol\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized Controlled Trials (RCTs)\",\n  \"PARAMETER\": [\"total cholesterol\", \"HDL-C\", \"LDL-C\", \"triglycerides\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"not specified in the text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"cholesterol\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "Cholesterol",
                        "cholesterol",
                        "total cholesterol",
                        "HDL-C",
                        "LDL-C",
                        "triglycerides"
                    ],
                    "Study": [
                        "RCT",
                        "RCT"
                    ]
                }
            ]
        ],
        [
            621,
            "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18].",
            [
                " {\n  \"DRUGS\": [\"HS\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"15 day study\",\n  \"PARAMETER\": [\"total cholesterol\", \"hypertensive patients\"],\n  \"FREQUENCY\": [\"significant increase\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"hypertensive patients\"],\n  \"DURATION\": [\"15 days\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"increase in total cholesterol\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Duration": [
                        "15 day"
                    ],
                    "Parameter": [
                        "total cholesterol"
                    ],
                    "Pathology": [
                        "hypertensive"
                    ],
                    "Herb name": [
                        "HS"
                    ]
                }
            ]
        ],
        [
            622,
            "More specifically, most studies did not make clear the type of RCT being conducted and in many cases there were study design problems.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Randomized Controlled Trial (RCT)\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "RCT"
                    ]
                }
            ]
        ],
        [
            623,
            "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59].",
            [
                " {\n  \"DRUGS\": [\"ACE inhibitors\"],\n  \"HERB NAME\": [\"HS extracts\"],\n  \"STUDY\": \"In vitro and in vivo studies\",\n  \"PARAMETER\": [\"vasodilation\", \"endothelium-derived relaxant pathways\", \"calcium influx\", \"new vessel formation\", \"reduction of myocardial mass\", \"anthocyanins\", \"active site\", \"blood viscosity\", \"cyclooxygenase inhibitory activity\", \"adipocyte differentiation\", \"PI3-K/Akt pathway\", \"ERK pathway\"],\n  \"FREQUENCY\": [\"several\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"in vitro\", \"in vivo\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"hypertension\"],\n  \"TARGET\": [\"endothelium-derived relaxant pathways\", \"calcium influx\", \"new vessel formation\", \"myocardial mass\", \"anthocyanins\", \"active site\", \"cyclooxygenase\", \"PI3-K/Akt pathway\", \"ERK pathway\"]\n}",
                {
                    "Study": [
                        "In vitro and in vivo studies"
                    ],
                    "Herb name": [
                        "HS extracts",
                        "anthocyanins"
                    ],
                    "Pathology": [
                        "hypotensive activity,",
                        "vasodilation"
                    ],
                    "Parameter": [
                        "calcium influx",
                        "myocardial mass",
                        "blood viscosity",
                        "cyclooxygenase inhibitory activity",
                        "adipocyte differentiation",
                        "PI3-K/Akt",
                        "ERK"
                    ],
                    "Target": [
                        "ACE"
                    ]
                }
            ]
        ],
        [
            624,
            "Studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses, but may be hepatotoxic at extremely high doses.",
            [
                " {\n  \"DRUGS\": [\"HS\"],\n  \"HERB NAME\": [\"HS\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"liver function\", \"kidney function\", \"hepatotoxicity\"],\n  \"FREQUENCY\": [\"lower doses\", \"extremely high doses\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"hepatotoxicity\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "HS"
                    ],
                    "Pathology": [
                        "hepatotoxic"
                    ]
                }
            ]
        ],
        [
            625,
            "In addition, electrolyte levels generally are not effected by ingesting HS extracts despite its diuretic effects.",
            [
                " {\n  \"DRUGS\": [\"HS extracts\"],\n  \"HERB NAME\": [\"HS extracts\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"electrolyte levels\", \"diuretic effects\"],\n  \"FREQUENCY\": [\"general\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "electrolyte levels"
                    ],
                    "Herb name": [
                        "HS extracts"
                    ],
                    "Pathology": [
                        "diuretic effects"
                    ]
                }
            ]
        ],
        [
            626,
            "As a service to our customers we are providing this early version of the manuscript.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": \"Not specified in the provided text\",\n  \"HERB PART\": \"Not specified in the provided text\",\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": \"Not specified in the provided text\",\n  \"SEX\": \"Not specified in the provided text\",\n  \"AGE\": \"Not specified in the provided text\",\n  \"AMOUNT\": \"Not specified in the provided text\",\n  \"ETHNIC GROUP\": \"Not specified in the provided text\",\n  \"PATHOLOGY\": \"Not specified in the provided text\",\n  \"TARGET\": \"Not specified in the provided text\",\n  \"EXTRACTION PROCESS\": \"Not specified in the provided text\"\n}",
                {}
            ]
        ],
        [
            627,
            "Interaction between imatinib and Schisandra lignans was unlikely to be of clinical importance.",
            [
                " {\n  \"DRUGS\": [\"imatinib\"],\n  \"HERB NAME\": [\"Schisandra\"],\n  \"STUDY\": \"interaction study\",\n  \"PARAMETER\": [\"clinical importance\"],\n  \"FREQUENCY\": [\"unlikely\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "imatinib"
                    ],
                    "Herb name": [
                        "Schisandra lignans"
                    ]
                }
            ]
        ],
        [
            628,
            "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure.",
            [
                " {\n  \"DRUGS\": [\"bosutinib\"],\n  \"HERB NAME\": [\"S. sphenanthera\"],\n  \"STUDY\": \"clinical study\",\n  \"PARAMETER\": [\"bosutinib systemic exposure\"],\n  \"FREQUENCY\": [\"three-fold increase\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"clinically-relevant dose\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "S. sphenanthera"
                    ],
                    "Drug": [
                        "bosutinib"
                    ]
                }
            ]
        ],
        [
            629,
            "Keywords: drug metabolism, herb\u2013drug interactions, modelling and simulation, physiologically\u2010based pharmacokinetic (PBPK) What is already known about this subject      Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches combined with in vitro to in vivo extrapolation techniques have been extensively used for predicting clinically meaningful pharmacokinetic drug interactions.",
            [
                " {\n  \"DRUGS\": [\"drug metabolism\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches combined with in vitro to in vivo extrapolation techniques\",\n  \"PARAMETER\": [\"drug interactions\", \"pharmacokinetics\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"drug interactions\"],\n  \"TARGET\": [\"enzymes\", \"transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "modelling approaches combined with in vitro to in vivo extrapolation techniques"
                    ]
                }
            ]
        ],
        [
            630,
            "21 Clearly, a reliable and systematic approach to predict these herb\u2013drug interactions is needed.",
            [
                " {\n  \"DRUGS\": [\"reliable\", \"systematic\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"predicting herb-drug interactions\",\n  \"PARAMETER\": [\"interactions\"],\n  \"FREQUENCY\": [\"needed\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"enzymes\", \"transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            631,
            "Go to: 2.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            632,
            "2.1.2.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            633,
            "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability.",
            [
                " {\n  \"DRUGS\": [\"potential mechanism\u2010based inhibitors\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"in vitro study\",\n  \"PARAMETER\": [\"potential mechanism\u2010based inhibitors\", \"CYP2C8 enzyme\", \"human liver microsomes\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"recombinant CYP2C8 enzyme (supersomes)\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"high lot\u2010to\u2010lot variability\"],\n  \"TARGET\": [\"CYP2C8 enzyme\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "in vitro study"
                    ],
                    "Parameter": [
                        "recombinant CYP2C8 enzyme (supersomes)",
                        "human liver microsomes (HLM)"
                    ]
                }
            ]
        ],
        [
            634,
            "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA).",
            [
                " {\n  \"DRUGS\": [\"NADPH\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"NADPH\"],\n  \"FREQUENCY\": [\"Not specified\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"Not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "NADPH"
                    ]
                }
            ]
        ],
        [
            635,
            "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered.",
            [
                " {\n  \"DRUGS\": [\"Competitive\", \"Noncompetitive\", \"Mixed-inhibition\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Type of study described\",\n  \"PARAMETER\": [\"Competitive\", \"Noncompetitive\", \"Mixed-inhibition\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Description of the cohort not provided in the text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            636,
            "Theoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when concentrations of substrates are much lower than their K m values, which is often the case in the clinical setting.",
            [
                " {\n  \"DRUGS\": [\"none\"],\n  \"HERB NAME\": [\"none\"],\n  \"STUDY\": \"Theoretical analysis of competitive and noncompetitive inhibition\",\n  \"PARAMETER\": [\"K m values\", \"concentrations of substrates\"],\n  \"FREQUENCY\": [\"not applicable\"],\n  \"HERB PART\": [\"none\"],\n  \"COHORT\": \"not applicable\",\n  \"DURATION\": \"not applicable\",\n  \"SEX\": \"not applicable\",\n  \"AGE\": \"not applicable\",\n  \"AMOUNT\": \"not applicable\",\n  \"ETHNIC GROUP\": \"not applicable\",\n  \"PATHOLOGY\": \"not applicable\",\n  \"TARGET\": [\"enzymes\", \"transporters\"],\n  \"EXTRACTION PROCESS\": \"not applicable\"\n}",
                {
                    "Parameter": [
                        "concentrations of substrates",
                        "K m values"
                    ]
                }
            ]
        ],
        [
            637,
            "8 Partition coefficients (log P) of neutral compounds are generally the most influential parameter dictating the extent of distribution to different tissues.",
            [
                " {\n  \"DRUGS\": [\"Partition coefficients (log P)\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Type of study not specified\",\n  \"PARAMETER\": [\"Partition coefficients (log P)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Partition coefficients (log P)\"],\n  \"TARGET\": [\"Partition coefficients (log P)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "Partition coefficients (log P)"
                    ]
                }
            ]
        ],
        [
            638,
            "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Type of study not specified\",\n  \"PARAMETER\": [\"log P\", \"tissue-to-plasma partition coefficients\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "log P",
                        "K p (tissue\u2010to\u2010plasma partition coefficients)"
                    ]
                }
            ]
        ],
        [
            639,
            "Prediction differences of pharmacokinetic parameters for the three lignans, expressed as the ratio of PBPK model prediction to clinically\u2010reported parameter values were also evaluated.",
            [
                " {\n  \"DRUGS\": [\"lignans\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical study\",\n  \"PARAMETER\": [\"pharmacokinetic parameters\", \"PBPK model prediction\", \"clinically-reported parameter values\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"clinically-reported parameter values\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "lignans"
                    ]
                }
            ]
        ],
        [
            640,
            "PBPK simulations were also carried out to evaluate the capability of PBPK models of Schisandra lignans in predicting the extent of interactions with midazolam and tacrolimus with trial designs as detailed in Table 3.",
            [
                " {\n  \"DRUGS\": [\"midazolam\", \"tacrolimus\"],\n  \"HERB NAME\": [\"Schisandra\"],\n  \"STUDY\": \"PBPK simulations\",\n  \"PARAMETER\": [\"interactions\", \"extent\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"trial designs\",\n  \"DURATION\": [\"Table 3\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Schisandra lignans\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Schisandra lignans"
                    ],
                    "Drug": [
                        "midazolam",
                        "tacrolimus"
                    ],
                    "Study": [
                        "trial designs"
                    ]
                }
            ]
        ],
        [
            641,
            "An external file that holds a picture, illustration, etc.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            642,
            "MBI, mechanism\u2010based inhibition Go to: 4.",
            [
                " {\n  \"DRUGS\": [\"MBI\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"mechanism\u2010based inhibition\",\n  \"PARAMETER\": [\"MBI\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"enzymes\", \"transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            643,
            "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction.",
            [
                " {\n  \"DRUGS\": [\"carbamazepine\", \"phenytoin\"],\n  \"HERB NAME\": [\"Schisandra\"],\n  \"STUDY\": \"chronic exposure study\",\n  \"PARAMETER\": [\"CYP3A inhibition\", \"CYP3A induction\"],\n  \"FREQUENCY\": [\"72\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified\",\n  \"DURATION\": [\"chronic exposure\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"CYP3A inhibition\"],\n  \"TARGET\": [\"CYP3A\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "carbamazepine",
                        "phenytoin"
                    ],
                    "Herb name": [
                        "Schisandra lignans"
                    ],
                    "Target": [
                        "CYP3A"
                    ]
                }
            ]
        ],
        [
            644,
            "Another limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates.",
            [
                " {\n  \"DRUGS\": [\"Schisandra\"],\n  \"HERB NAME\": [\"Schisandra\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"CYP substrates\"],\n  \"FREQUENCY\": [\"reliance on the assumption\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"interactions with CYP substrates\"],\n  \"TARGET\": [\"CYP substrates\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Schisandra lignans"
                    ],
                    "Parameter": [
                        "CYP"
                    ]
                }
            ]
        ],
        [
            645,
            "Constituents of S. sphenanthera extract also exhibited anti\u2010cancer activity, although with evidence strictly limited to in vitro data in different cancer cell lines.",
            [
                " {\n  \"DRUGS\": [\"S. sphenanthera\"],\n  \"HERB NAME\": [\"S. sphenanthera\"],\n  \"STUDY\": \"in vitro study\",\n  \"PARAMETER\": [\"anti-cancer activity\"],\n  \"FREQUENCY\": [\"limited evidence\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"different cancer cell lines\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"anti-cancer activity\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "S. sphenanthera extract"
                    ],
                    "Pathology": [
                        "anti\u2010cancer activity"
                    ]
                }
            ]
        ],
        [
            646,
            "Ginkgo biloba is available as an over-the-counter drug and reported to cause haemorrhage when coadministered with other antiplatelet agents.",
            [
                " {\n  \"DRUGS\": [\"Ginkgo biloba\"],\n  \"HERB NAME\": [\"Ginkgo biloba\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"haemorrhage\", \"antiplatelet agents\"],\n  \"FREQUENCY\": [\"not specified\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"not specified\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [\"not specified\"],\n  \"PATHOLOGY\": [\"haemorrhage\"],\n  \"TARGET\": [\"antiplatelet agents\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Ginkgo biloba"
                    ],
                    "Pathology": [
                        "haemorrhage"
                    ],
                    "Drug": [
                        "antiplatelet agents"
                    ]
                }
            ]
        ],
        [
            647,
            "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination.",
            [
                " {\n  \"DRUGS\": [\"warfarin\", \"Danshen\", \"Gegen\"],\n  \"HERB NAME\": [\"Danshen\"],\n  \"STUDY\": \"animal study\",\n  \"PARAMETER\": [\"Sprague\u2013Dawley rats\", \"0.2 mg/kg\", \"240 mg/kg\", \"480 mg/kg\"],\n  \"FREQUENCY\": [\"Sixty\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Sprague\u2013Dawley rats\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"0.2 mg/kg\", \"240 mg/kg\", \"480 mg/kg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "warfarin"
                    ],
                    "Amount": [
                        "0.2\u00a0mg/kg",
                        "240 or 480\u00a0mg/kg",
                        "240 or 480\u00a0mg/kg"
                    ],
                    "Herb name": [
                        "Danshen",
                        "Gegen"
                    ]
                }
            ]
        ],
        [
            648,
            "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM.",
            [
                " {\n  \"DRUGS\": [\"CYP\", \"VKOR\", \"TM\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Incubation study using microsomes\",\n  \"PARAMETER\": [\"CYP\", \"VKOR\", \"TM\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP\", \"VKOR\", \"TM\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP",
                        "VKOR",
                        "TM"
                    ]
                }
            ]
        ],
        [
            649,
            "We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis).",
            [
                " {\n  \"DRUGS\": [\"Danshen\", \"Gegen\"],\n  \"HERB NAME\": [\"Danshen\"],\n  \"STUDY\": \"Pharmacodynamic analysis\",\n  \"PARAMETER\": [\"activities\", \"mRNA\", \"protein expression levels\", \"VKOR\", \"TM\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"VKOR\", \"TM\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Danshen",
                        "Gegen"
                    ],
                    "Target": [
                        "VKOR",
                        "TM"
                    ]
                }
            ]
        ],
        [
            650,
            "The raw herbs were morphologically authenticated by an in-house herbalist and chemically by the thin layer chromatography in accordance with the Chinese Pharmacopoeia 2005 [36].",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [\"raw herbs\"],\n  \"STUDY\": \"chemical analysis\",\n  \"PARAMETER\": [\"thin layer chromatography\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"thin layer chromatography in accordance with the Chinese Pharmacopoeia 2005\"]\n}",
                {
                    "Ethnic group": [
                        "Chinese"
                    ]
                }
            ]
        ],
        [
            651,
            "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA).",
            [
                " {\n  \"DRUGS\": [\"Racemic warfarin\", \"diclofenac sodium\", \"naringin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Drug efficacy and standardization study\",\n  \"PARAMETER\": [\"Racemic warfarin\", \"diclofenac sodium\", \"naringin\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"Racemic warfarin\", \"diclofenac sodium\", \"naringin\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "warfarin",
                        "diclofenac sodium"
                    ],
                    "Herb name": [
                        "naringin"
                    ]
                }
            ]
        ],
        [
            652,
            "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Analytical method development\",\n  \"PARAMETER\": [\"linear gradient elution\", \"solvent A\", \"solvent B\", \"running time\", \"percentage\", \"minutes\"],\n  \"FREQUENCY\": [\"90 min\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"5 min\", \"13 min\", \"12 min\", \"10 min\", \"5 min\", \"15 min\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"5%\", \"10%\", \"17%\", \"35%\", \"90%\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"return to 5% and equilibrate\"]\n}",
                {}
            ]
        ],
        [
            653,
            "Compared with the vehicle control group, there was a significant increase of 420\u00a0% (P\u00a0<\u00a00.001) in the mRNA expression ratio of CYP2C6 in the positive control group.",
            [
                " {\n  \"DRUGS\": [\"CYP2C6\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Comparative study of mRNA expression ratios\",\n  \"PARAMETER\": [\"mRNA expression ratio of CYP2C6\"],\n  \"FREQUENCY\": [\"420% increase\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"positive control group\", \"vehicle control group\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"P < 0.001\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C6\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2C6"
                    ]
                }
            ]
        ],
        [
            654,
            "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group.",
            [
                " {\n  \"DRUGS\": [\"Danshen\"],\n  \"HERB NAME\": [\"Danshen\"],\n  \"STUDY\": \"Dose-dependent study\",\n  \"PARAMETER\": [\"mRNA expression level of CYP2C6\"],\n  \"FREQUENCY\": [\"dose-dependent\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"CYP2C6\"],\n  \"EXTRACTION PROCESS\": []\n}\n\nNote: Since the provided text does not contain specific details about the cohort, sex, age, amount, ethnic group, duration, or parts of the herb used, these fields are left empty. The extraction process for the herb is also not mentioned, so it is not included.",
                {
                    "Target": [
                        "CYP2C6"
                    ],
                    "Herb name": [
                        "Danshen"
                    ]
                }
            ]
        ],
        [
            655,
            "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"P-value\", \"vehicle control group\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            656,
            "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM.",
            [
                " {\n  \"DRUGS\": [\"Danshen\", \"Gegen\", \"warfarin\"],\n  \"HERB NAME\": [\"Danshen\", \"Gegen\"],\n  \"STUDY\": \"Clinical effects on microcirculation and platelet aggregation\",\n  \"PARAMETER\": [\"microcirculation\", \"platelet aggregation\", \"anticoagulant effect\", \"VKOR activity\", \"TM induction\"],\n  \"FREQUENCY\": [\"not specified\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"platelet aggregation\"],\n  \"TARGET\": [\"VKOR\", \"TM\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Danshen",
                        "Gegen"
                    ],
                    "Drug": [
                        "warfarin"
                    ],
                    "Target": [
                        "VKOR",
                        "TM"
                    ]
                }
            ]
        ],
        [
            657,
            "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32].",
            [
                " {\n  \"DRUGS\": [\"DFG-warfarin combination\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Previous study on the administration of a DFG-warfarin combination\",\n  \"PARAMETER\": [\"warfarin plasma concentration\", \"PT time\"],\n  \"FREQUENCY\": [\"reduction\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"rats\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"warfarin\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "DFG"
                    ],
                    "Drug": [
                        "warfarin",
                        "warfarin"
                    ],
                    "Parameter": [
                        "PT time"
                    ]
                }
            ]
        ],
        [
            658,
            "Taken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG.",
            [
                " {\n  \"DRUGS\": [\"DFG\"],\n  \"HERB NAME\": [\"Gegen\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"physiological or medical parameters\"],\n  \"FREQUENCY\": [\"not specified\"],\n  \"HERB PART\": [\"not specified\"],\n  \"COHORT\": \"not specified\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [\"not specified\"],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {
                    "Herb name": [
                        "Gegen",
                        "DFG"
                    ]
                }
            ]
        ],
        [
            659,
            "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322].",
            [
                " {\n  \"DRUGS\": [\"Gegen\", \"warfarin\"],\n  \"HERB NAME\": [\"Danshen\"],\n  \"STUDY\": \"case reports\",\n  \"PARAMETER\": [\"interactions between Gegen and warfarin\"],\n  \"FREQUENCY\": [\"several\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"interactions\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "clinical reports",
                        "case reports"
                    ],
                    "Herb name": [
                        "Gegen",
                        "Danshen"
                    ],
                    "Drug": [
                        "warfarin",
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            660,
            "CYP enzymes represent some of the most highly conserved entities among different species, with relatively small differences in the primary amino acid sequences of the CYP enzymes across different species [50, 51].",
            [
                " {\n  \"DRUGS\": [\"CYP enzymes\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Comparative study of CYP enzymes across different species\",\n  \"PARAMETER\": [\"primary amino acid sequences\", \"CYP enzymes\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"different species\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"small differences in primary amino acid sequences\"],\n  \"TARGET\": [\"CYP enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP enzymes",
                        "CYP enzymes"
                    ]
                }
            ]
        ],
        [
            661,
            "Although these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Comparative study of gene sequences and their catalytic specificity and activity\",\n  \"PARAMETER\": [\"catalytic specificity\", \"activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"rats and humans\"],\n  \"DURATION\": [],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"isoforms\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            662,
            "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54].",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Predictive modeling for warfarin dose\",\n  \"PARAMETER\": [\"genetic\", \"physical factors\"],\n  \"FREQUENCY\": [\"not specified\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"not specified\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [\"not specified\"],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            663,
            "Furthermore, CYP1A-, CYP2C- and CYP3A-inducing agents were found in the ethyl acetate extract, but not in the aqueous extract of Danshen [57].",
            [
                " {\n  \"DRUGS\": [\"ethyl acetate extract\", \"aqueous extract\", \"Danshen\"],\n  \"HERB NAME\": [\"Danshen\"],\n  \"STUDY\": \"chemical analysis of ethanol extracts\",\n  \"PARAMETER\": [\"CYP1A-inducing agents\", \"CYP2C-inducing agents\", \"CYP3A-inducing agents\"],\n  \"FREQUENCY\": [\"found in the ethyl acetate extract\", \"not found in the aqueous extract\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP1A-inducing agents\", \"CYP2C-inducing agents\", \"CYP3A-inducing agents\"],\n  \"EXTRACTION PROCESS\": [\"ethyl acetate extract\", \"aqueous extract\"]\n}",
                {
                    "Target": [
                        "CYP1A-",
                        "CYP2C-",
                        "CYP3A-"
                    ],
                    "Extraction process": [
                        "ethyl acetate extract",
                        "aqueous extract"
                    ],
                    "Herb name": [
                        "Danshen"
                    ]
                }
            ]
        ],
        [
            664,
            "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58].",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [\"Danshen\"],\n  \"STUDY\": \"Yueng\u2019s study\",\n  \"PARAMETER\": [\"warfarin hydroxylation\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"in vitro and in vivo\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"effects on warfarin hydroxylation\"],\n  \"TARGET\": [\"major tanshinone components\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "tanshinone",
                        "Danshen"
                    ],
                    "Extraction process": [
                        "aqueous extract"
                    ],
                    "Drug": [
                        "warfarin"
                    ],
                    "Study": [
                        "in vitro and in vivo"
                    ]
                }
            ]
        ],
        [
            665,
            "In our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of SAB.",
            [
                " {\n  \"DRUGS\": [\"SAB\"],\n  \"HERB NAME\": [\"Danshen\"],\n  \"STUDY\": \"In vivo study\",\n  \"PARAMETER\": [\"bioavailability\", \"absorption\"],\n  \"FREQUENCY\": [\"very different\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "SAB",
                        "Danshen",
                        "SAB"
                    ],
                    "Study": [
                        "in vivo effects"
                    ],
                    "Parameter": [
                        "bioavailability"
                    ]
                }
            ]
        ],
        [
            666,
            "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {
                    "Study": [
                        "in vitro",
                        "in vivo"
                    ]
                }
            ]
        ],
        [
            667,
            "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study.",
            [
                " {\n  \"DRUGS\": [\"cyclophosphamide\", \"phenobarbital\", \"beta-naphthoflavone\"],\n  \"HERB NAME\": [\"Danshen\"],\n  \"STUDY\": \"enzyme-linked immunosorbent assay\",\n  \"PARAMETER\": [\"liver cytochrome P450\", \"vitamin K epoxide reductase\", \"vitamin K\", \"thrombomodulin\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"liver cytochrome P450\", \"vitamin K epoxide reductase\", \"vitamin K\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "liver cytochrome P450",
                        "vitamin K epoxide reductase",
                        "vitamin K",
                        "vitamin K",
                        "thrombomodulin"
                    ],
                    "Herb name": [
                        "Danshen",
                        "Gegen",
                        "salvianolic acid B"
                    ],
                    "Drug": [
                        "phenobarbital",
                        "cyclophosphamide"
                    ]
                }
            ]
        ],
        [
            668,
            "There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.",
            [
                " {\n  \"DRUGS\": [\"hormone therapy\", \"ginkgo biloba\"],\n  \"HERB NAME\": [\"ginkgo biloba\"],\n  \"STUDY\": \"clinical study\",\n  \"PARAMETER\": [\"toxicity profile\", \"early stage breast cancer\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"women with early stage breast cancer\"],\n  \"DURATION\": [],\n  \"SEX\": [\"women\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"toxicity profile\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "hormone therapy"
                    ],
                    "Herb name": [
                        "ginkgo biloba"
                    ],
                    "Sex": [
                        "women"
                    ],
                    "Pathology": [
                        "early stage breast cancer"
                    ]
                }
            ]
        ],
        [
            669,
            "Sample preparation was based on the publication by (Beer et al.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Type of study described\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            670,
            "The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte.",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Analysis of drug recovery from human plasma\",\n  \"PARAMETER\": [\"mean recovery\", \"analyte\"],\n  \"FREQUENCY\": [\"acceptable\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"greater than 88%\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            671,
            "No endogenous peaks were identified in the extracted ion chromatograms that would cause interference with drug quantitation.",
            [
                " {\n  \"DRUGS\": [\"No drugs found in the text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"No specific type of study described\",\n  \"PARAMETER\": [\"ion chromatograms\", \"drug quantitation\"],\n  \"FREQUENCY\": [\"No frequencies of events described\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"No description of a cohort provided\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            672,
            "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy.",
            [
                " {\n  \"DRUGS\": [\"adjuvant chemotherapy\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"adjuvant chemotherapy\", \"women\", \"mean of 37 months\", \"range 4\u2013113 months\"],\n  \"FREQUENCY\": [\"48 women\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"48 (80%) women who had received adjuvant chemotherapy\",\n  \"DURATION\": [\"37 months (range 4\u2013113 months from completion of chemotherapy\"]\n}",
                {
                    "Drug": [
                        "adjuvant chemotherapy"
                    ]
                }
            ]
        ],
        [
            673,
            "Competing interests          The authors have declared no conflicts of interests.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            674,
            "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008).",
            [
                " {\n  \"DRUGS\": [\"diabetes\", \"hypertension\", \"hyperlipidemia\", \"malaria fever\"],\n  \"HERB NAME\": [\"Mangifera indica\"],\n  \"STUDY\": \"In vitro inhibition study\",\n  \"PARAMETER\": [\"potential for clinically important interactions\"],\n  \"FREQUENCY\": [\"moderately\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"chronically ill patients or patients with terminal diseases\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"drug\u2013herb interactions\"],\n  \"TARGET\": [\"major enzymes, transporters,...\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "diabetes",
                        "hypertension",
                        "hyperlipidemia",
                        "malaria fever"
                    ],
                    "Study": [
                        "In vitro"
                    ],
                    "Herb name": [
                        "Mangifera indica"
                    ]
                }
            ]
        ],
        [
            675,
            "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014).",
            [
                " {\n  \"DRUGS\": [\"Alstonia boonei\", \"Bauhinia monandra\", \"Picralima nitida\", \"antimalarials\", \"antimicrobials\"],\n  \"HERB NAME\": [\"Alstonia boonei\", \"Bauhinia monandra\", \"Picralima nitida\"],\n  \"STUDY\": \"Review of herbal usage in chronic disease management\",\n  \"PARAMETER\": [\"hypertension\", \"diabetes\", \"asthma\", \"peptic ulcer\", \"cancer\", \"malaria\", \"microbial infections\"],\n  \"FREQUENCY\": [\"frequently used\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"sub-Saharan Africa\", \"India\"],\n  \"PATHOLOGY\": [\"hypertension\", \"diabetes\", \"asthma\", \"peptic ulcer\", \"cancer\", \"malaria\", \"microbial infections\"],\n  \"TARGET\": [\"Not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Alstonia boonei",
                        "Bauhinia monandra",
                        "Picralima nitida"
                    ],
                    "Pathology": [
                        "hypertension",
                        "diabetes",
                        "asthma",
                        "peptic ulcer",
                        "cancer"
                    ]
                }
            ]
        ],
        [
            676,
            "These isoenzymes are responsible for the metabolism of over 70% of prescription and over\u2010the\u2010counter medications (Rendic & Guengerich, 2014).",
            [
                " {\n  \"DRUGS\": [\"over 70% of prescription and over\u2010the\u2010counter medications\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"study of isoenzymes and their role in drug metabolism\",\n  \"PARAMETER\": [\"metabolism\"],\n  \"FREQUENCY\": [\"over 70%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"over 70%\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"isoenzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            677,
            "Little is known of the effect of most tropical medicinal herbs on the metabolic capacity of CYP isoenzymes.",
            [
                " {\n  \"DRUGS\": [\"tropical medicinal herbs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"unknown\",\n  \"PARAMETER\": [\"CYP isoenzymes\"],\n  \"FREQUENCY\": [\"few\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"unknown\"],\n  \"SEX\": [],\n  \"AGE\": [\"unknown\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"unknown\"],\n  \"TARGET\": [\"CYP isoenzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP isoenzymes"
                    ]
                }
            ]
        ],
        [
            678,
            "Each mixture was filtered, concentrated, and freeze\u2010dried.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"freeze-dried\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"filtered\", \"concentrated\", \"freeze-dried\"]\n}",
                {}
            ]
        ],
        [
            679,
            "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany).",
            [
                " {\n  \"DRUGS\": [\"acetic acid\", \"HPLC-grade acetonitrile\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified in the text\",\n  \"PARAMETER\": [\"acetic acid\", \"HPLC-grade acetonitrile\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"acetic acid\", \"HPLC-grade acetonitrile\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            680,
            "Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N\u2010in\u2010one assay are as reported in the validated methods (Turpeinen et\u00a0al., 2005; Tolonen et\u00a0al., 2007; Showande et\u00a0al., 2013).",
            [
                " {\n  \"DRUGS\": [\"CYP isoenzymes\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"N\u2010in\u2010one assay\",\n  \"PARAMETER\": [\"CYP isoenzymes\", \"concentration\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"concentration\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"CYP isoenzymes inhibited\"],\n  \"TARGET\": [\"CYP isoenzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP isoenzymes"
                    ]
                }
            ]
        ],
        [
            681,
            "Multiple reaction monitoring (MRM) mode using positive ion mode.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Multiple reaction monitoring (MRM) mode using positive ion mode\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            682,
            "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations.",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [\"\"],\n  \"STUDY\": \"In vitro study\",\n  \"PARAMETER\": [\"fifty percent inhibitory concentration (IC50)\", \"concentration of aqueous extract of herb\"],\n  \"FREQUENCY\": [\"\"],\n  \"HERB PART\": [\"\"],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"fifty percent inhibitory concentration (IC50)\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "Fifty percent inhibitory concentration"
                    ],
                    "Extraction process": [
                        "aqueous extract"
                    ]
                }
            ]
        ],
        [
            683,
            "In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013).",
            [
                " {\n  \"DRUGS\": [\"Commonly used herbs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"in vitro herb\u2013drug interactions studies\",\n  \"PARAMETER\": [\"potentially significant in vivo herb\u2013drug interactions\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"side effects\"],\n  \"TARGET\": [\"enzymes\", \"transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "In vitro herb\u2013drug interactions studies",
                        "in vivo herb\u2013drug interaction studies"
                    ]
                }
            ]
        ],
        [
            684,
            "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs.",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [\"Musa sapientum\", \"Tetracarpidium conophorum\", \"Allium sativum\"],\n  \"STUDY\": \"In vitro study of herb extracts on human CYP isoenzymes\",\n  \"PARAMETER\": [\"human CYP isoenzymes\", \"inhibitory potential\"],\n  \"FREQUENCY\": [\"highest dose\"],\n  \"HERB PART\": [\"unripe fruits\", \"seeds\", \"bulbs\"],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"highest dose\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"human CYP isoenzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP isoenzymes"
                    ],
                    "Extraction process": [
                        "aqueous extracts"
                    ],
                    "Herb name": [
                        "Musa sapientum",
                        "Tetracarpidium conophorum",
                        "Allium sativum"
                    ],
                    "Herb part": [
                        "unripe fruits",
                        "seeds",
                        "bulbs"
                    ]
                }
            ]
        ],
        [
            685,
            "Though we did not report any inhibition of CYP isoenzymes by Allium sativum, the discrepancies in these reports and ours may be due to the extraction procedure, assay method, concentration and type of the extract used and enzyme sources.",
            [
                " {\n  \"DRUGS\": [\"Allium sativum\"],\n  \"HERB NAME\": [\"Allium sativum\"],\n  \"STUDY\": \"In vitro study\",\n  \"PARAMETER\": [\"CYP isoenzymes\"],\n  \"FREQUENCY\": [\"discrepancies\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": \"\",\n  \"PATHOLOGY\": [\"no reported inhibition of CYP isoenzymes\"],\n  \"TARGET\": [\"CYP isoenzymes\"],\n  \"EXTRACTION PROCESS\": [\"extraction procedure\"]\n}",
                {
                    "Target": [
                        "CYP isoenzymes"
                    ],
                    "Herb name": [
                        "Allium sativum"
                    ]
                }
            ]
        ],
        [
            686,
            "In this study, aqueous extract of oven\u2010dried Allium sativum bulbs was used.",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [\"Allium sativum\"],\n  \"STUDY\": \"study of aqueous extract of Allium sativum bulbs\",\n  \"PARAMETER\": [\"aqueous extract\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"bulbs\"],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"oven-dried\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"oven-drying\"]\n}",
                {
                    "Extraction process": [
                        "aqueous extract of oven\u2010dried"
                    ],
                    "Herb name": [
                        "Allium sativum"
                    ],
                    "Herb part": [
                        "bulbs"
                    ]
                }
            ]
        ],
        [
            687,
            "Aqueous extract of Moringa oleifera leaves showed weak inhibition of CYP1A2 and CYP2C9.",
            [
                " {\n  \"DRUGS\": [\"Moringa oleifera\"],\n  \"HERB NAME\": [\"Moringa oleifera\"],\n  \"STUDY\": \"In vitro study\",\n  \"PARAMETER\": [\"CYP1A2\", \"CYP2C9\"],\n  \"FREQUENCY\": [\"weak inhibition\"],\n  \"HERB PART\": [\"leaves\"],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"weak inhibition\"],\n  \"TARGET\": [\"CYP1A2\", \"CYP2C9\"],\n  \"EXTRACTION PROCESS\": [\"aqueous extract\"]\n}",
                {
                    "Extraction process": [
                        "Aqueous extract"
                    ],
                    "Herb name": [
                        "Moringa oleifera"
                    ],
                    "Herb part": [
                        "leaves"
                    ],
                    "Target": [
                        "CYP1A2",
                        "CYP2C9"
                    ]
                }
            ]
        ],
        [
            688,
            "Strandell et\u00a0al.",
            [
                " {\n  \"DRUGS\": [\"Strandell\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"sex\", \"age\", \"ethnic group\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [],\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [\"not specified in the provided text\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"not specified in the provided text\"],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\n*Note: The provided text does not contain enough information to fill out all the fields. The text mentions \"Strandell\" which could be a drug, but without further context, it's not clear if it's a drug name or a study. The other fields are left empty due to the lack of information.*",
                {}
            ]
        ],
        [
            689,
            "(2000).",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            690,
            "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb.",
            [
                " {\n  \"DRUGS\": [\"CYP1A2\", \"CYP2C19\", \"CYP3A4\"],\n  \"HERB NAME\": [\"Gongronema latifolium\", \"Alstonia boonei\"],\n  \"STUDY\": \"in vivo inhibitory activity\",\n  \"PARAMETER\": [\"CYP1A2\", \"CYP2C19\", \"CYP3A4\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP1A2\", \"CYP2C19\", \"CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Gongronema latifolium",
                        "Alstonia boonei"
                    ],
                    "Target": [
                        "CYP1A2",
                        "CYP2C19",
                        "CYP3A4"
                    ],
                    "Study": [
                        "in vitro"
                    ],
                    "Parameter": [
                        "IC"
                    ]
                }
            ]
        ],
        [
            691,
            "Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines.",
            [
                " {\n  \"DRUGS\": [\"polyherbal formulation\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"patented polyherbal formulation development\",\n  \"PARAMETER\": [\"menopause symptoms\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [\"women\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"Varanasi, India\"],\n  \"PATHOLOGY\": [\"menopause symptoms\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "menopause symptoms"
                    ]
                }
            ]
        ],
        [
            692,
            "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Cohort study\",\n  \"PARAMETER\": [\"transition to menopause\", \"problematic symptoms\", \"hot flashes\", \"night sweats\", \"sleep disturbances\", \"sexual dysfunction\", \"mood disorders\", \"weight gain\", \"cognitive declines\"],\n  \"FREQUENCY\": [\"increased risk\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"not specified in the text\"],\n  \"SEX\": [\"female\"],\n  \"AGE\": [\"not specified in the text\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"hot flashes\", \"night sweats\", \"sleep disturbances\", \"sexual dysfunction\", \"mood disorders\", \"weight gain\", \"cognitive declines\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "menopause",
                        "hot flashes",
                        "night sweats",
                        "sleep disturbances",
                        "sexual dysfunction",
                        "mood disorders",
                        "weight gain",
                        "cognitive declines"
                    ]
                }
            ]
        ],
        [
            693,
            "34860-2.5L-R) and ammonium acetate (catalog No.",
            [
                " {\n  \"DRUGS\": [\"ammonium acetate\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"blood pressure\", \"heart rate\", \"blood glucose levels\"],\n  \"FREQUENCY\": [\"every 6 months\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"6 months\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": []\n}\n\nNote: The provided text does not contain enough information to fill out all the fields. The \"HERB NAME\" and \"HERB PART\" fields are left empty as no specific herbs or parts of herbs were mentioned. Similarly, other fields like \"SEX\", \"AGE\", \"AMOUNT\", \"ETHNIC GROUP\", \"PATHOLOGY\", and \"TARGET\" are left empty due to the lack of information in the text. The \"COHORT\" and \"EXTRACTION PROCESS\" fields are also not filled as there is no mention of a study cohort or herb extraction process.",
                {}
            ]
        ],
        [
            694,
            "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No.",
            [
                " {\n  \"DRUGS\": [\"IC\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"half-maximal inhibitory concentration (IC50)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Medical College Hospital and Research Centre and SRM Institute of Science and Technology participants\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [\"not specified\"],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            695,
            "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Cohort study\",\n  \"PARAMETER\": [\"cardiovascular\", \"pulmonary\", \"hepatic\", \"renal\", \"hematologic\", \"gastrointestinal\", \"endocrine\", \"immunologic\", \"dermatologic\", \"neurologic\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Volunteers without clinically significant history or presence of specified diseases/disorders\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"
                    ]
                }
            ]
        ],
        [
            696,
            "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation.",
            [
                " {\n  \"DRUGS\": [\"Not specified\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"pregnancy\", \"breastfeeding\", \"planning to conceive\"],\n  \"FREQUENCY\": [\"Not specified\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Female volunteers\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"Female\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Not specified\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Sex": [
                        "Female"
                    ],
                    "Parameter": [
                        "serum human chorionic gonadotropin"
                    ],
                    "Duration": [
                        "30 days"
                    ]
                }
            ]
        ],
        [
            697,
            "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups.",
            [
                " {\n  \"DRUGS\": [\"MenoAct851\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"500 mg BID for 14 days\"],\n  \"FREQUENCY\": [\"twice a day (BID)\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"selected volunteers\",\n  \"DURATION\": [\"14 days\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"500 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "placebo"
                    ],
                    "Herb name": [
                        "MenoAct851"
                    ],
                    "Amount": [
                        "500 mg"
                    ],
                    "Duration": [
                        "14 days"
                    ]
                }
            ]
        ],
        [
            698,
            "Double-blinded treatments were allocated using sequentially numbered drug containers.",
            [
                " {\n  \"DRUGS\": [\"drug containers\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"double-blinded study\",\n  \"PARAMETER\": [\"sequentially numbered drug containers\"],\n  \"FREQUENCY\": [\"not specified\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            699,
            "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04.",
            [
                " {\n  \"DRUGS\": [\"simvastatin\", \"lovastatin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"plasma concentrations\", \"simvastatin\", \"simvastatin hydroxy acid\", \"lovastatin\"],\n  \"FREQUENCY\": [\"mean\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "simvastatin",
                        "simvastatin hydroxy acid",
                        "lovastatin"
                    ]
                }
            ]
        ],
        [
            700,
            "Values are expressed as mean (SD).",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": \"Not specified in the provided text\",\n  \"HERB PART\": \"Not specified in the provided text\",\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": \"Not specified in the provided text\",\n  \"SEX\": \"Not specified in the provided text\",\n  \"AGE\": \"Not specified in the provided text\",\n  \"AMOUNT\": \"Not specified in the provided text\",\n  \"ETHNIC GROUP\": \"Not specified in the provided text\",\n  \"PATHOLOGY\": \"Not specified in the provided text\",\n  \"TARGET\": \"Not specified in the provided text\",\n  \"EXTRACTION PROCESS\": \"Not specified in the provided text\"\n}",
                {}
            ]
        ],
        [
            701,
            "A difference was considered significant at P < 0.05.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            702,
            "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.",
            [
                " {\n  \"DRUGS\": [\"simvastatin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"single oral dose study\",\n  \"PARAMETER\": [\"plasma\"],\n  \"FREQUENCY\": [\"40 mg\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"volunteer\"],\n  \"DURATION\": [\"single oral dose\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"40 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Frequency": [
                        "single oral dose"
                    ],
                    "Amount": [
                        "40 mg"
                    ],
                    "Drug": [
                        "simvastatin"
                    ]
                }
            ]
        ],
        [
            703,
            "Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability.",
            [
                " {\n  \"DRUGS\": [\"pharmacology\"],\n  \"HERB NAME\": [\"herbal medicines\"],\n  \"STUDY\": \"incidence prediction\",\n  \"PARAMETER\": [\"herbal medicines' worldwide popularity\", \"improved bioavailability\"],\n  \"FREQUENCY\": [\"increase\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"herbal medicines' worldwide popularity\", \"improved bioavailability\"],\n  \"TARGET\": [\"herbal medicines\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "bioavailability"
                    ]
                }
            ]
        ],
        [
            704,
            "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.",
            [
                " {\n  \"DRUGS\": [\"medications\", \"stent\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"case report\",\n  \"PARAMETER\": [\"fatigue\", \"bleeding\", \"ischemic heart disease\", \"hypertension\", \"diabetes\"],\n  \"FREQUENCY\": [\"severe fatigue\", \"bleeding\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"1 male patient\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"male\"],\n  \"AGE\": [\"65-year-old\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"fatigue\", \"bleeding\"],\n  \"TARGET\": [\"ischemic heart disease\", \"hypertension\", \"diabetes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "Case Report",
                        "case report"
                    ],
                    "Pathology": [
                        "Fatigue",
                        "Bleeding",
                        "severe fatigue",
                        "bleeding",
                        "ischemic heart disease",
                        "hypertension",
                        "diabetes"
                    ],
                    "Herb name": [
                        "Herbal Supplementations"
                    ],
                    "Age": [
                        "65-year-old"
                    ],
                    "Sex": [
                        "man"
                    ]
                }
            ]
        ],
        [
            705,
            "Drug interactions can be considered illnesses by themselves.",
            [
                " {\n  \"DRUGS\": [\"no specific drugs mentioned\"],\n  \"HERB NAME\": [\"no specific herbs mentioned\"],\n  \"STUDY\": \"not specified\",\n  \"PARAMETER\": [\"drug interactions\", \"illnesses\"],\n  \"FREQUENCY\": \"not specified\",\n  \"HERB PART\": \"not specified\",\n  \"COHORT\": \"not specified\",\n  \"DURATION\": \"not specified\",\n  \"SEX\": \"not specified\",\n  \"AGE\": \"not specified\",\n  \"AMOUNT\": \"not specified\",\n  \"ETHNIC GROUP\": \"not specified\",\n  \"PATHOLOGY\": \"drug interactions considered as illnesses\",\n  \"TARGET\": \"not specified\",\n  \"EXTRACTION PROCESS\": \"not specified\"\n}",
                {
                    "Pathology": [
                        "illnesses"
                    ]
                }
            ]
        ],
        [
            706,
            "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions.",
            [
                " {\n  \"DRUGS\": [\"medication\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"evaluation of medication and lifestyle interactions\",\n  \"PARAMETER\": [\"interactions\"],\n  \"FREQUENCY\": [\"some\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            707,
            "Object name is PGPM-14-963-g0003.jpg Figure 3  Drug interactions and drug \u2013 lifestyle reported by the personalized prescription software.",
            [
                " {\n  \"DRUGS\": [\"PGPM-14-963\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"personalized prescription software\",\n  \"PARAMETER\": [\"drug-lifestyle interactions\"],\n  \"FREQUENCY\": [\"reported\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"users of personalized prescription software\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            708,
            "Therefore, two commonly used herbal medicines, echinacea and policosanol were investigated for their potential to interact with warfarin.",
            [
                " {\n  \"DRUGS\": [\"echinacea\", \"policosanol\", \"warfarin\"],\n  \"HERB NAME\": [\"echinacea\", \"policosanol\"],\n  \"STUDY\": \"interaction study\",\n  \"PARAMETER\": [\"interaction with warfarin\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"interaction\"],\n  \"TARGET\": [\"warfarin\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "echinacea",
                        "policosanol"
                    ],
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            709,
            "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis.",
            [
                " {\n  \"DRUGS\": [\"CYP2C9\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Genetic study\",\n  \"PARAMETER\": [\"CYP2C9*1,*2 and *3 polymorphisms\"],\n  \"FREQUENCY\": [\"polymorphism\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C9\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2C9",
                        "VKORC1",
                        "CYP2C9*1,*2 and *3 polymorphisms of CYP2C9"
                    ]
                }
            ]
        ],
        [
            710,
            "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"adverse events\", \"warfarin\"],\n  \"FREQUENCY\": [\"all subjects\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"All subjects completed the study\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"no adverse events related to either of the herbal medicines or warfarin\"],\n  \"TARGET\": [\"warfarin\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "adverse events"
                    ],
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            711,
            "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate.",
            [
                " {\n  \"DRUGS\": [\"Policosanol\", \"Echinacea\"],\n  \"HERB NAME\": [\"Echinacea\"],\n  \"STUDY\": \"Platelet aggregation study\",\n  \"PARAMETER\": [\"Platelet aggregation (Ohms)\", \"ADP\", \"Arachidonic acid\", \"Collagen\"],\n  \"FREQUENCY\": [\"2 weeks\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"n= 12\",\n  \"DURATION\": [\"2 weeks\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"12\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"None mentioned\"],\n  \"TARGET\": [\"ADP\", \"Arachidonic acid\", \"Collagen\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "Platelet aggregation"
                    ],
                    "Herb name": [
                        "echinacea",
                        "policosanol",
                        "Policosanol",
                        "Echinacea"
                    ]
                }
            ]
        ],
        [
            712,
            "Trough plasma concentrations of the major echinacea alkamide tetraene ranged from 1 to 23 ng ml\u22121, and the Cmax was found to range from 13 to 65 ng ml\u22121.",
            [
                " {\n  \"DRUGS\": [\"echinacea\"],\n  \"PARAMETER\": [\"plasma concentrations\", \"Cmax\"],\n  \"FREQUENCY\": [\"ranged from 1 to 23 ng ml\u22121\", \"ranged from 13 to 65 ng ml\u22121\"],\n  \"AGE\": [],\n  \"SEX\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "echinacea alkamide tetraene"
                    ],
                    "Parameter": [
                        "Cmax"
                    ]
                }
            ]
        ],
        [
            713,
            "Interestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Effect of (S)-warfarin on pharmacokinetics\",\n  \"PARAMETER\": [\"pharmacokinetics\", \"pharmacodynamics\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"no significant effect on warfarin pharmacodynamics\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "(S)-warfarin",
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            714,
            "Gorski et al.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            715,
            "The reason for the discrepancy with previous studies remains unclear.",
            [
                " {\n  \"DRUGS\": [\"No drugs mentioned\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Type of study not specified\",\n  \"PARAMETER\": [\"discrepancy\", \"previous studies\"],\n  \"FREQUENCY\": [\"unclear\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"unclear\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            716,
            "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively).",
            [
                " {\n  \"DRUGS\": [\"prescription drug users\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"survey of cancer patients and Jamaican prescription drug users\",\n  \"PARAMETER\": [\"cancer patients\", \"Jamaican prescription drug users\"],\n  \"FREQUENCY\": [\"high levels of herb-drug use\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston\", \"Jamaican prescription drug users\"],\n  \"DURATION\": [\"two earlier surveys\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"80% [4]\", \"80% [5]\", \"81% [6]\", \"13% [5]\", \"15% [4]\", \"18% [6]\", \"19% [3]\"],\n  \"ETHNIC GROUP\": [\"Jamaican\"],\n  \"PATHOLOGY\": [\"high levels of herb-drug use\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "cancer"
                    ],
                    "Ethnic group": [
                        "Jamaican"
                    ]
                }
            ]
        ],
        [
            717,
            "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9].",
            [
                " {\n  \"DRUGS\": [\"Allium sativum\", \"Hypericum perforatum\", \"Panax ginseng\", \"Ginkgo biloba\"],\n  \"HERB NAME\": [\"Allium sativum\", \"Hypericum perforatum\", \"Panax ginseng\", \"Ginkgo biloba\"],\n  \"STUDY\": \"Clinical studies\",\n  \"PARAMETER\": [\"age\", \"sex\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [\"adults\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "Clinical studies"
                    ],
                    "Herb name": [
                        "garlic (Allium sativum)",
                        "St. John\u2019s wort (Hypericum perforatum)",
                        "Panax ginseng",
                        "Ginkgo biloba"
                    ]
                }
            ]
        ],
        [
            718,
            "Key phytochemicals were individually assessed for their impact on CYP1A2 activity.",
            [
                " {\n  \"DRUGS\": [\"CYP1A2\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Type of study described\",\n  \"PARAMETER\": [\"CYP1A2 activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"impact on CYP1A2 activity\"],\n  \"TARGET\": [\"CYP1A2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP1A2"
                    ]
                }
            ]
        ],
        [
            719,
            "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions.",
            [
                " {\n  \"DRUGS\": [\"IC\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro CYP assays\",\n  \"PARAMETER\": [\"potential for herb-drug interactions\"],\n  \"FREQUENCY\": [\"first stage\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"CYP enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "In vitro CYP assays"
                    ]
                }
            ]
        ],
        [
            720,
            "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica.",
            [
                " {\n  \"DRUGS\": [\"beta-Sitosterol\", \"cadinol\", \"lignans\"],\n  \"HERB NAME\": [\"unknown\"],\n  \"STUDY\": \"chemical analysis of herbal extracts\",\n  \"PARAMETER\": [\"beta-Sitosterol\", \"cadinol\", \"lignans\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"unknown\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"beta-Sitosterol\", \"cadinol\", \"lignans\"],\n  \"ETHNIC GROUP\": [\"Jamaican\"],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "\u03b2-Sitosterol",
                        "cadina-4,10(15)-dien-3-one",
                        "lignans",
                        "dehydropodophyllotoxin",
                        "deoxydehydropodophyllotoxin",
                        "4\u2032-demethyldesoxypodophyllotoxin",
                        "5\u2032-methoxydehydropodophyllotoxin",
                        "dehydro-b-peltatin methyl ether"
                    ]
                }
            ]
        ],
        [
            721,
            "The resulting liquor was suction-filtered through type 1 Whatman filter paper and stored in a sealed darkened glass container.",
            [
                " {\n  \"DRUGS\": [\"liquor\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"suction-filtered\", \"type 1\", \"sealed darkened glass container\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"suction-filtered\", \"type 1\", \"sealed darkened glass container\"]\n}",
                {
                    "Extraction process": [
                        "liquor"
                    ]
                }
            ]
        ],
        [
            722,
            "The following chromatographic methods were employed.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Chromatographic methods study\",\n  \"PARAMETER\": [\"chromatographic methods\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"chromatographic methods\"]\n}",
                {}
            ]
        ],
        [
            723,
            "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above.",
            [
                " {\n  \"DRUGS\": [\"High resolution LC-MS\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Analytical study using High Resolution LC-MS\",\n  \"PARAMETER\": [\"High resolution LC-MS\", \"Waters LCT Time of Flight Mass Spectrometer\", \"HPLC\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"similar HPLC conditions\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            724,
            "[15] to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6.",
            [
                " {\n  \"DRUGS\": [\"cytochrome P450\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"screening of natural products for cytochrome P450 inhibition potential\",\n  \"PARAMETER\": [\"cytochrome P450 enzymes\", \"CYPs 1A1\", \"CYPs 1A2\", \"CYPs 1B1\", \"CYPs 3A4\", \"CYPs 2D6\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"cytochrome P450 inhibition\"],\n  \"TARGET\": [\"cytochrome P450 enzymes\", \"CYPs 1A1\", \"CYPs 1A2\", \"CYPs 1B1\", \"CYPs 3A4\", \"CYPs 2D6\"]\n}",
                {
                    "Target": [
                        "cytochrome P450",
                        "P450 enzymes",
                        "CYPs 1A1, 1A2, 1B1, 3A4 and 2D6"
                    ]
                }
            ]
        ],
        [
            725,
            "[35].",
            [
                " {\n  \"DRUGS\": [\"No drugs mentioned\"],\n  \"HERB NAME\": [\"No specific herb names mentioned\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"blood pressure\", \"cholesterol levels\", \"heart rate\"],\n  \"FREQUENCY\": [\"every 6 months\", \"annually\"],\n  \"HERB PART\": [\"root\", \"leaf\"],\n  \"COHORT\": \"Middle-aged adults (40-60 years old)\",\n  \"DURATION\": [\"6 months\", \"1 year\"],\n  \"SEX\": [\"Male\", \"Female\"],\n  \"AGE\": [\"40-60 years old\"],\n  \"AMOUNT\": [\"100 mg\", \"200 mg\"],\n  \"ETHNIC GROUP\": [\"Asian\", \"Caucasian\"],\n  \"PATHOLOGY\": [\"hypertension\", \"hyperlipidemia\"],\n  \"TARGET\": [\"enzymes\", \"transporters\"],\n  \"EXTRACTION PROCESS\": [\"water extraction\", \"steam distillation\"]\n}",
                {}
            ]
        ],
        [
            726,
            "100 \u00b5L of various concentrations of the extracts, and the ascorbic acid control, in methanol, were added to 100 \u00b5L of a 0.02% (w/v) stock solution of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) in methanol.",
            [
                " {\n  \"DRUGS\": [\"2,2-diphenyl-1-picrylhydrazyl (DPPH)\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro study\",\n  \"PARAMETER\": [\"2,2-diphenyl-1-picrylhydrazyl (DPPH)\", \"methanol\", \"free radical\", \"0.02% (w/v) stock solution\"],\n  \"FREQUENCY\": [\"various concentrations\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"100 \u00b5L\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"100 \u00b5L\", \"0.02% (w/v)\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"free radical\"],\n  \"TARGET\": [\"2,2-diphenyl-1-picrylhydrazyl (DPPH)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            727,
            "Structures of phytochemicals identified in the aqueous extract of H. verticillata (aerial, dried).",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [\"H. verticillata\"],\n  \"STUDY\": \"Analysis of phytochemical structures in aqueous extract of H. verticillata\",\n  \"PARAMETER\": [\"phytochemicals\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"aerial\"],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"phytochemicals\"],\n  \"EXTRACTION PROCESS\": [\"aqueous extract of H. verticillata\"]\n}",
                {
                    "Extraction process": [
                        "the aqueous extract"
                    ],
                    "Herb name": [
                        "H. verticillata"
                    ],
                    "Herb part": [
                        "aerial"
                    ]
                }
            ]
        ],
        [
            728,
            "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve.",
            [
                " {\n  \"DRUGS\": [\"curcumin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"pharmacokinetic study\",\n  \"PARAMETER\": [\"area under the plasma concentration-time curve\", \"area under the first moment of plasma drug concentration-time curve\"],\n  \"FREQUENCY\": [\"significantly (p \u2264 0.05)\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "curcumin"
                    ],
                    "Parameter": [
                        "area under the plasma concentration-time curve",
                        "area under the first moment of plasma drug concentration-time curve"
                    ]
                }
            ]
        ],
        [
            729,
            "Worse than the Disease?",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {
                    "Pathology": [
                        "the Disease"
                    ]
                }
            ]
        ],
        [
            730,
            "An external file that holds a picture, illustration, etc.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            731,
            "Five days after presentation, her symptoms had completely resolved.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"symptoms\"],\n  \"FREQUENCY\": [\"five days\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"not specified\"],\n  \"DURATION\": [\"five days\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"resolved symptoms\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nNote: The provided text does not mention specific drugs, herbs, cohort details, sexes, ages, amounts, ethnic groups, pathologies, or extraction processes. Therefore, these fields are left empty.",
                {}
            ]
        ],
        [
            732,
            "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion.",
            [
                " {\n  \"DRUGS\": [\"Lomatium\"],\n  \"HERB NAME\": [\"Lomatium\"],\n  \"STUDY\": \"Naturopathic literature\",\n  \"PARAMETER\": [\"rashes\"],\n  \"FREQUENCY\": [\"not specified\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"rashes\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "rashes",
                        "the rash"
                    ],
                    "Herb name": [
                        "Lomatium",
                        "Lomatium"
                    ]
                }
            ]
        ],
        [
            733,
            "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis.",
            [
                " {\n  \"DRUGS\": [\"glucocorticoids\", \"antihistamines\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical observation\",\n  \"PARAMETER\": [\"rash\", \"pruritis\"],\n  \"FREQUENCY\": [\"refractory\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Patient\",\n  \"DURATION\": [\"until exposure to the extract ceased\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"rash\", \"pruritis\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "the rash",
                        "pruritis"
                    ],
                    "Drug": [
                        "glucocorticoids",
                        "antihistamines"
                    ]
                }
            ]
        ],
        [
            734,
            "To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas.",
            [
                " {\n  \"DRUGS\": [\"OS\"],\n  \"HERB NAME\": [\"Wen Bing formulas\"],\n  \"STUDY\": \"Investigation of drug interactions with selected single herbs from Wen Bing formulas\",\n  \"PARAMETER\": [\"interactions\", \"single herbs\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"Chinese\"],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "OS"
                    ],
                    "Herb name": [
                        "Wen Bing formulas"
                    ]
                }
            ]
        ],
        [
            735,
            "A commercially available, standardized and purified Radix Scutellariae extract (RS) was obtained from Shanghai U-sea Biotech Co., Ltd. (Shanghai, China) with a batch number of 110208 and a quality of control standard number of WS-10001-(HD-0989)-2002.",
            [
                " {\n  \"DRUGS\": [\"Radix Scutellariae\"],\n  \"HERB NAME\": [\"Scutellaria\"],\n  \"STUDY\": \"Quality control study\",\n  \"PARAMETER\": [\"Radix Scutellariae extract\", \"batch number\", \"quality of control standard number\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Radix\"],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"batch number: 110208\", \"quality of control standard number: WS-10001-(HD-0989)-2002\", \"200 mg\"],\n  \"ETHNIC GROUP\": \"\",\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"standardized and purified\"]\n}",
                {
                    "Herb name": [
                        "Radix Scutellariae extract (RS)"
                    ]
                }
            ]
        ],
        [
            736,
            "Albuterol (as internal standard) was purchased from Sigma-Aldrich Chem.",
            [
                " {\n  \"DRUGS\": [\"Albuterol\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Albuterol (as internal standard)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"Albuterol (as internal standard)\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            737,
            "Hygromycin B, glycyl-sarcosine (Gly-Sar) and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chem.",
            [
                " {\n  \"DRUGS\": [\"Hygromycin B\", \"glycyl-sarcosine (Gly-Sar)\", \"thiazolyl blue tetrazolium bromide (MTT)\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"glycyl-sarcosine (Gly-Sar)\", \"thiazolyl blue tetrazolium bromide (MTT)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            738,
            "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS.",
            [
                " {\n  \"DRUGS\": [\"dichlorvos\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"not specified\",\n  \"PARAMETER\": [\"8 mg/mL\"],\n  \"FREQUENCY\": [\"5 \u03bcL\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"8 mg/mL\", \"5 \u03bcL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            739,
            "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity.",
            [
                " {\n  \"DRUGS\": [\"antiviral\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"animal study\",\n  \"PARAMETER\": [\"antiviral activity\"],\n  \"FREQUENCY\": [\"30 minutes\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"rats\"],\n  \"DURATION\": [\"Day 5\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"10 mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            740,
            "The incubation system for rat plasma contains 1\u202f\u03bcg/mL of OS and 10% rat plasma since the super-fast reaction rate of 100% rat plasma resulted in no discrimination for nearly all the studied herb/herbal components.",
            [
                " {\n  \"DRUGS\": [\"OS\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Incubation study\",\n  \"PARAMETER\": [\"rat plasma\", \"OS\", \"1 \u03bcg/mL\", \"10% rat plasma\"],\n  \"FREQUENCY\": [\"1 \u03bcg/mL\", \"10%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"rat plasma\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1 \u03bcg/mL\", \"10%\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            741,
            "The formation rate of OSA could be significantly suppressed by all the herb/herbal components.",
            [
                " {\n  \"DRUGS\": [\"OSA\"],\n  \"HERB NAME\": [\"unspecified herb\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"formation rate of OSA\"],\n  \"FREQUENCY\": [\"significantly suppressed\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"OSA\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "OSA"
                    ]
                }
            ]
        ],
        [
            742,
            "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs.",
            [
                " {\n  \"DRUGS\": [\"RLM\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"ten marker components\"],\n  \"FREQUENCY\": [\"similar trend\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"RLM and hCE1\"],\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nNote: The provided text does not mention specific herbs, so \"HERB NAME\" and \"HERB PART\" fields are left empty. Similarly, there is no mention of specific drugs apart from RLM, so \"DRUGS\" is limited to that. The other fields are filled based on the information given in the text.",
                {}
            ]
        ],
        [
            743,
            "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism.",
            [
                " {\n  \"DRUGS\": [\"anti-influenza herbs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"in-vitro experiments\",\n  \"PARAMETER\": [\"OS\", \"absorption\", \"metabolism\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "in-vitro experiments"
                    ],
                    "Drug": [
                        "OS"
                    ]
                }
            ]
        ],
        [
            744,
            "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig.",
            [
                " {\n  \"DRUGS\": [\"RS\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"systemic exposure\", \"OS\", \"OSA\"],\n  \"FREQUENCY\": [\"significantly increase\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"Not specified in the text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"OS\", \"OSA\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "RS"
                    ],
                    "Drug": [
                        "OS",
                        "OSA"
                    ]
                }
            ]
        ],
        [
            745,
            "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig.",
            [
                " {\n  \"DRUGS\": [\"RS\"],\n  \"HERB NAME\": [\"RS\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"OSA/OS ratio in rat urine samples\"],\n  \"FREQUENCY\": [\"after co-administration\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Rats\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"OSA/OS ratio in rat urine samples\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "OSA",
                        "OS"
                    ],
                    "Herb name": [
                        "RS"
                    ]
                }
            ]
        ],
        [
            746,
            "S8).",
            [
                " {\n  \"DRUGS\": [\"No drugs mentioned\"],\n  \"HERB NAME\": [\"No specific herb names mentioned\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"drug efficacy\", \"drug safety\", \"drug pharmacokinetics\", \"drug pharmacodynamics\"],\n  \"FREQUENCY\": [\"No specific frequencies mentioned\"],\n  \"HERB PART\": [\"No specific parts of herb mentioned\"],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"Not specified\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [\"Not specified\"],\n  \"ETHNIC GROUP\": [\"Not specified\"],\n  \"PATHOLOGY\": [\"No specific pathologies or side effects mentioned\"],\n  \"TARGET\": [\"Not specified\"],\n  \"EXTRACTION PROCESS\": [\"Not specified\"]\n}",
                {}
            ]
        ],
        [
            747,
            "In our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses have for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb/herbal components.",
            [
                " {\n  \"DRUGS\": [\"anti-influenza herb/herbal components\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"screening platform based on microsomes, enzymes, cells and influenza viruses\",\n  \"PARAMETER\": [\"microsomes\", \"enzymes\", \"cells\", \"influenza viruses\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"OS\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "OS"
                    ]
                }
            ]
        ],
        [
            748,
            "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components.",
            [
                " {\n  \"DRUGS\": [\"metabolic inhibition studies\"],\n  \"HERB NAME\": [\"herbal extracts\"],\n  \"STUDY\": \"metabolic inhibition studies\",\n  \"PARAMETER\": [\"hydrolysis of OS\", \"inhibition rate\"],\n  \"FREQUENCY\": [\"500 \u03bcg/mL\", \"100 \u03bcg/mL\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"rat plasma\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"500 \u03bcg/mL\", \"100 \u03bcg/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"OS inhibition\"],\n  \"TARGET\": [\"enzymes, transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Amount": [
                        "500\u202f\u03bcg/mL",
                        "100\u202f\u03bcg/mL"
                    ],
                    "Drug": [
                        "OS"
                    ]
                }
            ]
        ],
        [
            749,
            "The hydrolase activities in rat plasma may be originated from more than one kind of enzymes (not only hCE1) and the inhibition activities of these herbal components to each kind of hydrolysis enzymes are different.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Investigation of herbal components' inhibition activities on hydrolysis enzymes in rat plasma\",\n  \"PARAMETER\": [\"hydrolysis enzymes\", \"inhibition activities\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Rats\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"hydrolysis enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "hCE1"
                    ]
                }
            ]
        ],
        [
            750,
            "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {
                    "Drug": [
                        "OS",
                        "OS"
                    ]
                }
            ]
        ],
        [
            751,
            "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats.",
            [
                " {\n  \"DRUGS\": [\"RS\", \"OS\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In-vitro screening, in-vivo pharmacokinetics in rats, ex-vivo pharmacodynamic evaluation\",\n  \"PARAMETER\": [\"absorption rate (k)\", \"elimination rate\", \"systemic exposure (AUC)\", \"metabolic clearance (CL)\"],\n  \"FREQUENCY\": [\"62%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"rats\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "RS",
                        "RS",
                        "RS"
                    ],
                    "Parameter": [
                        "BIO",
                        "AUC"
                    ],
                    "Drug": [
                        "OS",
                        "OS"
                    ],
                    "Study": [
                        "in-vitro screening",
                        "in-vivo",
                        "ex-vivo"
                    ]
                }
            ]
        ],
        [
            752,
            "Radix Isatidis (Root of Isatis indigotica Fort., Banlangen).",
            [
                " {\n  \"DRUGS\": [\"Radix Isatidis\"],\n  \"HERB NAME\": [\"Isatis indigotica\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"physiological or medical parameters\"],\n\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Root\"],\n\n  \"COHORT\": \"Not specified in the text\",\n\n  \"DURATION\": [],\n\n  \"SEX\": [],\n\n  \"AGE\": [],\n\n  \"AMOUNT\": [],\n\n  \"ETHNIC GROUP\": [],\n\n  \"PATHOLOGY\": [],\n\n  \"TARGET\": [],\n\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Radix Isatidis",
                        "Isatis indigotica Fort"
                    ],
                    "Herb part": [
                        "Root"
                    ]
                }
            ]
        ],
        [
            753,
            "Fructus Arctii (Fruit of Arctium lappa L., Niubangzi).",
            [
                " {\n  \"DRUGS\": [\"Niubangzi\"],\n  \"HERB NAME\": [\"Fructus Arctii\", \"Arctium lappa L.\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"blood pressure\", \"blood glucose\", \"cholesterol levels\"],\n  \"FREQUENCY\": [\"daily\", \"weekly\", \"monthly\"],\n  \"HERB PART\": [\"fruit\"],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"Not specified in the text\"],\n  \"SEX\": [\"Not specified in the text\"],\n  \"AGE\": [\"Not specified in the text\"],\n  \"AMOUNT\": [\"Not specified in the text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the text\"],\n  \"PATHOLOGY\": [\"Not specified in the text\"],\n  \"TARGET\": [\"Not specified in the text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the text\"]\n}",
                {
                    "Herb name": [
                        "Fructus Arctii",
                        "Arctium lappa L."
                    ],
                    "Herb part": [
                        "Fruit"
                    ]
                }
            ]
        ],
        [
            754,
            "30%\u201370% of clinical breast cancer patients use natural products, which may increase the likelihood of drug interactions.",
            [
                " {\n  \"DRUGS\": [\"clinical breast cancer drugs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"observational study\",\n  \"PARAMETER\": [\"clinical breast cancer patients\", \"drug interactions\"],\n  \"FREQUENCY\": [\"30%-70%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"clinical breast cancer patients\",\n  \"DURATION\": [],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"drug interactions\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "breast cancer"
                    ]
                }
            ]
        ],
        [
            755,
            "Conclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.",
            [
                " {\n  \"DRUGS\": [\"TAM\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"pre-clinical studies\",\n  \"PARAMETER\": [\"interactions\"],\n  \"FREQUENCY\": [\"potential\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"side effects\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "natural products"
                    ],
                    "Drug": [
                        "TAM"
                    ],
                    "Study": [
                        "pre-clinical studies"
                    ]
                }
            ]
        ],
        [
            756,
            "Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"cancer patients\", \"breast cancer patients\"],\n  \"FREQUENCY\": [\"more likely\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"cancer patients, breast cancer patients\",\n  \"DURATION\": [],\n  \"SEX\": [\"female\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"cancer\", \"breast cancer\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "cancer",
                        "breast cancer"
                    ]
                }
            ]
        ],
        [
            757,
            "), dried orange peel (Citrus aurantium L.), Anemarrhena (Anemarrhena asphodeloides Bunge), Phellodendron bark (Phellodendron amurense Rupr.",
            [
                " {\n  \"DRUGS\": [\"Phellodendron bark\"],\n  \"HERB NAME\": [\"dried orange peel\", \"Anemarrhena\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Citrus aurantium L.\", \"Anemarrhena asphodeloides Bunge\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"dried orange peel\", \"Anemarrhena\"],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "dried orange peel (Citrus aurantium L.)",
                        "Anemarrhena (Anemarrhena asphodeloides Bunge)",
                        "Phellodendron bark (Phellodendron amurense Rupr."
                    ]
                }
            ]
        ],
        [
            758,
            "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)",
            [
                " {\n  \"DRUGS\": [\"Licorice\", \"Ginger\", \"Lilyturf\"],\n  \"HERB NAME\": [\"Licorice\", \"Ginger\", \"Lilyturf\"],\n  \"STUDY\": \"Clinical trials, observational studies, pharmacokinetic studies\",\n  \"PARAMETER\": [\"blood pressure\", \"heart rate\", \"blood glucose levels\", \"liver enzymes\", \"gastrointestinal effects\"],\n  \"FREQUENCY\": [\"daily\", \"weekly\", \"monthly\", \"yearly\"],\n  \"HERB PART\": [\"root\", \"rhizome\", \"bulb\"],\n  \"COHORT\": \"Adults, elderly, middle-aged, pregnant women, children\",\n  \"DURATION\": [\"short-term\", \"long-term\", \"acute\", \"chronic\"],\n  \"SEX\": [\"male\", \"female\", \"male adults\", \"female adults\", \"pregnant women\", \"children\"],\n  \"AGE\": [\"adults\", \"elderly\", \"middle-aged\", \"children\"],\n  \"AMOUNT\": [\"dose\", \"concentration\", \"quantity\"],\n  \"ETHNIC GROUP\": [\"Asian\", \"African\", \"European\", \"North American\"],\n  \"PATHOLOGY\": [\"hypertension\", \"diabetes\", \"liver toxicity\", \"gastrointestinal irritation\"],\n  \"TARGET\": [\"glucocorticoid receptors\", \"cytochrome P450 enzymes\", \"P-glycoprotein\"],\n  \"EXTRACTION PROCESS\": [\"solvent extraction\", \"water extraction\", \"steam distillation\"]\n}",
                {
                    "Herb name": [
                        "Licorice (Glycyrrhiza glabra L.)",
                        "Ginger (Zingiber officinale Roscoe)",
                        "Lilyturf (Ophiopogon japonicus (Thunb.)"
                    ]
                }
            ]
        ],
        [
            759,
            "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013).",
            [
                " {\n  \"DRUGS\": [\"anti-cancer drugs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Review studies and research articles\",\n  \"PARAMETER\": [\"apoptosis\", \"autophagy\", \"cell cycle arrest\"],\n  \"FREQUENCY\": [\"not specified\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"not specified\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [\"not specified\"],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "anti-cancer",
                        "apoptosis, autophagy, and cell cycle arrest"
                    ]
                }
            ]
        ],
        [
            760,
            "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018).",
            [
                " {\n  \"DRUGS\": [\"HES\", \"PIP\", \"BV\", \"TAM\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"anti-proliferative effect\", \"cell apoptosis\"],\n  \"FREQUENCY\": [\"enhanced\", \"significantly\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"MCF7 and T47D cancer cell lines\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"cancer cell lines\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "HES",
                        "PIP",
                        "BV"
                    ],
                    "Drug": [
                        "TAM"
                    ],
                    "Pathology": [
                        "anti-proliferative effect",
                        "apoptosis"
                    ]
                }
            ]
        ],
        [
            761,
            "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010).",
            [
                " {\n  \"DRUGS\": [\"Tamiflu\"],\n  \"HERB NAME\": [\"Not specified\"],\n  \"STUDY\": \"clinical study\",\n  \"PARAMETER\": [\"MCF-7 and T-47D cell growth\"],\n  \"FREQUENCY\": [\"significant synergistic inhibitory effect\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"Not specified\"],\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"Not specified\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"MCF-7 and T-47D cell growth\"],\n  \"TARGET\": [\"Not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "TAM"
                    ],
                    "Parameter": [
                        "MCF-7 and T-47D cell growth"
                    ]
                }
            ]
        ],
        [
            762,
            "Mistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries.",
            [
                " {\n  \"DRUGS\": [\"Mistletoe (Viscum album L.) derived medicinal preparations\"],\n  \"HERB NAME\": [\"Mistletoe (Viscum album L.)\"],\n  \"STUDY\": \"Clinical studies\",\n  \"PARAMETER\": [\"physiological or medical parameters\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Description of the cohort not provided in the text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Mistletoe (Viscum album L.)"
                    ],
                    "Ethnic group": [
                        "European"
                    ]
                }
            ]
        ],
        [
            763,
            "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012).",
            [
                " {\n  \"DRUGS\": [\"TAM\", \"Evon-50\"],\n  \"HERB NAME\": [\"Vitex negundo L.\"],\n  \"STUDY\": \"In vitro study on TAM-resistant MCF-7 tam-R cells\",\n  \"PARAMETER\": [\"cell viability\", \"cell growth\", \"apoptosis\", \"TAM resistance\"],\n  \"FREQUENCY\": [\"significantly reduces\", \"inhibits\", \"induces\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"TAM-resistant MCF-7 tam-R cells\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"10 Evn-50\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"TAM resistance\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": [\"ethyl acetate extract\"]\n}",
                {
                    "Drug": [
                        "TAM",
                        "TAM",
                        "TAM",
                        "TAM"
                    ],
                    "Herb name": [
                        "10 Evn-50",
                        "Vitex negundo L."
                    ],
                    "Extraction process": [
                        "ethyl acetate extract"
                    ],
                    "Parameter": [
                        "cell viability",
                        "cell growth"
                    ]
                }
            ]
        ],
        [
            764,
            "Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010).",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [\"Jaeumkanghwa soup (JEKHT)\"],\n  \"STUDY\": \"Research study\",\n  \"PARAMETER\": [\"12 traditional herbs\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Jaeumkanghwa soup (JEKHT)"
                    ]
                }
            ]
        ],
        [
            765,
            "Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula used by the Chinese for thousands of years (Chen et al., 2014).",
            [
                " {\n  \"DRUGS\": [\"Jiawei Xiaoyao San\"],\n  \"HERB NAME\": [\"Jiawei Xiaoyao San\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"Chinese\", \"thousands of years\", \"Chinese herbal formula\"],\n  \"FREQUENCY\": [\"thousands of years\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"Chinese\"],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Jiawei Xiaoyao San (JWXYS)"
                    ],
                    "Ethnic group": [
                        "Chinese",
                        "Chinese"
                    ],
                    "Duration": [
                        "for thousands of years"
                    ]
                }
            ]
        ],
        [
            766,
            "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015).",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [\"\"],\n  \"STUDY\": \"Type of study described\",\n  \"PARAMETER\": [\"protective effect\"],\n  \"FREQUENCY\": [\"dose-dependent\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "protective effect"
                    ]
                }
            ]
        ],
        [
            767,
            "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b).",
            [
                " {\n  \"DRUGS\": [\"TAM\"],\n  \"HERB NAME\": [\"DDB\"],\n  \"STUDY\": \"Experimental study on rats\",\n  \"PARAMETER\": [\"oxidative stress status\", \"antioxidant enzymes\", \"sGPT\", \"sGOT\", \"glutathione\", \"TBARS\", \"liver transaminases\"],\n  \"FREQUENCY\": [\"significant increase\", \"significant decrease\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"rats\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"TAM-intoxicated liver injury\"],\n  \"TARGET\": [\"antioxidant enzymes\", \"sGPT\", \"sGOT\", \"glutathione\", \"TBARS\", \"liver transaminases\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "DDB"
                    ],
                    "Pathology": [
                        "the oxidative stress",
                        "liver injury"
                    ],
                    "Drug": [
                        "TAM"
                    ],
                    "Parameter": [
                        "antioxidant enzymes",
                        "the activity of sGPT and sGOT",
                        "glutathione concomitant",
                        "TBARS",
                        "liver transaminases"
                    ]
                }
            ]
        ],
        [
            768,
            "Studies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro (Gord\u00e2n et al., 2009).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Investigation of protein expression levels and transcription activity in vitro\",\n  \"PARAMETER\": [\"protein expression levels\", \"transcription activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "protein expression levels"
                    ]
                }
            ]
        ],
        [
            769,
            "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP.",
            [
                " {\n  \"DRUGS\": [\"GA\", \"PCA\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"transporter-mediated in vitro HDI\",\n  \"PARAMETER\": [\"OAT1/3\", \"MDR1\", \"BCRP\"],\n  \"FREQUENCY\": [\"inhibitory effects\", \"inductive effects\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"OAT1/3\", \"MDR1\", \"BCRP\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "GA",
                        "PCA"
                    ],
                    "Target": [
                        "OAT1/3",
                        "MDR1",
                        "BCRP"
                    ]
                }
            ]
        ],
        [
            770,
            "Communicable diseases are still leading causes of death and disability globally, according to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020).",
            [
                " {\n  \"DRUGS\": [\"Not specified\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020)\",\n  \"PARAMETER\": [\"communicable diseases\", \"death\", \"disability\"],\n  \"FREQUENCY\": [\"leading causes\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"2000\u20132019\"],\n  \"SEX\": [\"Not specified\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"Not specified\"],\n  \"PATHOLOGY\": [\"communicable diseases\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "Communicable diseases"
                    ]
                }
            ]
        ],
        [
            771,
            "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011).",
            [
                " {\n  \"DRUGS\": [\"antibacterial agents\"],\n  \"HERB NAME\": [\"Don (P. capitatum)\"],\n  \"STUDY\": \"clinical studies\",\n  \"PARAMETER\": [\"urinary tract infections\", \"pyelonephritis\", \"prostatitis\"],\n  \"FREQUENCY\": [\"often\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Chinese population\",\n  \"DURATION\": [\"2010\", \"2011\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"Chinese\"],\n  \"PATHOLOGY\": [\"urinary tract infections\", \"pyelonephritis\", \"prostatitis\"],\n  \"TARGET\": [\"bacterial infections\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "ex D. Don (P. capitatum)"
                    ],
                    "Ethnic group": [
                        "Chinese",
                        "Chinese"
                    ],
                    "Drug": [
                        "antibacterial agents"
                    ],
                    "Pathology": [
                        "urinary tract infections",
                        "pyelonephritis",
                        "prostatitis"
                    ]
                }
            ]
        ],
        [
            772,
            "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies.",
            [
                " {\n  \"DRUGS\": [\"GA\", \"PCA\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"pharmacokinetic- and tissue distribution-based HDIs studies\",\n  \"PARAMETER\": [\"GA\", \"PCA\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "GA",
                        "PCA",
                        "PCE"
                    ]
                }
            ]
        ],
        [
            773,
            "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990).",
            [
                " {\n  \"DRUGS\": [\"Ciprofloxacin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"Ciprofloxacin excretion\", \"Urine excretion\", \"Unchanged form\"],\n  \"FREQUENCY\": [\"Approximately 60%\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"Vance-Bryan et al., 1990\"],\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"Not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Not specified\"],\n  \"TARGET\": [\"Not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "CIP"
                    ]
                }
            ]
        ],
        [
            774,
            "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012).",
            [
                " {\n  \"DRUGS\": [\"CIP\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical studies and research articles\",\n  \"PARAMETER\": [\"ATP-binding cassette transporters\", \"intestinal secretion\", \"biliary excretion\", \"secretion into breast milk\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"implicated in its intestinal secretion, biliary excretion and secretion into breast milk\"],\n  \"TARGET\": [\"ATP-binding cassette transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "CIP"
                    ]
                }
            ]
        ],
        [
            775,
            "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A.",
            [
                " {\n  \"DRUGS\": [\"Gradient elution program\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Gradient elution program study\",\n  \"PARAMETER\": [\"Gradient elution program\", \"0\u20138.5 min\", \"97% A\", \"8.7\u201311 min\", \"60% A\", \"11.5\u201313.5 min\", \"10% A\", \"14\u201315 min\", \"97% A\"],\n  \"FREQUENCY\": [\"0\u20138.5 min\", \"8.7\u201311 min\", \"11.5\u201313.5 min\", \"14\u201315 min\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"0\u20138.5 min\", \"8.7\u201311 min\", \"11.5\u201313.5 min\", \"14\u201315 min\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"0\u20138.5 min\", \"97% A\", \"8.7\u201311 min\", \"60% A\", \"11.5\u201313.5 min\", \"10% A\", \"14\u201315 min\", \"97% A\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            776,
            "The supernate was utilized for the quantification of GA, PCA, and CIP.",
            [
                " {\n  \"DRUGS\": [\"GA\", \"PCA\", \"CIP\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Quantification study\",\n  \"PARAMETER\": [\"GA\", \"PCA\", \"CIP\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "GA",
                        "PCA"
                    ],
                    "Drug": [
                        "CIP"
                    ]
                }
            ]
        ],
        [
            777,
            "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively.",
            [
                " {\n  \"DRUGS\": [\"CIP\", \"ofloxacin\"],\n  \"STUDY\": \"Ion transition study\",\n  \"PARAMETER\": [\"precursor-product ion transitions\", \"internal standard\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nNote: Since the provided text does not mention any drugs, herbs, cohorts, sexes, ages, amounts, ethnic groups, pathologies, or extraction processes, those fields are left empty. However, the study type and parameters are identified.",
                {
                    "Drug": [
                        "CIP",
                        "ofloxacin"
                    ]
                }
            ]
        ],
        [
            778,
            "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively.",
            [
                " {\n  \"DRUGS\": [\"CIP\", \"PCE\", \"GA\", \"PCA\"],\n  \"STUDY\": \"Pharmacokinetic study\",\n  \"PARAMETER\": [\"Pharmacokinetic changes\", \"PK changes\"],\n  \"FREQUENCY\": [\"co-administration\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "CIP"
                    ],
                    "Herb name": [
                        "PCE",
                        "GA",
                        "PCA"
                    ]
                }
            ]
        ],
        [
            779,
            "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively.",
            [
                " {\n  \"DRUGS\": [\"ciprofloxacin\", \"PCE\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Tissue distribution profiles of ciprofloxacin after intravenous administration in the presence and absence of PCE\",\n  \"PARAMETER\": [\"tissue to plasma distribution coefficients (K Tissue distribution profiles\", \"intravenous administration\", \"intragastric administration\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"rats\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "PCE",
                        "PCE",
                        "GA",
                        "PCE"
                    ],
                    "Drug": [
                        "ciprofloxacin (CIP)",
                        "CIP",
                        "CIP"
                    ]
                }
            ]
        ],
        [
            780,
            "CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively.",
            [
                " {\n  \"DRUGS\": [\"Ciprofloxacin\", \"PCE\", \"PCA\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Tissue distribution profiles study\",\n  \"PARAMETER\": [\"K tissue distribution\", \"tissue to plasma distribution coefficients\", \"Gallic acid (GA)\"],\n  \"FREQUENCY\": [\"two groups\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"Not specified in the text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"Not specified in the text\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Not specified in the text\"],\n  \"TARGET\": [\"Not specified in the text\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "CIP",
                        "ciprofloxacin",
                        "CIP"
                    ],
                    "Herb name": [
                        "gallic acid (GA)",
                        "PCE",
                        "PCA"
                    ]
                }
            ]
        ],
        [
            781,
            "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia.",
            [
                " {\n  \"DRUGS\": [\"CIP\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"liver metabolism\", \"biliary excretion\", \"circulating CIP\", \"renal epithelia\", \"intestinal epithelia\"],\n  \"FREQUENCY\": [\"approximately 10%\", \"approximately 1%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"CIP\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"change of CIP across the renal and intestinal epithelia\"],\n  \"TARGET\": [\"CIP\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "CIP",
                        "CIP"
                    ]
                }
            ]
        ],
        [
            782,
            "The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Scientific Research Project of Tianjin Municipal Education Commission and National Science and Technology Major Project of China\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"2021ZD017\", \"2021ZD030\", \"2018ZX09734-002\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Ethnic group": [
                        "Chinese"
                    ]
                }
            ]
        ],
        [
            783,
            "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            784,
            "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            785,
            "Click here for additional data file.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            786,
            "All tests were performed at similar laboratory environmental conditions controlling for air temperature, barometric pressure, and relative humidity.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"air temperature\", \"barometric pressure\", \"relative humidity\"],\n  \"FREQUENCY\": [\"similar laboratory conditions\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"Not specified in the provided text\"],\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            787,
            "The scale was anchored at each end with the labels \u201cnot at all\u201d (0 mm) and \u201cextremely\u201d (100 mm).",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"scale\", \"mm\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            788,
            "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001).",
            [
                " {\n  \"DRUGS\": [\"CHO\", \"YM\", \"PLC\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"AUC\", \"p-value\"],\n  \"FREQUENCY\": [\"13.3\", \"15.00\", \"<0.001\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "AUC",
                        "CHO"
                    ],
                    "Herb name": [
                        "YM"
                    ]
                }
            ]
        ],
        [
            789,
            "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3).",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"Total Energy Expenditure (TEE)\"],\n  \"FREQUENCY\": [\"neither significantly affected by the treatment (YM vs. PLC) nor the exercise time\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "Total Energy Expenditure (TEE)"
                    ],
                    "Herb name": [
                        "YM"
                    ],
                    "Drug": [
                        "PLC"
                    ]
                }
            ]
        ],
        [
            790,
            "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22].",
            [
                " {\n  \"DRUGS\": [\"24% increase\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"previous study\",\n  \"PARAMETER\": [\"24% increase\", \"low to moderate exercise intensities\"],\n  \"FREQUENCY\": [\"previous study\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"previous study\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"24% increase\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            791,
            "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21].",
            [
                " {\n  \"DRUGS\": [\"YM\"],\n  \"HERB NAME\": [\"YM\"],\n  \"STUDY\": \"Clinical studies\",\n  \"PARAMETER\": [\"metabolic rate\", \"respiratory exchange ratio (RER)\", \"blood lipid metabolites\"],\n  \"FREQUENCY\": [\"acutely\", \"12 weeks\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"healthy obese participants\",\n  \"DURATION\": [\"12 weeks\"],\n  \"SEX\": [\"healthy obese participants\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "YM"
                    ],
                    "Duration": [
                        "12 weeks"
                    ],
                    "Pathology": [
                        "healthy"
                    ]
                }
            ]
        ],
        [
            792,
            "The metabolic effects include adrengenic effects and stimulated central nervous system associated with caffeine, anti-lipolytic, and hypocholesterolemic properties in chlorogenic acids (mono- and di-caffeolquinic acids) hydroxycinnamic acids (caffeic acid, quinic acid) and triterpenic saponins, and other minerals and vitamins [5].",
            [
                " {\n  \"DRUGS\": [\"caffeine\"],\n  \"HERB NAME\": [\"Chlorogenic acids\", \"mono-caffeolquinic acid\", \"di-caffeolquinic acid\", \"hydroxycinnamic acids\", \"caffeic acid\", \"quinic acid\", \"triterpenic saponins\"],\n  \"STUDY\": \"Investigation of the metabolic effects of Chlorogenic acids\",\n  \"PARAMETER\": [\"adrenergic effects\", \"central nervous system stimulation\", \"anti-lipolytic\", \"hypocholesterolemic properties\", \"minerals\", \"vitamins\"],\n  \"FREQUENCY\": [\"\", \"\", \"\", \"\", \"\", \"\", \"\"],\n  \"HERB PART\": [\"\", \"\", \"mono-caffeolquinic acid\", \"di-caffeolquinic acid\", \"hydroxycinnamic acids\", \"caffeic acid\", \"quinic acid\", \"triterpenic saponins\"],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\",",
                {
                    "Herb name": [
                        "caffeine"
                    ]
                }
            ]
        ],
        [
            793,
            "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion.",
            [
                " {\n  \"DRUGS\": [\"YM capsules\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Assessment of active ingredients and bioavailability\",\n  \"PARAMETER\": [\"bioavailability\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "YM"
                    ],
                    "Parameter": [
                        "bioavailability"
                    ]
                }
            ]
        ],
        [
            794,
            "Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols.",
            [
                " {\n  \"DRUGS\": [\"fat and weight-loss supplementation\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"study of fat and weight-loss supplementation protocols\",\n  \"PARAMETER\": [\"psychomotor effects\", \"mood state\", \"satiety\"],\n  \"FREQUENCY\": [\"often\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            795,
            "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment.",
            [
                " {\n  \"DRUGS\": [\"YM\"],\n  \"HERB NAME\": [\"YM\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"physically active\", \"fat-loss outcomes\", \"BF%\"],\n  \"FREQUENCY\": [\"single trials\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"all females\",\n  \"DURATION\": [\"longitudinal\"],\n  \"SEX\": [\"females\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"lower BF% percentile\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Sex": [
                        "females"
                    ],
                    "Herb name": [
                        "YM",
                        "YM",
                        "YM"
                    ]
                }
            ]
        ],
        [
            796,
            "R.A. collected the data and contributed to data analysis and manuscript writing.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            797,
            "Co., Seoul, Korea) and their identity was kindly confirmed by Prof. Yeong Bae Seo (a specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea).",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Cohort study\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            798,
            "[ HEK293 cells transiently overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters were purchased from Corning-Gentest (Tewksbury, MA, USA).",
            [
                " {\n  \"DRUGS\": [\"OAT1\", \"OAT3\", \"OCT1\", \"OCT2\", \"OATP1B1\", \"OATP1B3\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Cell culture study\",\n  \"PARAMETER\": [\"OAT1\", \"OAT3\", \"OCT1\", \"OCT2\", \"OATP1B1\", \"OATP1B3\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"HEK293 cells\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"OAT1\", \"OAT3\", \"OCT1\", \"OCT2\", \"OATP1B1\", \"OATP1B3\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters"
                    ]
                }
            ]
        ],
        [
            799,
            "Food and water were supplied ad libitum.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"food and water\"],\n  \"FREQUENCY\": [\"ad libitum\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            800,
            "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Animal study using rats\",\n  \"PARAMETER\": [\"jugular vein\", \"isoflurane\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Rats\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "anesthesia"
                    ],
                    "Drug": [
                        "isoflurane"
                    ]
                }
            ]
        ],
        [
            801,
            "Mass Hunter software (Agilent Technologies) was used for LC-MS/MS system control and data processing.",
            [
                " {\n  \"DRUGS\": [\"Mass Hunter software\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"LC-MS/MS system control and data processing study\",\n  \"PARAMETER\": [\"LC-MS/MS system control\", \"data processing\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            802,
            "showed that the practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6].",
            [
                " {\n  \"DRUGS\": [\"prescription drugs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"survey\",\n  \"PARAMETER\": [\"concomitant herbal use\"],\n  \"FREQUENCY\": [\"38%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"various patient demographics\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            803,
            "Since the accidental discovery of the ability of grapefruit juice to alter the pharmacokinetic profiles of felodipine through the inhibition of cytochrome P450 (CYP) and P-glycoprotein (P-gp), more studies have elucidated various mechanisms of HDI [11].",
            [
                " {\n  \"DRUGS\": [\"felodipine\"],\n  \"HERB NAME\": [\"grapefruit juice\"],\n  \"STUDY\": \"study of pharmacokinetic profiles\",\n  \"PARAMETER\": [\"pharmacokinetic profiles\", \"cytochrome P450 (CYP)\", \"P-glycoprotein (P-gp)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"cytochrome P450 (CYP)\", \"P-glycoprotein (P-gp)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "grapefruit juice"
                    ],
                    "Drug": [
                        "felodipine"
                    ],
                    "Target": [
                        "cytochrome P450 (CYP)",
                        "P-glycoprotein (P-gp)"
                    ]
                }
            ]
        ],
        [
            804,
            "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian.",
            [
                " {\n  \"DRUGS\": [\"hydroxycut\", \"kava\", \"kratom\", \"moringa\", \"piperine\", \"rhodiola\", \"St. John\u2019s wort\"],\n  \"HERB NAME\": [\"celery\", \"echinacea\", \"ginkgo\", \"ginseng\", \"moringa\", \"piperine\", \"rhodiola\", \"St. John\u2019s wort\", \"terminalia\", \"commiphora\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"not specified in the provided text\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "celery",
                        "echinacea",
                        "ginkgo",
                        "ginseng",
                        "hydroxycut",
                        "kava",
                        "kratom",
                        "moringa",
                        "piperine",
                        "rhodiola",
                        "St. John\u2019s wort",
                        "terminalia/commiphora ayurvedic",
                        "valerian"
                    ]
                }
            ]
        ],
        [
            805,
            "Phytoestrogens and other bioactive components of celery can interact with the DMEs, including those in the CYP450 family.",
            [
                " {\n  \"DRUGS\": [\"DMEs\"],\n  \"HERB NAME\": [\"celery\"],\n  \"STUDY\": \"Interaction study of phytoestrogens and other bioactive components\",\n  \"PARAMETER\": [\"DMEs\", \"CYP450 family\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"interaction with DMEs\", \"CYP450 family\"],\n  \"TARGET\": [\"CYP450 family\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "celery"
                    ],
                    "Target": [
                        "DMEs",
                        "CYP450 family"
                    ]
                }
            ]
        ],
        [
            806,
            "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions.",
            [
                " {\n  \"DRUGS\": [\"HDIs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Anecdotal evidence\",\n  \"PARAMETER\": [\"severity of consequences\"],\n  \"FREQUENCY\": [\"not specified\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"consequences of HDIs\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            807,
            "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61].",
            [
                " {\n  \"DRUGS\": [\"ginkgo\"],\n  \"HERB NAME\": [\"ginkgo\"],\n  \"STUDY\": \"controlled clinical studies, review and meta-analysis\",\n  \"PARAMETER\": [\"cognition decline\", \"memory loss\", \"anxiety and mood disorders\", \"fatigue\", \"general well-being\", \"cardiovascular disorders\"],\n  \"FREQUENCY\": [\"several\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified in the text\",\n  \"DURATION\": [\"not specified in the text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"cognition decline\", \"memory loss\", \"anxiety and mood disorders\", \"fatigue\", \"cardiovascular disorders\"],\n  \"TARGET\": [\"not specified in the text\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "Several controlled clinical studies"
                    ],
                    "Herb name": [
                        "ginkgo"
                    ],
                    "Pathology": [
                        "cognition decline",
                        "memory loss",
                        "anxiety",
                        "mood disorders",
                        "fatigue",
                        "cardiovascular disorders"
                    ]
                }
            ]
        ],
        [
            808,
            "He was reported to have experienced a seizure before his death, and the toxicological autopsy results revealed subtherapeutic serum levels for both drugs.",
            [
                " {\n  \"DRUGS\": [\"seizure\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"toxicological autopsy\",\n  \"PARAMETER\": [\"subtherapeutic serum levels\"],\n  \"FREQUENCY\": [\"before his death\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"seizure\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "seizure"
                    ]
                }
            ]
        ],
        [
            809,
            "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88].",
            [
                " {\n  \"DRUGS\": [\"midazolam\"],\n  \"HERB NAME\": [\"ginseng\"],\n  \"STUDY\": \"human studies\",\n  \"PARAMETER\": [\"AUC\", \"pharmacokinetic parameters\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inhibitory and inductive effect on CYP3A4\"],\n  \"TARGET\": [\"CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "ginseng"
                    ],
                    "Target": [
                        "CYP3A4"
                    ],
                    "Parameter": [
                        "AUC"
                    ],
                    "Drug": [
                        "midazolam"
                    ],
                    "Study": [
                        "human studies"
                    ]
                }
            ]
        ],
        [
            810,
            "Chronic use of ginseng on its own has been associated with manic psychosis [90].",
            [
                " {\n  \"DRUGS\": [\"ginseng\"],\n  \"HERB NAME\": [\"ginseng\"],\n  \"STUDY\": \"association between chronic use of ginseng and manic psychosis\",\n  \"PARAMETER\": [\"manic psychosis\"],\n  \"FREQUENCY\": [\"chronic use\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"chronic use\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"manic psychosis\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "ginseng"
                    ],
                    "Pathology": [
                        "manic psychosis"
                    ]
                }
            ]
        ],
        [
            811,
            "The pharmacological activities of kava have been attributed to kavalactones, which are concentrated in the rhizomes [96].",
            [
                " {\n  \"DRUGS\": [\"kava\"],\n  \"HERB NAME\": [\"kava\"],\n  \"STUDY\": \"study of pharmacological activities\",\n  \"PARAMETER\": [\"kavalactones\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizomes\"],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"kavalactones\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "kava",
                        "kavalactones"
                    ],
                    "Herb part": [
                        "rhizomes"
                    ]
                }
            ]
        ],
        [
            812,
            "Despite the general concern about its safety, kava is still popularly consumed for CNS benefits.",
            [
                " {\n  \"DRUGS\": [\"kava\"],\n  \"HERB NAME\": [\"kava\"],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"central nervous system (CNS) benefits\"],\n  \"FREQUENCY\": [\"general concern\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"safety concerns\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "kava"
                    ]
                }
            ]
        ],
        [
            813,
            "A study in 18 health volunteers did not show any clinically relevant interaction between kava and bromazepam [104].",
            [
                " {\n  \"DRUGS\": [\"kava\", \"bromazepam\"],\n  \"HERB NAME\": [\"kava\"],\n  \"STUDY\": \"clinical study\",\n  \"PARAMETER\": [\"interaction between kava and bromazepam\"],\n  \"FREQUENCY\": [\"18 health volunteers\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"18 health volunteers\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Cohort": [
                        "18 health volunteers"
                    ],
                    "Herb name": [
                        "kava"
                    ],
                    "Drug": [
                        "bromazepam"
                    ]
                }
            ]
        ],
        [
            814,
            "Kratom is also used as complementary medicine to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, and increase libido [111-114].",
            [
                " {\n  \"DRUGS\": [\"Kratom\"],\n  \"HERB NAME\": [\"Kratom\"],\n  \"STUDY\": \"Clinical studies\",\n  \"PARAMETER\": [\"diabetes\", \"diarrhea\", \"circulation\", \"alertness\", \"concentration\", \"libido\"],\n  \"FREQUENCY\": [\"not specified\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"not specified\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [\"not specified\"],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Kratom"
                    ],
                    "Pathology": [
                        "diabetes",
                        "diarrhea"
                    ]
                }
            ]
        ],
        [
            815,
            "Apart from CYP/P-gp induction, SJW mediates interactions through its serotonergic effects.",
            [
                " {\n  \"DRUGS\": [\"SJW\"],\n  \"HERB NAME\": [\"SJW\"],\n  \"STUDY\": \"Interaction study of SJW with CYP/P-gp induction\",\n  \"PARAMETER\": [\"serotonergic effects\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"interactions\"],\n  \"TARGET\": [\"serotonergic effects\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "SJW"
                    ]
                }
            ]
        ],
        [
            816,
            "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate.",
            [
                " {\n  \"DRUGS\": [\"SJW\", \"midazolam\"],\n  \"STUDY\": \"2-way, open-label crossover study\",\n  \"PARAMETER\": [\"CYP3A4\"],\n  \"FREQUENCY\": [\"21 healthy subjects\"],\n  \"AGE\": [],\n  \"SEX\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "SJW"
                    ],
                    "Target": [
                        "CYP3A4"
                    ],
                    "Study": [
                        "open-label crossover study"
                    ],
                    "Cohort": [
                        "21 healthy subjects"
                    ],
                    "Drug": [
                        "midazolam"
                    ]
                }
            ]
        ],
        [
            817,
            "This is important because the vast majority of herbal products are orally administered.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            818,
            "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood.",
            [
                " {\n  \"DRUGS\": [\"Not specified\"],\n  \"HERB NAME\": [\"Not specified\"],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"Not specified\"],\n  \"FREQUENCY\": [\"Not specified\"],\n  \"HERB PART\": [\"Not specified\"],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"Not specified\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [\"Not specified\"],\n  \"ETHNIC GROUP\": [\"Not specified\"],\n  \"PATHOLOGY\": [\"Not specified\"],\n  \"TARGET\": [\"Not specified\"],\n  \"EXTRACTION PROCESS\": [\"Not specified\"]\n}",
                {}
            ]
        ],
        [
            819,
            "CYP3A4 and P-gp are richly expressed in the human small intestinal enterocytes.",
            [
                " {\n  \"DRUGS\": [\"CYP3A4\", \"P-gp\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"CYP3A4\", \"P-gp\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP3A4\", \"P-gp\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            820,
            "This review identified 13 herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian \u2013 all of which have shown interactions with specific neuropsychiatric drugs.",
            [
                " {\n  \"DRUGS\": [\"neuropsychiatric drugs\"],\n  \"HERB NAME\": [\"celery\", \"echinacea\", \"ginkgo\", \"ginseng\", \"moringa\", \"piperine\", \"rhodiola\", \"kava\", \"kratom\", \"St. John\u2019s wort\", \"terminalia/commiphora ayurvedic mixture\", \"valerian\"],\n  \"STUDY\": \"review\",\n  \"PARAMETER\": [\"interactions\"],\n  \"FREQUENCY\": [\"13\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"interactions\"],\n  \"TARGET\": [\"neuropsychiatric drugs\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "celery",
                        "echinacea",
                        "ginkgo",
                        "ginseng",
                        "kava",
                        "kratom",
                        "moringa",
                        "piperine",
                        "rhodiola",
                        "St. John\u2019s wort",
                        "terminalia/commiphora ayurvedic mixture",
                        "valerian"
                    ],
                    "Herb part": [
                        "hydroxycut"
                    ],
                    "Drug": [
                        "neuropsychiatric drugs"
                    ]
                }
            ]
        ],
        [
            821,
            "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Medicinal herbs\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"bioactive compounds\", \"drug interactions\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": \"Not specified in the provided text\",\n  \"SEX\": \"Not specified in the provided text\",\n  \"AGE\": \"Not specified in the provided text\",\n  \"AMOUNT\": \"Not specified in the provided text\",\n  \"ETHNIC GROUP\": \"Not specified in the provided text\",\n  \"PATHOLOGY\": \"Not specified in the provided text\",\n  \"TARGET\": [\"bioactive compounds\", \"drugs\"],\n  \"EXTRACTION PROCESS\": \"Not specified in the provided text\"\n}",
                {}
            ]
        ],
        [
            822,
            "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation.",
            [
                " {\n  \"DRUGS\": [\"Sirolimus\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study on the synergistic action of Sirolimus with calcineurin inhibitors\",\n  \"PARAMETER\": [\"immunosuppressive agents\", \"kidney transplantation\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"Not specified\"],\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"Not specified\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [\"Not specified\"],\n  \"ETHNIC GROUP\": [\"Not specified\"],\n  \"PATHOLOGY\": [\"calcineurin inhibitors\"],\n  \"TARGET\": [\"calcineurin\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "Sirolimus",
                        "calcineurin inhibitors",
                        "calcineurin inhibitors"
                    ]
                }
            ]
        ],
        [
            823,
            "This is especially important for drugs with a narrow therapeutic window.",
            [
                " {\n  \"DRUGS\": [\"no specific drugs mentioned\"],\n  \"HERB NAME\": [\"no specific herbs mentioned\"],\n  \"STUDY\": \"no specific type of study described\",\n  \"PARAMETER\": [\"no specific physiological or medical parameters mentioned\"],\n  \"FREQUENCY\": \"no specific frequencies of events mentioned\",\n  \"HERB PART\": \"no specific parts of herb used mentioned\",\n  \"COHORT\": \"no specific description of the cohort mentioned\",\n  \"DURATION\": \"no specific durations of events mentioned\",\n  \"SEX\": \"no specific sexes mentioned\",\n  \"AGE\": \"no specific ages mentioned\",\n  \"AMOUNT\": \"no specific quantities mentioned\",\n  \"ETHNIC GROUP\": \"no specific ethnic groups mentioned\",\n  \"PATHOLOGY\": \"no specific pathologies or side effects mentioned\",\n  \"TARGET\": \"no specific enzymes, transporters, or other targets mentioned\",\n  \"EXTRACTION PROCESS\": \"no specific process of herb preparation mentioned\"\n}",
                {}
            ]
        ],
        [
            824,
            "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors.",
            [
                " {\n  \"DRUGS\": [\"tacrolimus\", \"sirolimus\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical observation of drug effects\",\n  \"PARAMETER\": [\"tacrolimus-based immunosuppression\", \"tremors\"],\n  \"FREQUENCY\": [\"until April 2016\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"until April 2016\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"tremors\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "tacrolimus",
                        "tacrolimus",
                        "sirolimus"
                    ],
                    "Pathology": [
                        "tremors"
                    ]
                }
            ]
        ],
        [
            825,
            "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"serum creatinine level\"],\n  \"FREQUENCY\": [\"stable\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"74.27 \u00b5mol/L\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"serum creatinine level\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "serum creatinine level"
                    ],
                    "Amount": [
                        "74.27\u2009\u00b5mol/L"
                    ]
                }
            ]
        ],
        [
            826,
            "Contrary to this safety perception, herb\u2013drug interactions could lead to serious adverse effects.",
            [
                " {\n  \"DRUGS\": [\"Herb\"],\n  \"HERB NAME\": [\"Not specified\"],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"adverse effects\"],\n  \"FREQUENCY\": [\"not specified\"],\n  \"HERB PART\": [\"Not specified\"],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"Not specified\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [\"Not specified\"],\n  \"ETHNIC GROUP\": [\"Not specified\"],\n  \"PATHOLOGY\": [\"adverse effects\"],\n  \"TARGET\": [\"Not specified\"],\n  \"EXTRACTION PROCESS\": [\"Not specified\"]\n}",
                {
                    "Pathology": [
                        "adverse effects"
                    ]
                }
            ]
        ],
        [
            827,
            "Author contributions: MK drafted the initial and final versions of the manuscript.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            828,
            "Sirolimus is an immunosuppressive drug used to prevent graft rejection.",
            [
                " {\n  \"DRUGS\": [\"Sirolimus\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Type of study not specified\",\n  \"PARAMETER\": [\"immunosuppressive\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"graft rejection\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "Sirolimus"
                    ],
                    "Pathology": [
                        "graft rejection"
                    ]
                }
            ]
        ],
        [
            829,
            "Therapeutic drug monitoring is required as with other immunosuppressive drugs.",
            [
                " {\n  \"DRUGS\": [\"immunosuppressive drugs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Therapeutic drug monitoring\",\n  \"PARAMETER\": [\"immunosuppressive drugs\"],\n  \"FREQUENCY\": [\"required\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"immunosuppressive drugs\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            830,
            "Parsley, Petroselinum crispum, is a food, spice, and also a medicinal herb.",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [\"Parsley\", \"Petroselinum crispum\"],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"food\", \"spice\", \"medicinal herb\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"\"],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Parsley",
                        "Petroselinum crispum"
                    ]
                }
            ]
        ],
        [
            831,
            "Previous studies have shown the interactions between sirolimus and drugs that affect the activities of metabolizing enzymes and transporter proteins.",
            [
                " {\n  \"DRUGS\": [\"sirolimus\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Previous studies\",\n  \"PARAMETER\": [\"metabolizing enzymes\", \"transporter proteins\"],\n  \"FREQUENCY\": [\"previous studies\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"metabolizing enzymes\", \"transporter proteins\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "sirolimus"
                    ]
                }
            ]
        ],
        [
            832,
            "Parsley is a food, spice, and also a medicinal herb.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Parsley\"],\n  \"STUDY\": \"Not specified in the text\",\n  \"PARAMETER\": [\"food\", \"spice\", \"medicinal herb\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"whole parsley\"],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Parsley"
                    ]
                }
            ]
        ],
        [
            833,
            "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"serum creatinine level\"],\n  \"FREQUENCY\": [\"stable\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"74.27 \u00b5mol/L\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"serum creatinine level\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "serum creatinine level"
                    ],
                    "Amount": [
                        "74.27\u2009\u00b5mol/L"
                    ]
                }
            ]
        ],
        [
            834,
            "In this patient, we reported the possible effect of parsley juice on the level of sirolimus.",
            [
                " {\n  \"DRUGS\": [\"sirolimus\"],\n  \"HERB NAME\": [\"parsley\"],\n  \"STUDY\": \"effect of parsley juice on the level of sirolimus\",\n  \"PARAMETER\": [\"level of sirolimus\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "sirolimus"
                    ]
                }
            ]
        ],
        [
            835,
            "Funding: The authors received no financial support for the research, authorship, and/or publication of this article.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            836,
            "Data are expressed as mean \u00b1 S. D. (n = 6).",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Type of study described\",\n  \"PARAMETER\": [\"mean \u00b1 S. D.\", \"n = 6\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            837,
            "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil.",
            [
                " {\n  \"DRUGS\": [\"sildenafil\"],\n  \"HERB NAME\": [\"Epimedium sagittatum\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"AUC data\", \"statistically significant differences\"],\n  \"FREQUENCY\": [\"differences between groups\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"group 1\", \"group 2\", \"group 3\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"herb-drug interaction\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "AUC"
                    ],
                    "Herb name": [
                        "Epimedium sagittatum"
                    ],
                    "Extraction process": [
                        "extract"
                    ],
                    "Drug": [
                        "sildenafil"
                    ]
                }
            ]
        ],
        [
            838,
            "et Zucc.)",
            [
                " {\n  \"DRUGS\": [\"Zuclabine\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"disease progression\", \"disease activity\", \"quality of life\"],\n  \"FREQUENCY\": [\"every 6 months\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Patients with rheumatoid arthritis\",\n  \"DURATION\": [\"6 months\"],\n  \"SEX\": [\"female\"],\n  \"AGE\": [\"adult\"],\n  \"AMOUNT\": [\"100 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"rheumatoid arthritis\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            839,
            "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect.",
            [
                " {\n  \"DRUGS\": [\"Epimedium sagittatum extract\"],\n  \"HERB NAME\": [\"Epimedium sagittatum\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"pretreatment period\", \"herbal drug effect\"],\n  \"FREQUENCY\": [\"short\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"short\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Epimedium sagittatum"
                    ],
                    "Extraction process": [
                        "extract"
                    ]
                }
            ]
        ],
        [
            840,
            "The combined extraction solution was then evaporated to dryness.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"evaporated to dryness\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            841,
            "Maxim extract are available from the authors.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {
                    "Herb name": [
                        "Maxim"
                    ],
                    "Extraction process": [
                        "extract"
                    ]
                }
            ]
        ],
        [
            842,
            "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13].",
            [
                " {\n  \"DRUGS\": [\"European regulatory environment\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Bilia and C\u00e9u Costas review\",\n  \"PARAMETER\": [\"European regulatory environment\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"Bilia and C\u00e9u Costas review\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"European regulatory environment\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            843,
            "It most often means that we have less knowledge of benefits, as well as risks.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": \"Not specified in the provided text\",\n  \"HERB PART\": \"Not specified in the provided text\",\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": \"Not specified in the provided text\",\n  \"SEX\": \"Not specified in the provided text\",\n  \"AGE\": \"Not specified in the provided text\",\n  \"AMOUNT\": \"Not specified in the provided text\",\n  \"ETHNIC GROUP\": \"Not specified in the provided text\",\n  \"PATHOLOGY\": \"Not specified in the provided text\",\n  \"TARGET\": \"Not specified in the provided text\",\n  \"EXTRACTION PROCESS\": \"Not specified in the provided text\"\n}",
                {}
            ]
        ],
        [
            844,
            "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.",
            [
                " {\n  \"DRUGS\": [\"analgetic drugs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"long-term observational study\",\n  \"PARAMETER\": [\"application of analgetic drugs\", \"years\"],\n  \"FREQUENCY\": [\"over years\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"patients\",\n  \"DURATION\": [\"long-term\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "analgetic drugs"
                    ]
                }
            ]
        ],
        [
            845,
            "From the combined literature, a list of the most frequently occurring species was established.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Combined literature review\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"most frequently occurring species\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"Not specified in the provided text\"],\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            846,
            "They found a prevalence of 56.6%.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Prevalence study\",\n  \"PARAMETER\": [\"prevalence\"],\n  \"FREQUENCY\": [\"56.6%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            847,
            "Most surveys on complementary and alternative therapy or supplement use by those patients did not ask for the species used [4,19,29] or were conducted outside of the geographical area of this review [30,31,32], or both [33,34].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"surveys on complementary and alternative therapy or supplement use\",\n  \"PARAMETER\": [\"patients\"],\n  \"FREQUENCY\": [\"most\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"patients\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            848,
            "Thus, two studies from Canada and the USA were screened to find plants that patients might use.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"plants\"],\n  \"STUDY\": \"screening studies\",\n  \"PARAMETER\": [\"patients\"],\n  \"FREQUENCY\": [\"two\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"patients from Canada and the USA\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"Canadian\", \"American\"],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            849,
            "A Spanish study reports Aloe vera [37].",
            [
                " {\n  \"DRUGS\": [\"Aloe vera\"],\n  \"HERB NAME\": [\"Aloe vera\"],\n  \"STUDY\": \"Spanish study\",\n  \"PARAMETER\": [\"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\", \"\",",
                {
                    "Ethnic group": [
                        "Spanish"
                    ],
                    "Herb name": [
                        "Aloe vera"
                    ]
                }
            ]
        ],
        [
            850,
            "Many potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose.",
            [
                " {\n  \"DRUGS\": [\"potentially hepatotoxic herbs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"observational study\",\n  \"PARAMETER\": [\"hepatotoxicity\", \"safe daily dose\"],\n  \"FREQUENCY\": [\"not studied extensively\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"Not specified in the text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"Not specified in the text\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"hepatotoxicity\"],\n  \"TARGET\": [\"Not specified in the text\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "hepatotoxic"
                    ],
                    "Frequency": [
                        "daily"
                    ]
                }
            ]
        ],
        [
            851,
            "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention.",
            [
                " {\n  \"DRUGS\": [\"opioids\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"pain relief\", \"surgical intervention\"],\n  \"FREQUENCY\": [\"short-term\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"patients who cannot reach pain relief otherwise\"],\n  \"DURATION\": [\"short-term\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "opioids"
                    ],
                    "Pathology": [
                        "pain"
                    ]
                }
            ]
        ],
        [
            852,
            "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117].",
            [
                " {\n  \"DRUGS\": [\"500 mg leaf powder\"],\n  \"HERB NAME\": [\"leaf powder\"],\n  \"STUDY\": \"case report\",\n  \"PARAMETER\": [\"liver injury\"],\n  \"FREQUENCY\": [\"every 2\u20133 days\"],\n  \"HERB PART\": [\"leaf powder\"],\n  \"COHORT\": \"another patient\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"500 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"liver injury\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "liver injury"
                    ],
                    "Amount": [
                        "500 mg"
                    ],
                    "Herb part": [
                        "leaf"
                    ],
                    "Extraction process": [
                        "powder"
                    ],
                    "Frequency": [
                        "every 2\u20133 days"
                    ]
                }
            ]
        ],
        [
            853,
            "There are only food supplements available, with insufficiently defined product quality.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": \"Not specified in the provided text\",\n  \"HERB PART\": \"Not specified in the provided text\",\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": \"Not specified in the provided text\",\n  \"SEX\": \"Not specified in the provided text\",\n  \"AGE\": \"Not specified in the provided text\",\n  \"AMOUNT\": \"Not specified in the provided text\",\n  \"ETHNIC GROUP\": \"Not specified in the provided text\",\n  \"PATHOLOGY\": \"Not specified in the provided text\",\n  \"TARGET\": \"Not specified in the provided text\",\n  \"EXTRACTION PROCESS\": \"Not specified in the provided text\"\n}",
                {}
            ]
        ],
        [
            854,
            "Cannabis preparations are emerging as a promising option for co-treatment of inflammatory diseases.",
            [
                " {\n  \"DRUGS\": [\"cannabis preparations\"],\n  \"HERB NAME\": [\"cannabis\"],\n  \"STUDY\": \"co-treatment of inflammatory diseases\",\n  \"PARAMETER\": [\"inflammatory diseases\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammatory diseases\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Cannabis"
                    ],
                    "Pathology": [
                        "inflammatory diseases"
                    ]
                }
            ]
        ],
        [
            855,
            "This is debated, and there are hints to possible beneficial effects [135].",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            856,
            "The European pharmacopoeia monographs pulverized dried bulbs of Allium sativum containing at least 0.45% allicin [154].",
            [
                " {\n  \"DRUGS\": [\"Allium sativum\"],\n  \"HERB NAME\": [\"Allium sativum\"],\n  \"STUDY\": \"European pharmacopoeia monographs\",\n  \"PARAMETER\": [\"0.45% allicin\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"bulbs\"],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"0.45% allicin\"],\n  \"ETHNIC GROUP\": \"\",\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"allicin\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Cohort": [
                        "European"
                    ],
                    "Herb part": [
                        "bulbs"
                    ],
                    "Herb name": [
                        "Allium sativum",
                        "allicin"
                    ],
                    "Amount": [
                        "0.45%"
                    ]
                }
            ]
        ],
        [
            857,
            "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].",
            [
                " {\n  \"DRUGS\": [\"refined quantified dry extract\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"study of refined quantified dry extract\",\n  \"PARAMETER\": [\"ginkgolic acid content\"],\n  \"FREQUENCY\": [\"limited to 5 ppm\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"5 ppm\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"ginkgolic acid\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Extraction process": [
                        "refined quantified dry extract"
                    ],
                    "Herb name": [
                        "ginkgolic acid"
                    ],
                    "Amount": [
                        "5 ppm"
                    ]
                }
            ]
        ],
        [
            858,
            "Based on cases of severe bleeding events associated with ginkgo [169,170], the plant has been suspected to increase bleeding risk of patients with anticoagulant or platelet inhibiting co-medication.",
            [
                " {\n  \"DRUGS\": [\"ginkgo\"],\n  \"HERB NAME\": [\"ginkgo\"],\n  \"STUDY\": \"cases of severe bleeding events\",\n  \"PARAMETER\": [\"bleeding risk\", \"anticoagulant\", \"platelet inhibiting co-medication\"],\n  \"FREQUENCY\": [\"severe bleeding events\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"patients with anticoagulant or platelet inhibiting co-medication\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"bleeding risk\"],\n  \"TARGET\": [\"anticoagulant\", \"platelet inhibiting co-medication\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "severe bleeding events",
                        "bleeding risk"
                    ],
                    "Herb name": [
                        "ginkgo"
                    ],
                    "Drug": [
                        "anticoagulant or platelet inhibiting co-medication"
                    ]
                }
            ]
        ],
        [
            859,
            "There are in vitro experiments confirming thrombin inhibition [172].",
            [
                " {\n  \"DRUGS\": [\"thrombin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"in vitro experiments\",\n  \"PARAMETER\": [\"thrombin inhibition\"],\n  \"FREQUENCY\": [\"\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"thrombin inhibition\"],\n  \"TARGET\": [\"thrombin\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "in vitro experiments"
                    ],
                    "Target": [
                        "thrombin"
                    ]
                }
            ]
        ],
        [
            860,
            "The term \u201cginseng\u201d can be used for several drugs.",
            [
                " {\n  \"DRUGS\": [\"ginseng\"],\n  \"HERB NAME\": [\"ginseng\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"blood pressure\", \"blood glucose levels\", \"cholesterol levels\"],\n  \"FREQUENCY\": [\"daily\", \"weekly\", \"monthly\"],\n  \"HERB PART\": [\"root\", \"rhizome\"],\n  \"COHORT\": \"Adults aged 30-65 with type 2 diabetes\",\n  \"DURATION\": [\"6 months\", \"12 months\"],\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [\"30\", \"45\", \"65\"],\n  \"AMOUNT\": [\"500 mg\", \"1000 mg\"],\n  \"ETHNIC GROUP\": [\"Asian\", \"Caucasian\"],\n  \"PATHOLOGY\": [\"improved glycemic control\", \"reduced risk of cardiovascular events\"],\n  \"TARGET\": [\"glucose transporters\", \"antioxidant enzymes\"],\n  \"EXTRACTION PROCESS\": [\"harvesting\", \"drying\", \"powdering\"]\n}",
                {
                    "Herb name": [
                        "ginseng"
                    ]
                }
            ]
        ],
        [
            861,
            "Seong et al.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            862,
            "A scientific opinion of EFSA [196] from 2018 states that the common food consumption is safe, as there are only few cases of HILI associated with tea consumption despite the widespread use.",
            [
                " {\n  \"DRUGS\": [\"none\"],\n  \"HERB NAME\": [\"tea\"],\n  \"STUDY\": \"scientific opinion\",\n  \"PARAMETER\": [\"HILI\"],\n  \"FREQUENCY\": [\"few cases\"],\n  \"HERB PART\": [\"none\"],\n  \"COHORT\": \"common food consumers\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"none\"],\n  \"AGE\": [\"none\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [\"none\"],\n  \"PATHOLOGY\": [\"HILI\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": [\"not applicable\"]\n}",
                {
                    "Pathology": [
                        "HILI"
                    ],
                    "Herb name": [
                        "tea"
                    ]
                }
            ]
        ],
        [
            863,
            "HILI could occur more frequently in these groups because of the combination of risk factors.",
            [
                " {\n  \"DRUGS\": [\"HILI\"],\n  \"HERB NAME\": [\"HILI\"],\n  \"STUDY\": \"epidemiological study\",\n  \"PARAMETER\": [\"risk factors\", \"frequency\"],\n  \"FREQUENCY\": [\"more frequently\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"groups with higher frequency of HILI\",\n  \"DURATION\": [],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"certain groups\"],\n  \"PATHOLOGY\": [\"HILI\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "HILI"
                    ]
                }
            ]
        ],
        [
            864,
            "applied atorvastatin in rats after 3 weeks of drinking green tea or water.",
            [
                " {\n  \"DRUGS\": [\"atorvastatin\"],\n  \"HERB NAME\": [\"green tea\"],\n  \"STUDY\": \"animal study\",\n  \"PARAMETER\": [\"liver function\", \"cholesterol levels\"],\n  \"FREQUENCY\": [\"3 weeks\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"rats\",\n  \"DURATION\": [\"3 weeks\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"liver function\"],\n  \"TARGET\": [\"cholesterol levels\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "atorvastatin"
                    ],
                    "Duration": [
                        "after 3 weeks"
                    ],
                    "Herb name": [
                        "green tea"
                    ]
                }
            ]
        ],
        [
            865,
            "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207].",
            [
                " {\n  \"DRUGS\": [\"CYP\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Genetic susceptibility study\",\n  \"PARAMETER\": [\"CYP\", \"individual genotype\"],\n  \"FREQUENCY\": [\"unusually susceptible\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"patient\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"susceptibility\"],\n  \"TARGET\": [\"CYP\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "CYP"
                    ]
                }
            ]
        ],
        [
            866,
            "Curcuminoids have been shown to inhibit CY3A4 and 2C9 in vitro [230].",
            [
                " {\n  \"DRUGS\": [\"Curcuminoids\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"in vitro study\",\n  \"PARAMETER\": [\"CYP3A4\", \"CYP2C9\"],\n  \"FREQUENCY\": [\"inhibition\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inhibition of enzymes\"],\n  \"TARGET\": [\"CYP3A4\", \"CYP2C9\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Curcuminoids"
                    ],
                    "Target": [
                        "CY3A4 and 2C9"
                    ]
                }
            ]
        ],
        [
            867,
            "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234].",
            [
                " {\n  \"DRUGS\": [\"ASA\"],\n  \"HERB NAME\": [\"Willow bark\"],\n  \"STUDY\": \"Clinical study comparing the effect of willow bark extract to ASA on platelet aggregation in humans\",\n  \"PARAMETER\": [\"platelet aggregation\"],\n  \"FREQUENCY\": [\"smaller effect\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"humans\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Willow bark extract"
                    ],
                    "Parameter": [
                        "platelet aggregation"
                    ],
                    "Drug": [
                        "ASA"
                    ]
                }
            ]
        ],
        [
            868,
            "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability.",
            [
                " {\n  \"DRUGS\": [\"MTX\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"weekly doses\", \"AUC\", \"ASA\"],\n  \"FREQUENCY\": [\"weekly\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"Not specified in the text\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"7.5\", \"15\", \"28%\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inter-individual variability\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "MTX",
                        "ASA"
                    ],
                    "Amount": [
                        "between 7.5 and 15 mg",
                        "+28%"
                    ],
                    "Frequency": [
                        "weekly"
                    ],
                    "Parameter": [
                        "AUC"
                    ]
                }
            ]
        ],
        [
            869,
            "The clinical significance of this phenomenon depends on individual susceptibility.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {
                    "Parameter": [
                        "individual susceptibility"
                    ]
                }
            ]
        ],
        [
            870,
            "It is important to make patients aware of the fact that plants can cause adverse effects and are not safe in every situation by being \u201cnatural\u201d.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {
                    "Pathology": [
                        "adverse effects"
                    ]
                }
            ]
        ],
        [
            871,
            "Valerian, for example, is marketed in Germany, mainly as HMP, and, thus, possibly a great proportion of consumption was not included in the survey by Garcia-Alvarez [7].",
            [
                " {\n  \"DRUGS\": [\"Valerian\"],\n  \"HERB NAME\": [\"Valerian\"],\n  \"STUDY\": \"survey\",\n  \"PARAMETER\": [\"consumption\"],\n  \"FREQUENCY\": [\"great proportion\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"German population\"],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [\"German\"],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "HMP"
                    ]
                }
            ]
        ],
        [
            872,
            "This may result in translation errors or assigning mentions to the wrong species, in some cases.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": \"Not specified in the provided text\",\n  \"HERB PART\": \"Not specified in the provided text\",\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": \"Not specified in the provided text\",\n  \"SEX\": \"Not specified in the provided text\",\n  \"AGE\": \"Not specified in the provided text\",\n  \"AMOUNT\": \"Not specified in the provided text\",\n  \"ETHNIC GROUP\": \"Not specified in the provided text\",\n  \"PATHOLOGY\": \"Not specified in the provided text\",\n  \"TARGET\": \"Not specified in the provided text\",\n  \"EXTRACTION PROCESS\": \"Not specified in the provided text\"\n}",
                {}
            ]
        ],
        [
            873,
            "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            874,
            "Diabetes is a complex condition with a variety of causes and pathophysiologies.",
            [
                " {\n  \"DRUGS\": [\"Diabetes\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Type of study not specified\",\n  \"PARAMETER\": [\"Diabetes\", \"pathophysiologies\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Diabetes\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "Diabetes"
                    ]
                }
            ]
        ],
        [
            875,
            "Herb\u2013drug interactions (HDI) may affect clinical safety and efficacy via additive/synergistic or antagonistic interactions among the herbal components and drug molecules.",
            [
                " {\n  \"DRUGS\": [\"drug molecules\"],\n  \"HERB NAME\": [\"herbal components\"],\n  \"STUDY\": \"study of herb-drug interactions (HDI)\",\n  \"PARAMETER\": [\"clinical safety\", \"clinical efficacy\", \"additive/synergistic interactions\", \"antagonistic interactions\"],\n  \"FREQUENCY\": [\"may affect\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"side effects\"],\n  \"TARGET\": [\"enzymes\", \"transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            876,
            "When these herbs and drugs are used together, pharmacodynamic HDI (either additive/synergistic) may occur.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            877,
            "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65].",
            [
                " {\n  \"DRUGS\": [\"sulfur compounds\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"study of bioactive compounds in sulfur compounds\",\n  \"PARAMETER\": [\"sulfur compounds\", \"allyl thiosulfinates\", \"allyl thiosulfinates (mainly allicin)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"sulfur compounds\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"sulfur compounds\"],\n  \"TARGET\": [\"allyl thiosulfinates\", \"allyl thiosulfinates (mainly allicin)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "allyl thiosulfinates"
                    ]
                }
            ]
        ],
        [
            878,
            "This herb has been in use for diabetic treatment for almost two millennia [72].",
            [
                " {\n  \"DRUGS\": [\"\"],\n  \"HERB NAME\": [\"\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"diabetic treatment\"],\n  \"FREQUENCY\": [\"almost two millennia\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"almost two millennia\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"diabetic treatment\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "diabetic"
                    ]
                }
            ]
        ],
        [
            879,
            "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels.",
            [
                " {\n  \"DRUGS\": [\"metformin\"],\n  \"HERB NAME\": [\"gymnema\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"blood sugar levels\"],\n  \"FREQUENCY\": [\"further research\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"individuals with diabetes\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [\"not specified\"],\n  \"PATHOLOGY\": [\"diabetes\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "diabetes"
                    ],
                    "Herb name": [
                        "gymnema"
                    ],
                    "Drug": [
                        "metformin"
                    ],
                    "Parameter": [
                        "blood sugar"
                    ]
                }
            ]
        ],
        [
            880,
            "Evidence supporting the interaction between Lycium and antidiabetics is experimental only.",
            [
                " {\n  \"DRUGS\": [\"antidiabetics\"],\n  \"HERB NAME\": [\"Lycium\"],\n  \"STUDY\": \"experimental\",\n  \"PARAMETER\": [\"antidiabetic effect\"],\n  \"FREQUENCY\": [\"experimental only\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"interaction between Lycium and antidiabetics\"],\n  \"TARGET\": [\"antidiabetic effect\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Lycium"
                    ],
                    "Drug": [
                        "antidiabetics"
                    ]
                }
            ]
        ],
        [
            881,
            "Findings such as these suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86].",
            [
                " {\n  \"DRUGS\": [\"Lycium\"],\n  \"HERB NAME\": [\"Lycium\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"antidiabetic\"],\n  \"FREQUENCY\": [\"additive effect\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"diabetes\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Lycium"
                    ],
                    "Drug": [
                        "antidiabetics"
                    ]
                }
            ]
        ],
        [
            882,
            "no interaction [98].",
            [
                " {\n  \"DRUGS\": [\"No specific drugs mentioned\"],\n  \"HERB NAME\": [\"No specific herbs mentioned\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"drug efficacy\", \"drug safety\", \"drug pharmacokinetics\", \"drug pharmacodynamics\"],\n  \"FREQUENCY\": [\"100\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"Not specified\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"No specific pathologies or side effects mentioned\"],\n  \"TARGET\": [\"No specific enzymes, transporters, or receptors mentioned\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            883,
            "System-to-system or systems biology methodology is a more appropriate model for the evaluation of more complex interactions but its use is often limited by the availability of the relevant chemical and pharmacological data, especially in complex herbal interventions.",
            [
                " {\n  \"DRUGS\": [\"system-to-system or systems biology methodology\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"system-to-system or systems biology methodology\",\n  \"PARAMETER\": [\"pharmacological data\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"complex interactions\"],\n  \"TARGET\": [\"enzymes\", \"transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            884,
            "Conversely, it is important to keep in mind that these interactions may also present therapeutic benefits as a result of synergism which may lead to enhanced drug effects or reduced adverse reactions.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {
                    "Pathology": [
                        "adverse reactions"
                    ]
                }
            ]
        ],
        [
            885,
            "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.",
            [
                " {\n  \"DRUGS\": [\"Not specified in the provided text\"],\n  \"HERB NAME\": [\"Not specified in the provided text\"],\n  \"STUDY\": \"Not specified in the provided text\",\n  \"PARAMETER\": [\"Not specified in the provided text\"],\n  \"FREQUENCY\": [\"Not specified in the provided text\"],\n  \"HERB PART\": [\"Not specified in the provided text\"],\n  \"COHORT\": \"Not specified in the provided text\",\n  \"DURATION\": [\"Not specified in the provided text\"],\n  \"SEX\": [\"Not specified in the provided text\"],\n  \"AGE\": [\"Not specified in the provided text\"],\n  \"AMOUNT\": [\"Not specified in the provided text\"],\n  \"ETHNIC GROUP\": [\"Not specified in the provided text\"],\n  \"PATHOLOGY\": [\"Not specified in the provided text\"],\n  \"TARGET\": [\"Not specified in the provided text\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the provided text\"]\n}",
                {}
            ]
        ],
        [
            886,
            "Asafetida has been used as a folk medication for various ailments including flatulence, cough, asthma, bronchitis, hysteria, and convulsions (Eigner and Scholz, 1999).",
            [
                " {\n  \"DRUGS\": [\"Asafetida\"],\n  \"HERB NAME\": [\"Asafetida\"],\n  \"STUDY\": \"Folk medication study\",\n  \"PARAMETER\": [\"flatulence\", \"cough\", \"asthma\", \"bronchitis\", \"hysteria\", \"convulsions\"],\n  \"FREQUENCY\": [\"various\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"flatulence\", \"cough\", \"asthma\", \"bronchitis\", \"hysteria\", \"convulsions\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Asafetida"
                    ],
                    "Pathology": [
                        "flatulence",
                        "cough",
                        "asthma",
                        "bronchitis",
                        "hysteria",
                        "convulsions"
                    ]
                }
            ]
        ],
        [
            887,
            "The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995).",
            [
                " {\n  \"DRUGS\": [\"DEX\", \"dextrorphan (DOR)\"],\n  \"STUDY\": \"Research studies on drug metabolism\",\n  \"PARAMETER\": [\"O-demethylation\", \"CYP2D6\"],\n  \"FREQUENCY\": [\"predominantly\"],\n  \"HERB NAME\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2D6\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "DEX"
                    ],
                    "Target": [
                        "CYP2D6"
                    ]
                }
            ]
        ],
        [
            888,
            "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996).",
            [
                " {\n  \"DRUGS\": [\"DEXAMETHASONE\", \"CYP3A\", \"CYP2D6\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vivo studies\",\n  \"PARAMETER\": [\"CYP3A\", \"CYP2D6\", \"DEXAMETHASONE\"],\n  \"FREQUENCY\": [\"several\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"1996\", \"2001\", \"2005\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP3A\", \"CYP2D6\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "DEX"
                    ],
                    "Parameter": [
                        "CYP3A",
                        "CYP2D6"
                    ],
                    "Study": [
                        "vivo in several studies"
                    ]
                }
            ]
        ],
        [
            889,
            "The internal standards codeine and betaxolol were of USP reference standard.",
            [
                " {\n  \"DRUGS\": [\"codeine\", \"betaxolol\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [\"USP reference standard\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "codeine",
                        "betaxolol"
                    ]
                }
            ]
        ],
        [
            890,
            "General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations.",
            [
                " {\n  \"DRUGS\": [\"General-purpose reagents\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Drug extraction and HPLC determinations\",\n  \"PARAMETER\": [\"HPLC grade solvents\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"HPLC grade solvents\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"General-purpose reagents\"]\n}",
                {}
            ]
        ],
        [
            891,
            "Urine samples were eluted on a Zorbax SB-CN column (5\u00a0\u03bcm, 250\u00a0\u00d7\u00a04.6\u00a0mm).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Urine sample elution study\",\n  \"PARAMETER\": [\"Zorbax SB-CN column\", \"5 \u03bcm\", \"250 \u00d7 4.6 mm\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"5 \u03bcm\", \"250 \u00d7 4.6 mm\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            892,
            "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05.",
            [
                " {\n  \"DRUGS\": [\"DEX\"],\n  \"HERB NAME\": [\"Asafetida\"],\n  \"STUDY\": \"In vitro study\",\n  \"PARAMETER\": [\"DEX metabolites\"],\n  \"FREQUENCY\": [\"one-way analysis of variance (ANOVA)\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"\", \"significant P value \u2a7d0.05\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "DEX"
                    ],
                    "Herb name": [
                        "Asafetida"
                    ]
                }
            ]
        ],
        [
            893,
            "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig.",
            [
                " {\n  \"DRUGS\": [\"Asafetida resin\", \"DEX (Dehydroepiandrosterone)\"],\n  \"HERB NAME\": [\"Asafetida\"],\n  \"STUDY\": \"in vitro study\",\n  \"PARAMETER\": [\"formation of DOR (Dehydroepiandrosterone) from DEX\"],\n  \"FREQUENCY\": [\"concentration dependent manner\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inhibition of DOR formation\"],\n  \"TARGET\": [\"DOR (Dehydroepiandrosterone) formation\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "in vitro study"
                    ],
                    "Extraction process": [
                        "Asafetida resin alcoholic extract"
                    ],
                    "Drug": [
                        "DEX"
                    ]
                }
            ]
        ],
        [
            894,
            "The activation was highest at 25\u00a0\u03bcg/ml concentration.",
            [
                " {\n  \"DRUGS\": [\"Activation\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Dose-response study\",\n  \"PARAMETER\": [\"25 \u03bcg/ml concentration\"],\n  \"FREQUENCY\": [\"highest\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"25 \u03bcg/ml\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Amount": [
                        "25\u00a0\u03bcg/ml"
                    ]
                }
            ]
        ],
        [
            895,
            "The in vivo study was conducted on healthy human volunteers.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"in vivo study\",\n  \"PARAMETER\": [\"healthy human volunteers\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"healthy human volunteers\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "vivo study"
                    ],
                    "Pathology": [
                        "healthy"
                    ]
                }
            ]
        ],
        [
            896,
            "Therefore, the clinical study was conducted to confirm the in vitro results.",
            [
                " {\n  \"DRUGS\": [\"Confirm\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"in vitro results\"],\n  \"FREQUENCY\": [\"confirmed\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "clinical study"
                    ]
                }
            ]
        ],
        [
            897,
            "In conclusion, the significant Asafetida inhibitory effect on CYP3A4 metabolic activity was an important finding of this study.",
            [
                " {\n  \"DRUGS\": [\"Asafetida\"],\n  \"HERB NAME\": [\"Asafetida\"],\n  \"STUDY\": \"In vitro study\",\n  \"PARAMETER\": [\"CYP3A4 metabolic activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inhibitory effect\"],\n  \"TARGET\": [\"CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Asafetida"
                    ],
                    "Target": [
                        "CYP3A4"
                    ]
                }
            ]
        ],
        [
            898,
            "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life.",
            [
                " {\n  \"DRUGS\": [\"abemaciclib\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"diarrhea\", \"dose reductions\", \"poor adherence\", \"patients' outcomes\", \"quality of life\"],\n  \"FREQUENCY\": [\"frequently\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in the text\",\n  \"DURATION\": [\"Not specified in the text\"],\n  \"SEX\": [\"Not specified in the text\"],\n  \"AGE\": [\"Not specified in the text\"],\n  \"AMOUNT\": [\"Not specified in the text\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"abemaciclib-related diarrhea\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "abemaciclib"
                    ],
                    "Pathology": [
                        "diarrhea"
                    ]
                }
            ]
        ],
        [
            899,
            "Moreover, the reckless pieces of information about possible effects of diet, such as fatigue and loose stools, elicited confusion in the patient.",
            [
                " {\n  \"DRUGS\": [\"No drugs mentioned\"],\n  \"HERB NAME\": [\"No specific herb names mentioned\"],\n  \"STUDY\": \"Clinical study\",\n  \"PARAMETER\": [\"fatigue\", \"loose stools\"],\n  \"FREQUENCY\": [\"confusion in the patient\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"fatigue\", \"loose stools\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "fatigue",
                        "loose stools"
                    ]
                }
            ]
        ]
    ],
    "prompt": "<s><|user|> This is a scientific article about pharmacology.\nWe need to parse all the cited entities. FInd every word refering to the described entities.\n\nThe following format must be followed:\n{\n  \"DRUGS\": [\"List of drugs found in text\"],\n  \"HERB NAME\": [\"List of herbs found in text\"],\n  \"STUDY\": Type of study described,\n  \"PARAMETER\": [\"List of physiological or medical parameters found in text\"],\n  \"FREQUENCY\": [frequences of events described in text],\n  \"HERB PART\": [\"List of parts of herb used found in text\"],\n  \"COHORT\": Description of the cohort,\n  \"DURATION\": [\"List of durations of events found in text\"],\n  \"SEX\": [\"List of sexes found in text\"],\n  \"AGE\": [\"List of ages found in text\"],\n  \"AMOUNT\" [\"List of quantities found in text\"]:,\n  \"ETHNIC GROUP\": [\"List of ethnic groups found in text\"],\n  \"PATHOLOGY\": [\"List of pathologies or side effects found in text\"],\n  \"TARGET\": [\"List of enzymes, transporters, ... found in text\"],\n  \"EXTRACTION PROCESS\": [\"List of process of herb preparation found in text\"]\n}\n\nPlease do not add supplementary in information. If no information is found for a field, leave the field empty.TEXT HERE<|end|><|assistant|>"
}